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The successful resolution of inflammation requires removal of neutrophils from the 
inflammatory site to prevent release of histotoxic contents that may potentiate 
inflammatory processes and promote progression to a chronic state associated with 
impaired repair mechanisms and/or autoimmune responses. Macrophages are 
“professional” phagocytes required for rapid and efficient clearance of apoptotic 
neutrophils. Macrophage phagocytic capacity can be critically regulated by a number 
of environmental factors, including cytokines, bacterial products, and glucocorticoids. 
We have hypothesised that modulation of macrophage phagocytic capacity may 
represent an effective strategy for promoting resolution of inflammation in diseases 
where clearance of neutrophils may be impaired or inefficient. The aim of this thesis 
was to investigate the molecular mechanisms underlying glucocorticoid-augmentation 
of macrophage phagocytosis. We have demonstrated that long-term exposure of 
human peripheral blood monocytes to the synthetic glucocorticoid dexamethasone 
dramatically increases phagocytic capacity for “early” membrane-intact apoptotic 
neutrophils. Increased phagocytic potential was associated with a “switch” from a 
serum-independent to a serum-dependent apoptotic cell recognition mechanism. We 
initially employed an “add back” approach to rule out several well-defined opsonins in 
apoptotic neutrophil clearance, including immune complexes, IgG, complement 
proteins, pentraxin-3, fibronectin, annexin I, and platelet-derived factors. Using a 
multi-step purification scheme involving anion exchange and gel filtration 
chromatography, we purified a high molecular weight fraction that contained the pro-
phagocytic activity of serum and analysis by mass spectrometry identified C4-binding 
protein as a candidate protein. C4-binding protein circulates in human plasma bound 
predominately in a >570kDa complex with protein S and the presence of protein S in 
high molecular weight fractions was confirmed by immunoblotting. We found that 
protein S was equivalent to unfractionated serum in its ability to enhance phagocytosis 
of apoptotic neutrophils by dexamethasone-treated monocyte-derived macrophages 
(Dex-MDM) and that immunodepletion of protein S resulted in loss of pro-
phagocytic activity. Protein S was found to opsonise apoptotic neutrophils in a 
calcium-dependent manner and enhanced phagocytic potential by Dex-MDM 
 iv
through stimulation of Mer tyrosine kinase (Mertk), a receptor that is upregulated on 
the surface of Dex-MDM compared to untreated MDM.  
 
The studies presented in this thesis have provided novel insight into the underlying 
molecular mechanisms required for high capacity clearance of apoptotic neutrophils 
by macrophages following treatment with glucocorticoids and may form the 
foundations for further studies investigating glucocorticoid action for development of 
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CHAPTER 1: INTRODUCTION 
 
1.1 Inflammation: an overview 
 
1.1.1 Polymorphonuclear phagocytes 
Neutrophil granulocytes are terminally differentiated cells produced in the bone 
marrow from myeloid stem cells. It is estimated that around 100 billion neutrophils 
are released into the bloodstream daily, making them the most prominent cellular 
component of the human innate immune system (Athens et al., 1961, Bainton et al., 
1971, Walker and Willemze, 1980). Studies of intravenously infused radiolabeled 
rabbit neutrophils suggest that neutrophils circulate in peripheral blood with a half-
life of approximately 6 hours before localising to the spleen, bone marrow or liver 
(Haslett et al., 1989). However, during acute inflammation, neutrophils are rapidly 
recruited to inflamed sites via localised expression of chemoattractant signals and 
upregulation of adhesion molecule expression on vascular endothelial cells (fig. 1.1) 
(Strieter et al., 1993, Carlos and Harlan, 1994, Tekstra et al., 1996). Neutrophils are 
highly efficient phagocytes and contain or produce an impressive arsenal of 
degradative enzymes and toxic metabolites, including cationic proteins, lysozyme 
and reactive oxygen species, which represent the neutrophil’s defence against 
invading microbes (Klebanoff, 1980, Beaman and Beaman, 1984, Passo and Weiss, 
1984, Borregaard and Cowland, 1997). Neutrophils can also exert systemic 
inflammatory effects through the release of pro-inflammatory mediators, including 
cytokines (IL-1, IL-6 and TNF) and chemokines (IL-8 and MIP-1) (Cassatella, 
1995), which induce the recruitment of additional inflammatory cells. The 
importance of neutrophils in host defence is emphasised in patients with deficiencies 
either in neutrophil number (neutropaenia) or function (leukocyte adhesion 
deficiency, Chediak Higashi syndrome, chronic granulomatous disease) who are 
susceptible to recurrent bacterial infections (Kamani and Infante, 2000, Roos and 

















Figure 1.1: Recruitment of neutrophils to inflamed sites. 
Neutrophil recruitment is a coordinated process involving attachement to endothelial 
cells and migration into inflamed tissues. Resident tissue macrophages are often 
initiators of the inflammatory cascade, responding to microbial infection by secreting 
TNF and IL-1 cytokines that locally activate endothelial cells to induce the 
expression of several adhesion molecules. Sialyl-Lewisx moieties on neutrophils 
form weak affinity interactions with P-selectin and E-selectin on the surface of 
activated endothelial cells, resulting in rolling of neutrophils along the surface of the 
endothelial wall. Upon neutrophil activation by the chemokine IL-8, LFA-1 integrin 
is converted to a high affinity state and binds to ICAM-1 induced on the surface of 
endothelial cells, promoting tight binding of neutrophils to the endothelial wall. 
Chemokines such as IL-8 then induce extravasation of neutrophils through the 
endothelial wall via homotypic binding of CD31 (PECAM-1) present on both 
neutrophils and intracellular junctions of endothelial cells. Neutrophils penetrate the 
basement membrane by the release of proteolytic enzymes in a process known as 
diapedesis, and migrate toward the chemokine gradient. Neutrophils rapidly 
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1.1.2 Mononuclear phagocytes 
Macrophages are mononuclear cells that differentiate from blood monocytes upon 
recruitment into tissues in response to chemokines such as monocyte chemoattractant 
protein-1 (MCP)-1 (Lu et al., 1998). Macrophages reside in different organs and 
tissues of the body, including the lung (alveolar macrophages), liver (Kupffer cells), 
kidney (glomerular mesangial cells), spleen, neural tissue (microglia), gut and lymph 
nodes where they play an essential role in immune surveillance. Macrophages have 
the capacity to ingest and destroy pathogenic agents using enzymes and toxic 
mediators such as lysozyme, superoxide radicals and nitric oxide (Vazquez-Torres et 
al., 2000), and can secrete pro-inflammatory mediators that promote recruitment of 
neutrophils from the circulation (fig. 1.1) (Schroder et al., 1987, Koch et al., 1991). 
 
Macrophages show considerable heterogeneity in terms of morphology and function 
that may depend on the local microenvironment they are exposed to during 
differentiation from monocytes (Dougherty and McBride, 1984, Kreutz et al., 1992, 
Laskin et al., 2001, Gordon and Taylor, 2005). In vitro studies by Akagawa and 
colleagues showed that human monocytes cultured in human serum, or in the 
presence of macrophage colony-stimulating factor (M-CSF) added to foetal bovine 
serum (FBS), differentiated into two distinct monocyte-derived macrophage 
(MDM) populations that differed in morphology and protein expression (Akagawa 
et al., 1988). Additionally, human monocytes differentiated in vitro in human serum 
are a highly heterogeneous population of MDM in terms of phagocytic potential 
(Giles et al., 2001). Indeed, serum is a complex source of cytokines and growth 
factors that may “program” macrophage function during differentiation. IFN and 
TNF are pro-inflammatory mediators associated with “classical” activation of 
macrophages (M-1 phenotype), induction of pro-inflammatory responses and 
propagation of a TH1-like response (North, 1978, Goerdt et al., 1999, Mills et al., 
2000). In contrast, cytokines such as IL-4, IL-10 and IL-13 and glucocorticoids 
“alternatively” activate macrophages (M-2 phenotype), characterised by 
downregulation of pro-inflammatory cytokine responses, development of TH2-like 
responses, increased debris scavenging activity and wound healing (Becker and 
 4
Daniel, 1990, Stein et al., 1992, Bogdan and Nathan, 1993). In vitro programming 
may be dependent on the first stimuli encountered (Erwig et al., 1998), and 
monocytes infiltrating into the inflamed site at different periods of the inflammatory 
response may acquire specialised phenotypic characteristics important for performing 
diverse functions. However, more recent evidence suggests that macrophages may 
have the capacity to continuously adapt their functional phenotype in response to the 
changing environment of a progressive inflammatory response (Stout and Suttles, 
2004). 
 
Successful restoration of a tissue to its original state after an inflammatory insult 
requires that the processes involved in the initiation and progression of inflammation 
must be reversed. Pro-inflammatory cytokine expression is switched off, recruitment 
of inflammatory cells is ceased, and large numbers of extravasated neutrophils are 
cleared from the inflamed site. The physiological mechanisms for removal must be 
efficient and non-inflammatory to ensure that effete neutrophils do not cause host 
tissue damage through the inappropriate release of intracellular contents (Haslett et 
al., 1994, Klebanoff, 2005). During this resolution phase of inflammation, recruited 
neutrophils undergo apoptosis and are subsequently removed by phagocytosis (fig. 
1.2) (Savill et al., 1989b, Cox et al., 1995). Phagocytic clearance is a rapid and 
efficient process involving a complex system of phagocyte receptors, soluble 
bridging molecules and apoptotic cell ligands that importantly does not stimulate 


























Figure 1.2: Fate of dying neutrophils. 
The physiological mechanisms for removal of neutrophils from tissues must be 
efficient and non-inflammatory to ensure that effete neutrophils do not cause tissue 
damage through the inappropriate release of intracellular contents. Neutrophils 
undergo apoptosis followed by recognition and phagocytosis of intact apoptotic 
neutrophils by macrophages, a process that is associated with the release of anti-
inflammatory mediators such as TGF, PGE2, PAF by macrophages and the 
resolution of inflammation. In contrast, necrotic cell death results in loss of 
membrane integrity and subsequent release of a vast array of histotoxic granular 
contents that cause tissue injury and induce further recruitment of inflammatory 
cells. Inefficient or defective clearance of apoptotic cells results in secondary 

















TGF, PGE2, PAF 
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1.2 Resolution of inflammation 
 
1.2.1 Neutrophil apoptosis 
Apoptosis is a programmed form of cell death (Kerr et al., 1972) that regulates the 
number and fate of neutrophils both in vitro and in vivo (fig. 1.2) (Savill et al., 
1989b). There has been extensive research into the molecular mechanisms relating to 
the regulation of neutrophil apoptosis in vitro. During apoptosis, neutrophils activate 
an intrinsic suicide program that results in a well-choreographed sequence of events 
such as chromatin condensation (often with margination to the nuclear envelope), 
increased cytoplasmic density, cell shrinkage, DNA fragmentation and cytoplasmic 
vacuolation, with little evidence of apoptotic body formation or surface blebbing that 
has been reported for other cells (Savill et al., 1989b, Payne et al., 1994). Most 
importantly, the plasma membrane and cytoplasmic granules remained structurally 
intact in apoptotic neutrophils (Savill et al., 1989b). The morphological changes 
observed in neutrophils undergoing constitutive apoptosis are concomitant with 
activation of caspases (Fadeel et al., 1998), cysteine proteases which play a central 
role in the execution of the apoptotic process by cleaving their target proteins at 
specific aspartic acid residues (Earnshaw et al., 1999), and are accompanied by 
downregulation of cellular functions. Neutrophils that have entered the apoptotic 
process lose the ability of chemokinesis, chemotaxis, phagocytosis, and the 
potentially injurious responses of oxidative burst and degranulation in response to 
receptor-mediated stimuli (Whyte et al., 1993). Functional attenuation is also 
achieved by surface changes during the apoptotic process, including down-regulation 
of FcγRIII (CD16) and L-selectin expression, and uncoupling of β2 integrins, key 
receptors that mediate neutrophil phagocytosis and adhesion events (Dransfield et al., 
1994, Dransfield et al., 1995). Thus, apoptosis is an important physiological 
clearance mechanism that acts to limit tissue damage by isolating effete neutrophils 
from exogenous stimuli and may be a prerequisite for resolution of acute 
inflammatory processes.  
 
During inflammatory states, for example microbial infection, neutrophils are exposed 
to multiple cytokines, chemokines and microbe-derived molecules which have 
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dramatic effects on neutrophil function and survival. Neutrophils have a relatively 
short half-life in the circulation in vivo, but can survive in inflamed tissues for 1 to 2 
days (Homburg and Roos, 1996) due to the presence of mediators such as IL-1, 
TNF, IFN, G-CSF, GM-CSF, C5a or bacterial-derived LPS that delay the 
constitutive apoptotic pathway (Colotta et al., 1992, Lee et al., 1993, Cox, 1995, 
Murray et al., 1997). Delay of apoptosis in neutrophils coincides with preservation of 
function, indicating that retardation of apoptosis at inflamed sites maintains 
neutrophil functional longevity to deal with microbial infection (Lee et al., 1993, Cox 
and Austin, 1997). Treatment with translational inhibitors (e.g. cycloheximide) or 
transcriptional inhibitors (e.g. actinomycin D) accelerated the constitutive rate of 
apoptosis, suggesting that delayed apoptosis requires the continual production of a 
survival protein (Whyte et al., 1997). Indeed, NFκB-dependent gene expression has a 
central role in the regulation of granulocyte survival (Ward et al., 1999a). 
Neutrophils also express pro- (Bax, Bid, Bak and Bad) and anti-apoptotic (Mcl-1, A1 
and Bcl-xL) Bcl-2 family members that critically regulate the rate at which 
neutrophils undergo apoptosis in response to exogenous signals (Moulding et al., 
1998, Chuang et al., 1998, Dibbert et al., 1999, Akgul et al., 2001). 
 
1.2.2 Phagocytosis 
Physiological clearance of apoptotic cells is believed to play a critical role during 
many biological processes including development, tissue remodelling, and normal 
tissue turnover (Han, 1993, Hopkinson-Woolley et al., 1994). Resolution of 
inflammation also requires that cells dying by apoptosis be disposed of (fig. 1.2). 
Senescent cells are removed by phagocytosis, a process first described in the late 
19th century by Elie Metchnikoff who used a light microscope to observe that 
neutrophils were “englobed” by macrophages in injured tadpole fins. Studies of the 
interaction between human MDM and neutrophils in vitro have shown that while 
freshly isolated neutrophils are not phagocytosed by MDM, time-dependent 
apoptosis in the aging neutrophil population leads to recognition and ingestion of 
neutrophils by MDM in vitro and in vivo at a stage when their cell membrane 
appears structurally and functionally intact (Newman et al., 1982, Savill et al., 
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1989b). Although “semi-professional” phagocytes, including fibroblasts, hepatocytes 
and endothelial cells have the capacity for recognition and removal of apoptotic cells 
and may play a contributory role to the regulation of apoptotic cell load within 
tissues (Hall et al., 1994, Dini et al., 1995), macrophages are the “professional” 
phagocyte that are required for rapid and efficient removal of potentially histotoxic 
apoptotic neutrophils during the resolution of inflammation (Savill, 1997). The 
remarkable efficiency by which macrophages ingest apoptotic neutrophils in vivo is 
observed in pneumococcal pneumonia where, despite an immense infiltration of 
inflammatory neutrophils into the lung, the inflammatory response resolves with 
neutrophil apoptosis and subsequent clearance by macrophages, and the normal lung 
architecture is preserved (Haslett et al., 1994). 
 
Phagocytosis is not only an important mechanism for disposing of potentially 
injurious neutrophils, but also has profound effects on phagocyte function. 
Phagocytosis of human apoptotic neutrophils fails to induce the release of pro-
inflammatory mediators such as eicosanoids or GM-CSF, IL-8, and MCP-1 
chemoattractants from the phagocytic cell (Meagher et al., 1992, Hughes et al., 1997, 
Fadok et al., 1998). Additionally, ingestion of apoptotic cells induces 
immunosuppressive and anti-inflammatory effects in monocytes/macrophages by 
decreasing secretion of TNF, IL-1 and IL-12 and increasing the release of IL-10, 
TGFβ, PGE2 and platelet-activating factor, mediators that dampen inflammatory 
responses (Voll et al., 1997, Fadok et al., 1998, McDonald et al., 1999). Thus, rapid 
recognition, ingestion and degradation of apoptotic neutrophils by macrophages in a 
non-phlogistic manner is consistent with a ‘safe’ pathway for disposal of potentially 
harmful inflammatory cells that is obligatory for the resolution of inflammation. 
 
 
1.3 Macrophage phagocytosis of apoptotic cells 
 
1.3.1 Apoptotic cell ligands 
In addition to the morphological changes observed in neutrophils undergoing 
apoptosis, there are also molecular consequences to the apoptotic process. Human 
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apoptotic neutrophils display specific surface alterations that serve to identify them 
as targets for phagocytic removal (table 1) (Savill et al., 1989b, Hart et al., 2000, 
Dransfield et al., 1994). These surface changes occur early on during apoptosis to 
ensure removal of neutrophils at a stage when they are still intact, and may result 
from either decreased expression of certain receptors or else the appearance of new 
surface molecules. Non-apoptotic neutrophils display surface ligands like platelet-
endothelial cell adhesion molecule-1 (PECAM-1) or CD31 that protect them from 
ingestion by MDM (Brown et al., 2002). This function is disabled during apoptosis 
allowing MDM to bind and ingest apoptotic neutrophils. Neutrophils also express 
CD47, the ligand for macrophage signal regulatory protein (SIRP) (Vernon-Wilson 
et al., 2000). Antibody blockade of the CD47-SIRP interaction was found to 
promote engulfment of viable neutrophils (Gardai et al., 2005), indicating that CD47 
that may function as a “don’t eat me” signal on viable neutrophils. Additional 
modifications include changes in neutrophil surface charge and the pattern of 
glycosylation of cell surface proteins (Savill et al., 1989a).  
 
The most characterised surface change associated with apoptosis is exposure of 
phosphatidylserine (PS) (Martin et al., 1995). In viable cells, PS is normally retained 
in the inner leaflet of the plasma membrane through the action of aminophospholipid 
translocase, and inactivation of phospholipid asymmetry during neutrophil apoptosis, 
possibly as a consequence of loss of phospholipid translocase activity or activation of 
phospholipid scramblases or flippases, leads to the appearance of PS on the outer 
leaflet (Homburg et al., 1995, Vermes et al., 1995, Bevers et al., 1999, Daleke and 
Lyles, 2000, Sims and Wiedmer, 2001). PS surface exposure is an early feature of 
apoptosis, occurring at a stage when the cell membrane is still intact (Chan et al., 
1998). The ability of PS-containing vesicles to partially block apoptotic cell 
phagocytosis suggests that PS may be an important signal for apoptotic cell ingestion 
(Fadok et al., 1992b, Savill, 1997). Another molecule exposed on the cell surface 
during apoptosis is annexin-1. Interestingly, annexin-1 is thought to co-localise with 
PS on the surface of apoptotic cells and facilitate apoptotic cell recognition, with 
siRNA-mediated silencing of annexin-1 gene expression associated with defective 
phagocytosis of apoptotic cells (Arur et al., 2003).  
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In contrast to in vitro assay conditions, apoptotic cells and phagocytes may not be 
located in close proximity in vivo, and additional mechanisms may be required to 
signal the presence of apoptotic cells to phagocytes before they can undergo lysis. 
Lauber et al identified lysophosphatidylcholine, generated by the actions of a 
calcium-independent phospholipase A2 (iPLA2) during apoptosis, as a factor 
released by apoptotic cells that had chemotactic effects on phagocytes (Lauber et al., 
2003), raising the possibility that apoptotic cells can produce soluble signals to 
actively recruit phagocytes in vivo. A recent study by Peter et al has identified the G-
protein-coupled receptor G2A as a putative receptor that may mediate 
lysophosphatidylcholine-dependent macrophage recruitment (Peter et al., 2008). 
 
1.3.2 Opsonins 
An important aspect of the immune response is the recognition of pathogen-
associated molecular patterns on microbes by soluble host factors such as 
complement proteins, immunoglobulins, and acute phase proteins which target 
microbes for removal by phagocytes (Savill et al., 2002). This process of 
opsonisation also plays a critical role in apoptotic cell clearance, where soluble 
components bind directly to the altered apoptotic cell surface, for example via PS, 
and facilitate clearance through opsonin-mediated phagocytosis (table 2). 
Interestingly, many of the pattern recognition molecules important for microbial 
recognition can also modulate apoptotic cell clearance, including complement 
factors, collectins such as mannan-binding lectin (MBL) and surfactant protein A 
(SP-A) and SP-D, and pentraxins such as serum amyloid P (SAP), C-reactive protein 
(CRP) and pentraxin-3 (Mevorach et al., 1998a, Bickerstaff et al., 1999, Gershov et 
al., 2000, Rovere et al., 2000, Ogden et al., 2001, Gaipl et al., 2001, Schagat et al., 
2001, Mold et al., 2002, Nauta et al., 2003b). Additional factors that may be 
important in apoptotic cell recognition include TSP-1, 2-GPI, MFG-E8, properdin, 
galectin-3, protein S and Gas6 (Savill et al., 1992, Balasubramanian et al., 1997, 
Scott et al., 2001, Hanayama et al., 2002, Anderson et al., 2003, Kemper et al., 2008, 
Karlsson et al., 2009). These components may be constitutively present in serum 
(e.g. protein S) or generated from inactive precursors (e.g. complement). In some 
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cases, the source of the opsonins may be the phagocyte itself (Hanayama et al., 2002, 
Faust et al., 2002, Maderna et al., 2005).  
 
Experimental evidence in support of the role of several of these molecules in 
apoptotic cell clearance in vivo is provided by studies of knockout mice (Vandivier et 
al., 2002, Sano et al., 2003, Stuart et al., 2005). However, only C1q-deficiency has 
been reported to have significant in vivo consequences both in mice and humans, 
where impaired clearance of apoptotic cells is thought to contribute to the 
development of a lupus-like autoimmune disease characterised by high titres of 
autoantibodies against nuclear antigens and glomerulonephritis (Botto, 1998, Taylor 
et al., 2000). It is possible that no single opsonin dominates in apoptotic cell 
clearance in vivo, or different opsonins may be important for different locations 
(Schagat et al., 2001). Moreover, several reports have suggested apoptotic cell 
opsonisation to be a relatively late event, occurring at a stage when the cell 
membrane is no longer intact (Nauta et al., 2003c, Hart et al., 2005). The pattern of 
opsonisation may therefore have significant consequences in terms of the phagocyte 
response to ingestion of apoptotic cells, both with respect to the phagocyte 
population engaged by opsonised apoptotic cells and the inflammatory outcome of 




Apoptosis-associated changes Macrophage receptor Reference 
Lose “don’t eat me” signals: 
          CD31 





(Brown et al., 2002) 
(Gardai et al., 2005) 
Gain “eat me” signals: 
          Phosphatidylserine 
           






(Miyanishi et al., 2007) 
(Park et al., 2008) 
(Arur et al., 2003) 
Secrete “find me” signals: 




(Peter et al., 2008) 
 
Table 1: Changes associates with apoptosis 




Apoptotic cell opsonin Macrophage receptor Reference 
Complement: 
          C3b 
          C1q 
          Properdin  (via C3b opsonisation) 
          CRP (via C3b opsonisation) 
CR3 and CR4 
Calreticulin/CD91 
CR3 and CR4 
CR3 and CR4 
 
(Mevorach et al., 1998a) 
(Ogden et al., 2001) 
(Kemper et al., 2008) 
(Gershov et al., 2000) 
Collectins: 
          MBL 





(Ogden et al., 2001) 
(Vandivier et al., 2002) 
Pentraxins: 













(Savill et al., 1992) 
(Hanayama et al., 2002) 
(Uehara and Shacter, 2008) 
(Scott et al., 2001) 
 
Table 2: Opsonins and receptors associated with apoptotic cell clearance.  
Abbreviations: CRP, C-reactive protein; MBL, mannose-binding lectin; SP-A, 
surfactant protein A; SAP, serum amyloid protein; TSP-1, thrombospondin-1; MFG-
E8, milk fat globule EGF factor 8; Gas6, growth arrest-specific gene 6; CR3, 
complement receptor 3. 
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1.3.3 Receptors for apoptotic cell recognition  
Phagocytes display an impressive array of receptors that bestow the capacity for 
recognition of a diverse particle range. Many of these receptors have been 
acknowledged in the direct recognition and engulfment of apoptotic cells by 
phagocytes (table 1), including lectins, scavenger receptors, CD31, CD14 and the 
putative PS receptors TIM4 and stabilin-2 (Platt et al., 1996, Devitt et al., 1998, 
Vernon-Wilson et al., 2006, Michlewska et al., 2007, Miyanishi et al., 2007, Park et 
al., 2008). Other phagocyte receptors can indirectly recognise apoptotic cells that 
have been opsonised with soluble factors, such as complement receptors, integrins 
and the tyrosine kinase receptor, Mertk (table 2) (Savill et al., 1992, Mevorach et al., 
1998a, Finnemann and Rodriguez-Boulan, 1999, Ogden et al., 2001, Scott et al., 
2001).  
 
With the exception of Mertk (Scott et al., 2001), blocking individual receptors on 
phagocytes only partially inhibits phagocytosis of apoptotic cells, suggesting that 
recognition pathways may operate in parallel to ensure efficient apoptotic cell 
clearance. CD36, a class B scavenger receptor with a very short C-terminal 
cytoplasmic domain, has been proposed to cooperate with the vitronectin receptor 
(v3) for internalisation of TSP-1-opsonised apoptotic neutrophils by MDM 
(Savill et al., 1992), and C1q-dependent ingestion of apoptotic cells is thought to 
require stimulation of calreticulin and CD91 (Ogden et al., 2001, Vandivier et al., 
2002). This cross talk between two distinct phagocyte receptors illustrates the 
extraordinary complexity underlying apoptotic cell phagocytosis. Furthermore, v3 
integrin-dependent phagocytosis can also be stimulated by MFG-E8 on the surface of 
apoptotic cells (Hanayama et al., 2002), adding another layer of complexity through 
promiscuity of phagocyte receptors for opsonins and may allow phagocytes to adapt 
to environmental signals. The contributions of receptors to apoptotic cell clearance 
likely depends upon the phagocytic and apoptotic target cell types (Fadok et al., 
1992a), with the cytokine milieu and presence of activatory signals, for example 
bacterial LPS, also having an influence over the activation state of the phagocyte, 
surface receptor expression and the availability of opsonins. 
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1.4 Disease: Failure of Natural Resolution Process? 
 
Although the mechanisms responsible for tipping the balance towards persistent 
inflammation are likely multifactoral, failure or inefficient resolution processes may 
represent a common factor contributing to the pathogenesis of many diverse 
inflammatory diseases (Haslett et al., 1994). Neutrophils have been implicated in the 
pathogenesis of a variety of inflammatory disorders, such as chronic obstructive 
pulmonary disease (COPD), systemic lupus erythematosus (SLE) and rheumatoid 
arthritis (Stockley, 1999, Wipke and Allen, 2001, Ren et al., 2003). The persistent 
recruitment and/or survival of activated neutrophils may result from dysregulated 
expression of pro-inflammatory genes, such as cytokines (IL-1, TNFα, GM-CSF, 
etc.), chemokines (IL-8, IL-5, MIP-1α), and adhesion molecules (ICAM-1 and E-
selectin) (Ottonello et al., 2002, Cosio et al., 2005), contributing to neutrophil 
accumulation in chronically inflamed tissues. In situations where cells are stimulated 
to undergo apoptosis at a high rate, as demonstrated in vivo by anti-Fas treatment of 
mice (Ogasawara et al., 1993), the tissue load of apoptotic cells may be in danger of 
exceeding the removal capacity by phagocytes and failure to remove intact apoptotic 
cells efficiently before lysis may have pathological consequences. In contrast to 
apoptosis, neutrophil necrosis is characterised by loss of membrane integrity and 
release of toxic granular contents that have the capacity to damage the surrounding 
tissue and stimulate pro-inflammatory macrophage responses (Searle et al., 1982, 
Taylor et al., 2007). Secondary necrosis of neutrophils has been observed in vivo 
during intense neutrophil-rich inflammation (Rydell-Tormanen et al., 2006). Release 
of cellular contents with immunogenic potential, such as chromatin and DNA, may 
contribute to the induction of autoimmune reactions (Mevorach et al., 1998b). 
Indeed, mice with defects in apoptotic cell removal develop many of the 
characteristics associated with autoimmune disease (Botto, 1998, Scott et al., 2001), 
and impaired phagocytosis of apoptotic cell material has been implicated in the 
severity of disease observed in cystic fibrosis airways and human SLE (Herrmann et 
al., 1998, Vandivier et al., 2002, Gaipl et al., 2006, Tas et al., 2006). 
Pharmacological manipulation of the processes involved in physiological clearance 
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of neutrophils from inflamed sites may therefore represent a therapeutic approach to 
treatment of inflammatory diseases where ineffective clearance has been implicated. 
 
 
1.5 Regulation of macrophage phagocytosis of apoptotic cells 
 
1.5.1 Inflammatory mediators (lipoxins, cytokines, LPS) 
The presence of endogenously produced mediators or bacterial products at inflamed 
sites can affect the ability of phagocytes to ingest apoptotic cells. Lipoxins (LXs), a 
family of mediators generated from transcellular metabolism of arachidonic acid, are 
actively synthesised during the resolution phase of inflammation (Serhan and Savill, 
2005, Serhan et al., 2007). LXA4 exerts anti-inflammatory effects by inhibiting 
further extravasation of neutrophils into inflamed sites and stimulating recruitment of 
mononuclear cells (Maddox and Serhan, 1996, Hachicha et al., 1999). Furthermore, 
LXA4 exhibits pro-resolving properties by stimulating non-phlogistic macrophage 
phagocytosis of apoptotic neutrophils both in vitro (Godson et al., 2000, Reville et 
al., 2006) and in vivo (Mitchell et al., 2002). Various inflammatory cytokines (GM-
CSF, IL-, IFN, TNF and by TGF-1) have been suggested to potentiate apoptotic 
neutrophil clearance in vitro. Short-term incubation (4 hours) of human MDMD 
with any of these mediators increased both the proportion of MDM capable of 
recognising apoptotic neutrophils, and the phagocytic capacity of individual MDM, 
yet the potentiating effect was small (Ren and Savill, 1995). More recent studies 
have reported that LPS-induced TNF production may exert inhibitory effects, while 
IL-10 promoted MDM phagocytosis of apoptotic neutrophils (Michlewska et al., 
2009). Thus, the in vivo efficacy of apoptotic neutrophil clearance by macrophages is 
complex and may involve a dynamic interplay between pro- and anti-inflammatory 
mediators. 
 
1.5.2 Adhesion signalling (CD44, cAMP) 
The adhesive status of the macrophage also regulates the capacity for apoptotic cell 
clearance. CD44 is a cell-surface glycoprotein that acts as a receptor for a variety of 
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extracellular matrix molecules including hyaluronate, fibronectin, and collagen 
(Aruffo et al., 1990, Culty et al., 1990, Jalkanen and Jalkanen, 1992, Lesley et al., 
1997). Many diverse functions have been attributed to CD44, including cellular 
adhesion and migration, and activation and proliferation of lymphocytes (Lesley et 
al., 1993). Cross-linking of human MDM surface CD44 with a bivalent CD44 
monoclonal antibody (mAb) rapidly and specifically augmented uptake of apoptotic 
neutrophils, but not apoptotic lymphocytes (Hart et al., 1997). Additionally, adhesion 
to fibronectin rapidly increased MDM capacity for internalisation of apoptotic 
neutrophils (McCutcheon et al., 1998). The critical role of CD44 in the resolution 
phase of inflammation is evident in CD44-deficient mice (Teder et al., 2002). 
Following non-infectious lung injury induced by treatment with bleomycin, these 
mice succumb to an unremitting inflammation characterised by impaired clearance of 
apoptotic neutrophils from the lung.  
 
Elevation of intracellular cyclic adenosine monophosphate (cAMP) in MDM 
rapidly and specifically inhibited phagocytosis of apoptotic neutrophils (Rossi et al., 
1998). Elevation of intracellular cAMP within macrophages results in changes in the 
localisation of actin and talin cytoskeletal proteins, suggesting that altered adhesion 
can regulate macrophage phagocytic capacity.  
 
 
1.6 Inflammatory regulation by glucocorticoids 
 
1.6.1 Endogenous and synthetic glucocorticoids 
Endogenous glucocorticoids like cortisol and corticosterone  are produced by 
activation of the hypothalamic-pituitary-adrenal axis in response to a variety of 
stressors (starvation, pain, trauma, infection) and are essential for regulating 
homeostatic mechanisms associated with metabolic control and inflammation 
(Munck et al., 1984, Stephanou et al., 1992, Harbuz et al., 1992). Since the seminal 
work of Hench and his co-workers 50 years ago, where small doses of cortisone were 
found to dramatically improve the symptoms of patients with rheumatoid arthritis 
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(Hench et al., 1949), powerful synthetic glucocorticoids were developed (Munck et 
al., 1984), which, despite their unwelcome side effects, remain the mainstay of anti-
inflammatory and immunosuppressive therapy. Glucocorticoids are beneficial in the 
treatment of diverse inflammatory diseases such as rheumatoid arthritis, 
inflammatory bowel disease, and asthma through their pleiotropic actions on multiple 
inflammatory cells and signalling pathways, both during the early and late 
manifestations of acute inflammation and the subsequent repair phase (Barnes, 1998, 
Goulding et al., 1998). Recent advances in understanding how these drugs exert their 
effects at the cellular and molecular level (Barnes and Adcock, 2003, Rhen and 
Cidlowski, 2005) has provided a valuable insight into how glucocorticoids operate as 
anti-inflammatory agents. 
 
1.6.2 Glucocorticoid receptor 
Glucocorticoids exert most of their effects by binding to intracellular glucocorticoid 
receptors (GR), expressed in many immune cells including monocytes/macrophages, 
granulocytes, and all lymphocyte subpopulations (Goulding, 2004). Alternative 
splicing of the gr gene can generate isoforms of GR with distinct functions. GR is 
the prevalent isoform and mediates glucocorticoid binding, whereas GRβ is a C-
terminally truncated variant that lacks glucocorticoid-binding ability and instead 
heterodimerises with GR to regulate its effect on transcription (Bamberger et al., 
1995, Oakley et al., 1999). The GR consists of a C-terminal ligand-binding domain, a 
central DNA binding region composed of two zinc finger motifs, plus an N-terminal 
domain that facilitates trascriptional activity and interation with other transcription 
factors (Buckingham, 2006). Inactive GR resides in the cytoplasm bound in a multi-
protein complex with chaperone molecules including immunophilin and heat shock 
proteins (HSP90) (Pratt and Toft, 1997). Interaction with HSP90 is essential for 
maintaining the correct configuration of GR and also masks a nuclear localisation 
signal to prevent nuclear translocation of the unoccupied GR (Barnes, 2006). Upon 
binding of glucocorticoid to the GR, the chaperone proteins dissociate from the GR 
to allow translocation of the ligand-activated complex to the nucleus, where it can 
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regulate the transcription of multiple target genes at transcriptional and post-
transcriptional levels (Barnes, 2006). 
 
 
1.6.3 Immunosuppressive effects  
Expression of many inflammatory genes, including cytokines, chemokines, 
inflammatory enzymes and receptors, is achieved via activation of transcription 
factors such as nuclear factor-B (NFB) and activator protein-1 (AP-1). These pro-
inflammatory transcription factors are activated during inflammatory disease and 
play a critical role in amplifying the inflammatory process (Rahman and MacNee, 
1998, Di Stefano et al., 2002, Muller-Ladner et al., 2002). Inflammatory gene 
expression requires NFκB- and AP-1-mediated recruitment and activation of 
coactivator proteins, such as cAMP response element binding (CREB) binding 
protein (CBP) and p300/CBP-associated factor, which have intrinsic histone 
acetyltransferase (HAT) activity to initiate histone acetylation and remodelling of 
chromatin required for gene transcription (fig. 1.3) (Urnov and Wolffe, 2001, Adcock 
et al., 2004). Repression of genes requires reversal of histone acetylation, controlled 
by corepressor proteins such as histone deacetylases (HDACs) and nuclear receptor 
corepressor (NcoR) (Barnes, 1998).  
 
A major effect of glucocorticoids is to switch off the multiple inflammatory genes 
that have been activated during chronic inflammation by inhibiting the 
transcriptional effects of NFB and AP-1, a process known as transrepression (table 
3) (Barnes and Karin, 1997, Barnes, 1998). Transrepression is thought to occur 
through protein-protein interactions of the GR with the activated transcription 
factors, either directly (De Bosscher et al., 2000, Karin and Chang, 2001) or through 
recruitment of corepressors such as HDACs (Ito et al., 2000), resulting in reversal of 
histone acetylation and gene “silencing” (fig. 1.3). For example, glucocorticoids have 














Figure 1.3: Effect of the GR on chromatin remodelling, HATs and HDACs 
Gene expression and repression are regulated by modification of core histones. 
In the resting state, DNA is tightly coiled around histones and is inaccessible to 
transcriptional cofactors and RNA polymerase II. Upon binding to DNA, NFB 
and AP-1 recruit and activate coactivator proteins such as CBP and p300/CBP-
associated factor, which have intrinsic HAT activity. Histone acetylation results 
in slackening of chromatin and unwinding of DNA, allowing the transcriptional 
machinery to gain access to genes and initiate transcription. Deacetylation is 
controlled by corepressor proteins such as HDACs and NcoR and is associated 
with gene repression. Activated GRs may interact with HATs and HDACs to 
regulate their function. Suggested mechanisms of GR transrepression include; 
(1) GR competes with NFB and AP-1 for binding to coactivators, (2) Direct 
suppression of HAT activity of coactivators by GR, (3) recruitment of 
corepressors by GR to reverse histone acetylation (McColl et al., 2007). 
Abbreviations: GR, glucocorticoid receptor; AP-1, activator protein-1; NFB, 
nuclear factor B; HAT, histone acetyltransferase; CBP, cAMP response element 





HATs: CBP, p300 
COREPRESSORS 

















Table 3: Mechanism of glucocorticoid action and genes regulated.  
Abbreviations: SLPI, secretory leukocyte proteinase inhibitor; MKP-1, MAPK 




Mechanism of glucocorticoid action Genes affected 
Transactivation: 
Induction of anti-inflammatory gene expression 
SLPI 







Suppression of pro-inflammatory gene expression 
Cytokines (IL-1, TNF, GM-CSF) 
Chemokines (IL-8, MIP-1) 
Adhesion molecules (ICAM-1, E-selectin) 
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histone acetylation (Ito et al., 2000). Reichardt and colleagues developed a GRdim 
mouse, where a point mutation A458T introduced into the D-loop of the central 
domain produced a GR that was DNA binding-, dimerisation- and transactivation-
deficient (Reichardt et al., 1998, Tuckermann et al., 1999, Reichardt et al., 2001). 
Transrepression of NFκB- and AP-1–mediated gene expression remained intact, 
suggesting that this process is mediated by monomeric GR. Although it fails to bind 
palindromic sequences in glucocorticoid-responsive genes, a caveat with the GRdim 
mutant is the ability to bind an alternative class of glucocorticoid response elements 
to modulate gene expression (Adams et al., 2003). This must be taken into 
consideration in studies attempting to dissect out the transactivation action of 
glucocorticoids based on GR functioning as a homodimer, an approach that may be 
an oversimplification of the underlying mechanisms of GR action.  
 
 
1.6.4 Anti-inflammatory effects  
Glucocorticoids can regulate inflammatory responses by increasing the expression of 
molecules with anti-inflammatory functions, a process known as transactivation (fig. 
1.3 and table 3). Ligand-activated GRs bind to palindromic glucocorticoid-
responsive elements (GREs) found in the promoter region of glucocorticoid-
responsive genes (Chandler et al., 1983, Drouin et al., 1992) and recruit 
transcriptional coactivator proteins to initiate transcription (Barnes, 1998). The 
central domain of the GR contains two zinc fingers essential for GR dimerisation and 
binding to GRE sequences (Dahlman-Wright et al., 1991, Drouin et al., 1992), with a 
point mutation in the D-loop of the central domain abolishing transactivation 
(Reichardt et al., 1998). Thus, transcription of glucocorticoid-responsive genes 
requires homodimeric GR. This mechanism requires long-term exposure to 
glucocorticoids, and directly modulates the expression of anti-inflammatory 
molecules like C1q, annexin-1, secretory leukocyte proteinase inhibitor (SLPI), IL-1 
receptor antagonist, and IL-10 (Abbinante-Nissen et al., 1995, Hodge et al., 1999, de 
Coupade et al., 2001, Pousset et al., 2001, Faust et al., 2002). 
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Glucocorticoids also enhance the expression of proteins that may be vital for 
switching off signalling pathways engaged during persistant inflammation, including 
mitogen-activated protein kinase (MAPK) phosphatase 1 (MKP-1), IκB and 
glucocorticoid-inducible leucine zipper (GILZ). MKP-1 expression is induced by 
glucocorticoids in a wide variety of cell types including mast cells, monocytes and 
macrophages (Kassel et al., 2001, Abraham and Clark, 2006, Bhattacharyya et al., 
2007). Glucocorticoid-induced expression of MKP-1 in macrophages results in 
dephosphorylation and inactivation of p38 MAPK to inhibit expression of Cox-2, 
IFN, TNF and IL-1 (Abraham and Clark, 2006) and destabilise mRNA for Cox-2 
(Lasa et al., 2002). This may be an important anti-inflammatory mechanism as it 
allows glucocorticoids to post-transcriptionally restrict the ongoing production of 
inflammatory proteins. Glucocorticoids also enhance the expression of IB, an 
inhibitor of NFB that prevents NFB translocation to the nucleus (Auphan et al., 
1995, Scheinman et al., 1995), and GILZ, which interacts with both NFB and AP-1 
to repress their transactivation function (Riccardi et al., 1999, Mittelstadt and 
Ashwell, 2001, Berrebi et al., 2003). Thus, glucocorticoids induce the expression of 
protective proteins that boost innate immune defence, and pro-resolving proteins that 
suppress pro-inflammatory signalling. 
 
Glucocorticoids can exert anti-inflammatory effects both at transcriptional and post-
transcriptional levels via transrepression and transcriptional activation, with 
inhibition of NFB representing a common mechanism. However, it is likely that 
these mechanisms of action are not mutually exclusive and optimal glucocorticoid 
action probably requires a combination of both, the extent of which may depend on 
many factors such as cell type, target of suppression or modulation, and requirement 
for long or short exposure to glucocorticoid.  
 
1.6.5 Regulation of inflammatory cell survival 
Glucocorticoids can regulate the processes involved in the normal resolution of an 
inflammatory response. For example, the synthetic glucocorticoids dexamethasone 
(Dex), methylprednisolone, and hydrocortisone all prolonged neutrophil viability 
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from 12 to 48 hours by delaying constitutive neutrophil apoptosis in vitro (Liles et 
al., 1995, Meagher et al., 1996, Madsen-Bouterse et al., 2006). The inhibitory effect 
of glucocorticoids on neutrophil apoptosis was dose-dependent, with maximal effects 
found with Dex at 10-6M (Cox, 1995, Meagher et al., 1996). The non-glucocorticoid 
progesterone failed to inhibit the development of apoptosis, indicating that non-
specific effects of high dose glucocorticoids are not responsible. Glucocorticoid-
induced neutrophil survival was found to be GR-dependent and reversible by 
inhibitors of protein synthesis and blockade of NFB signalling (Meagher et al., 
1996), suggesting that survival requires continual synthesis of a pro-survival factor 
such as the anti-apoptotic protein, Mcl-1 (Cox and Austin, 1997, Saffar et al., 2008). 
Although neutrophil capacity for superoxide generation in response to stimulation 
with FMLP remains intact (Cox, 1995), glucocorticoids generally exert significant 
inhibitory effects on neutrophil activation and functions such as chemotaxis, 
adhesion, phagocytosis, and cytokine release (Cox, 1995, Goulding et al., 1998). 
Overall, the paradoxical effect of enhancing survival and subsequent accumulation of 
neutrophils with the potential for superoxide production into an already inflamed 
tissue may represent an effect that accentuates inflammation and contributes to the 
resistance of glucocorticoid action in COPD, a neutrophil-mediated disease 
(Zainudin, 1997).  
 
Direct pharmacological triggering of neutrophil apoptosis pathways may represent a 
novel therapeutic strategy in the treatment of inflammatory disorders (Serhan et al., 
2007, Rossi et al., 2007). To be successful, this approach may require additional 
tactics to ensure rapid and efficient removal of the apoptotic neutrophils before 
progression to secondary necrosis and release of cell contents. 
 
1.6.6 Regulation of macrophage phagocytosis for apoptotic cells 
Glucocorticoids can regulate MDM clearance of apoptotic neutrophils in vitro (Liu 
et al., 1999, Giles et al., 2001) and possibly in vivo (Gilmour et al., 2006). Freshly 
isolated human monocytes lack the capacity to ingest apoptotic neutrophils, but 
acquire phagocytic ability during in vitro culture as adherent monocytes differentiate 
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into MDM (Newman et al., 1982). Several drugs of the glucocorticoid family 
(methylprednisolone, hydrocortisone or Dex) were found to significantly enhance the 
phagocytic capacity of human MDM following in vitro culture for 5 days and 
greater potentiation was observed when monocytes were exposed to glucocorticoids 
earlier during maturation (Liu et al., 1999, Giles et al., 2001). In contrast to the 
specificity of CD44-enhanced human MDM phagocytosis for apoptotic neutrophils 
(Hart et al., 1997), glucocorticoids augment human MDM phagocytic capacity for 
alternative apoptotic targets, including Jurkat T cells and eosinophils, and also 
promote uptake of apoptotic neutrophils by alternative phagocytes, including human 
glomerular mesangial cells (Liu et al., 1999). Importantly, glucocorticoid-enhanced 
MDM phagocytosis of apoptotic neutrophils did not stimulate the release of pro-
inflammatory mediators, including MCP-1 and IL-8 chemokines (Liu et al., 1999). 
Therefore, glucocorticoids promote “safe” clearance of neutrophils dying by 
apoptosis and may directly contribute to the resolution of inflammation. 
 
 
1.7 Glucocorticoid resistance 
 
Although glucocorticoids are the most effective clinical treatment for various 
inflammatory disorders, a small proportion of patients with severe asthma do not 
respond well to glucocorticoid treatment, even when given high doses (Barnes and 
Adcock, 2003). Inhaled glucocorticoids also provide little therapeutic benefit for 
patients with COPD, with no reduction in inflammatory cells, cytokines or proteases 
in the inflamed lung (Keatings et al., 1997, Culpitt et al., 1999, Loppow et al., 2001). 
Several mechanisms have been postulated to contribute to glucocorticoid resistance. 
Increased expression of the GRβ isotype in response to pro-inflammatory cytokines 
may interfere with GRα function (Bamberger et al., 1995, Oakley et al., 1999, 
Webster et al., 2001). Interestingly, the level of GRβ may be increased in peripheral 
blood mononuclear cells from patients with glucocorticoid-resistant rheumatoid 
arthritis (Kozaci et al., 2007). The ineffectiveness of glucocorticoids in COPD has 
been linked to factors such as smoking and oxidative stress that may reduce HDAC2 
function, a corepressor protein important for glucocorticoid-mediated gene 
repression (Ito et al., 2001, Ito et al., 2006). 
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1.8 Glucocorticoids side effects 
 
There are potential limitations to the applications of glucocorticoids in disease, 
particularly the undesirable side effects associated with long-term treatment. The 
nature of glucocorticoid action is pleiotropic and relatively non-specific, and many 
tissue and organ systems are affected resulting in diabetes, hypertension, 
osteoporosis, behavioural changes, and sleep disorders (Rosen and Miner, 2005). 
Many of these effects represent “on target” actions mediated by physiological levels 
of endogenous glucocorticoid, but result in “undersirable” effects in the presence of 
high-dose synthetic glucocorticoids. An indication of this is the induction of 
gluconeogenesis, which under normal physiological conditions represents an 
important component of the body’s response to stress, but represents an underlying 
cause of glucocorticoid-induced diabetes. The central role of glucocorticoids in the 
regulation of glucose levels is evident in glucocorticoid-deficient patients with low 
glucose levels (Addison’s disease), and patients with glucocorticoid excess (Cushing 
syndrome) who exhibit glucose intolerance (Andrews and Walker, 1999).  
 
Despite these adverse effects, glucocorticoids remain one of the most used 
therapeutic approaches for the treatment of chronic inflammatory diseases. 
Elucidation of the precise molecular and cellular mechanisms of glucocorticoid 
action would potentially allow the development of more specific therapies with fewer 
adverse effects. Side effects have generally been linked to transactivation of gene 
expression by ligand-activated GR, with a suggested role for glucocorticoid-
inducible phosphoenol pyruvate carboxykinase (PEPCK) in regulating 
gluconeogenesis (Schacke et al., 2002). The finding that transactivation-deficient 
GRdim mutants retain many of their beneficial anti-inflammatory effects through 
transrepression of NFκB- and AP-1–mediated gene expression (Reichardt et al., 
1998, Tuckermann et al., 1999, Reichardt et al., 2001) raised the possibility that these 
transcriptional functions of the GR could be separated, and prompted a search for GR 
ligands that induce transrepression but not transactivation. These ‘dissociated’ 
steroids, including RU24858 and RU40066, have anti-inflammatory effects in vitro 
(Vayssiere et al., 1997) and in vivo (Schacke et al., 2004), however, RU24858 
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induced side effects including loss of body weight and bone mass (Belvisi et al., 
2001). More recently, Miner et al developed a series of GR ligands like LGD5552 
that retained strong anti-inflammatory transrepressional activity, but reduced ability 
to activate transcription at some genes due to diminished interaction with coactivator 
proteins and an enhanced interaction with corepressor proteins (Miner et al., 2007). 
Importantly, LGD5552 displayed reduced side effects when compared to 
glucocorticoids, including weight gain and decreased bone formation. Such 
compounds may represent an attractive therapeutic strategy for “safer” treatment of 
inflammatory diseases through this ability to convey the beneficial actions of 
glucocorticoids with reduced adverse effects (Catley, 2007). However, some side 
effects such as skin atrophy and suppression of the hypothalamic-pituitary-adrenal 
axis may be mediated by the transrepressive function of the GR or may even involve 
a combination of both GR mechanisms that would complicate the use of dissociated 
steroids in therapy (Schacke et al., 2002). Furthermore, unlike GR-mediated 
transactivation of other genes, induction of MKP-1 gene expression does not seem to 
require GR dimerisation and GRdim mutants retain the ability to express MKP-1 
(Abraham and Clark, 2006). Upregulation of MKP-1 by glucocorticoids has been 
suggested to contribute to metabolic dysregulation via impairment of insulin-induced 
glucose uptake by adipocytes (Bazuine et al., 2004). Therefore, dissociation of 
glucocorticoid-mediated side effects from anti-inflammatory actions based on GR 
functioning as a monomer or dimer may be an oversimplification of the underlying 
mechanisms. Additionally, many of the anti-inflammatory effects of glucocorticoids 
have yet to be fully characterised, and it remains possible that induction of gene 
expression by glucocorticoids plays a more significant role in the inhibition of 
inflammatory responses than originally assumed. It is imperative that the specific 
molecular mechanisms involved in glucocorticoid-mediated immune regulation are 









The primary aims of this study were to investigate the mechanisms required for high 
capacity phagocytosis of apoptotic neutrophils following long-term treatment of 
human peripheral blood monocyte-derived macrophages with the synthetic 
glucocorticoid, Dex. Before these studies were initiated, there was limited 
experimental evidence on the molecular mechanisms involved in glucocorticoid-
augmentation of macrophage phagocytosis. Although glucocorticoids have been 
shown to alter macrophage cytoskeletal organisation and adhesive ability, the 
phagocytic pathway employed by macrophages following exposure to 
glucocorticoids has remained uncharacterised. Considering the pivotal role of 
apoptotic neutrophil clearance in resolution processes, we hypothesised that 
glucocorticoids specifically induce a distinct mechanism for apoptotic cell clearance. 
Specifically, we wanted to investigate the following two key issues:  
 
1. The effect of glucocorticoids on the phagocytic potential of human macrophages 
using confocal and time-lapse microscopy, and, primarily, flow cytometry. In 
particular, we wished to identify the subpopulation of apoptotic neutrophils that 
are targeted for clearance.  
 
2. To characterise the molecular basis for apoptotic cell phagocytosis by 
glucocorticoid-treated macrophages by;  
 
Performing inhibitor studies of phagocytosis using receptor antagonists and 
“blocking” antibodies 
Evaluating the contribution of serum components  





CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Sera, serum proteins and other reagents 
All chemicals were purchased from Sigma (www.sigmaaldrich.com) unless 
otherwise stated. Culture media (Iscove’s modified Dulbecco’s medium (IMDM)), 
buffers (HBSS and PBS without divalent cations) and Trypsin-EDTA were obtained 
from PAA Laboratories (www.paa.com). Dextran T500 was from Pharmacosmos 
(www.pharmacosmos.com). Percoll was obtained from GE Healthcare 
(www.gehealthcare.com). Dex was from Organon (www.organon.co.uk). Autologous 
serum was freshly prepared by re-calcification of human platelet-rich plasma (PRP) 
(220l of 1M CaCl2/10ml plasma, final concentration 22mM, 37C for 1 hour). 
Serum was also obtained from the following species and stored at -70C for no more 
than two weeks prior to analysis: murine (C57BL/6 mice; a kind donation from 
Mauro Perretti), goat (Sigma), and FBS (Biowest; heat-inactivated). Proteins purified 
from human serum/plasma were obtained form the following sources: protein S 
(Enzyme Research Laboratories, www.enzymeresearch.co.uk), pentraxin-3 (R&D 
Systems; www.rndsystems.com), C1q (Merck; www.merckbiosciences.co.uk), IgG 
(a kind donation from Simon Hart), and fibronectin (R&D Systems). Roscovitine and 
gliotoxin were from Merck. Human tumour necrosis factor- (TNF) was from 
R&D Systems. Human recombinant interferon- (IFN) was from Peprotech 
(www.peprotechec.com). TACE-inhibitor peptide (KD–1X–73.5) was a kind 




Primary antibodies were from the following sources: polyclonal rabbit anti-human 
protein S antibody (Dako, www.dako.com), anti-human C4BP mAb (Enzyme 
Research Laboratories), anti-human Mer mAb (IgG1 isotype, R&D Systems), anti-
human v5 (IgG1 isotype, R&D Systems), anti-CD44 mAb (clone 5A4; provided 
by G. Dougherty, University of California, San Francisco, CA) and anti-FcRII 
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(clone IV.3; a kind donation from Stelios Bournazos). Control mouse IgG1 was from 
Serotec (www.ab-direct.com) and rabbit IgG was from Sigma. Horseradish 
peroxidase (HRP)-conjugated goat anti-rabbit and goat anti-mouse immunoglobulins, 
and FITC-conjugated F(ab’)2 goat anti-mouse immunoglobulin were from Dako. 
APC-conjugated annexin V was from Invitrogen (www.invitrogen.com) 
 
 
2.3 Cell isolation  
Mononuclear (MNC) and polymorphonuclear (PMN) leukocytes were isolated as 
previously described (Dransfield et al., 1994). In brief, freshly drawn peripheral 
blood from healthy volunteers was collected into sodium citrate (final concentration 
0.4%) in 50ml Falcon tubes. Centrifugation at 350 x g for 20min resulted in an upper 
layer of PRP, which was aspirated for immediate preparation of autologous serum  
(see 2.1 Sera, serum proteins and other reagents) and a lower cell pellet. Erythrocytes 
were removed by sedimentation with 0.6% (w/v) dextran T500 (2.5ml dextran/10ml 
cell pellet, made up to 50ml total volume with saline) for approximately 30min at 
room temperature. The upper leukocyte-rich layer was then removed and washed 
with saline (final volume 50ml, 350 x g for 6min) to remove excess dextran. 
Leukocytes were fractionated over a discontinuous Percoll™ gradient. Percoll was 
made isotonic with 10x PBS, generating a 90% stock solution from which final 
concentrations of 55%, 70%, and 81% Percoll were made. Gradients were prepared 
by overlaying 3ml of each 81% (bottom layer), 70% (middle layer) and 55% (upper 
layer, used to resuspend leukocyte pellet prior to layering) and centrifuged at 720 x g 
for 20min at room temperature. MNC were aspirated from the 55/70% interface, and 
PMN from the 70/81% interface, with residual erythrocytes pelleted at the bottom. 
Leukocytes were washed twice in PBS (without divalent cations) before assessment 
of purity (see 2.4 Quality control) and cell culture. 
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2.4 Quality control 
MNC and PMN preparations were assessed for purity by flow cytometry and 
morphological analysis.  Figure 2.1A shows the light scatter profiles of MNC and 
PMN preparations using a FACScan flow cytometer. MNC and PMN preparations 
were routinely above 95% purity. Figure 2.1B shows cytospins of MNC and PMN 
preparations. 4 x 105 cells were cytocentrifuged at 300 x g for 3min, fixed in 100% 




2.5 Generation of monocyte-derived macrophages (MDM) 
MNC were resuspended at 4 x 106/ml in IMDM and allowed to adhere to Falcon 
tissue culture plates for 1 hour at 37°C in 5% CO2. Non-adherent lymphocytes were 
removed by washing 3 times with IMDM and adherent monocytes were cultured for 
5 days in IMDM (containing penicillin and streptomycin) containing 10% autologous 
serum  1M Dex. Previous studies showed that >90% of cells are CD14-positive at 
5 days (Giles et al., 2001). 
 
 
2.6 Induction of neutrophil apoptosis 
Neutrophils were resuspended at 4 x 106/ml in IMDM  10% autologous serum and 
cultured in Falcon tissue culture flasks at 37°C in 5% CO2 atmosphere for 20-24 
hours, during which time a proportion of the cells underwent apoptosis (Savill et al., 
1989b). Alternatively, neutrophils were resuspended in IMDM at 2 x 107/ml and 
labelled with the fluorescent cell tracker dye 5-chloromethylfluorescein diacetate 
(CMFDA; Invitrogen), 2g/ml final concentration for 15min at 37°C. Neutrophils 
were then washed and cultured for 20-24 hours in IMDM  10% autologous serum 























Figure 2.1:  Purity of leukocyte preparations. 
Mononuclear (MNC) and polymorphonuclear (PMN) leukocytes were isolated from 
freshly drawn, citrated human blood by dextran sedimentation and centrifugation 
over a discontinuous Percoll™ gradient. MNC (panels A and C) and PMN (panels B 
and D) preparations were assessed for purity by flow cytometry and morphological 
analysis. Neutrophils are characterised by the presence of multi-lobed nuclei (panel 
D). 
Flow plots were generated with a FACScan flow cytometer. Purity ratios for panel A, 
monocytes: 24.2%, lymphocytes: 72.8%, neutrophils: 1.8%; for panel B, monocytes: 











2.7 Assessment of neutrophil apoptosis 
After culture for 20-24 hours, unlabelled neutrophils were pelleted by centrifugation 
at 200 x g for 5min then resuspended in IMDM, and the percentage of apoptotic and 
secondarily necrotic neutrophils was determined by annexin V-FITC binding (Roche 
Applied Sciences, www.roche-applied-science.com) and propidium iodide staining 
(Sigma), respectively.  
 
2.7.1 Annexin V binding and propidium iodide staining  
PS exposure on apoptotic cells is shown by calcium-dependent binding of 
fluorescently-labelled annexin V (Vermes et al., 1995). 280l of annexin V-FITC 
solution (diluted 1:500 with HBSS containing 5mM CaCl2) was added to 20l of a 
neutrophil suspension (2.5 x 106/ml), mixed gently, and incubated for 10min on ice. 
1l of 1mg/ml propidium iodide was added to the sample before immediate analysis 
by two-colour flow cytometry for annexin V binding on FL-1 and propidium iodide 
staining on FL-2. Neutrophil populations cultured in serum-free conditions for 20-24 
hours exhibit a similar percentage (63-70%, n=35, 95% confidence limit) of annexin 
V+/propidium iodide- (apoptotic) cells when compared with neutrophils cultured in 
the presence of 10% autologous serum (62-72%, n=10, 95% confidence limit) (figs. 
2.2a and b). However, there were significantly higher percentages of annexin 
V+/propidium iodide+ (secondarily necrotic) neutrophils when cultured in serum-
free conditions. 
 
2.7.2 Morphological analysis 
Cytocentrifugation and morphological analysis (see 2.4 Quality control) was used to 
confirm levels of cell death in neutrophil populations (figs. 2.2c and d). The multi-
lobed nuclear morphology characteristic of viable neutrophils becomes pyknotic in 





























Figure 2.2:  Assessment of neutrophil apoptosis. 
Peripheral blood neutrophils were cultured for 20-24 hours in IMDM in the presence 
(panels A and C) or absence (panels B and D) of 10% fresh autologous serum. 
Neutrophil viability was determined by flow cytometric analysis of annexin V-FITC 
binding on FL-1 and propidium iodide staining on FL-2 (panels A and B). Data for 
the proportion of viable (annexin V-/propidium iodide-), apoptotic (annexin 
V+/propidium iodide-) and secondary necrotic (annexin V+/propidium iodide+) 
neutrophils are shown as 95% confidence limits. Morphological analysis of 
cytocentrifuge preparations shows the presence of pyknotic nuclei (condensed and 
rounded) characteristic for apoptotic neutrophils (panels C and D). 
 
18 – 26% Necrotic 
63 – 70% Apoptotic




8 – 17% Necrotic 
62 – 72%Apoptotic 
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A 
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2.8 Macrophage phagocytosis assay 
Phagocytosis was assessed by flow cytometry, confocal microscopy and time-lapse 
video microscopy. Due to restrictions on blood donations, MDM and neutrophils 
used for phagocytosis assays were derived from different human donors (allogeneic 
phagocytosis). Fresh autologous serum used during phagocytosis was obtained from 
the neutrophil donor, unless otherwise stated. 
 
2.8.1 Flow cytometry 
MDMwere cultured for 5 days  1M Dex in 48-well Falcon tissue culture plates 
(approximately 200,000/well), washed gently with IMDM then co-incubated with 
0.5ml CMFDA-labelled apoptotic neutrophils (centrifuged at 200 x g and 
resuspended at 2.5 x 106/ml in IMDM; a ratio of approximately 6 neutrophils per 
macrophage) for 30min at 37°C in 5% CO2. Medium was then aspirated from the 
wells and replaced with 0.5ml Trypsin-EDTA. Cells were incubated for 15min at 
37°C, then 15min on ice followed by vigorous pipetting to ensure detachment of all 
adherent cells. MDMphagocytosis of apoptotic neutrophils was assessed by flow 
cytometry using a FACScan (Becton-Dickinson, www.bdbiosciences.com). 
Uningested neutrophils were identified by the combination of their green 
fluorescence (FL-1 positive) due to CMFDA labelling and their relatively smaller 
size (FSC) when compared with the MDM (fig. 2.3a). MDMpopulations were 
gated based on forward and side scatter characteristics, and MDMdemonstrating 
green fluorescence (FL-1 positive) were deemed to have ingested apoptotic 
neutrophils (fig. 2.3b). 
This assay has previously been carefully characterised and can be used to 
discriminate between bound and internalised apoptotic neutrophils, comparing 
favourably with analysis by light microscopy (Jersmann et al., 2003). For details on 
receptor inhibitors or purified proteins added to MDMor apoptotic neutrophils, see 




















Figure 2.3:  Quantitation of MDM phagocytosis of apoptotic neutrophils. 
The percentage of human MDM that could phagocytose CMFDA-labelled apoptotic 
neutrophils was determined in a 30 minute in vitro phagocytosis assay by flow 
cytometry using a FACScan flow cytometer. A, Dot plot showing FSC and SSC of 
MDM and apoptotic neutrophils following phagocytosis assays. B, Dot plot of 
CMFDA-labelled apoptotic neutrophils detected on FL-1. C, MDM were identified 
by their distinct forward and side scatter properties. Gate R1 corresponds to FL-1 
positive MDM that have phagocytosed apoptotic neutrophils, whereas Gate R2 















2.8.2 Time-lapse video microscopy 
MDMwere cultured for 5 days  1M Dex in plastic chamber slides (12 x 106 
MNC/chamber slide), washed once in IMDM then overlaid with 3ml of serum-free 
cultured apoptotic neutrophils (centrifuged at 200 x g for 5min and resuspended at 1 
x 106/ml in IMDM)  10% autologous serum. Time-lapse video microscopy of 
phagocytosis was carried out at 37C using a phase contrast microscope and Leica 
QWin V3 software with the time lapse sequence set to capture images every 30 
seconds for 30 min (see attached CD for videos). 
 
2.8.3 Confocal microscopy 
MDMwere cultured for 5 days  1M Dex in plastic chamber slides (12 x 106 
MNC/chamber slide), washed once in IMDM then overlaid with 3ml of serum-free 
cultured apoptotic neutrophils (centrifuged at 200 x g for 5min and resuspended at 
2.5 x 106/ml in IMDM)  10% autologous serum. After co-incubation for 30min at 
37°C in 5% CO2, medium was aspirated from the wells and MDM were washed 
carefully with IMDM to remove excess neutrophils. Adherent MDM were fixed 
with 0.5ml 3% paraformaldehyde for 15min then washed once with PBS (without 
divalent cations). Slides were removed from the chambers and mounted with mowial 
before analysis by confocal laser scanning microscopy using a Carl Zeiss confocal 
microscope. Analysis of imagery was carried out using Zeiss LSM image browser.  
 
 
2.9 Serum fractionation 
Fractionation experiments were carried out using fresh autologous serum obtained 
from the neutrophil donor.  
 
2.9.1 Ultracentrifugation of serum 
Immediately after preparation, human autologous serum (200l/tube) was 
ultracentrifuged at 330,000 x g for 1 hour at 4C using a TL-100 rotor (settings: 
acceleration 9, brake 9). This centrifugal force generated three distinct serum layers: 
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a top opalescent lipid layer, a medium straw-coloured protein layer and a pellet 
containing aggregated protein. The protein layer was carefully removed to prevent 
perturbation of the pellet, and resuspended to original volume (200l) with IMDM. 
 
2.9.2 Ultrafiltration of serum 
Human serum (0.5ml/membrane) was filtered through Centricon YM-50 membranes 
(Millipore; molecular weight cut off 50-kDa) at 3,000 x g for 1 hour in a swinging 
bucket rotor. At this centrifugal force, solvent and low molecular weight (LMW) 
components less than 50-kDa in molecular mass were driven through the membrane 
and collected as the filtrate. Components larger than 50-kDa in molecular mass were 
retained above the membrane, and this retentate was collected by inverted 
centrifugation at 300 x g for 3min. Both filtrate and retentate were resuspended to 
original volume (0.5ml) with IMDM. This procedure was repeated using YM-100 
membranes (1,000 x g for 12min). 
 
 
2.10 Protein purification techniques 
Chromatography techniques were applied for protein purification from human serum. 
Purifications were performed using fresh serum from a single donor.  
 
2.10.1 Anion exchange chromatography 
Anion exchange chromatography was carried out using mono Q Sepharose (Sigma), 
an anion exchanger. A 5cm mono Q Sepharose column was packed under gravity 
and stored at 4C. All subsequent steps were performed at 4C under flow pressure 
(2ml/min using a pharmacia LKB pump P-1).  
 
2.10.1.1 Optimisation of pH 
Buffering solutions were prepared at pH6 (50mM MES and 0.14M NaCl), pH7 and 
pH8 (50mM HEPES and 0.14M NaCl). Human serum was loaded into dialysis 
tubing (molecular weight cut off 12,400da, Sigma) and equilibrated overnight at 4C 
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to the corresponding pH buffer used to run the column. Mono Q Sepharose was 
equilibrated with 50ml pH6 buffer before application of 40ml pH6-equilibrated 
serum. Proteins with an incorrect surface charge at this pH passed through the 
column and were collected as the flow through. Non-specifically bound proteins 
were removed by washing the column with 150ml pH6 buffer until A280 of the flow 
through fell below 0.1. Specifically bound proteins were eluted from the column 
following application of pH6 buffer containing 0.5M NaCl. 1ml fractions (up to 15) 
were collected using a fraction collector. Protein concentration in eluted fractions 
was estimated by measurement of absorbance at 280nm (A280) using a UV 
spectrophotometer (zero to pH6 buffer containing 0.5M NaCl). To obtain a good 
protein yield, three fractions containing the highest concentration of protein were 
combined and dialysed overnight to pH6 buffer (0.14M NaCl) to remove excess salt. 
The mono Q Sepharose column was regenerated upon washing with 20ml pH6 buffer 
containing 1M NaCl to remove any remaining bound proteins, and equilibrated with 
50ml 0.14M NaCl pH6 buffer to prepare for the next experiment. 
This method was repeated using pH7 and pH8 buffering solutions and equilibrated 
serum. Flow through and elution fractions collected from columns at the various pH 
values were stored at 4°C for no more than 1 week before assessment for phagocytic 
activity. 
 
2.10.1.2 Optimisation of ionic strength 
Anion exchange chromatography was performed as described above (2.10.1.1 
Optimisation of pH). Serum proteins bound to mono Q Sepharose at pH7 were eluted 
using a salt gradient of 0.2M to 0.5M NaCl prepared in pH7 buffer. A fraction 
collector was used to collect 1.6ml fractions. Protein concentration in eluted fractions 
was estimated by measurement of A280 (zero to pH7 buffer of appropriate ionic 
strength) or by using a Pierce BCA kit. For the BCA kit procedure, 10l of sample 
was pipetted on a 96-well microtiter plate and incubated with 200l of the reagent 
mixture. After incubation for 30min at 37C, the plate was allowed to cool to room 
temperature and the optical density measured at 560nm with an ELISA plate reader. 
Calibration was performed with BSA in a concentration range of 0.25 to 2mg/ml. 
Fractions containing the highest concentration of protein were combined and 
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dialysed overnight to pH7 buffer (0.14M NaCl) to remove excess salt. Protein 
content in eluted fractions was standardised prior to assessment of phagocytic 
activity. 
 
2.10.2 Gel Filtration 
Gel filtration was carried out using Sephacryl S-300 gel (GE Healthcare). 250ml of 
Sephacryl S-300 was prepared in an equal volume of 1 x TBS buffer (0.5M Tris, 9% 
NaCl, pH 7.6), loaded into a gel packing reservoir attached to the top of a gel 
filtration column (a resin bed 90cm in height was used), and filled to the top with 1 x 
TBS buffer. The column was packed under flow pressure (3ml/min for 2 hours), 
stored at 4C and washed with 50ml of 1 x TBS buffer prior to each experiment. All 
steps were performed at 4C under flow pressure (2ml/min). Due to the direction of 
liquid flow during column preparation (top to bottom), the gel was more packed at 
the bottom and samples were therefore applied to the column in the reverse direction 
using a three-way tap. 
 
2.10.2.1 Calibration of the gel filtration column 
The gel filtration column was calibrated with cytochrome c (12.4-kDa), carbonic 
anhydrase (29-kDa), human serum albumin (66-kDa), alcohol dehydrogenase (150-
kDa), -amylase (200-kDa) and blue dextran (2,000-kDa) from MW-GF-200 kits 
(Sigma). Protein standards were reconstituted to 10mg/ml in 1 x TBS running buffer 
and stored at 4C. Standards were freshly prepared to the final concentrations 
recommended in manufacturer guidelines prior to gel filtration. Carbonic anhydrase 
and alcohol dehydrogenase, and cytochrome c and -amylase were mixed and run 
together on the column, and the remaining proteins were run individually. Standards 
were applied to the column using the same sample volume (250l sample) and flow 
rate (2ml/min). 1.6ml fractions were collected from the point of sample application 
and elution of proteins was detected by absorbance readings at 280nm.  
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2.10.2.2 Gel filtration of 0.2M anion exchange sample 
Pooled 0.2M fractions obtained following anion exchange chromatography of serum 
at pH7 were concentrated almost 10-fold under pressure using an amicon 
concentrator, and applied to a Sephacryl S-300 column using the same sample 
volume (250l sample) and flow rate (2ml/min) used for blue dextran and protein 
standards. 1.6ml fractions (up to 80) were collected from the point of sample 
application and protein concentration determined spectrophotometrically by A280 
measurement. Gel filtration fractions containing protein were stored at 4C for less 
than 1 week before assessment of phagocytic activity. Fractions were reconstituted 
with 1mM CaCl2 and normalised for protein content (based upon A280 readings or 
by Pierce BCA kit microplate procedure; a final concentration of 50g/ml was used) 
prior to addition to phagocytosis assays. 
 
2.10.3 Mass spectrometry 
Gel filtration fractions containing phagocytic activity were resolved by SDS 
polacrylamide gel electrophoresis (SDS PAGE) (as described in 2.13 SDS 
polyacrylamide gel electrophoresis) on 12% gels under reducing conditions and the 
major proteins were identified by tryptic digestion followed by matrix assisted laser 
desorbtion ionisation (MALDI) and analysis using the protein prophet program (2 
separate analyses by Jim Creanor, University of Edinburgh, UK). 
 
 
2.11 Reduction and alkylation  
Fresh autologous serum and high molecular weight (HMW) gel filtration fractions 
were treated with 5mM dithiothreitol (DTT; prepared at 1M in dH2O) at 37C for 1 
hour at 300 x g to break disulfide linkages between cysteine residues of proteins, 
followed by alkylation with 25mM iodoacetamide (IOA; prepared at 1M in dH2O) at 
room temperature for 1 hour in the dark to prevent disulphide bonds reforming. 
Samples were loaded into dialysis tubing and dialysed overnight in 200ml IMDM at 
4C in the dark with continual stirring to remove excess DTT and IOA. 
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2.12 Protein immunodepletion from human serum  
Pooled 0.2M fractions from anion exchange chromatography were incubated with 
200g/ml of rabbit anti-human protein S or mouse anti-human C4BP antibodies for 1 
hour on ice. Immunodepletion was achieved by incubation for 1 hour with agarose-
coupled goat anti-rabbit IgG (Sigma) or goat anti-mouse IgG (Sigma) at 4C on a 
rotator. The serum-agarose mixture was centrifuged at 200 x g for 2min, and the 
supernatant transferred to a fresh epindorph. Three rounds of depletion were 
performed to ensure efficient protein depletion from 0.2M fractions. Excess antibody 
was removed by a final incubation with agarose. Rabbit IgG or mouse IgG added to 
the same volume of 0.2M fractions was used for mock control depletions. 
Immunodepleted samples were diluted 1 in 100 with 0.2M NaCl buffer (50mM 
HEPES, pH7) and proteins resolved by SDS-PAGE using 9% acrylamide gels (see 
2.13 SDS polyacrylamide gel electrophoresis) Proteins were transferred 
electrophoretically onto PVDF membrane and immunoblotted for protein S or C4BP 
as described in 2.14 Western blotting. See individual figure legends for antibody 
concentrations used for immunoblotting. 
 
 
2.13 SDS polyacrylamide gel electrophoresis  
Samples were boiled for 5min in 4x sample buffer (125mM Tris pH6.8, 4% v/v SDS, 
27.5% v/v glycerol) then resolved by SDS-PAGE typically using 9% acrylamide gels 
(37.5mM Tris pH 8.8, 0.1% v/v SDS, 0.2% v/v TEMED, 0.04% w/v APS) and 1 x 
Tris/Glyine running buffer (25mM Tris, 192mM glycine, pH8.3, 0.1% SDS). Gels 
were run under non-reducing conditions unless otherwise stated, and 2% v/v -
mercaptoethanol was added to sample buffer for reducing conditions. 5l marker 
(Invitrogen) was loaded to gels for estimation of protein molecular weight in 
samples. Protein was detected in resolved gels with Coombassie blue staining (0.5% 
w/v in 40% v/v ethanol and 10% v/v acetic acid) for 1 hour followed by incubation 
in destain solution (40% v/v methanol and 10% acetic acid v/v) for up to 4 hours to 
reduce background staining. 
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2.14 Western blotting 
Protein from unstained gels was transferred electrophoretically (80V, 50 min, 4C) 
onto PVDF membrane (Millipore, www.millipore.com) in 25mM Tris, 192mM 
glycine, pH8.3, 20% v/v methanol transfer buffer. Membranes were blocked 
overnight at 4C in 1 x TBS buffer (0.5M Tris, 9% NaCl, pH 7.6) containing 0.1% 
Tween (TBS/T), then incubated for 1 hour with continual mixing at room 
temperature with primary and then secondary antibodies prepared in TBS/T. 
Between incubation steps, membranes were washed three times for 5min each in 
TBS/T. Detection was performed using enhanced chemilluminescence (GE 
Healthcare). For antibody concentrations used, see individual figure legends. Total 




2.15 Flow cytometry 
MDM were cultured for 5 days  1M Dex in 48-well tissue culture plates, washed 
once in IMDM and detached by incubation in HBSS without divalent cations 
containing 0.1% BSA and 3mM EDTA (15min at 37C, then 15min on ice followed 
by vigorous pipetting to dislodge adherent cells). After washing once with ice-cold 
HBSS containing 2% FBS, MDM (105/assay) were pelleted in 96-well U-bottom 
flexiwell plates by centrifugation at 300 x g for 2min at 4C. All subsequent 
incubations were performed on ice to prevent internalisation of antibody. MDM 
were resuspended and incubated for 30min with 10g/ml anti-Mer or anti-v5 
(1:50), 1:50 of an isotype-matched mouse IgG1 as a negative control, or 1:50 anti-
CD44 as a positive control, then washed twice in HBSS containing 2% FBS. Binding 
was detected through incubation for 30min with a FITC-conjugated F(ab’)2 goat anti-
mouse immunoglobulin (1:50) before analysis using a FACScan flow cytometer. 
Duplicate wells were used for each experiment, and the experiment was repeated at 
least three times using different monocyte donors.  
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2.16 Statistical analysis 
Data were analysed using the GraphPad Prism statistical analysis package. Paired 
tests were chosen as control and treatment groups were obtained from the same 
donor, and were from a Gaussian distribution. Results were analysed by repeated 
measures one-way ANOVA with a Bonferroni post test and are presented as mean  










CHAPTER 3: GLUCOCORTICOID AUGMENTATATION OF 
MACROPHAGE PHAGOCYTOSIS OF APOPTOTIC 
NEUTROPHILS IS SERUM-DEPENDENT 
 
3.1 Introduction  
The normal resolution of inflammation requires the coordinated removal of large 
numbers of extravasated neutrophils from inflamed sites through induction of 
apoptosis and nonphlogistic removal by macrophages (Savill et al., 1989b, Meagher 
et al., 1992). However, dysregulation in either apoptosis or phagocytic clearance may 
result in the accumulation of neutrophils and their potentially injurious contents at 
inflamed sites, and contribute to the pathogenesis of a number of diverse diseases 
such as rheumatoid arthritis, COPD and SLE (Haslett et al., 1994, Wipke and Allen, 
2001, Ren et al., 2003, Brown et al., 2009). Modulation of the processes involved in 
physiological clearance of neutrophils from inflamed sites may therefore represent a 
therapeutic approach to treatment of inflammatory diseases.  
 
NFB is a pro-inflammatory transcription factor normally held in the cytoplasm in 
an inactive state by an inhibitory protein from the IB family, IBa (Fujihara et al., 
2002). Following TNF treatment, the IB subunit is rapidly phosphorylated and 
ubiquitinated (Fujihara et al., 2002), targeting it for proteolytic degradation by the 
proteasome, thereby allowing nuclear translocation of NFB and initiation of gene 
transcription (Matthews and Hay, 1995, Karin, 1999). In addition to promoting 
synthesis of pro-inflammatory mediators, NFB plays a critical role in regulation of 
neutrophil apoptosis by inducing the synthesis of a pro-survival protein(s) (Ward et 
al., 1999a, Ward et al., 1999b, Ward et al., 2004) that protects neutrophils against the 
caspase-dependent pro-apoptotic properties of TNF (Fujihara et al., 2002). Hence, 
simultaneous ligation of death receptors (TNF) along with blocking IB 
degradation and NFB activation (gliotoxin) induces rapid and synchronous 
granulocyte apoptosis (Pahl et al., 1996, Ward et al., 1999a, Fujihara et al., 2002). 
Cyclin-dependent kinases (CDKs), key regulators of cell cycle progression, also 
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regulate the rate of apoptosis. In a recent study, Rossi et al demonstrated that the 
CDK-inhibitor drug R-roscovitine induced caspase-dependent apoptosis of human 
neutrophils, and this correlated with a reduction in expression of the anti-apoptotic 
Bcl-2 family member, Mcl-1 (Rossi et al., 2006). 
 
Despite their undesirable side effects, glucocorticoids are powerful anti-
inflammatory drugs often used in the treatment of many inflammatory conditions 
owing to their capacity to inhibit many processes important in initiation and 
progression of acute inflammation, including inflammatory cell recruitment and 
expression of pro-inflammatory molecules, and their ability to manipulate processes 
important for the resolution of inflammation (Takahira et al., 2001, Schramm and 
Thorlacius, 2004, Schleimer, 2004, McColl et al., 2007). Synthetic glucocorticoids 
(methylprednisolone, hydrocortisone or Dex) specifically enhance nonphlogistic 
macrophage phagocytosis of intact apoptotic neutrophils in vitro (Liu et al., 1999), an 
effect that was associated with altered macrophage morphology, adhesive ability and 
motility (Giles et al., 2001). Further characterisation revealed that long-term 
exposure to glucocorticoids (5-days) induced a more homogenous population of 
smaller, more rounded and less well-spread macrophages with reduced 
phosphorylation and, hence, recruitment of paxillin and pyk2 to sites of adhesion, 
and loss of actin- and paxillin-containing podosomes (Giles et al., 2001). 
Glucocorticoid treatment was also associated with reduced expression of p130cas 
(Giles et al., 2001), an important adaptor molecule in integrin adhesion signalling 
through the DOCK180/Crk/p130cas pathway (Hasegawa et al., 1996, O'Neill et al., 
2000). Despite their altered adhesion, glucocorticoid-treated macrophages remain 
highly membrane active through extension and retraction of cellular process, 
possibly due to high levels of active Rac (Giles et al., 2001). Macrophages exposed 
to glucocorticoids also display homogeneity in surface receptor expression, including 
a more uniform expression of HLA-DR, CD14, and CD44 (Giles et al., 2001). 
Although glucocorticoid-treated macrophages express elevated levels of the 
haemoglobin scavenger receptor CD163, no single surface receptor was identified in 
previous studies that could account for the prophagocytic phenotype. A recent study 
by Ehrchen and coworkers signified the multitide of glucocorticoid action in human 
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monocytes/macrophages, where glucocorticoids modulated the expression of over 
100 genes (Ehrchen et al., 2007). Interestingly, the products of many of these genes 
are important for monocyte/macrophage functions such as phagocytosis, apoptosis, 
migration and adhesion. The expression of CD163, FPR1, and Mertk receptors, and 
MFG-E8 and C1q serum proteins, all known to be associated with apoptotic cell 
phagocytosis, were upregulated in monocytes exposed to glucocorticoids. However, 
the relevance of this to the process of glucocorticoid-enhancement of apoptotic 
neutrophil clearance was unclear. 
 
Despite these advances in understanding the molecular mechanisms associated with 
acquisition of a pro-phagocytic macrophage phenotype, the receptor mechanism 
employed by glucocorticoid-treated macrophages for high-capacity clearance of 
apoptotic neutrophils remains elusive. In this chapter, I describe the characteristics 
required for augmentation of macrophage phagocytic capacity for apoptotic 





3.2 Materials and methods  
 
3.2.1 Induction of neutrophil apoptosis 
Neutrophils were isolated from peripheral blood as described in Chapter 2, 2.3 Cell 
isolation. CMFDA-labelled neutrophils were cultured at 4 x 106/ml in IMDM  10% 
autologous serum at 37C in a 5% CO2 atmosphere for 20-24 hours to render 
neutrophils apoptotic. Alternatively, apoptosis was actively induced in CMFDA-
labelled neutrophil cultures (4 x 106/ml) after 4 hour serum-free incubation in IMDM 
in the absence or presence of either 20M roscovitine, or 10pg/ml TNF in 
combination with 0.1g/ml gliotoxin. Neutrophil populations were then centrifuged 
at 200 x g for 5min and resuspended in fresh IMDM to remove treatments prior to 








3.3.1 Glucocorticoids augment macrophage phagocytic capacity for apoptotic 
neutrophils 
Previous studies relating to glucocorticoid-enhanced phagocytosis of apoptotic cells 
used human MDM and apoptotic neutrophils that had been cultured in the presence 
of human serum (Liu et al., 1999, Giles et al., 2001). To confirm these observations, 
human peripheral blood monocytes were cultured in vitro for 5 days in the absence 
or presence of 1M Dex to generate MDM, human neutrophils were rendered 
apoptotic following culture in IMDM containing 10% autologous serum for 20-24 
hours (see Chapter 2, 2.7 Assessment of neutrophil apoptosis, and Chapter 2, figs. 
2.2a and c) and phagocytosis of serum-cultured apoptotic neutrophils by untreated 
and Dex-MDM was assessed by flow cytometry (see Chapter 2, 2.8.1 Flow 
cytometry for characterisation of phagocytosis). Dex treatment was found to 
significantly increase (over 2-fold) MDM phagocytosis of apoptotic neutrophils, an 
effect that did not require the addition of autologous serum during the assay (fig. 
3.1a; *** p<0.001, n=8). Interestingly, when serum-cultured neutrophils were 
washed once in PBS (without divalent cations) prior to phagocytosis, the ability of 
Dex-MDM to phagocytose apoptotic neutrophils was diminished (~50% loss in 
phagocytic activity when compared to untreated control), an effect which could be 
reversed by addition of 10% autologous serum during the phagocytosis assay (fig. 
3.1b; * p<0.05, n=5). We were therefore interested in investigating the role of serum 
















































Figure 3.1:  Effect of dexamethasone on human MDM phagocytosis of serum-
cultured apoptotic neutrophils. 
Adherent human MDM were cultured in the absence or presence of 1M 
dexamethasone (Dex) for 5 days, and heterologous neutrophils were cultured in the 
presence of 10% fresh autologous serum for 20-24 hours. Phagocytosis was 
measured as the percentage of untreated (white bars) and Dex-treated (black bars) 
MDM that had phagocytosed serum-cultured apoptotic neutrophils in a 30-minute 
phagocytosis assay. A, Dex treatment augments MDM phagocytosis of apoptotic 
neutrophils, and this did not require the presence of autologous serum during the 
phagocytosis assay. Results presented as mean percent phagocytosis  SEM for 8 
separate experiments. B, Dex-enhanced MDM phagocytosis of apoptotic 
neutrophils was suppressed when serum-cultured neutrophils were pre-washed with 
PBS and could be restored with 10% autologous serum. Mean phagocytosis  SEM, 
n=5 where n = the number of different macrophage donors. (*, p<0.05; *** p<0.001 





3.3.2 Glucocorticoid augmentation of macrophage phagocytosis of apoptotic 
neutrophils is serum-dependent 
To evaluate the potential role of serum opsonisation in promoting apoptotic 
neutrophil clearance, neutrophils were rendered apoptotic by culture for 20-24 hours 
in serum-free conditions. Serum-free cultured neutrophils exhibit a similar 
percentage of annexin V+/propidium iodide- (apoptotic) cells when compared with 
neutrophils cultured in the presence of 10% autologous serum (see Chapter 2, figs. 
2.2a and b. Serum cultured: 62–72% apoptosis, n=11; serum-free cultured: 63–70% 
apoptosis, n=35. Data presented as 95% confidence limits). However, there were 
significantly higher percentages of annexin V+/propidium iodide+ (secondarily 
necrotic) neutrophils in serum-free cultures (see Chapter 2, figs. 2.2a and b. Serum 
cultured: 8–17% necrosis, n=11; serum-free cultured: 18–26% necrosis, n=35). 
Furthermore, morphological analysis of neutrophil cultures revealed significantly 
more advanced nuclear pyknosis and cytoplasmic condensation in many of the 
neutrophils in the serum-free cultures, which mirrored tighter populations of 
neutrophils observed by flow cytometry (see Chapter 2, figs. 2.2b and d). Thus, 
neutrophils proceed through the apoptotic process more quickly when cultured in the 
absence of serum, consistant with the presence of a survival factor in serum. 
 
Phagocytosis of serum-free cultured apoptotic neutrophils by untreated and Dex- 
MDM was assessed by flow cytometry. Surprisingly, there was no significant 
augmentation of phagocytosis of serum-free apoptotic neutrophils observed for Dex-
MDM, with phagocytosis by Dex-MDM actually slightly lower compared to 
untreated control (figs. 3.2a and c; ** p<0.01, n = 80) (McColl et al., 2009). The 
addition of 10% autologous serum to the assay medium revealed increased 
phagocytic capacity for Dex-MDM (3-fold) (figs. 3.2b and c; *** p<0.001, n=80). 
The presence of serum also had a small, but statistically significant stimulatory effect 
upon phagocytosis of apoptotic neutrophils by untreated MDM (fig. 3.2c; *** 
p<0.001, n=80). By altering the concentration of serum present during the 
phagocytosis assay, the effect of serum on Dex-MDM phagocytosis was found to 
be concentration-dependent and reached significance at 1% (figs. 3.3a and b). In 
these experiments, phagocytosis of apoptotic neutrophils by untreated MDM was 
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not augmented at any concentration of serum (fig 3.3b). As the most significant 
augmentation of Dex-MDM phagocytosis was observed using 10% 
autologousserum, we used this concentration for subsequent experiments. 
 
Although we consistently observed a serum-dependent augmentation in Dex-MDM 
phagocytosis compared to untreated MDM for each experiment (fig. 3.2c), the inter-
donor levels of phagocytosis proved to be highly variable, ranging from 7.4% to 
55.9% for untreated MDM and from 28.5% to 81.4% for Dex-MDM in the 
presence of 10% autologous serum, and a significant correlation was found between 
two MDM populations (fig. 3.4, *** p<0.001, n=80). The “n” value was calculated 
based upon the number of independent experiments performed using different 
macrophage donors. However, upon reaching a high n value (n=80, using a pool of 
~30 donors) it is highly likely that the cumulative data contained repeat macrophage 
donors. Therefore, we next sought to compare Dex-MDM phagocytic capacity for 
apoptotic neutrophils obtained from different donors. Significant differences in the 
phagocytic capacity were observed (donor AR: 49.71%, 61.35% and 72.43% 
phagocytosis), and did not appear to correlate with the level of necrosis in the 
phagocytic target population (data not shown). Furthermore, preliminary experiments 
suggested that phagocytosis was also independent of the proportion of apoptotic cells 
present in neutrophil cultures, with similar levels of phagocytosis achieved when 
phagocytic targets were reduced by 50% (2.5 x 106/ml neutrophil targets: 49.8%; 
1.25 x 106/ml neutrophil targets: 46.4%. n=2). Although there appears to be a 
discrepancy in the effect of serum on untreated MDM phagocytosis of apoptotic 
neutrophils (figs. 2 and 3), this may be due to the highly variable levels of 
phagocytosis observed in the presence of serum and random choice of donors within 
our donor pool for each experiment. Interestingly, in a large series of experiments 
(n=80), there were a few non-responders to Dex treatment (untreated: 30.9%; Dex 



































Figure 3.2: Dex-MDM phagocytosis of serum-free cultured apoptotic neutrophils is 
serum-dependent. 
MDM were cultured in the absence or presence of 1M Dex for 5 days, and 
phagocytosis of serum-free cultured heterologous apoptotic neutrophils by untreated 
(white bars) and Dex-treated (black bars) MDM was assessed by flow cytometry. 
Dot plot showing Dex-MDM phagocytosis of serum-free cultured apoptotic 
neutrophils in the absence (A) or presence (B) of 10% fresh autologous serum. FL-1 
positive MDM in gate R1 have phagocytosed CMFDA-labelled apoptotic 
neutrophils. C, Dex-MDM phagocytosis of serum-free cultured apoptotic 
neutrophils required addition of 10% autologous serum (AS) during the phagocytosis 
assay. Serum also had a small, but statistically significant pro-phagoctyic effect on 
untreated MDM phagocytosis of serum-free cultured apoptotic neutrophils. Mean 
phagocytosis  SEM, n=80 where n = the number of phagocytosis assays performing 
using a pool of ~30 different macrophage donors. (**, p<0.01; *** p<0.001, one-way 
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Figure 3.3: Effect of serum serial dilution on Dex-MDM phagocytosis of apoptotic 
neutrophils 
Phagocytosis assays were performed as described in Figure 3.2. A and B, Fresh 
autologous serum enhanced phagocytosis of serum-free cultured heterologous 
apoptotic neutrophils by Dex-MDM (black bars), but not untreated MDM (white 
bars), in a concentration-dependent manner. Mean phagocytosis  SEM, n=4 where n 
= the number of different macrophage donors. (**, p<0.01; *** p<0.001 when 
compared to uptake by Dex-MDM in the absence of serum, one-way ANOVA with 








Figure 3.4: Levels of phagocytosis by untreated and Dex-MDM in the presence of 
serum are highly variable 
Phagocytosis assays were performed as described in Figure 3.2. Data distribution of 
untreated vs Dex-MDM phagocytosis of heterologous apoptotic neutrophils in the 
presence of 10% fresh autologous serum. Data were analysed using the Pearson 
correlation test, *** p<0.001, n=80 (where n = the number of phagocytosis assays 
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3.3.3 Effect of sera from different human donors or alternative species on 
phagocytosis of apoptotic neutrophils by Dex-MDM 
Fresh autologous serum used for phagocytosis assays was derived from the 
neutrophil donor. This led us to perform a series of experiments to determine if the 
serum-dependent augmentation of Dex-MDM phagocytosis of apoptotic neutrophils 
was a donor-specific phenomenon, i.e. required serum obtained from the neutrophil 
or macrophage donor, or if serum from any human donor could convey this effect. 
We found that serum enhanced phagocytosis of apoptotic neutrophils by Dex-MDM 
irrespective of whether the serum was derived from the neutrophil donor (fig. 3.2c; 
*** p<0.001, n=80), macrophage donor (fig. 3.5a; *** p<0.001, n=4) or a non-
autologous donor (fig. 3.5b; *** p<0.001, n=6). Based upon the lack of donor 
restriction on the serum effect, we were also interested in investigating whether the 
pro-phagocytic effect was restricted to human serum, or if serum from alternative 
species could reproduce this enhancing effect on Dex-MDM phagocytosis. Addition 
of 10% serum (frozen) from mice with a C57BL/6 background during the 
phagocytosis assay enhanced Dex-MDM phagocytosis to comparable levels 
observed for 10% autologous serum (fig. 3.5c; ** p<0.01, n=3). A similar pro-
phagocytic effect was observed with addition of 10% FBS (frozen, and heat-
inactivated) (fig. 3.5d; *** p<0.001, n=6). This data suggests that a common 
component(s) in these distinct sera has a pro-phagocytic effect on Dex-MDM. 
Interestingly, we found that 10% goat serum (frozen) did not confer augmentation of 
Dex-MDM phagocytosis, and instead had a slight inhibitory effect (fig 3.5e; 

















































































































Figure 3.5: Effects of sera from different human donors or from different species on 
Dex-MDM phagocytosis of apoptotic neutrophils. 
Phagocytosis assays were performed as described in Figure 3.2. Dex-MDM 
phagocytosis (black bars) of serum-free cultured heterologous apoptotic neutrophils 
was enhanced in the presence of 10% serum derived from the macrophage donor 
(fresh) (A, n=4) or a non-autologous human donor (fresh) (B, n=6), and serum from 
C57/BL6 mice (frozen) (C, n=3), and FBS (frozen, heat-inactivated) (D, n=6). In 
contrast, 10% goat serum (frozen) (E, n=6) had a slight inhibitory effect on Dex-
MDM phagocytosis. Mean phagocytosis  SEM (**, p<0.01; *** p<0.001 when 
compared to uptake by Dex-MDM in the absence of serum, one-way ANOVA with 
a Bonferroni post test). Phagocytosis by untreated MDM (white bars) is shown for 







3.3.4 Glucocorticoids promote swift uptake of apoptotic neutrophils by Dex-MDM 
When phagocytosis of serum-free cultured apoptotic neutrophils by Dex-MDM was 
observed in real-time by time-lapse video microscopy (see attached CD for videos 1 
to 4), it became evident that phagocytic uptake by Dex-MDM was a quick process 
as several macrophages in the serum-containing chamber had already internalised 
apoptotic neutrophils in the 10min it took to set up the experiment and start 
acquisition. Indeed, macrophages treated with Dex are highly active and mobile in 
the presence of serum, and essentially searching for apoptotic prey though the 
continual extension and retraction of processes. Time-course analysis of MDM 
phagocytosis by flow cytometry showed that ~40% of Dex-MDM phagocytosed 
apoptotic neutrophils within 10min compared to ~18% of untreated MDM, reaching 
~65% after 20min compared to ~32% for untreated MDM (fig. 3.6). Hence, 
macrophages treated with Dex are highly efficient phagocytes both in terms of 
phagocytic capacity and swiftness of action. 
 
 
3.3.5 Serum may act to promote internalisation of apoptotic neutrophils by Dex-
MDM 
MDM phagocytosis of serum-free cultured apoptotic neutrophils was also assessed 
by confocal microscopy, as described in Chapter 2, 2.8.3 Confocal microscopy. 
Preliminary data showed that both untreated and Dex-MDM bound a significant 
number of apoptotic neutrophils in the absence of serum, with only a few MDM 
containing internalised neutrophils (figs. 3.7a and b). However, the differential 
phagocytic capacity of untreated and Dex-MDM was again evident in the presence 
of serum. Whilst most neutrophils remained bound to untreated MDM with very 
few internalised (fig. 3.7c), almost all Dex-MDM had internalised bound apoptotic 
neutrophils (fig. 3.7d), and the presence of more than one apoptotic neutrophil in 
Dex-MDM indicated the efficiency of this process. Our data suggests that serum 



























Figure 3.6: Time-course analysis of serum-dependent phagocytosis of apoptotic 
neutrophils by Dex-MDM. 
MDM were cultured in the absence or presence of 1M Dex for 5 days, and 
phagocytosis of serum-free cultured heterologous apoptotic neutrophils by untreated 
(white bars) and Dex-treated (black bars) MDM was assessed at 10min intervals by 
flow cytometry. 10% fresh autologous serum enhanced Dex-MDM phagocytosis of 
apoptotic neutrophils compared to untreated MDM at every time point. Mean 
phagocytosis  SEM, n=3 where n = the number of different macrophage donors. (*, 
p<0.05; **, p<0.01 when compared to uptake by untreated MDM, one-way 
















Figure 3.7: Analysis of Dex-MDM phagocytosis of apoptotic neutrophils by 
confocal microscopy. 
MDM were cultured in the absence or presence of 1M Dex for 5 days, and 
phagocytosis of serum-free cultured heterologous apoptotic neutrophils by untreated 
(panels A and C) and Dex-treated MDM (panels B and D) was visualised by 
confocal microscopy. The representative micrographs (n=2) illustrate that 10% fresh 
autologous serum promotes internalisation of apoptotic neutrophils by Dex-MDM 





3.3.6 Glucocorticoid augmentation of macrophage phagocytosis requires serum 
opsonisation of apoptotic neutrophils 
We next sought to investigate whether serum-enhanced phagocytosis by Dex-MDM 
required opsonisation of apoptotic neutrophils with a serum component(s). For this, 
serum-free cultured apoptotic neutrophils were pre-incubated in the absence or 
presence of 10% autologous serum for 1 hour, then centrifuged at 200 x g for 5min 
and resuspended in IMDM before assessment of MDM phagocytosis by flow 
cytometry. Maximal Dex-MDM phagocytic capacity was found to require pre-
incubation of apoptotic neutrophils with serum (no serum: 24.7%; 10% serum 1 hour 
pre-incubation: 68.5%. *** p<0.001, n=10) (fig. 3.8a), generating equivalent levels 
of Dex-MDM phagocytosis to those observed when serum was added during the 
phagocytosis assay (no serum: 19.9%; 10% serum during: 59.9%. *** p<0.001, 
n=80) (fig. 3.2c). These data excluded the possibility that serum acts to directly 
regulate the phagocytic activity of macrophages, instead suggesting that enhanced 
phagocytosis by Dex-MDM required binding of a serum component(s) to apoptotic 
neutrophils. Interestingly, when apoptotic neutrophils pre-incubated with serum were 
washed in IMDM containing 5mM EDTA prior to phagocytosis, the phagocytic 
effect was significantly reduced, suggesting that a calcium-dependent serum opsonin 
was required (fig. 3.8b; *** p<0.001, n=3). However, EDTA did not completely 
reduce phagocytosis to untreated control levels. Furthermore, a slight decrease in 
Dex-MDMphagocytosis was observed when apoptotic neutrophils were pre-
incubated in serum and subsequently washed in calcium-containing medium 
(IMDM) (fig. 3.8b; p>0.05, n=3), indicating that serum may also have a calcium-
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Figure 3.8: Phagocytosis of apoptotic neutrophils by Dex-MDM requires a serum 
opsonisation event. 
MDM were cultured in the absence or presence of 1M Dex for 5 days. Serum-free 
cultured heterologous apoptotic neutrophils were pre-incubated in the absence or 
presence of 10% fresh autologous serum for 1 hour prior to assessment of 
phagocytosis by untreated (white bars) and Dex-treated (black bars) MDM by flow 
cytometry. Serum preincubation of apoptotic neutrophils enhanced subsequent 
uptake by Dex-MDM (A, n=10), an effect that was significantly reduced by 
washing serum-preincubated apoptotic neutrophils with EDTA-containing medium 
prior to phagocytosis (B, n=3). Mean phagocytosis  SEM (*** p<0.001 when 
compared to uptake by Dex-MDM in the absence of serum, ** p<0.01 when 
compared to uptake by Dex-MDM in the presence of autologous serum, one-way 






3.3.7 Glucocorticoids augment phagocytosis of ‘early’ apoptotic neutrophils by 
macrophages 
We next carried out a temporal analysis of neutrophil apoptosis during serum-free 
culture and subsequent phagocytosis of these neutrophil cultures by Dex-MDM. 
Preliminary evidence using freshly isolated neutrophils showed that there was almost 
negligible cell death in these cultures (<1% annexin V+ cells, n=2), and fresh 
neutrophils were not phagocytosed by Dex-MDM (no serum: 4.8%; 10% serum: 
3.78%, n=2), in support of previous studies that human MDM phagocytosis requires 
apoptosis-related changes in the neutrophils (Savill et al., 1989b). 4-hour serum-free 
neutrophil cultures contained some apoptotic neutrophils (32–43% annexin 
V+/propidium iodide-, n=3. Results presented as 95% confidence limits), with little 
evidence of necrosis (1–3% annexin V+/propidium iodide+, n=3), and a significant 
percentage of Dex-MDM phagocytosed apoptotic neutrophils obtained from 4-hour 
cultures (fig. 3.9a; * p<0.05, n=3). Maximal Dex-MDM phagocytosis was observed 
when neutrophils populations were cultured in serum-free conditions for 12 hours 
(fig. 3.9a; ** p<0.01, n=3). 12-hour neutrophil cultures demonstrated higher levels of 
apoptosis (40-44% annexin V+/propidium iodide-, n=3), and very low levels of 
necrosis (<3% annexin V+/propidium iodide+, n=3). Importantly, Dex-MDM 
ingested 12-hour cultured neutrophils to a comparable rate observed for 20-hour 
neutrophil cultures (** p<0.01, n=3), a time-point where levels of apoptosis are 
higher (63–70%, n=35), and a significant proportion of neutrophils have become 
secondarily necrotic (18–26%, n=35).  
 
Neutrophils undergo apoptosis in a relatively heterogeneous manner during serum-
free culture in vitro (see Chapter 2, fig. 2.2b), making it difficult to determine 
whether enhanced phagocytosis following opsonisation with serum depends upon the 
stage of cell death. To overcome the issue of heterogeneity of phagocytic target 
populations, neutrophil cell death was actively induced by culture for 4 hours in 
serum-free conditions in the absence or presence of either 20M roscovitine, or 
10pg/ml TNF in combination with 0.1g/ml gliotoxin. After 4 hours in serum-free 
culture without treatment, there was a small proportion of apoptotic cells present 
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(32–43% annexin V+/propidium iodide-, n=3) with negligible secondarily necrosis 
(1–3% annexin V+/propidium iodide+, n=3) (fig. 3.9b). Neutrophil cultures treated 
with roscovitine exhibit a high percentage of apotosis (80–90% annexin 
V+/propidium iodide-, n=3) with little evidence of secondary necrosis (1–3% 
annexin V+/propidium iodide+, n=3). Similarly, treatment with TNF and gliotoxin 
generated high levels of apoptosis (79–91% annexin V+/propidium iodide-, n=3) 
with a slightly higher level of secondary necrosis (1–7% annexin V+/propidium 
iodide+, n=3). Thus, the target cells for use in phagocytosis assays will be at an early 
stage of apoptosis and allow determination of the effect of serum on uptake of 
apoptotic neutrophils in the absence of secondary necrosis. 
 
When untreated 4-hour serum-free cultured neutrophils were used as targets for 
phagocytosis, there was a small but statistically significant enhancement of Dex-
MDM phagocytosis in the presence of serum (fig. 3.9c; * p<0.05, n=3). However, a 
significant serum-dependent augmentation of Dex-MDM phagocytosis was 
observed for neutrophil cultures induced to undergo apoptosis by treatment with 
roscovitine or TNF/gliotoxin (fig. 3.9c; *** p<0.001, n=3). These data suggest that 
serum promotes internalisation of “early” apoptotic neutrophils by Dex-MDM and 








































































Figure 3.9: Effect of serum on Dex-MDM phagocytosis of “early” apoptotic 
neutrophils 
MDM were cultured in the absence or presence of 1M Dex for 5 days. A, The 
effect of 10% fresh autologous serum on MDM phagocytosis of serum-free cultured 
heterologous neutrophils (4h, 12h or 20h cultures) was assessed by flow cytometry. 
B and C, Neutrophils were untreated or treated with either 20M roscovitine, or 
10pg/ml TNF plus 0.1g/ml gliotoxin for 4h in serum-free medium. Neutrophil 
viability was determined by annexin V-FITC binding on FL-1 and propidium iodide 
staining on FL-2 (B) and MDM phagocytosis of 4h apoptotic neutrophils was 
assessed by flow cytometry (C). Mean phagocytosis  SEM, n=3 where n = the 
number of different macrophage donors. (*, p<0.05; **, p<0.01; *** p<0.001, one-
way ANOVA with a Bonferroni post test).  
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3.4.1 The role of serum in MDM phagocytosis of apoptotic neutrophils 
The environmental cues monocytes are exposed to during maturation has a profound 
influence on their phenotype and hence their capacity for phagocytosis. Under our 
standard culture conditions (IMDM containing 10% autologous serum), 5-day 
cultured untreated MDM were composed of a heterogeneous population of cells 
with different morphologies: multinucleated giant cells (MNGCs), spread cells that 
showed evidence of membrane ruffling, and more rounded cells that were weakly 
adherent (Giles et al., 2001). The morphological appearance of untreated MDM 
correlates with their phagocytic capability, where large multinucleated MDM were 
poorly phagocytic compared to efficient phagocytosis by smaller, more rounded 
macrophages (Heasman et al., 2004). Hence, the morphological and functional 
heterogeneity of MDM preparations may represent a complication when assessing 
the capacity for phagocytosis of apoptotic neutrophils and the role of serum in this 
process. Indeed, data obtained from studies of “serum-free” in vitro phagocytosis 
assays using such untreated MDM as phagocytes and serum-cultured neutrophils as 
apoptotic targets (Newman et al., 1982, Savill et al., 1989b) suggested that the 
presence of different concentrations of serum (0-75%) in the culture medium had no 
effect on the subsequent phagocytosis of apoptotic neutrophils by untreated MDM 
(Newman et al., 1982). However, Newman and colleagues assessed phagocytosis 
using 4-hour neutrophil cultures instead of the 20-hour cultures used in my study, 
therefore it is possible that maximal phagocytosis by untreated MDM was reached 
irrespective of serum. One possibility is that at this early time point of apoptosis, 
neutrophils may not have undergone the surface changes required for binding of 
serum opsonins that promote clearance by untreated MDM. Based upon these early 
reports, it has been widely assumed that serum is not required for apoptotic cell 
clearance. However, other studies have reported a serum requirement for untreated 
human MDM phagocytosis of apoptotic cells in vitro (Mevorach et al., 1998a, Bijl 
et al., 2003, Kask et al., 2004).  
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The in vivo importance of apoptotic cell clearance is well illustrated in the case of 
systemic lupus erythematosus (SLE), a systemic chronic inflammatory disease 
characterised by high titres of autoantibodies against nuclear constituents and 
deposition of immune complexes in kidney glomeruli (Haas, 1994, Reichlin, 1994) 
that may result from impaired clearance of apoptotic cells by macrophages before 
lysis and divulgence of cellular contents (Herrmann et al., 1998, Baumann et al., 
2002, Roos et al., 2004, Tas et al., 2006, Gaipl et al., 2007). Bijl et al reported that 
reduced uptake of apoptotic Jurkat cells by untreated MDM from human SLE 
patients was not an intrinsic macrophage defect, but was serum-dependent and could 
be reversed by addition of normal human serum (Bijl et al., 2006). This observation 
raised the possibility that the phagocytic capacity of MDM is not entirely dependent 
on the inherent capability of macrophages, but in certain conditions serum 
components may also play an important role. The contrasting reports on the role of 
serum in apoptotic cell clearance by untreated MDM may be a consequence of 
differences in methodology, semantics for definition of apoptosis/necrosis, the cell 
types used as apoptotic targets or the nature of the phagocyte population, and the 
conditions used for culture of phagocytic targets. Furthermore, it is unclear whether 
the “phagocytosis” signal in some of these studies may be a consequence of a failure 
to distinguish tethering of apoptotic cells from internalisation (Mevorach et al., 
1998a). Using a carefully validated in vitro phagocytosis assay (Jersmann et al., 
2003), we have shown that phagocytosis of serum-cultured neutrophils by untreated 
MDM occurred at an equivalent level in the absence or presence of serum during 
the phagocytosis assay. However, serum had a small (<8%) but statistically 
significant effect on untreated MDM phagocytosis of serum-free cultured 
neutrophils. When performing the EDTA washing experiment, we found that pre-
incubation of serum-free cultured neutrophils with autologous serum for 1 hour prior 
to phagocytosis resulted in a slight increase in uptake by untreated MDM, an effect 
that could be reversed by washing in EDTA-containing medium, but not calcium-
containing medium (IMDM) (no serum: 35.4%; 10% serum (1h): 44%; 10% serum 
(1h) EDTA wash: 35.7%; 10% serum (1h) IMDM wash: 42.5%). The “serum-free” 
phagocytosis assays performed by others used human neutrophils and MDM 
cultured in serum-containing medium, and both cell types were washed in calcium-
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containing HBSS before assessment of phagocytosis in the absence of added serum 
(Savill et al., 1989a, Savill et al., 1989b, Savill et al., 1992). Thus, previous studies 
may have missed a role for supplementary serum. 
 
 
3.4.2 Glucocorticoid augmentation of macrophage phagocytosis of apoptotic 
neutrophils is serum-dependent 
The effects of glucocorticoids on apoptotic cell clearance was first described by Liu 
et al, who demonstrated that short term exposure (final 24 hours) of 5-day human or 
murine MDM to the synthetic glucocorticoids methylprednisolone, Dex and 
hydrocortisone, increased phagocytosis of apoptotic neutrophils (Liu et al., 1999). 
Giles et al expanded this observation by showing Dex to enhance phagocytosis in a 
time-dependent manner, with the greatest effect observed following prolonged 
exposure (5 days) during in vitro culture (Giles et al., 2001). In order to investigate 
the mechanism of glucocorticoid-augmented phagocytosis, we employed an in vitro 
model using primary human MDM as phagocytes and neutrophils as apoptotic prey. 
This system may reflect in vivo conditions following an acute inflammatory event, 
where large numbers of extravasated neutrophils must be efficiently removed by 
undergoing apoptosis and ingestion by macrophages. Indeed, monocytes 
differentiating in vitro acquire many of the characteristics of mature macrophages 
(Musson et al., 1980, Newman et al., 1980). An advantage of using neutrophils as 
apoptotic targets is that they can isolated from peripheral blood in large numbers and 
easily separated from other leukocytes, providing nearly pure cell suspensions 
(routinely >95% purity). By necessity of experimental design, these studies were 
performed with neutrophils and MDM obtained from different donors, i.e. 
allogeneic phagocytosis. However, my own work and previously published data 
suggest that this does not affect MDM phagocytic potential.  
 
In this chapter, I demonstrated that enhanced phagocytosis by human MDM 
following long-term (5 days) exposure to 1M Dex involved a serum-dependent 
mechanism. The influence of serum may have been overlooked in previous studies 
where neutrophils were rendered apoptotic following in vitro culture in serum-
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containing media (Liu et al., 1999, Giles et al., 2001). In previous studies, MDM 
and apoptotic neutrophils were washed out of serum-containing medium before 
assessment of phagocytosis in the “absence” of serum. Based upon our findings, the 
presence of autologous serum during apoptosis induction was sufficient to confer 
augmentation of Dex-MDM phagocytosis, and no further enhancement was 
achieved following addition of serum during the phagocytosis assay. The precise role 
of serum in modulating the phagocytic process was only uncovered when apoptotic 
neutrophils were prepared in the absence of serum. When used in serum-free 
phagocytosis assays, serum-free cultured neutrophils were ingested by untreated and 
Dex-MDM at an equivalent rate. For Dex-MDM, this may represent the basal 
level of phagocytosis that is serum-independent. The addition of serum to serum-free 
neutrophil cultures immediately before phagocytosis restored Dex-MDM 
phagocytic capacity in a concentration-dependent manner, finally reaching levels 
observed for serum-cultured neutrophils at 10% serum. Similarly, Cortes-Hernandez 
et al demonstrated that Dex (200nM, 24h pre-treatment) significantly increased 
murine mesangial cell phagocytosis (2.5 fold) of apoptotic neutrophils in a serum-
dependent manner (Cortes-Hernandez et al., 2002). A comparison of the effects of 
different sera revealed that the serum effect was not restricted to autologous serum, 
i.e. serum prepared from PRP obtained from the macrophage or neutrophil donor, as 
non-autologous human serum or serum derived from alternative species, including 
mouse and FBS, were also capable of enhancing Dex-MDM phagocytosis. An 
exception was found with goat serum, which surprisingly conferred a slight 
inhibitory effect on Dex-MDM phagocytosis, an effect that may be a consequence 
of the presence of thimerosal preservative (0.01%) in goat serum that has been shown 




3.4.3 Glucocorticoid-treated macrophages are highly efficient phagocytes in terms 
of phagocytic capacity and swiftness of action 
Preliminary experiments suggested that acquisition of MDM phagocytic capacity 
for apoptotic neutrophils was accelerated following exposure to Dex, with Dex-
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MDM displaying enhanced levels of phagocytosis compared to untreated MDM as 
early as day 3 following isolation (data not shown). Temporal analysis of apoptotic 
neutrophil ingestion by 5-day Dex-MDM revealed serum-dependent uptake to be a 
rapid process, as ~40 and ~65% of Dex-MDM had internalised apoptotic 
neutrophils after only 10 and 20min, respectively, compared to ~18% and ~32% of 
untreated MDM at these time points. Although the percentage of untreated MDM 
that had internalised apoptotic neutrophils increased considerably after 30min of co-
incubation, we found that phagocytosis by Dex-MDM was consistently more than 
two-fold higher at this time point. Glucocorticoids also improve phagocytic 
efficiency by increasing the capacity of individual MDM to ingest multiple 
apoptotic neutrophils, and by promoting removal of alternative apoptotic targets like 
eosinophils and Jurkat T cells (Liu et al., 1999, Giles et al., 2001). Cortes-Hernandez 
et al confirmed this using a murine model, where Dex-treated mesangial cells were 
efficient phagocytes irrespective of lineage of apoptotic cells used (Cortes-
Hernandez et al., 2002). 
 
Previous work in our lab gave an insight into the intracellular molecular events 
associated with glucocorticoid-induction of a highly phagocytic macrophage 
phenotype (Giles et al., 2001). Despite their rounded appearance, scanning electron 
microscopy revealed Dex-MDM to form attachments with tissue culture plastic, 
however there was decreased cell spreading when compared with untreated MDM 
(Giles et al., 2001). Altered adhesion status was also observed by Ehrchen et al 
following short-term treatment (24 hours) of human monocytes with 10nM of the 
glucocorticoid, fluticasone propionate (Ehrchen et al., 2007). Interestingly, 
expression of surface molecules involved in cell adhesion, including CD44, CD11a, 
CD36 and ficolin, were downregulated following glucocorticoid treatment (Giles et 
al., 2001, Ehrchen et al., 2007). Furthermore, Dex-MDM display ruffled 
membranes and filopodial processes (Giles et al., 2001). These distinct 
morphological changes were associated with alteration of signalling complexes that 
play an essential role in adhesion processes, and have also been strongly implicated 
in regulation of MDM phagocytic capability. This link between regulation of 
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cytoskeletal machinery and phagocytic capacity has also been demonstrated upon 
ligation of CD44 (Hart et al., 1997) or adhesion to fibronectin (McCutcheon et al., 
1998), both of which significantly increased apoptotic neutrophil uptake by human 
untreated MDM. In contrast, elevation of cAMP using dibutryl-cAMP has been 
shown to disrupt cytoskeletal and adhesion contacts and inhibit phagocytosis of 
apoptotic neutrophils (Rossi et al., 1998).  
 
Despite these marked changes in cytoskeletal organisation and phosphorylation 
induced by Dex treatment, time-lapse video microscopy analysis of in vitro 
phagocytosis assays by Giles et al suggested that Dex-MDM were extremely 
membrane active through rapid extension and retraction of cellular processes 
sufficient for phagocytosis of serum-cultured neutrophils, a finding that correlated 
with increased levels of active Rac in these cells (Giles et al., 2001). Efficient 
clearance of apoptotic neutrophils in vivo is likely to be highly dependent on cell 
motility as it is unlikely that phagocytic macrophages would be in the immediate 
vicinity of apoptotic neutrophils. Indeed, our examination of time-lapse video 
sequences revealed that Dex-MDM continually contacted adjacent cells by sending 
out and retracting processes, and it is tempting to speculate that this allowed Dex-
MDM to detect signs of apoptosis. Once identified, apoptotic neutrophils were 
internalised swiftly. This active search for apoptotic prey required the presence of 
autologous serum, and may contribute to the swiftness of serum-dependent clearance 
by Dex-MDM. In contrast to our findings, time-lapse microscopy analysis of in 
vitro phagocytosis assays by Giles et al suggested that Dex-MDM did not appear 
actively motile during a 20-minute time-lapse sequence (Katherine Giles, 
unpublished data). It is important to mention that there were differences in the 
experimental methods used for time-lapse video microscopy in this study compared 
to that used in previous studies. Giles et al used serum-cultured neutrophils that were 
washed once prior to phagocytosis in the absence of serum. Based upon my data, I 
would predict that this was sufficient to trigger apoptotic neutrophil ingestion due to 
the presence of serum opsonins on the apoptotic sufarce. In contrast, we cultured 
neutrophils in the absence of serum and supplemented with autologous serum 
immediately prior to assessment of phagocytosis. Therefore, it is possible that the 
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motility observed in our Dex-MDM cultures is an additional serum-dependent 
process that is independent of the serum opsonisation phenomenon. 
 
As well as enhanced motility in the presence of autologous serum, many Dex-
MDM appeared more adherent and polarised in nature compared to the more 
rounded appearance of Dex-MDM in the absence of serum, possibly due to 
enhanced Rac activity in these cells. Intriguingly, a few of the Dex-MDM appeared 
to chase apoptotic neutrophils until they were bound and internalised. Interestingly, 
real-time analysis of Dex-MDM “wound” assays, performed by wounding MDM 
monolayers with a pipette tip followed by imaging of MDM migration into the 
wound, indicated that Dex-MDM had altered migratory potential (Sarah Heasman, 
unpublished data). When compared to untreated MDM, a polarised population of 
cells that showed formation of large lamellipodia and directed migration, Dex-
MDM migrated much faster and randomly extended and retracted membrane 
processes. However, in the intitial 3 hours of imaging, Dex-MDM displayed 
occasional formation of lamellipodia, suggesting that these cells had the potential for 
directed migration. The capacity of Dex-MDM for directed migration could be 
tested experimentally by performing transwell assays to examine the migratory 
potential of Dex-MDM added to Boyden chambers in the absence or presence of 
10% autologous serum, towards serum-free apoptotic neutrophil-conditioned 
medium or towards a defined macrophage chemoattractant like MCP-1. Interestingly, 
exposure to Dex may result in decreased phosphorylation and hence activity of 
extracellular signal-related kinase (ERK) (Katherine Giles, unpublished data), a 
signalling molecule thought to be important for directed migration (Klemke et al., 
1998, Cheresh et al., 1999). ERK activity can be stimulated by serum factors, 
including the ‘find me’ signal lysophosphatidylcholine (Dikic et al., 1996, Lauber et 
al., 2003), however ERK activity in Dex-MDM was not recovered by serum 
replenishment (Katherine Giles, unpublished data). Intriguingly, glucocorticoid-
treated monocytes display enhanced capacity for spontaneous migration (Ehrchen et 
al., 2007). Furthermore, microarray analysis and real-time PCR analysis of 
glucocorticoid-treated monocytes revealed increased expression of formyl peptide 
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receptor (FPR), the receptor for the potent chemoattractant fMLP (Ehrchen et al., 
2007). Upregulation of FPR at the protein level was confirmed by flow cytometry 
and correlated with increased chemotactic capacity of glucocorticoid-treated 
macrophages toward fMLP. Moreover, glucocorticoid treatment upregulated 
expression of intracellular signalling molecules involved in cell motility and 
chemotaxis of monocytes, including Traf2 and NCK interacting kinase and 
metastasis suppressor (Ehrchen et al., 2007). Despite these advances in 
understanding glucocorticoid effects on monocyte/macrophage motility, no study has 
evaluated the role of serum in this process. Hence, further experiments are required 
to investigate the serum effect on Dex-MDM motility and whether this is important 
for the augmented phagocytic capability of these cells. 
 
 
3.4.4 Glucocorticoids augment phagocytosis of ‘early’ apoptotic neutrophils by 
macrophages 
One of the problems with biochemical analysis of neutrophil apoptosis is the 
relatively heterogeneous manner in which neutrophils enter apoptosis during in vitro 
culture. Differences in the methodology used for inducing cell death in phagocytic 
targets may influence the extent of necrosis and/or opsonisation with serum 
components and thus directly affect the molecular pathways that are engaged in 
phagocytosis. It has been previously shown that neutrophils can be easily maintained 
in serum-free media (Payne et al., 1994). However, we found that serum-free 
cultured neutrophils progressed through the apoptotic process quicker than their 
serum-cultured counterparts, as evident by a slightly higher proportion of secondarily 
necrotic cells, consistent with the presence of a survival factor(s) in serum. Serum-
free culture also had a profound influence on the biochemical status of neutrophils, 
with surface expression of CD16, CD62L, CD11b and CD32 receptors significantly 
reduced after 20-24 hour culture in serum-free medium compared to neutrophil 
popuations maintained in serum-containing conditions (Stelios Bournazos, personal 
communication). The presence of a significant proportion of annexin V+/propidium 
iodide+ (secondarily necrotic) neutrophils within the phagocytic target population 
after induction of cell death in serum-free conditions may influence the effect of 
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serum on phagocytosis. In support of previous studies, freshly isolated neutrophils 
were not phagocytosed by Dex-MDM (Savill et al., 1989b). Instead, phagocytosis 
by Dex-MDM required neutrophils to undergo apoptotic-related processes during in 
vitro culture for at least 4 hours. Maximal Dex-MDM phagocytosis was observed 
with neutrophils cultured for 12 hours, where the proportion of apoptotic cells was 
much higher. Interestingly, a similar level of Dex-MDM were capable of serum-
dependent phagocytosis of 20-hour cultured neutrophils, despite the presence of 
significantly high levels of secondarily necrotic neutrophils, suggesting that post-
apoptotic changes were not required for the serum-enhancing effect.  
 
To overcome the issue of heterogeneity of neutrophil targets, we used the 
pharmacological methods described in Chapter 3, 3.1 Introduction to actively induce 
neutrophil cell death and allow investigation of the role of serum in Dex-MDM 
phagocytosis of apoptotic neutrophils in the absence of necrosis. We used a 4-hour 
treatment period since this was reported to be optimal both for synergistic effects of 
TNF and gliotoxin and for roscovitine, and we found that these treatments induced 
apoptosis in serum-free neutrophil cultures with little sign of secondary necrosis. 
These experiments showed that Dex-MDM still significantly ingested these 
apoptotic targets, indicating that serum promotes ingestion of “early” apoptotic 
neutrophils by Dex-MDM and the presence of secondarily necrotic neutrophils was 
not required. Our findings are in confirmation of work by Cortes-Hernandez et al, 
who reported that serum-dependent uptake by Dex-treated murine mesangial cells 
was specific for apoptotic neutrophils, and was not observed for viable or necrotic 
neutrophils (Cortes-Hernandez et al., 2002). The prompt clearance1 of cells at an 
early stage of apoptosis is essential to avoid the deleterious consequences that occur 
upon leakage of cellular contents during the later stages of apoptosis, including 
stimulation of pro-inflammatory responses by macrophages (Searle et al., 1982) and 
autoimmune reactions (Mevorach et al., 1998b, Botto, 1998, Herrmann et al., 1998, 
                                                 
1 Apoptotic cell clearance is a multi-step process requiring binding, internalisation, degradation and 
metabolism of apoptotic cell contents within the macrophage. The pattern of apoptotic cell 
opsonisation, the condition of the apoptotic cell (membrane intact/lysed, viral infection), and the 
receptor pathway employed by macrophages can have significant inflammatory and immunological 
consequences. 
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Scott et al., 2001, Gaipl et al., 2006, Tas et al., 2006), and may be a prerequisite for 
effective resolution of inflammation.  
 
 
3.4.5 Levels of phagocytosis by human MDM are highly variable 
Macrophages play a central role in triggering, instructing and terminating immune 
responses, and their ability to do so depends on the functional phenotype they 
acquire in response to environmental signals. As a result of these signals, 
macrophages can be markedly heterogeneous in their phenotype, allowing 
specialisation of function within particular microenvironments (Taylor et al., 2005). 
Hence, variation in phagocytic potential may result from the conditions monocytes 
are exposed to during in vitro culture. After isolation from peripheral blood, 
monocytes were selected by adherence to tissue culture plastic for 1 hour, after 
which the non-adherent lymphocytes were removed by washing. However, a residual 
number of lymphocytes will persist for the duration of the culture, releasing a 
number of cytokines including IL-10, IFN and IL-4, which can affect monocyte 
maturation/differentiation processes, including macrophage phagocytic capacity (Ren 
and Savill, 1995, Erwig et al., 1998, Michlewska et al., 2009). Additionally, 
autologous serum likely contains a number of cytokines and other modulatory 
agents, which may be variable between donors depending on factors such as 
immunological status and stress levels that may alter the MDM phagocytic 
response. Untreated cultures contain a highly heterogeneous population of MDM, 
and variation in capacity for phagocytosis may result from different levels of these 
cytokines in the culture medium. Although Dex induces a more homogeneous 
macrophage phenotype, the phagocytic potential of these cells may also be regulated 
by culture conditions, including the presence of immunoregulatory cytokines such as 
IFN and TNF (Heasman et al., 2004, Michlewska et al., 2009). It might be 
desirable to reduce lymphocyte contamination, with relatively pure monocyte 
populations achievable using the Macs system, or to use alternatives to autologous 
serum such as M-CSF. 
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Another important aspect to be considered is the proportion of apoptotic or 
secondarily necrotic cells in the target population. However, the phagocytic potential 
of Dex-MDM was not significantly altered by the percentage of secondary necrosis 
or by the number of apoptotic cells available in serum-free neutrophil cultures, as 
Dex-MDM phagocytosis was unaffected using neutrophil populations diluted to 
50% (3:1 ratio of apoptotic prey to Dex-MDM) of the normal concentration. This is 
further evidence that Dex-MDM are highly efficient in seeking out apoptotic prey, 
even when present in low numbers.  
 
 
3.4.6 Serum opsonises apoptotic neutrophils to promote their internalisation by 
Dex-MDM 
Macrophage phagocytosis of apoptotic cells is a highly complex process involving 
macrophage receptors and serum components that seem to operate in a redundant 
manner. Furthermore, macrophage receptors have distinct functions for direct 
binding of apoptotic cells, indirect binding of serum-opsonised apoptotic cells, and 
for internalisation, and it is likely that coordinated engagement of these phagocytic 
pathways is required for efficient uptake of apoptotic cells. Analysis of in vitro 
phagocytosis assays by confocal microscopy revealed that Dex-MDM we capable 
of binding apoptotic neutrophils in the absence of serum, but that serum was required 
to promote internalisation of bound apoptotic neutrophils. Macrophage phagocytic 
capacity can be regulated by serum in two ways: direct stimulation of macrophages 
to promote ingestion, or opsonisation of apoptotic cells to promote efficient removal. 
From serum pre-incubation studies, we demonstrated that serum opsonises apoptotic 
neutrophils to promote their ingestion by Dex-MDM. Furthermore, phagocytosis of 
serum-opsonised apoptotic neutrophils by Dex-MDM involved both cation-
dependent and cation-independent opsonisation events, suggesting that more than 
one serum-dependent pathway may participate in the opsonisation phenomenon and 
that cooperative action may be required for highly efficient clearance of apoptotic 
cells. Surprisingly, given the potential importance of apoptotic cell removal in so 
many diverse processes, there have been few studies that have compared molecular 
mechanisms and functional consequences of phagocytic clearance of early and late 
 77
apoptotic cells. Although reports on serum-dependent clearance have suggested that 
serum opsonins such as MBL, SAP and pentraxin-3 bind to late, membrane 
permeable (secondarily necrotic) cells to modulate their clearance by macrophages 
(Nauta et al., 2003c, van Rossum et al., 2004), our results suggest that serum 
opsonises “early” apoptotic cells for removal by Dex-MDM.  
 
The data presented in this chapter led to my initial attempts to identify the serum 
component(s), where I employed an “add-back” approach to assess the involvement 





CHAPTER 4: IDENTIFICATION OF A SERUM OPSONIN 




During in vitro culture, human neutrophils undergo spontaneous apoptosis and 
display a distinct surface molecular phenotype, including down-regulation of FcγRIII 
(CD16) and L-selectin expression, altered glycosylation of cell surface proteins, 
changes in surface charge, loss of CD31 detachment function, and exposure of PS 
(Dransfield et al., 1994, Dransfield et al., 1995, Martin et al., 1995, Hart et al., 2000, 
Brown et al., 2002). These changes distinguish them from viable neutrophils and 
signal their specific removal by human macrophages (Savill et al., 1989b). The 
phagocytic potential of macrophages may be enhanced by a number of soluble 
molecules that bind to or “opsonise” apoptotic neutrophils to promote their clearance 
through opsonin-specific receptors like integrins (Savill et al., 1992, Hanayama et al., 
2002) or complement receptors (Mevorach et al., 1998a, Ogden et al., 2001, 
Vandivier et al., 2002). The importance of apoptotic cell opsonisation is evident in 
C1q-deficiency, which leads to the development of an SLE-like autoimmune disease 
in mouse models and in humans characterised by impaired clearance of apoptotic 
cells (Botto, 1998, Taylor et al., 2000). Interestingly, many of the soluble molecules 
with a putative function as apoptotic cell opsonins are present in human 
plasma/serum (Rimoldi et al., 1989, Sorensen et al., 1996, Mevorach et al., 1998a) 
and therefore could mediate the pro-phagocytic effect of serum on Dex-MDM 
phagocytosis of apoptotic neutrophils. 
 
Analysis of surface receptor expression through mAb binding and flow cytometry 
revealed that glucocorticoids induce homogeneity in MDM surface receptor 
expression of HLA-DR, CD14, and CD44 (Giles et al., 2001). However, initial 
studies suggested that there was no apparent increase in the expression of putative 
phagocytic receptors that could account for the serum-dependent pro-phagocytic 
phenotype displayed by Dex-MDM. Functional inhibitor studies of phagocytosis 
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using specific mAbs and soluble ligand inhibitors failed to identify a dominant 
phagocytic pathway employed by Dex-MDM, with inhibition of CD36 or v3 
using SM mAb (1:50 ascites) or 0.5mM RGDS peptide respectively, or 10mM 
glucosamine (thought to inhibit a charge sensitive mechanism employing 
CD36/v3/TSP-1), or inhibition of PS-dependent recognition of apoptotic cells 
using 2mM phospho-L-serine, only partially suppressing Dex-MDM phagocytosis 
of apoptotic neutrophils (Giles et al., 2001). Ligation of CD44 on untreated human 
MDM induced a rapid increase in phagocytic uptake of apoptotic neutrophils (Hart 
et al., 1997), however CD44 was shown to be downregulated on Dex-MDM and 
preliminary studies suggested that CD44 ligation did not convey augmented 
clearance of apoptotic neutrophils (Giles et al., 2001). 
 
In the previous chapter, I demonstrated that augmented phagocytosis by Dex-MDM 
required serum-dependent opsonisation of apoptotic neutrophils. In this chapter, I 
employed an “add-back” approach in order to evaluate whether molecules with a 




4.2 Materials and methods 
 
4.2.1 Proteins and sera 
Fresh human platelet-poor plasma (PPP) was obtained following centrifugation of 
PRP at 13,000 x g for 1 minute to deplete the majority of platelets and leave an upper 
PPP layer that was transferred to a fresh epindorph. To obtain platelet releasate, 
platelets purified from human blood were prepared by washing in EDTA-containing 
PBS with 50mM glucose, then resuspended in PBS with 50mM glucose at 20U/ml at 
37C. Thrombin was added and left for 10min at 37C, after which a thrombin-
inhibitor was added and the material was centrifuged at 200 x g to remove 
aggregated platelets and the supernatant was retained. Serum, from coagulated whole 
blood, was obtained by cardiac puncture from wild-type, annexin 1-deficient 
(Hannon et al., 2003) and C1q-deficient (Botto, 1998) mice on a C57BL/6 
background. C1q-depleted human serum and purified human C1q were obtained 
from Merck. A soluble recombinant form of human complement receptor 1 (sCR1) 
(a kind donation from Paul Morgan) was used for inhibition of C3 activation in 
serum (Piddlesden et al., 1994). A dose of 250g/ml completely blocks complement 
activity as assessed by haemolytic assays (Paul Morgan, personal communication). 
The FPRL1 antagonist was a kind donation from Peter Barlow.  
 
4.2.2 Induction of neutrophil apoptosis 
CMFDA-labelled neutrophils were cultured at 4 x 106/ml in serum-free medium 
(IMDM) at 37C for 20-24 hours to render neutrophils apoptotic. Neutrophil 
populations were then centrifuged at 200 x g for 5min and resuspended in fresh 




4.3 Results  
 
4.3.1 Ultrafiltration of serum into size-specific fractions: a serum factor(s) larger 
than 50-kDa enhances uptake of apoptotic neutrophils by Dex-MDM 
From the results obtained in the previous chapter, it became clear that generation of 
apoptotic neutrophils in serum-containing medium was sufficient to confer 
augmentated clearance by Dex-MDM. To obviate the difficulty associated with 
serum opsonisation of apoptotic neutrophils during in vitro culture on investigating 
phagocytic pathways, we continued to use a system where neutrophils were rendered 
apoptotic in serum-free medium in order to address the role of single serum 
components or MDM receptor usage. Serum contains many different components 
that may mediate apoptotic neutrophil clearance, ranging from small molecules to 
very large protein complexes. In view of this, we sought to investigate the molecular 
weight of human serum components to narrow down the number of potential 
candidate molecules. To achieve this, autologous serum was fractionated using YM-
50 and YM-100 membranes, as described in Chapter 2, 2.9.2 Ultrafiltration of serum. 
Addition of 10% YM-50 retentate, but not YM-50 filtrate, enhanced phagocytosis of 
apoptotic neutrophils by Dex-MDM to similar levels conveyed by 10% unfiltered 
serum (fig. 4.1; *** p<0.001, n=4), indicating that the pro-phagocytic serum 
component(s) was larger than 50-kDa in molecular mass. Furthermore, preliminary 
data obtained using serum ultrafiltered through YM-100 membranes suggested that 
the serum component(s) was larger than 100-kDa in molecular mass (Dex 5d, No 
serum: 23%; 10% serum: 66.4%, 10% YM-100 filtrate (<100kDa): 20.3%; 10% YM-





























Figure 4.1: Effect of serum fractionation into size-specific fractions on uptake of 
apoptotic neutrophils by Dex-MDM. 
MDM were cultured in the absence or presence of 1M Dex for 5 days, and 
phagocytosis of serum-free cultured heterologous apoptotic neutrophils by untreated 
(white bars) and Dex-treated (black bars) MDM was assessed by flow cytometry. 
Dex-MDM phagocytosis of apoptotic neutrophils required a serum component 
larger than 50-kDa in molecular mass. Mean phagocytosis  SEM, n=4 where n = the 
number of different macrophage donors. (*** p<0.001 when compared to uptake by 
Dex-MDM in the absence of serum, one-way ANOVA with a Bonferroni post test). 








4.3.2 Boiling, but not heat-inactivation, significantly reduced the ability of serum 
to augment Dex-MDM phagocytosis 
Next, we wanted to investigate the biochemical nature of the serum component(s). 
For this, freshly prepared autologous serum was either boiled for 3min at 95C, or 
heat-inactivated for 30min at 56C, and then tested immediately for phagocytic 
activity. We found serum-dependent augmentation of Dex-MDM phagocytic 
capacity to be unaltered when the serum was heat-inactivated (fig. 4.2; p>0.05, n=3), 
suggesting that the component(s) was not heat-labile. However, boiling the serum 
significantly reduced the pro-phagocytic activity (fig. 4.2; ** p<0.01, n=3), 
suggesting that the required component(s) might be a protein.    
 
 
4.3.3 Ultracentrifugation of serum into particle-specific fractions: protein 
aggregates are not required for augmentation of Dex-MDM phagocytosis 
Due to the high molecular weight of the serum component indicated by serum 
fractionation (fig. 4.1), and the implication that the component was protein in nature 
(fig. 4.2), we decided to investigate whether serum-enhanced Dex-MDM 
phagocytosis involved binding of aggregated proteins to apoptotic neutrophils. Fresh 
autologous serum was ultracentrifuged to pellet out protein aggregates (see Chapter 
2, 2.9.1 Ultracentrifugation of serum). The middle straw-coloured protein layer was 
carefully removed to avoid disturbing the pellet or mixing with the upper lipid layer, 
and reconstituted to the original volume (200l) with IMDM. 10% of this 
ultracentrifuged fraction significantly enhanced Dex-MDM phagocytosis of 
apoptotic neutrophils to a similar extent as non-centrifuged serum (fig. 4.3; *** 
p<0.001, n=4), demonstrating that protein aggregates such as denatured proteins or 
immune complexes are not required. 
 
After gaining some insight into the molecular weight and biochemical nature of the 
serum component(s), we decided to take a more systematic approach through ‘add-



























Figure 4.2: Effect of boiling and heat-inactivation on the pro-phagocytic effect of 
serum. 
Phagocytosis assays were performed as described in Figure 4.1. Boiling, but not 
heat-inactivation, significantly reduced the pro-phagocytic effect of 10% fresh 
autologous serum on Dex-MDM (black bars) phagocytosis of heterologous 
apoptotic neutrophils. Mean phagocytosis  SEM, n=3 where n = the number of 
different macrophage donors. (*** p<0.001 when compared to uptake by Dex-
MDM in the absence of serum, ** p<0.01 when compared to Dex-MDM 


































Figure 4.3: Effect of ultracentrifugation on the pro-phagocytic effect of serum. 
Phagocytosis assays were performed as described in Figure 4.1. Ultracentrifugation 
(US AS) did not alter the pro-phagocytic effect of 10% fresh autologous serum (AS) 
on Dex-MDM (black bars) phagocytosis of heterologous apoptotic neutrophils. 
Mean phagocytosis  SEM, n=4 where n = the number of different macrophage 
donors. (** p<0.01, *** p<0.001 when compared to uptake by Dex-MDM in the 




4.3.4 High abundance human serum proteins, albumin and IgG, are not required 
for augmented phagocytosis by Dex-MDM 
Our serial dilution experiments from the previous chapter indicated that 
augmentation of Dex-MDM phagocytosis was still significant at 1% final serum 
concentration, suggesting that the pro-phagocytic component(s) may be present at a 
high concentration in serum. Albumin is the most abundant protein in serum, 
constituting around 60% of protein content (Travis et al., 1976). However, human 
serum albumin (HSA) at 1% final concentration did not increase Dex-MDM 
phagocytosis, instead conferring a slight inhibition on uptake of serum-free cultured 
apoptotic neutrophils compared to that in the absence of serum (fig. 4.4a; p>0.05, 
n=4), demonstrating that albumin is not required. Furthermore, preliminary data 
indicated that 1% albumin could also significantly inhibit serum-dependent 
phagocytosis of apoptotic neutrophils by Dex-MDM (untreated MDM, 10% 
serum: 28.3%; Dex-MDM, 10% serum: 76.2%, 10% serum plus 1% albumin: 
31.6%. n = 2). These data demonstrate that human serum albumin is not required for 
the serum effect. 
 
IgG, another prominent protein in serum, has been reported to stimulate uptake of 
apoptotic targets through Fc receptors on macrophages (Hart et al., 2004). However, 
addition of 2mg/ml human IgG during the assay did not enhance Dex-MDM 
phagocytosis above untreated control levels (fig. 4.4b; p>0.05, n=3), a finding that 
suggests IgG is not the pro-phagocytic component in serum and confirms previous 
reports that phagocytosis by Dex-MDM does not engage a pro-inflammatory 
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Figure 4.4: Effect of human albumin and IgG on uptake of apoptotic neutrophils by 
Dex-MDM. 
Phagocytosis assays were performed as described in Figure 4.1. In contrast to 10% 
fresh autologous serum (AS), 1% HSA (A, n=4) and 2mg/ml human IgG (B, n=3) 
failed to enhance Dex-MDM (black bars) phagocytosis of heterologous apoptotic 
neutrophils. Mean phagocytosis  SEM (*** p<0.001 when compared to uptake by 
Dex-MDM in the absence of serum, one-way ANOVA with a Bonferroni post test). 








4.3.5 Serum dependent-enhancement of Dex-MDM phagocytosis of apoptotic 
neutrophils does not require complement activation 
A number of complement proteins have been implicated in apoptotic cell 
opsonisation (Korb and Ahearn, 1997, Mevorach et al., 1998a). On this basis, we 
wanted to determine whether phagocytosis of serum-free cultured neutrophils by 
Dex-MDM required complement-dependent opsonisation, focusing on C1q and 
C3b opsonins. To investigate whether enhanced Dex-MDM phagocytic capacity for 
apoptotic neutrophils required opsonisation with C3b, autologous serum was pre-
treated for 10min with 250g/ml of a soluble recombinant form of human 
complement receptor 1 (sCR1) to inhibit C3 activation in serum prior to addition to 
apoptotic neutrophils (as described in 4.2.1 Proteins and sera). The pro-phagocytic 
effect of serum was still evident after inhibition of complement activation, with 10% 
C3-inhibitor-treated serum generating levels of Dex-MDM phagocytosis 
indistinguishable from those observed for 10% control PBS-treated serum (fig. 4.5a; 
p>0.05, n=4) (McColl et al., 2009).  
 
Initially, we assessed the phagocytic potential of complement C1q using 
commercially available C1q-depleted human serum and purified human C1q. 
Interestingly, 10% C1q-depleted human serum failed to enhance phagocytosis by 
Dex-MDM above levels observed in the absence of serum (fig. 4.5b; p>0.05, n=3), 
suggesting that C1q was the serum opsonin binding to apoptotic neutrophils for 
enhanced clearance by Dex-MDM. However, addition of 70g/ml purified human 
C1q alone or to C1q-depleted serum did not restore phagocytosis by Dex-MDM to 
levels observed in the presence of 10% autologous serum (fig. 4.5b; *** p<0.001, 
n=3). In order to further characterise the role of C1q, we took advantage of the 
observation that murine serum conferred augmentation of Dex-MDM phagocytosis 
(see Chapter 3, fig. 3.5c) and assessed phagocytic activity of serum obtained from 
C1q-deficient mice. We found that serum derived from either male (♂) or female (♀) 
C1q-deficient mice was able to confer augmentation of Dex-MDM phagocytosis of 
apoptotic neutrophils (fig. 4.5c; ** p<0.01, n=3) (McColl et al., 2009), demonstrating 


















































































Figure 4.5: Effect of C1q and C3b complement proteins on Dex-MDM 
phagocytosis. 
Phagocytosis assays were performed as described in Figure 4.1. A, Pre-treatment of 
10% fresh autologous serum (AS) with 250g/ml sCR1 to inhibit C3 activation had 
no effect on serum-enhanced phagocytosis by Dex-MDM (n=4). B, The pro-
phagocytic effect of human serum (frozen) was lost upon depletion of C1q, an effect 
that was not restored by addition of 70g/ml purified C1q (n=3). C, Serum from 
male (♂) or female (♀) C1q-deficient mice (frozen) enhanced Dex-MDM 
phagocytosis (n=3). Mean phagocytosis  SEM (*** p<0.001 compared to uptake by 
Dex-MDM in the presence of serum, ** p<0.01 compared to uptake by Dex-
MDM in the absence of serum, one-way ANOVA with a Bonferroni post test). N = 






The inability of C1q-depleted human serum to confer augmentation of phagocytosis 
by Dex-MDM may be attributable to the addition of EDTA during commercial 
depletion. Our data suggests that EDTA can inhibit binding of the serum opsonin(s) 
to apoptotic neutrophils and reduce ingestion by Dex-MDM. However, we did not 
observe a calcium-independent opsonising effect of C1q-depleted serum that was 
evident from autologous serum pre-incubation studies, and it is possible that 
contaminating EDTA in the assay medium may also directly inhibit Dex-MDM 
phagocytic capacity by chelating calcium required for initiating phagocytosis 
(Gronski et al., 2009). An alternative possibility is that through the method of C1q-
depletion, using anti-C1q bound to a column, C1q-binding proteins may have been 
inadvertently depleted. Interestingly, fibronectin and pentraxin-3, both proteins with 
an ability to bind C1q, may modulate human untreated MDM phagocytosis of 
apoptotic neutrophils in vitro (McCutcheon et al., 1998, van Rossum et al., 2004). 
However, addition of 50g/ml of human fibronectin (fig. 4.6a) or 5g/ml of human 
pentraxin-3 (fig. 4.6b) alone, or in combination with 70g/ml human C1q (data not 
shown), did not confer augmentation of Dex-MDM phagocytosis.  
 
Finally, we were surprised by preliminary data obtained using two independent 
sources of C1q, which inhibited serum-dependent phagocytosis by Dex-MDM (Dex 
5d, 10% serum: 67.8% phagocytosis; 10% serum plus 70g/ml C1q (Merck): 36.6% 
phagocytosis; 10% serum plus 70g/ml C1q (kindly supplied by Simon Hart): 40.9% 
phagocytosis. n=2, duplicate wells). Preliminary data suggested this inhibitory effect 
was specific to C1q, as serum-dependent augmentation of Dex-MDM phagocytosis 
was unaltered by addition of 20g/ml alpha-2 macroglobulin (10% serum: 67.8%; 
10% serum plus alpha-2 macroglobulin (Sigma): 68.1%. n=2, duplicate wells).  
 
This series of experiments demonstrating a lack of requirement of complement C3b 
and C1q for serum-enhanced Dex-MDM phagocytosis of apoptotic neutrophils was 
in confirmation of the heat-inactivation data (fig. 4.3), as activation of the 
complement system requires proteins that are heat-labile. Further investigations are 






















































Figure 4.6: Effect of the C1q-binding proteins, fibronectin and pentraxin-3, on Dex-
MDM phagocytosis. 
Phagocytosis assays were performed as described in Figure 4.1. In contrast to 10% 
fresh autologous serum (AS), 50g/ml human fibronectin (A) and 5g/ml human 
pentraxin-3 (B) failed to enhance Dex-MDM (black bars) phagocytosis of 
heterologous apoptotic neutrophils. Mean phagocytosis  SEM, n=3 where n = the 
number of different macrophage donors. (** p<0.01 when compared to uptake by 






4.3.6 The annexin-1/FPRL1 pathway is not utilised by Dex-MDM during removal 
of apoptotic neutrophils 
Annexin-1 is a glucocorticoid-inducible protein that exerts anti-inflammatory effects 
by signalling through members of the FPR family, in particular FPRL1 (Walther et 
al., 2000, Perretti et al., 2001, Perretti et al., 2002, Ernst et al., 2004, Hayhoe et al., 
2006, John et al., 2007). Annexin-1 and annexin-1 derived peptides have been 
reported to stimulate FPRL1-dependent phagocytosis of apoptotic neutrophils by 
human untreated MDM in vitro (Maderna et al., 2005, Scannell et al., 2007). To 
evaluate whether this pathway was utilised by Dex-MDM for phagocytosis of 
apoptotic neutrophils, Dex-MDM were pre-treated with 10M WRW4, an FPRL1 
antagonist, for 1 hour prior to assessment of phagocytosis. However, we found that 
inhibition of the FRPL1 pathway did not abolish serum-dependent phagocytosis by 
Dex-MDM (fig. 4.7a; p>0.05, n=3).  Despite a slight enhancing effect of WRW4 
pre-treatment on serum-dependent uptake by Dex-MDM (p>0.05, n=3), pre-
treatment with WRW4 did not augment Dex-MDM phagocytosis in the absence of 
serum (18.5% phagoctyosis, n=2), nor did it have any effect on phagocytosis by 
untreated MDM in the presence of serum (23.6% phagocytosis, n=3). 
 
We decided to further characterise the phagocytic potential of annexin-1 using 
annexin-1-deficient mouse serum, and found the effect of 10% annexin-1-deficient 
serum to be indistinguishable from control matched annexin-1 wild type serum in 
enhancement of Dex-MDM phagocytosis of apoptotic neutrophils (fig. 4.7b; 
p>0.05, n=3). Interestingly, both wild type and annexin-1-deficient mouse sera 
conferred an even more significant enhancement of Dex-MDM phagocytic capacity 
than observed for autologous serum (fig. 4.7b; ** p<0.01, *** p<0.001, n=3). 
 
Together, these data suggest that the annexin-1/FPRL1-dependent pathway is not 
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Figure 4.7: Effect of the annexin-1 on phagocytosis by Dex-MDM. 
Phagocytosis assays were performed as described in Figure 4.1. A, Pre-treatment of 
Dex-MDM (black bars) with 10M WRW4, an FPRL-1 antagonist, failed to inhibit 
the uptake of heterologous apoptotic neutrophils in the presence of 10% fresh 
autologous serum (AS). B, Annexin-1 deficiency did not reduce the ability of mouse 
sera (frozen) to enhance Dex-MDM phagocytosis. Mean phagocytosis  SEM, n=3 
where n = the number of different macrophage donors. (* p<0.05, ** p<0.01, *** 
p<0.001 when compared to uptake by Dex-MDM in the absence of serum, one-way 





4.3.7 Dex-MDM phagocytosis of apoptotic neutrophils does not require a 
platelet-derived factor 
Fresh autologous serum was prepared by recalcification of human plasma, a process 
which induces platelet aggregation and stimulates the abundant release of platelet 
factors. It was therefore imperative to determine whether a platelet-derived product 
such as TSP-1 was responsible for enhancement of Dex-MDM phagocytosis of 
apoptotic neutrophils. We initially evaluated Dex-MDM phagocytic capacity in the 
presence of human platelet-poor plasma (PPP), prepared by centrifugation of whole 
plasma to deplete platelets (as described in 4.2.1 Proteins and sera). Addition of 10% 
PPP to the culture medium resulted in formation of a “jelly-like” material, 
presumably due to activation of the coagulation cascade. As discussed in the 
previous chapter, serial dilution experiments showed that 1% serum was sufficient to 
significantly enhance Dex-MDM phagocytosis (see Chapter 3, fig. 3.3). 
Accordingly, the use of 1% PPP avoided the complication of coagulation during the 
assay and demonstrated that platelet depletion had no significant effect on the ability 
of human plasma to augment Dex-MDM phagocytosis of apoptotic neutrophils (fig. 
4.8a; p>0.05 when compared to uptake in the presence of 1% autologous serum, 
n=3). To further investigate the phagocytic potential of platelet-derived factors, we 
assessed phagocytosis in the presence of platelet releasate, prepared as described in 
4.2.1 Proteins and sera. However, we found that 50g/ml platelet releasate did not 
enhance apoptotic neutrophil uptake by Dex-MDM (fig. 4.8b). These data 
suggested that Dex-MDM phagocytosis does not require a platelet-derived factor.  
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Figure 4.8: Effect of human platelet-poor plasma and platelet releasate on 
phagocytosis by Dex-MDM. 
Phagocytosis assays were performed as described in Figure 4.1. A, 1% fresh human 
platelet poor plasma (PPP) was equivalent to 1% fresh autologous serum (AS) in 
enhancement of Dex-MDM phagocytosis of heterologous apoptotic neutrophils. B, 
50g/ml platelet releasate did not confer augmentation of Dex-MDM phagocytosis. 
Mean phagocytosis  SEM, n=3 where n = the number of different macrophage 
donors. (*** p<0.001 when compared to uptake by Dex-MDM in the absence of 




4.4 Discussion  
 
4.4.1 Opsonisation plays an essential role in apoptotic cell clearance: effect on 
macrophage phagocytic potential and immunological consequences  
The uptake of apoptotic cells by macrophages involves two stages; firstly, the 
recognition and “tethering” of the apoptotic cell by the macrophage, and secondly, its 
ingestion and destruction within the macrophage (Henson et al., 2001). Macrophages 
express a multitude of surface receptors that bestow the capacity for apoptotic cell 
recognition. Although some of these receptors have been suggested to mediate direct 
recognition and tethering of apoptotic cells prior to engulfment, including scavenger 
receptors, CD31, CD14 and CD36 (Rigotti et al., 1995, Platt et al., 1996, Devitt et 
al., 1998, Vernon-Wilson et al., 2006), most macrophage receptors do not directly 
bind to apoptotic cells. Rather, efficient clearance by macrophages requires soluble 
host proteins that may “opsonise” the altered apoptotic cell surface and provide a 
mechanism for phagocytic removal that does not require general “apoptotic cell” 
receptors, allowing diversity of phagocyte responses both in terms of the apoptotic 
cell type recognised and the phagocytic cell that is capable of recognition based on 
opsonin receptor expression. As demonstrated in the previous chapter, Dex-MDM 
efficiently recognised and ingested neutrophils that had undergone spontaneous 
apoptosis during culture in 10% serum, but did not display phagocytic potential for 
serum-free cultured neutrophils (Chapter 3, figs. 3.1 and 3.2). Ingestion of serum-free 
cultured apoptotic neutrophils instead required opsonisation of apoptotic neutrophils 
with serum proteins prior to phagocytic interaction (Chapter 3, figs. 3.8). Many 
plasma/serum components have been accredited with an ability to function as 
apoptotic cell opsonins including pentraxins (SAP, CRP and pentraxin-3), collectins 
(MBL, SP-A and SP-D), complement proteins, antibody, TSP-1, 2-GPI, MFG-E8, 
properdin and galectin-3 (Savill et al., 1992, Balasubramanian et al., 1997, Mevorach 
et al., 1998a, Bickerstaff et al., 1999, Gershov et al., 2000, Rovere et al., 2000, Gaipl 
et al., 2001, Schagat et al., 2001, Ogden et al., 2001, Mold et al., 2002, Hanayama et 
al., 2002, Nauta et al., 2003c, Zwart et al., 2004, Xu et al., 2008, Karlsson et al., 
2009), promoting apoptotic cell clearance through opsonin-specific receptors (Savill 
et al., 1992, Mevorach et al., 1998a, Finnemann and Rodriguez-Boulan, 1999, Ogden 
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et al., 2001, Vandivier et al., 2002, Hanayama et al., 2002). Interestingly, many of 
these soluble proteins are important effectors in innate recognition of microbial 
products. How similar opsonin-dependent receptor mechanisms can be used to 
generate both pro- and anti-inflammatory outcomes to foreign and self-antigens, 
respectively, is unclear, but is likely to require complex pathways of integrated 
signalling to generate these diverse responses. Furthermore, the pattern of 
opsonisation may have significant consequences in terms of the cellular response to 
apoptotic cells, both with respect to the phagocyte population engaged and the 
inflammatory outcome of this interaction. For example, opsonisation with of 
apoptotic neutrophils with immune complexes may induce a pro-inflammatory 
macrophage phenotype upon ingestion, inducing the release of TNF and IL-6 
presumably as the result of ligation of macrophage FcRs (Hart et al., 2004), whereas 
ingestion of CRP-opsonised cells is associated with release of anti-inflammatory 
mediators by macrophages (Gershov et al., 2000). Many of these soluble proteins 
may be produced locally by the macrophages themselves (Ezekowitz et al., 1984, 
Hanayama et al., 2002, Faust et al., 2002, Maderna et al., 2005), allowing 
macrophages to influence the pattern of apoptotic cell opsonisation through opsonin 
availability and subsequently the clearance mechanism(s) engaged based on the 
different environmental signals received by macrophages during normal tissue 
homeostasis, inflammation and chronic disease. Interestingly, glucocorticoids 
upregulate monocyte/macrophage opsonin and scavenging mechanisms known to be 
associated with apoptotic cell recognition and uptake, including MFG-E8, C1q, 
collectins (MBL, SP-A and SP-D), SLPI and annexin I opsonins, and FPR1 and 
Mertk receptors (Abbinante-Nissen et al., 1995, de Coupade et al., 2001, Faust et al., 
2002, Maderna et al., 2005, Ehrchen et al., 2007), which would be consistent with 
involvement of an opsonisation mechanism for apoptotic neutrophil clearance by 
glucocorticoid-treated macrophages.  
 
There are discrepancies in reports of the stage of cell death necessary for binding of 
such recognition molecules, which may partially be explained by differences in 
semantics, experimental design and phagocytic readout. Several reports have 
suggested opsonisation with serum proteins like IgG, TSP-1, collectins and 
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pentraxins to be a relatively late event in apoptosis, proceeding PS exposure and loss 
of mitochrondrial membrane potential and instead occurring when cells have become 
membrane-permeable (i.e. secondary necrotic cells), possibly as a mechanism for 
regulating removal of these potentially damaging cells and their contents (Hart et al., 
2000, Rovere et al., 2000, Gershov et al., 2000, Gaipl et al., 2001, Navratil et al., 
2001, Vandivier et al., 2002, Nauta et al., 2003c, Bijl et al., 2003, van Rossum et al., 
2004, Zwart et al., 2004, Hart et al., 2005). The role of serum opsonisation in the 
uptake of “early” apoptotic cells has not yet been fully established. In order to assess 
the role of serum opsonisation in uptake of “early” apoptotic neutrophils by Dex-
treated macrophages, we initally employed an “add-back” approach using well-
defined apoptotic cell serum opsonins.  
 
 
4.4.2 Serum fractionation identified a fraction larger than 50-kDa with phagocytic 
activity that was not due high abundance serum proteins or protein 
aggregates 
Due to the abundance of factors in serum with the ability to modulate apoptotic cell 
clearance, we decided to minimise the number of potential components through 
serum fractionation techniques. The pro-phagocytic effect of serum was only evident 
in serum fractions containing components larger than 50-kDa in molecular weight, 
allowing us to rule out stimulation of Dex-MDM phagocytosis by cytokines or 
small lipid mediators such as prostaglandins that have previously demonstrated to 
modulate untreated MDM phagocytosis of apoptotic neutrophils (Ren and Savill, 
1995, Rossi et al., 1998). The abolishment of phagocytic activity upon boiling serum 
(95 for 3min) indicated that the serum effect likely required a protein component. A 
small number of proteins represent a high percentage of the total protein content in 
serum, including albumin and IgG, which have a molecular weight of >50-kDa (Steel 
et al., 2003, Best et al., 2006). However, these high abundance proteins did not 
confer augmentation of Dex-MDM phagocytosis for apoptotic neutrophils. We 
were surprised to find that HSA actually exerted a slight inhibitory effect on basal 
levels of phagocytosis and significantly abrogated serum-enhanced phagocytosis by 
Dex-MDM. Decreased spreading of neutrophils in the presence of HSA (Nathan et 
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al., 1993), and possibly a similar effect on Dex-MDM, may have impacted on the 
phagocytic interaction and subsequent serum-dependent internalisation of apoptotic 
neutrophils. Visualisation of the effect of albumin on Dex-MDM phagocytosis by 
time-lapse video microscopy might provide a valuable insight into the characteristics 
required for highly efficient phagocytosis by these cells in the presence of serum. 
 
Many human inflammatory diseases like SLE are associated with the production, 
circulation and tissue deposition of immune complexes (Gaipl et al., 2007, Yung and 
Chan, 2008), and inflammatory processes can be mimicked by administration of 
immune complexes in animal models (Yamaguchi et al., 1975, Guo and Ward, 
2002). In diseases such as antiphospholipid syndrome (APLS), autoantibodies may 
be produced against phospholipid-associated serum proteins such as 2-GPI, which 
binds to apoptotic cells via PS (Price et al., 1996, Subang et al., 2000). Previous work 
in our lab demonstrated specific opsonisation of apoptotic, but not viable human 
neutrophils with human IgG-containing immune complexes in an FcRIIA-
dependent manner (Hart et al., 2004). Although surface expression of FcRIIA was 
reduced on apoptotic neutrophils, the receptor may have been functionally “enabled” 
during apoptosis to generate increased avidity for immune complex binding. We 
have shown that removal of immune complexes and other aggregated proteins by 
ultracentrifugation had no effect on the pro-phagocytic activity of serum. 
Furthermore, monomeric IgG does not bind significantly to apoptotic neutrophils 
(Hart et al., 2004) or enhance their removal by Dex-MDM. The data presented here 
indicate that serum-dependent augmentation of Dex-MDM phagocytic capacity for 




4.4.3 The role of the complement system in apoptotic cell clearance 
The complement system is an integral part of innate immune defence against 
invading pathogens. One important consequence of activation of the complement 
cascade is the cleavage of complement C3 to generate large amounts of C3b product 
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(Volanakis, 1990), which exerts a major effector function of complement via 
opsonisation of pathogens or infected target cells (Yuste et al., 2008). Most of this 
surface-bound C3b is rapidly converted by the serum protease factor I to C3bi, a 
more stable product that retains opsonic activity (Nagasawa and Stroud, 1977). 
Complement receptors mediate binding and ingestion of target cells opsonised with 
complement proteins or their degradation products, including CR1 (CD35), which 
binds C3b, C4b and C1q (Fearon, 1980, Klickstein et al., 1997), and the relatively 
C3bi-specific receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18) (Brown, 1991, 
Sengelov, 1995, Carroll, 1998). Human monocytes/macrophages express all three of 
these receptors (Mevorach et al., 1998a), highlighting their essential role in 
phagocytic removal of complement-opsonised targets.  
 
Apoptotic cells have also been shown to trigger complement activation to become 
opsonised with C3b/C3bi (Tsuji et al., 1994, Matsui et al., 1994, Takizawa et al., 
1996). Neutrophils undergoing apoptosis down-regulate surface expression of 
complement regulatory molecules DAF (CD55), MCP (CD46), and CR1 (CD35) 
(Jones and Morgan, 1995) that may allow complement activation to proceed on the 
cell surface and lead to opsonisation with these complement factors. Furthermore, 
exposure of PS on apoptotic cells has been suggested to contribute to this 
opsonisation phenomenon (Mevorach et al., 1998a). Using an entirely autologous 
system of MDM, apoptotic neutrophils and serum from the same human donor, 
Mevorach et al showed that phagocytic interaction between untreated MDM and 
apoptotic neutrophils in vitro could be enhanced ~4-fold by the presence of 10-15% 
serum, with little association of apoptotic cells with macrophages in the absence of 
serum (Mevorach et al., 1998a). Serum-dependent augmentation of phagocytosis 
required C3bi opsonisation of apoptotic neutrophils for removal through CR3 and 
CR4 on untreated MDM. C3bi-dependent uptake of apoptotic cells via CR3 and 
CR4 has also been demonstrated by Takizawa et al using alternative apoptotic targets 
and phagocytes (Takizawa et al., 1996). This requirement for complement activation 
in the clearance of apoptotic cells is contrary to the common perception that 
apoptotic cell clearance is a non-inflammatory process, as it imposes the risk of 
assembly of membrane-attack complexes on the apoptotic cell surface and 
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inflammatory consequences following cell lysis. However, CR3-mediated 
phagocytosis by macrophages does not trigger release of leukotrienes (Aderem et al., 
1985) or generate a respiratory burst (Wright and Silverstein, 1983), as well as 
suppressing production of pro-inflammatory cytokines like IL-12 (Marth and Kelsall, 
1997). Interestingly, Mevorach et al rendered neutrophils apoptotic (20-30% annexin 
V+) following incubation in medium in the absence of serum for 6 hours, a time 
point when very low levels of necrosis were obtained (<5% propidium iodide-
positive), indicating that the presence of necrosis was not required for C3bi-
dependent phagocytosis (Mevorach et al., 1998a). However, untreated MDM 
phagocytosis required significantly higher ratios of apoptotic targets to macrophages 
(40:1), and the pro-phagocytic effect of serum was significantly diminished 
following heat-inactivation of serum (56 for 30min) or depletion of C3b (Mevorach 
et al., 1998a). Of note, levels of phagocytosis in these studies were low and efficient 
uptake required longer interaction times of up to 3 or 4 hours (Takizawa et al., 1996). 
Furthermore, the methods used by Mevorach et al to measure phagocytic ability did 
not distinguish between binding and internalisation of apoptotic cells by MDM, and 
indeed there appeared to be a significant amount of binding in their microscopy 
images of phagocytosis (Mevorach et al., 1998a). Through pre-treatment of serum 
with sCR1 to inhibit complement C3 activation, we have shown that serum enhanced 
apoptotic neutrophil uptake by Dex-MDM independently of complement activation, 
suggesting that CR3 and CR4 receptor pathways are not utilised by Dex-MDM. 
Although a dose of 250g/ml sCR1 completely blocks complement activity as 
assessed by haemolytic assays (Paul Morgan, personal communication), experiments 
to confirm inhibition of C3bi opsonisation of apoptotic neutrophils were not 
performed in this study and could be assessed by immunofluorescence via flow 
cytometry or microscopy using specific mAbs. The lack of requirement for C3bi 
opsonisation in MDM clearance of apoptotic neutrophils has been previously 
demonstrated in vitro, where blocking with mAb to macrophage CR3 and CR4 failed 
to affect uptake by untreated MDM (Savill et al., 1989a), and also in vivo using 
CD11b- and CD18-deficient mice, which lack the CR3 receptor (Ren et al., 2001). 
Furthermore, macrophages from patients with leukocyte adhesion deficiency, a 
condition caused by deficiency of CD18, display normal phagocytic capacity for 
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apoptotic neutrophils (Davies et al., 1991). However, the consequence of 
complement receptor deficiency for serum-dependent phagocytosis by 
glucocorticoid-treated MDM remains to be determined. 
 
C1q, a ~440-kDa protein comprising six heterotrimeric chains arranged to form a C-
terminal globular head region (GHR) and an N-terminal collagen-like tail region, is 
an important subcomponent of complement C1 that activates the classical pathway 
upon binding to immune complexes or CRP via the GHR recognition domain (Reid 
and Porter, 1976, Gaboriaud et al., 2003, Kishore et al., 2004). In addition to this 
function in activation of the complement cascade, C1q also interacts with cells to 
modulate their function. C1q binds specifically to the surface blebs of human 
apoptotic cells in vitro via the GHR domain (Korb and Ahearn, 1997, Navratil et al., 
2001). Although surface blebbing during apoptosis in neutrophils is a rare process 
(Savill et al., 1989b, Payne et al., 1994), apoptotic neutrophils have been shown to 
bind C1q (Ogden et al., 2001, Donnelly et al., 2006). Interestingly, pre-incubation of 
apoptotic neutrophils with C1q increased subsequent ingestion by untreated human 
MDM upon stimulation of a calreticulin/CD91 complex (Ogden et al., 2001), 
suggesting that C1q can function as an apoptotic cell opsonin. C1q binding occurs at 
an early stage of apoptosis, concurrent with exposure of PS on the surface of the 
apoptotic cell (Paidassi et al., 2008). The importance of C1q in apoptotic cell 
opsonisation has been highlighted by in vivo studies of C1q-deficiency (Botto, 1998, 
Taylor et al., 2000), where impaired clearance of apoptotic cells is thought to 
contribute to the development of an SLE-like autoimmune disease characterised by 
high titres of autoantibodies and accumulation of apoptotic cells in glomeruli of C1q-
deficient mice. Interestingly, defective clearance of apoptotic cells is also observed in 
human SLE patients (Herrmann et al., 1998, Gaipl et al., 2006, Tas et al., 2006) and 
may contribute to disease pathogenesis (Mevorach et al., 1998b). Additionally, 
human C1q deficiency leads to SLE in ~90% of cases (Petry et al., 1997), suggesting 
that C1q may protect against development of SLE by targeting early apoptotic cells 
for clearance before they become membrane-permeable and expose self-antigenic 
material to the immune system (Paidassi et al., 2008). Indeed, C1q-deficient 
untreated human MDM cultured in autologous serum show impaired phagocytosis 
 103
of apoptotic cells, and phagocytic ability can be restored with purified human C1q 
(Taylor et al., 2000). Furthermore, normal human serum depleted of C1q lost its pro-
phagocytic activity on apoptotic cell clearance by untreated MDM (Mevorach et al., 
1998a, Kask et al., 2004). Interestingly, glucocorticoids increase C1q expression in 
human monocytes/macrophages (Armbrust et al., 1997, Faust et al., 2002, Ehrchen et 
al., 2007), suggesting that this innate protein may convey an anti-inflammatory 
function of glucocorticoids. We initially obtained encouraging data using 
commercially available C1q-depleted human serum, which failed to confer 
augmentation of apoptotic neutrophil uptake by Dex-MDM. However, addition of 
purified human C1q during the phagocytosis assay in the absence of serum, or even 
when added along with the corresponding C1q-depleted human serum, did not 
restore phagocytosis by Dex-MDM to the levels observed in the presence of 
autologous serum. One possible explaination is that the commercially obtained C1q 
was functionally inactive, and one approach to investigating this would be to perform 
a complement fixation test to assess the ability of C1q to activate complement-
induced lysis of antibody-coated sheep red blood cells in the presence of C1q-
depleted human serum. Binding of C1q to apoptotic neutrophils could also be 
evaluated by immunofluorescence via flow cytometry or microscopy using specific 
mAbs.  
 
The lack of pro-phagocytic role for purified human C1q when added alone during 
phagocytosis was also observed by Mevorach et al, who suggested that instead of 
acting as a direct opsonin for apoptotic neutrophil clearance, C1q in the presence of 
serum may activate the complement system to generate C3b/iC3b opsonins for 
enhanced phagocytosis by untreated MDM (Mevorach et al., 1998a). However, as 
discussed above, inhibition of C3 activation and subsequent generation of C3b/iC3b 
opsonins did not abrogate the serum-enhancing effect on Dex-MDM. Moreover, 
C1q-deficient mouse serum was able to confer phagocytic activity, demonstrating 
that C1q is not involved. Alteratively, the method used to prepare commercially 
available C1q-depleted serum, where normal human serum was passed through an 
anti-C1q column, may have removed other serum proteins involved in the 
recognition of apoptotic neutrophils. Fibronectin, a high molecular weight 
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glycoprotein present in soluble form in plasma, is a functional C1q-binding protein 
(Pearlstein et al., 1982, Sorvillo et al., 1983) that can also bind to the surface of 
neutrophils (Hoffstein et al., 1981) and function as an opsonin in vivo and in vitro 
(Saba and Jaffe, 1980). Although adhesion of untreated human MDM to 
immobilised fibronectin rapidly augments uptake of apoptotic neutrophils 
(McCutcheon et al., 1998), soluble human plasma-derived fibronectin did not exert 
this effect (Vernon-Wilson et al., 2006). We did not find a pro-phagocytic effect for 
soluble fibronectin in apoptotic neutrophil uptake by Dex-MDM, even when used in 
combination with C1q. Several members of the pentraxin family have been 
demonstrated to bind C1q, including C-reactive protein, serum amyloid protein and 
pentraxin-3 (Hicks et al., 1992, Nauta et al., 2003a, Baruah et al., 2006). 
Interestingly, opsonisation with C1q has been suggested to target apoptotic cells to 
dendritic cells (Nauta et al., 2004), and pentraxin-3 binding to C1q in the fluid phase 
can inhibit C1q-mediated uptake of apoptotic cells by these phagocytes (Baruah et 
al., 2006). This suggests that binding to other serum opsonins may regulate C1q 
function in apoptotic cell clearance, both in terms of the phagocyte targeted and 
inflammatory outcome. In terms of macrophage phagocytic potential, pentraxin-3 has 
been suggested to inhibit phagocytosis of late apoptotic neutrophils (van Rossum et 
al., 2004). However, the phagocytic potential of Dex-MDM for apoptotic 
neutrophils was unaltered in the presence of pentraxin-3. IgM represents an 
additional C1q binding protein (Zwart et al., 2004) that functions as an apoptotic cell 
opsonin (Kim et al., 2003). However, a role for IgM in promoting phagocytosis by 
Dex-MDM has been disproved previously in our lab (data not shown).  
 
Finally, examination of Dex-MDM phagocytosis of apoptotic neutrophils by time-
lapse video microscopy indicated that phagocytosis was an active process mediated 
by extension of membrane process around the particle followed by rapid 
internalisation (Giles et al., 2001). This is not indicative of complement receptor-
dependent phagocytosis, where complement-opsonised particles instead sink into the 
phagocyte surface and are engulfed without the extension of pseudopodia (Kaplan, 
1977). Dex-enhanced phagocytosis of apoptotic neutrophils in a serum-dependent 
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but complement-independent manner has also been reported in a murine model of 
phagocytosis using Dex-treated mesangial cells (Cortes-Hernandez et al., 2002).  
 
 
4.4.4 The role of the annexin-1/FPR-L1 pathway in apoptotic cell clearance  
Annexin-1 is a glucocorticoid-inducible protein thought to mediate many of the anti-
inflammatory actions of glucocorticoids in vivo, as demonstrated by altered 
expression of annexins, COX-2, and cytoplasmic phospholipase A2 (cPLA2); 
exaggerated responses to carrageenin- or zymosan-induced inflammation; and partial 
resistance to the anti-inflammatory effects of glucocortocoids in annexin-1-deficient 
mice (Hannon et al., 2003, Yang et al., 2004, Yang et al., 2006). Administration of 
exogenous annexin-1 conferred anti-inflammatory activity in some models of 
inflammatory disease (Arur et al., 2003), being particularly effective in the 
carrageenin paw oedema model where an intense accumulation of neutrophils is 
observed (Cirino et al., 1989). Conversely, infusion of annexin-1 antibodies 
neutralises the effect of annexin-1 and abrogates the anti-inflammatory activities of 
glucocorticoids (Duncan et al., 1993, Yang et al., 1999). It has been suggested that 
autoantibodies to annexin-1 may contribute to glucocorticoid resistance and the 
pathogenesis found in inflammatory diseases where glucocorticoids may be used as a 
treatment, such as rheumatoid arthritis and SLE (Goulding et al., 1989, Podgorski et 
al., 1992).  
 
Although undetectable in plasma, annexin-1 is expressed in many leukocytes and 
tissues (Morand et al., 1995, Voermans et al., 1997, Solito et al., 1998, de Coupade et 
al., 2000) and has been suggested to have a multifactoral role in modulating 
apoptotic neutrophil clearance. Predominately localised in the cytosol of resting 
neutrophils (Perretti, 1998), annexin-1 may undergo caspase-dependent recruitment 
to the outer plasma membrane during apoptosis and colocalise with surface-exposed 
PS to facilitate recognition by macrophages (Arur et al., 2003). Additionally, 
annexin-1 released by macrophages (Maderna et al., 2005) or apoptotic neutrophils 
(Scannell et al., 2007) may function as a pro-phagocytic factor, actively promoting 
FPRL1-dependent clearance of apoptotic neutrophils by human MDM in a non-
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phlogistic and concentration-dependent manner, and bone marrow-derived 
macrophages from annexin-1-deficient mice show defective phagocytosis of 
apoptotic neutrophils compared to wild-type mice (Maderna et al., 2005). 
Interestingly, expression and release of annexin-1 by murine neutrophils (Perretti and 
Flower, 1996) and human monocytes/macrophages (Comera and Russo-Marie, 1995, 
Maderna et al., 2005), and FPRL1 expression by human monocytes (Sawmynaden 
and Perretti, 2006) are increased following glucocorticoid treatment. Furthermore, 
soluble annexin-1 binds in a PS-dependent manner to promote tethering and 
internalisation of apoptotic cells, suggesting an opsonic function (Arur et al., 2003). 
However, experiments using a FPRL1 antagonist, or using annexin-1-deficient 
mouse serum demonstrated that this pathway is not utilised by Dex-MDM for 
recognition of serum-opsonised apoptotic neutrophils. This may also rule out a role 
for LXA4, another FPRL1 ligand known to stimulate non-phlogistic phagocytosis of 
apoptotic neutrophils by human MDM in vitro (Godson et al., 2000) and in vivo 
(Mitchell et al., 2002), however additional experiments using a purified form of 
lipoxin A4 are required in order to evaluate the precise role of this molecule with 
respect to Dex-MDM phagocytic potential. Annexin-1 is a relatively small 
molecule of 37-kDa (Hannon et al., 2003), hence the lack of requirement for 
annexin-1 opsonisation is consistant with data obtained from serum fractionation 
experiments, where phagocytic activity was only present in serum fractions 
containing components larger than 50-kDa in molecular mass.  
 
 
4.4.5 Platelet-derived factors are not required for phagocytosis of apoptotic 
neutrophils by Dex-MDM 
Autologous serum in our system was prepared by recalcification of human PRP, a 
process that induces platelet aggregation and the release of platelet factors (Browder 
et al., 2000). TSP-1 is a platelet-derived product that has been reported to enhance 
clearance of apoptotic neutrophils through a CD36/v3 receptor complex on the 
surface of untreated human MDM (Savill et al., 1992). Enhanced macrophage 
recognition was still evident if apoptotic neutrophils were pre-incubated with TSP-1, 
indicating that TSP-1 may function as an opsonin of apoptotic neutrophils (Savill et 
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al., 1992). The role of CD36 class B scavenger receptor and v3 vitronectin 
receptor in the uptake of serum-opsonised apoptotic neutrophils has been 
demonstrated in blocking studies using specific mAbs and the tetrapeptide arg-gly-
asp-ser (RGDS) to block CD36 and v3 integrin receptor function, respectively 
(Savill et al., 1990, Savill et al., 1992). Mevorach et al also observed inhibition of 
serum-dependent uptake of apoptotic cells by untreated human MDM in the 
presence of RGDS peptide, albeit the inhibition was only partial (20%) (Mevorach et 
al., 1998a). Although Cortes-Hernandez et al demonstrated serum-dependent 
phagocytosis of murine apoptotic cells by Dex-treated murine glomerular mesangial 
cells to be entirely inhibitable by RGDS tetrapeptide (Cortes-Hernandez et al., 2002), 
inhibitors of CD36 (sm mAb 1:50 ascites) and v3 (0.5mM RGDS peptide) did 
not prevent serum-dependent phagocytosis of apoptotic neutrophils by human Dex-
MDM (Giles et al., 2001). It is possible that augmentation of phagocytosis 
following treatment with glucocorticoids may require different receptor mechanisms 
based on phagocytic cell type or species origin. I have demonstrated in this chapter 
that PPP still contains phagocytic activity whereas platelet releasate displayed no 
enhancing effect on Dex-MDM. Taken together, these data indicate that the 
CD36/v3/TSP-1 pathway does not play a major role in apoptotic neutrophil 
uptake by Dex-MDM in an entirely human system. Furthermore, this may rule out a 
role for MFG-E8, a bridging molecule that binds to PS on apoptotic cells to promote 
their removal through v3 integrin on macrophages (Hanayama et al., 2002). 
However, future experiments are required to test the phagocytic potential of human 
purified MFG-E8 on apoptotic neutrophil ingestion by Dex-MDM. 
 
In this chapter, I employed an “add back” approach to assess the contribution of 
well-defined opsonins in clearance of apoptotic neutrophils by Dex-MDM. We 
have shown phagocytosis to be serum-dependent, requiring a protein opsonin larger 
than 50-kDa in molecular weight that is not an antibody, complement protein, 
annexin I, or a platelet-derived factor. To identify the component, we next undertook 
a more investigative approach to obtain a serum fraction with pro-phagocytic activity 
using chromatography techniques. 
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CHAPTER 5: PURIFICATION OF THE PRO-PHAGOCYTIC 
PROTEIN USING CHROMATOGRAPHY TECHNIQUES 
 
5.1 Introduction 
Based upon the data presented in chapters 3 and 4, I have demonstrated that highly 
efficient clearance of apoptotic neutrophils by Dex-MDM involves a serum-
dependent mechanism, and using an “add-back” approach during in vitro 
phagocytosis assays I was unable to demonstrate a requirement for several well-
characterised apoptotic cell opsonins. A limitation to using whole serum for 
identification of our apoptotic cell opsonin is that serum represents a highly complex 
mixture of proteins, and while many of these proteins such as SP-A, SAP and 
complement proteins have been suggested to promote apoptotic neutrophil clearance 
by untreated macrophages when added individually to in vitro “serum-free” 
phagocytosis assays (Mevorach et al., 1998a, Schagat et al., 2001, Mold et al., 2002), 
only deficiency in C1q or MFG-E8 appears to have significant in vivo consequences 
in terms of impaired clearance of apoptotic cells (Botto, 1998, Taylor et al., 2000, 
Hanayama et al., 2004), suggesting possible redundancy in serum-dependent 
apoptotic cell clearance mechanisms. It was therefore unlikely that the serum 
opsonin would be discovered using a “scouting” approach. Proteins can be purified 
from complex sources using chromatography techniques that separate them 
according to differences in specific properties. We hypothesised that our serum 
opsonin could be isolated from human serum using a multi-step purification scheme 
involving anion exchange and gel filtration chromatography to fractionate serum 
proteins based on surface charge and molecular weight, respectively. Importantly, 
these chromatography methods offer high binding capacities and high-resolution 
separation, make them ideal for purification of proteins from serum. Indeed, ion 
exchange and/or gel filtration chromatography techniques have been applied in 
several studies for protein purification from human plasma/serum, including isolation 
of ferritin (Worwood et al., 1976), IgA (Loomes et al., 1991) and complement 
proteins (Hammer et al., 1981), and more specifically for isolation of proteins 
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involved in apoptotic cell clearance, such as human C-reactive protein (Mold et al., 
2001), human C1q (Kishore et al., 1998) and human fibronectin (Buck et al., 1992).  
 
5.1.1 Purification strategy 
In order to test our hypothesis that the pro-phagocytic factor could be isolated from a 
complex protein mixture in human serum, we firstly decided to fractionate serum 
proteins according to their net surface charge using anion exchange chromatography. 
This technique is recommended as a first step in purification (i.e. protein capture) 
when little is known about the target molecule. We chose to perform anion exchange 
using positively charged mono Q Sepharose that associates only with negatively 
charged proteins or “anions”. The net charge on a given protein and hence its ability 
to bind to mono Q Sepharose can be significantly influenced by altering the buffering 
conditions, especially pH. The isoelectric point (pI) of a protein, the pH at which a 
particular protein has an overall neutral charge and will not bind to either a cationic 
(negative) or anionic (positive) exchanger, can be used to determine protein binding 
capabilities at a particular pH. Only proteins with a pI below the pH of the buffering 
solution will have a net negative charge and hence bind to the anion exchanger. 
Bound proteins are eluted from mono Q Sepharose by increasing the ionic strength of 
the buffering solution. To achieve better separation of crude protein fractions 
containing the pro-phagocytic activity of serum obtained following optimisation of 
anion exchange chromatography, we decided to further fractionate proteins 
according to molecular weight via gel filtration. Since preliminary experiments 
indicated the serum opsonin to be larger than 100-kDa in molecular mass (see 
Chapter 4, fig. 4.1b), we decided to use Sephacryl S-300 gel. Fractionation by gel 
filtration is based on differential diffusion of proteins into the gel; high molecular 
weight proteins (HMW) do not enter the gel pores and pass through the column 
quicker than low molecular weight proteins (LMW). Thus, proteins elute from the 
column in order of decreasing molecular weight, allowing size-specific fractions to 
be tested for pro-phagocytic activity. 
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5.2 Materials and methods 
 
5.2.1 Serum proteins and antibodies 
Protein S, obtained from Enzyme Research Laboratories, was isolated from human 
plasma and supplied as lyophilized powder (>95% purity by SDS PAGE analysis) 
that was reconstituted at 1mg/ml in dH2O.  
 
5.2.2 Induction of neutrophil apoptosis 
CMFDA-labelled neutrophils were cultured at 4 x 106/ml in serum-free medium 
(IMDM) at 37C for 20-24 hours to render neutrophils apoptotic. Neutrophil 
populations were then centrifuged at 200 x g for 5min and resuspended in fresh 
IMDM prior to assessment of phagocytosis. 
 
5.2.3 Flow cytometry 
Neutrophils cultured for 20-24 hours in serum-free conditions were pre-incubated for 
1 hour with 2.5g/ml human protein S or 10% autologous serum as a source of 
protein S, then incubated for 30min with 10g/ml of unlabelled polyclonal rabbit 
anti-human protein S antibody or rabbit IgG as a control, washed twice then 
incubated for 30min with a secondary FITC-conjugated anti-rabbit antibody. 
Neutrophil cultures were washed twice before assessment of protein S binding by 
flow cytometry. IMDM was used throughout for incubations and washes. Duplicate 
wells were used for each experiment, and the experiment was repeated twice more 






5.3.1 Serum fractionation by anion exchange chromatography using variations in 
pH: the serum factor binds at pH7 
Many serum proteins have a pI of around 5 – 8, some of which are indicated in Table 
1. We hypothesised that altering the pH of the buffering solution used for anion 
exchange chromatography would allow binding and hence purification of different 
proteins from serum. In order to investigate this, we prepared buffering solutions at 
pH6 (50mM MES and 0.14M NaCl), pH7 and pH8 (50mM HEPES and 0.14M 
NaCl) and fractionation of serum proteins by anion exchange was performed as 
previously described (see Chapter 2, 2.10.1.1 Optimisation of pH). As shown in 
Figure 5.1, the pro-phagocytic component in fresh human serum was bound to mono 
Q Sepharose at pH7 or pH8 at an ionic strength of 0.14M NaCl, and was eluted with 
0.5M NaCl. Furthermore, the component bound very efficiently at pH7 and pH8, as 
there was no phagocytic activity in the flow through at these pH values (fig. 5.1). No 
significant phagocytic activity was found in either the flow through or eluted 
fractions when ion exchange was performed using pH6 buffer (50mM MES and 
0.14M NaCl). One possibility is that slight acidification may have resulted in 
irreversible loss of the serum factor required for enhanced Dex-MDM phagocytosis, 
an effect that could be tested via acidification of human serum prior to addition to 
phagocytosis assays. Alternatively, the serum factor may only be stable above pH6, 
resulting in reduced binding to mono Q Sepharose at pH6. 
 
Thus, the pro-phagocytic component(s) of human serum bound to mono Q Sepharose 
at pH7, indicating that the component(s) has a pI value below 7. We chose to 
perform subsequent anion exchange chromatography experiments at pH7 since we 
anticipated that fewer proteins would bind at this pH and thus facilitate identification 





Protein pI value Reference 
Albumin 4.7 www.sigmaaldrich.com 
Thrombospondin 4.7 (Lawler et al., 1978) 
Alpha-2 macroglobulin 5.2 (Barrett et al., 1979) 
Protein S 5 – 5.5 (DiScipio and Davie, 1979)  
IgM 5.5 – 6.7 (Prin et al., 1995) 
C4BP 6.7 (Nagasawa and Stroud, 1980) 
 
 
Table 1: Approximate pI values of proteins in human plasma/serum.  





























Figure 5.1: Isolation of a fraction displaying the pro-phagocytic activity of serum by 
anion exchange chromatography. 
MDM were cultured in the absence or presence of 1M Dex for 5 days, and 
phagocytosis of serum-free cultured heterologous apoptotic neutrophils by untreated 
(white bars) and Dex-treated (black bars) MDM was assessed by flow cytometry. 
Fresh human serum proteins bound to mono Q Sepharose at pH7 or pH8 (50mM 
HEPES and 0.14M NaCl) enhanced uptake of apoptotic neutrophils by Dex-MDM, 
with no pro-phagocytic activity observed in the flow through at these pH values. No 
pro-phagocytic activity was observed in either bound or flow through fractions 
obtained from anion exchange of human serum at pH6 (50mM MES and 0.14M 
NaCl). Mean phagocytosis  SEM, n=3 where n = the number of different 
macrophage donors. (*** p<0.001 when compared to uptake by Dex-MDM in the 
absence of serum, one-way ANOVA with a Bonferroni post test). Phagocytosis by 
untreated MDM is shown for comparison.  
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5.3.2 Serum fractionation by anion exchange chromatography using a salt 
gradient: 0.2M fractions contain the pro-phagocytic activity 
Proteins display different binding capacities that can influence how/when they are 
eluted from mono Q Sepharose. We hypothesised that altering the ionic strength of 
the buffering solution used during the elution step would allow further separation of 
proteins according to strength of binding. In order to investigate this, fresh serum 
proteins bound to mono Q Sepharose at pH7 were eluted using a linear salt gradient 
of 0.2M to 0.5M NaCl prepared in pH7 buffer (50mM HEPES) as described in 
Chapter 2, 2.10.1.2 Optimisation of ionic strength, and elution of bound proteins was 
determined spectrophotometrically at 280nm (fig. 5.2a). Fractions were resolved by 
SDS PAGE on 9% gels under reducing conditions, as described in Chapter 2, 2.13 
SDS polyacrylamide gel electrophoresis (fig. 5.2b). Most serum proteins bound to 
mono Q Sepharose at pH7 were eluted with 0.2M NaCl, with less protein evident in 
0.3M NaCl elutions and negligible protein in 0.4M and 0.5M NaCl elutions (figs. 
5.2a and b). Protein concentration in 0.2M and 0.3M fractions, estimated by the 
Pierce BCA method, was routinely found to be 15mg/ml and 1.5mg/ml, respectively. 
When added at a final concentration of 1.5mg/ml, we found that 0.2M NaCl, but not 
0.3M NaCl elutions contained the pro-phagocytic activity of serum (fig. 5.2c and d). 
The effect on Dex-MDM phagocytosis of apoptotic neutrophils was found to be 
dependent on the protein concentration of the 0.2M fraction and reached significance 
at 100g/ml (fig. 5.3), suggesting that the pro-phagocytic component may be a 
prominent protein in 0.2M fractions. 
 
Thus, we have shown that the pro-phagocytic component(s) of serum binds to mono 
Q Sepharose at pH7 at an ionic strength of 0.14M NaCl, and can be eluted with 0.2M 






















































Figure 5.2: 0.2M anion exchange fractions contain the pro-phagocytic activity of 
serum. 
A, A280 measurements of anion exchange fractions eluted from mono Q Sepharose 
at pH7 using a salt gradient. B, Anion exchange fractions were resolved by SDS 
PAGE on 9% gels under reducing conditions then stained with Coombassie blue. 
Lane 1, 1:10 pH7-equilibrated serum; lane 2, 1:10 pH7 anion exchange flow through; 
lane 3, 0.2M elution; lane 4, 0.3M elution; lane 5, 0.4M elution. Anion exchange 
fractions were not standardised, showing that bound protein was mostly eluted with 
0.2M NaCl. C and D, Serum proteins bound to mono Q Sepharose at pH7 and eluted 
with 0.2M NaCl (D, n=6), but not 0.3M NaCl (C, n=3) (final concentration of 
1.5mg/ml used for each) enhanced uptake of heterologous apoptotic neutrophils by 
Dex-MDM to a similar extent as unfractionated human serum. Mean phagocytosis 
 SEM (*** p<0.001 when compared to uptake by Dex-MDM in the absence of 
serum, one-way ANOVA with a Bonferroni post test). N = the number of different 
macrophage donors. 



























































Figure 5.3: Effect of altering the protein concentration of 0.2M anion exchange 
fractions on uptake of apoptotic neutrophils by Dex-MDM. 
Phagocytosis assays were performed as described in Figure 5.1. 0.2M anion 
exchange fractions enhanced Dex-MDM phagocytosis of heterologous apoptotic 
neutrophils in a concentration-dependent manner, reaching half-maximal and 
maximal activity at a final concentration of 0.1mg/ml and 3mg/ml, respectively. 
Mean phagocytosis  SEM, n=3 where n = the number of different macrophage 
donors. (* p<0.05, ** p<0.01, *** p<0.001 when compared to uptake by Dex-
MDM in the absence of serum, one-way ANOVA with a Bonferroni post test). 
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5.3.3 Identification of a high molecular weight fraction with phagocytic activity by 
gel filtration 
Selection of the appropriate buffering pH for protein binding and ionic strength of 
buffer for protein elution allowed optimal isolation of the pro-phagocytic protein 
from fresh human serum during anion exchange chromatography. However, a 
considerable number of protein contaminants were also evident when 0.2M fractions 
were resolved by SDS PAGE followed by staining with Coomassie blue (fig. 5.2b). 
In order to acheive better resolution, we decided to further separate proteins in 0.2M 
anion exchange elutions according to molecular weight by gel filtration.  
 
A Sephacryl S-300 gel filtration column was calibrated with protein standards using 
the same sample volume (250l), flow rate (2ml/min) and fraction volume 
(1.6ml/tube) throughout (as described in Chapter 2, 2.10.2.1 Calibration of the gel 
filtration column) and elution of proteins was determined spectrophotometrically at 
280nm (fig. 5.4a). The volume of 1 x TBS buffer required to elute protein standards 
was calculated by measuring the volume collected from the point of protein 
application to the centre of the elution peak (Table 2). Two partially overlapping 
peaks of protein with descending molecular weight were consistently obtained 
following fractionation of 0.2M anion exchange samples (figs. 5.4a and b) (McColl 
et al., 2009). We have shown the serum opsonin to be calcium-dependent, so gel 
filtration fractions were reconstituted with 1mM CaCl2 prior to addition to 
phagocytosis assays. Fractions A and B from the leading edge of the first peak, 
representing HMW proteins (>300-kDa) were found to contain the pro-phagocytic 
activity of serum, whereas LMW protein fractions were devoid of phagocytic activity 











































Figure 5.4: High molecular weight gel filtration fractions contain the pro-phagocytic 
activity of serum. 
Serum proteins were fractionated by anion exchange followed by gel filtration of 
0.2M elutions. A, Protein elution profile of a typical gel filtration separation (of 4 
that were performed) determined by measurement of absorbance at 280 nm (A280) 
reveals two partially overlapping peaks of protein. B, Gel filtration samples (labelled 
A-G) were separated on a 9% acrylamide gel under reducing conditions and bands 
visualised with 0.5% Coomassie blue (IE: 0.2M ion exchange fraction). C, Gel 
filtration fractions (labelled A-G) were standardised for protein content (final 
concentration of 50g/ml). HMW fractions A and B significantly augmented Dex-
MDM (black bars) phagocytosis of heterologous apoptotic neutrophils. Mean 
phagocytosis  SEM, n=3 where n = the number of different macrophage donors. (** 
p<0.01, *** p<0.001 when compared to uptake by Dex-MDM in the absence of 

































Protein standard (molecular weight) Ve 
Blue dextran (2,000-kDa) 57.6ml 
-amylase (200-kDa) 78.4ml 
Alcohol dehydrogenase (150-kDa) 83.2ml 
Albumin (66-kDa) 89.6ml 
Carbonic anhydrase (29-kDa) 97.6ml 
Cytochrome c (12.4-kDa) 110.4ml 
 
TABLE 2: Determination of the elution volume (Ve) for proteins standards. 
To calculate the elution volume, the volume of effluent collected from the point of 






5.3.4 Analysis of high molecular weight gel filtration fractions by Mass 
Spectrometry: Identification of C4-binding protein, IgM and alpha-2 
macroglobulin as candidate proteins  
HMW proteins in gel filtration fraction A were resolved by SDS PAGE using 12% 
gels under reducing conditions (fig. 5.5). Analysis of protein bands by mass 
spectrometry revealed three of the principle proteins present in this active fraction as 
high molecular mass IgM, 2-macroglobulin and C4-binding protein (C4BP) (fig.5. 
5). Previous work has eliminated a role for IgM in the augmentation of Dex-MDM 
phagocytosis of apoptotic cells (data not shown). Addition of 20g/ml 2-
macroglobulin failed to restore augmented phagocytosis by Dex-MDM, suggesting 
that 2-macroglobulin was not involved (fig. 5.6a; p>0.05, n=3) (McColl et al., 
2009). C4BP acts to prevent excessive complement activation and cell lysis 
occurring as a consequence of assembly of the membrane attack complex. In order to 
investigate whether C4BP contributed to the prophagocytic effect of serum on Dex-
MDM, we attempted to immunodeplete C4BP from 0.2M anion exchange fractions 
using a mouse anti-human C4BP mAb (see Chapter 2, 2.12 Protein immunodepletion 
from human serum). However, 0.2M fractions resolved on 12% gels and 
immunoblotted for C4BP demonstrated that C4-binding protein (~75-kDa) could not 
be effectively depleted using this mAb (fig. 5.6b). Interestingly, the multiple C4BP 
bands observed under reducing conditions correlate well with the protein bands 
observed on 12% reduced gels stained with Coombassie blue (fig. 5.5 and 6b). The 
slight decrease in phagocytosis observed for C4BP- and control-depleted fractions 
may be a consequence of dilution of the phagocytic activity upon addition of a large 
volume of anti-C4BP in attempt to successfully deplete C4BP, or mouse IgG as a 
control (20l per 100l 0.2M fractions for each of three rounds of depletion) (fig. 
5.6b and c).  
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Figure 5.5: Analysis of high molecular weight fractions by mass spectrometry. 
Proteins in HMW gel filtration fraction A were resolved by SDS PAGE using 12% 
gels under reducing conditions. Bands selected for analysis by mass spectrometry are 
numbered according to decreasing molecular weight. The accompanying table shows 
the putative proteins present in each band. Abbreviations: MW, molecular weight. 
 
Band Hypothetical Protein (s) MW (kDa) 
1 Lipoprotein ~233 
2 
Fibronectin 1 isoform 6 
preproprotein 
~ 243 
3 IgM heavy chain ~ 50 
4 




5 C4-binding protein alpha chain ~ 69 
6 Cullin 4A isoform 1 ~ 88 
7 
C4-binding protein alpha chain 
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Figure 5.6: Effect of alpha-2 macroglobulin and C4BP on uptake of apoptotic 
neutrophils by Dex-MDM. 
A, 20g/ml 2-macroglobulin failed to enhance uptake of heterologous apoptotic 
neutrophils by Dex-MDM (black bars). B, 0.2M anion exchange fractions were 
separated on a 9% gel under reducing or non-reducing conditions and immunoblotted 
for C4BP using 1:500 anti-C4BP and 1:2500 HRP-conjugated goat anti-mouse Ig. 
Lane 1, 0.2M fraction; lane 2, C4BP-depleted 0.2M fraction; lane 3, mock control-
depleted 0.2M fraction. Immunodepletion experiments using a mouse anti-human 
C4BP mAb failed to successfully deplete C4BP (B) or reduce the pro-phagocytic 
effect of 0.2M fractions when compared to a mouse IgG mock control depletion (C). 
(0.2M, 0.2M eluate; C4BPd, 0.2M C4BP-depleted; C4BPmd, 0.2M mock C4BP-
depleted; +, 250 ng/ml purified protein S). Mean phagocytosis  SEM, n=3 where n 
= the number of different macrophage donors. (* p<0.05, ** p<0.01, *** p<0.001 
when compared to uptake by Dex-MDM in the absence of serum, one-way 






















5.3.5 Protein S promotes phagocytosis of apoptotic neutrophils by Dex-MDM 
C4BP exists as a >570-kDa high affinity complex with protein S (Dahlback et al., 
1983). Whilst the C4BP-protein S complex has been suggested to inhibit 
phagocytosis of apoptotic cells, free protein S has been reported to stimulate uptake 
of early, membrane-intact (annexin V+/propidium iodide-) apoptotic cells by 
untreated human MDM (Anderson et al., 2003, Kask et al., 2004). Protein S exists 
in human plasma at ~25g/ml, and addition of 25g/ml human purified protein S to 
the assay medium fully restored Dex-MDM phagocytosis of apoptotic neutrophils 
to levels conferred by 10% autologous seurm (fig. 5.7).  To determine the effect of 
protein S concentration on Dex-MDM phagocytosis of apoptotic neutrophils, we 
altered the final concentration added to apoptotic neutrophils before use in a 
phagocytosis assay. The effect of protein S on Dex-MDM phagocytosis was found 
to be dose-dependent, reaching half-maximal activity at 75ng/ml (fig. 5.7; * p<0.05, 
n=3) with full stimulatory effects observed at concentrations of 250ng/ml or above 
(fig. 5.7; *** p<0.001, n=3) (McColl et al., 2009). The pro-phagocytic effect of 
protein S was lost at 25ng/ml (equivalent to 1:1000 concentration in serum). As the 
most significant augmentation of Dex-MDM phagocytosis was observed using 
2.5g/ml protein S, a concentration found in 10% human serum, we used this 
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Figure 5.7: Effect of protein S on uptake of apoptotic neutrophils by Dex-MDM. 
Phagocytosis assays were performed as described in Figure 5.1. Purified human 
protein S enhanced phagocytosis of serum-free cultured heterologous apoptotic 
neutrophils by Dex-MDM (black bars) in a concentration-dependent manner. Mean 
phagocytosis  SEM, n=3 where n = the number of different macrophage donors. (*, 
p<0.05; *** p<0.001 when compared to uptake by Dex-MDM in the absence of 
serum, one-way ANOVA with a Bonferroni post test).  
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5.3.6 Pro-phagocytic activity in 0.2M anion exchange fractions was lost upon 
depletion of protein S 
To find the best concentration of anti-protein S antibody for immunoblotting, several 
wells of 15l of 2.5g/ml purified human protein S were resolved by SDS PAGE 
under non-reducing conditions using 9% gels. Following transfer to PVDF (80V for 
50min), the membrane was cut and immunoblotting performed using different 
dilutions of anti-protein S (fig. 5.8a). A dilution of 1:5000 was deemed to produce 
the most satisfactory results and was used for subsequent protein S immunoblotting 
experiments. 
 
Although protein S was not identified by mass spectrometry, we confirmed the 
presence of protein S in 0.2M fractions eluted from mono Q Sepharose at pH7 and in 
HMW gel filtration fractions, presumably in complex with C4BP (figs. 5.8b and c). 
To investigate whether protein S was the protein in human serum required for 
augmented phagocytosis by Dex-MDM, we immunodepleted protein S from 0.2M 
anion exchange fractions using a polyclonal rabbit anti-human protein S antibody, 
and rabbit IgG was added to the same volume of 0.2M fractions as a control (see 
Chapter 2, 2.12 Protein immunodepletion from human serum). 0.2M samples were 
resolved on 9% agarose gels under non-reducing conditions and immunoblotting 
with anti-protein S antibody provided a single band for protein S at ~80-kDa that was 
still evident in control-depleted 0.2M samples, but absent from protein S-depleted 
0.2M samples (fig. 5.8c). The molecular weight reported here for human protein S is 
similar to that found in previous studies (Lu et al., 1997). Protein S-depleted 0.2M 
fractions were devoid of phagocytic activity, while control preparations retained the 
ability to stimulate Dex-MDM phagocytosis of apoptotic neutrophils (fig. 5.8d) 
(McColl et al., 2009). Addition of 250ng/ml human protein S to protein S-depleted 
0.2M fractions restored augmented phagocytosis by Dex-MDM (fig. 5.8d). Loss of 
pro-phagocytic activity upon specific immunodepletion of protein S from 0.2M 
fractions implies that protein S is an important pro-phagocytic component in serum. 
Together with data presented in Figure 5.3c, these data suggested that protein S, 
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Figure 5.8: Effect of protein S depletion on the pro-phagocytic activity of 0.2M 
anion exchange fractions. 
A, B and C, Protein samples were resolved by SDS PAGE on 9% gels under non-
reducing conditions. A, Protein S immunoblot, performed with 2.5g/ml purified 
protein S, 1:1000 and 1:5000 dilutions of an anti-protein S polyclonal antibody and 
1:2500 HRP-conjugated goat anti-rabbit Ig. B, Immunoblotting with 1:5000 anti-
protein S showed that protein S is present in HMW gel filtration fraction A. Blots 
were also stained with colloidal gold to show total protein content. C, The presence 
of protein S (~80-kDa monomer) in 0.2M anion exchange fractions was confirmed 
by immunoblotting. Protein S was effectively depleted from 0.2M fractions using a 
polyclonal rabbit anti-protein S Ab, but not control rabbit IgG. (0.2M, 0.2M eluate; 
PSd, 0.2M protein S-depleted; PSmd, 0.2M mock protein S-depleted; PSp, 250 ng/ml 
purified protein S). D, Protein S depletion significantly reduced the pro-phagocytic 
effect of 0.2M fractions (protein concentration ~150g/ml) when compared to mock 
control depletions, an effect that was restored upon addition of 250ng/ml protein S to 
depleted sera. Mean phagocytosis  SEM, n=4 where n = the number of different 
macrophage donors. (** p<0.01, when compared to uptake by Dex-MDM in the 
presence of 0.2M fractions, one-way ANOVA with a Bonferroni post test). 
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5.3.7 Reduction and alkylation of gel filtration fractions to irreversibly dissociate 
disulfide-bonded proteins: effect on pro-phagocytic activity  
Although immunodepletion of protein S from 0.2M anion exchange fractions 
resulted in loss of pro-phagocytic activity that could be restored upon “add-back” of 
commercially purified human protein S (fig. 5.8d), it was unclear whether serum-
derived human protein S in free form or in complex with C4BP, or indeed both, was 
required for the serum augmentation effect on Dex-MDM phagocytosis. Based 
upon data obtained from gel filtration experiments, which strongly indicated that 
fractions conferring Dex-MDM phagocytic capacity were of HMW (>300-kDa) 
(fig. 5.4c), we hypothesised that protein S in complex with C4BP also enhanced 
phagocytosis. In order to address the role of the C4BP-protein S complex, we 
attempted to irreversibly dissociate protein complexes into single polypeptide chains 
through reduction and alkylation using 5mM DTT and 25mM IOA, respectively (see 
Chapter 2, 2.11 Reduction and alkylation). Samples were resolved by SDS PAGE on 
9% acrylamide gels followed by staining with Coombassie blue to visualise protein 
bands (as described in Chapter 2, 2.13 SDS polyacrylamide gel electrophoresis). 
DTT- and IOA-treatment of HMW gel filtration fractions (>300-kDa) resulted in the 
appearance of lower molecular weight protein bands, suggesting that disulfide bonds 
had been successfully dissociated (fig. 5.9a). LMW gel filtration fractions (~80-kDa) 
were treated with DTT and IOA as a control (figs. 5.9a and b). Reduction and 
alkylation of HMW fractions resulted in a complete loss of pro-phagocytic activity 
(fig. 5.9b), an effect that could not be reversed upon removal of the reducing agent 
by overnight dialysis prior to addition to phagocytosis assays, suggesting that DTT-
induced reduction may have irreversibly altered the phagocytic potential of these 
protein fractions (fig. 5.9b). Interestingly, protein S in DTT- and IOA-treated HMW 
fractions appeared as a doublet of ~60-kDa and ~70-kDa when compared to a single 
band of ~80-kDa for PBS control-treated fractions, and a lower molecular weight 
protein S band was still evident upon removal of DTT by dialysis (fig. 5.9a), 













































Figure 5.9: Effect of reduction and alkylation on the pro-phagocytic activity of gel 
filtration fractions. 
A, HMW and LMW gel filtration fractions were treated with 5mM DTT followed by 
25mM IOA to irreversibly dissociate protein disulfide bonds. Proteins were resolved 
by SDS PAGE on 9% gels under non-reducing conditions followed by staining with 
Coombassie blue. Alternatively, proteins were transferred to PVDF membrane and 
immunoblotted for protein S. Lane 1, PBS control; lane 2, DTT- and IOA-treated; 
lane 3, DTT-treated. B, Reduction (R) and alkylation (A) abolished the pro-
phagocytic effect of HMW gel filtration fractions on Dex-MDM (black bars), an 
effect that could not be reversed upon removal of the reducing agent by overnight 
dialysis. Mean phagocytosis  SEM, n=3 where n = the number of different 
macrophage donors.. (** p<0.01 when compared to uptake by Dex-MDM in the 
absence of serum, *** p<0.001 when compared to uptake by Dex-MDM in the 
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5.3.8 Protein S binds to apoptotic neutrophils in a calcium-dependent and 
phosphatidylserine-independent manner  
We next sought to investigate whether protein S could function as an opsonin of 
apoptotic neutrophils. Since protein S has the ability to bind multivalent ions and has 
been suggested to associate with membranes in a calcium-dependent manner 
(Nelsestuen et al., 1978, Schwalbe et al., 1990, Stenflo, 1999), we performed binding 
experiments using the same calcium-containing medium used for phagocytosis 
(IMDM) for incubations and washes (see 5.2.3 Flow cytometry). Protein S binding to 
serum-free cultured neutrophils (82.8% of gated neutrophils) correlated with annexin 
V-APC binding (81.6% of gated neutrophils), suggesting that protein S bound 
specifically to apoptotic neutrophils (figs. 5.10a, b and c). However, we were unable 
to demonstrate inhibition of protein S binding to apoptotic neutrophils with annexin 
V-APC, irrespective of whether annexin V-APC was added prior to or subsequent to 
protein S, indicating that the protein S binding site on apoptotic neutrophils may be 
distinct from PS (figs. 5.10c and d). Indeed, preliminary results obtained from 
phagocytosis assays using serum-free cultured apoptotic neutrophils pre-incubated 
for 10min with 1:50 annexin V-APC prior to phagocytosis in the absence or presence 
of 10% fresh autologous serum or 2.5g/ml protein S, supports the suggestion that 
protein S enhances Dex-MDM phagocytosis of apoptotic neutrophils in a PS-
independent manner (Dex 5d. No Serum: 14.5%; No Serum + Annexin V-APC: 
15.11%; Serum: 55.8%; Serum + Annexin V-APC: 57.5%; Protein S: 72.3%; Protein 





















Figure 5.10: Protein S binds to apoptotic neutrophils in a phosphatidylserine-
independent manner. 
Analysis of protein S binding to serum-free cultured apoptotic neutrophils by flow 
cytometry using a FACS Calibur. A, Dot plots showing apoptotic neutrophils gated 
out from necrotic cells and cellular debris, and protein S binding on FL-1. B, 
Histogram of protein S binding (black line) compared to untreated neutrophils 
(dashed line) and IgG control (thin line). C, Human protein S (HPS) binding to 
apoptotic neutrophils (82.8% of gated neutrophils) correlated with AnV-APC 
binding (81.6% of gated neutrophils). However, protein S failed to reduce the 
percentage of AnV-APC positive neutrophils. (1) 1 hour pre-incubation, followed by 
(2) 15min incubation. Data are presented as Mean  SEM, n=3 where n = the number 
of different neutrophil donors.. D, Dot plots showing protein S (FL-1) and annexin 
V-APC binding (FL-4) to neutrophils, resulting in a population of double-positive 
cells. Percentages shown are representative of 1 of three experiments.  
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5.3.9 Glucocorticoid augmentation of MDM phagocytosis requires protein S 
opsonisation of apoptotic neutrophils 
I have demonstrated that the enhancing effect of human serum on Dex-MDM 
phagocytosis required calcium-dependent binding of a serum factor(s) to apoptotic 
neutrophils (see Chapter 3, fig. 3.8). To investigate whether protein S could perform 
this function, neutrophils were rendered apoptotic by culture for 20-24 hours in 
serum-free conditions then pre-incubated in the absence or presence of 2.5g/ml 
protein S for 1 hour, centrifuged at 200 x g for 5min and then resuspended in IMDM 
before assessment of phagocytosis by flow cytometry. Enhanced Dex-MDM 
phagocytic capacity was found to require pre-incubation of apoptotic neutrophils 
with protein S (fig. 5.11) (McColl et al., 2009), generating levels of phagocytosis 
equivalent to those observed when the same concentration of protein S was added 
during phagocytosis assays (fig. 5.7). The pro-phagocytic effect of protein S pre-
incubation was significantly reduced when the opsonised apoptotic neutrophils were 
washed once in calcium-free medium (EDTA) prior to phagocytosis assays, but 
maintained following washing in calcium-containing medium (IMDM), consistent 
with protein S opsonisation being a calcium-dependent event that is required for 
enhanced uptake of apoptotic neutrophils by Dex-MDM (fig. 5.11). However, our 
findings from the EDTA washing experiments performed using serum pre-incubated 
neutrophils indicated that there was also a calcium-independent effect of serum 
(Chapter 3, fig. 3.8), suggesting that an additional calcium-independent serum 
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Figure 5.11: Effect of protein S pre-incubation of apoptotic neutrophils on 
phagocytosis by Dex-MDM. 
Pre-incubation of serum-free cultured heterologous apoptotic neutrophils with 
2.5g/ml human protein S enhanced subsequent uptake by Dex-MDM (black bars), 
an effect that was reduced by washing pre-incubated neutrophils in calcium-free 
medium (EDTA), but not calcium-containing medium (IMDM) prior to 
phagocytosis. Mean phagocytosis  SEM, n=3 where n = the number of different 
macrophage donors. (*** p<0.001 when compared to uptake of unwashed protein S-
preincubated apoptotic neutrophils by Dex-MDM, one-way ANOVA with a 
Bonferroni post test). 
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5.3.10 Anti-protein S antibody does not inhibit the pro-phagocytic effect of human 
serum on Dex-MDM 
Based upon our observation that protein S binding to apoptotic neutrophils could be 
detected by indirect immunofluorescence using an anti-protein S antibody (fig. 5.10), 
we hypothesised that pre-incubation of protein S-coated neutrophils with anti-protein 
S would be sufficient to block the pro-phagocytic effect of protein S on Dex-MDM. 
For this, 20-hour serum-free cultured neutrophils were pre-incubated for 1 hour with 
fresh autologous serum as a source of protein S, and 10g/ml anti-protein S was 
added to neutrophils for 10min prior to assessment of phagocytosis. Due to the 
relatively high concentration of protein S in human serum, we chose to use 1% 
autologous serum for this experiment, a concentration that significantly augments 
Dex-MDM phagocytosis of apoptotic neutrophils (see Chapter 3, fig. 3.3). We were 
surprised to find that pre-incubation of protein S-opsonised apoptotic neutrophil 
cultures with anti-protein S did not reduce their uptake by Dex-MDM, instead 
stimulating slightly higher levels of Dex-MDM phagocytosis than achieved by 
protein S-opsonisation alone (fig. 5.12). Relating to studies of phagocytosis, it must 
be taken into consideration that cross-linking of Fc receptors on macrophages by 
“blocking” antibody may activate intracellular signalling pathways that may 
modulate phagocytic potential independently of the specific macrophage receptor 
engaged by protein S. One way of avoiding non-specific stimulation of macrophage 
Fc receptors is to use Fab’ fragments of antibody, an approach taken by Flora et al to 
investigate the role of CD14 in untreated MDM phagocytosis of apoptotic 
neutrophils (Flora and Gregory, 1994). However, we decided to block macrophage 
FcRII (CD32) by pre-incubating Dex-MDM with 20g/ml IV.3 antibody for 
10min prior to overlaying anti-protein S pre-incubated apoptotic neutrophils, an 
approach that reduced the slight stimulatory effect of anti-protein S on Dex-MDM 
phagocytosis (fig. 5.12). However, treatment with IV.3 did not influence protein S-
dependent phagocytosis, possibly indicating the involvement of other Fc receptors 








































Comparison of Dex-MDM phagocytosis P value 
No Serum 1% AS P < 0.01 
No Serum 1% AS + anti-HPS P < 0.001 
No Serum 1% AS + IV.3 + anti-HPS P < 0.01 
No Serum 1% AS + IV.3 + IgG P< 0.01 
1% AS 1% AS + anti-HPS P > 0.05 
1% AS + anti-HPS 1% AS + IV.3 + anti-HPS P > 0.05 
 
Figure 5.12: Effect of anti-protein S on protein S-enhanced Dex-MDM 
phagocytosis of apoptotic neutrophils. 
Pre-incubation of serum-free cultured heterologous apoptotic neutrophils with 1% 
fresh autologous serum (AS) enhanced subsequent uptake by Dex-MDM (black 
bars), an effect that was not reduced by pre-incubation of serum-opsonised apoptotic 
neutrophils with an anti-human protein S (HPS) Ab. Dex-MDM were pre-incubated 
with an anti-FcRII Ab (clone IV.3) to block Fc receptors, and rabbit IgG added to 
serum-preincubated apoptotic neutrophils was used as a control for anti-protein S. 
Mean phagocytosis  SEM, n=3 where n = the number of different macrophage 
donors. (** p<0.01, *** p<0.001 when compared to uptake of apoptotic neutrophils 
by Dex-MDM in the absence of serum, one-way ANOVA with a Bonferroni post 
test). Table indicates comparison of Dex-MDM phagocytosis in the presence of 
different add-back treatments, with the p value shown. 
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5.3.11 Short-term treatment of human MDM with dexamethasone induces 
acquisition of a protein S-dependent pro-phagocytic pathway 
Previous studies in our lab reported that the Dex effect on macrophage phagocytic 
potential appeared to be mediated early during the monocyte to macrophage 
differentiation process (Giles et al., 2001). Treatment of monocytes with Dex during 
the first 24 hours of culture was found to confer maximal phagocytosis of apoptotic 
neutrophils when phagocytic capacity of MDM was tested at 5 days. However, the 
study by Giles et al did not demonstrate a rapid induction of capacity for 
phagocytosis of apoptotic neutrophils in monocytes following Dex treatment. Thus, 
we wanted to evaluate the effects of short-term treatment of human MDM with Dex 
upon the protein S dependency of phagocytosis of apoptotic neutrophils. For this, 
MDM that had been cultured in the absence of Dex for 96 hours were then exposed 
to Dex for the final 24 hours of culture, a time-point that has previously been shown 
to enhance human MDM phagocytosis of serum-cultured apoptotic neutrophils (Liu 
et al., 1999). Compared to untreated MDM, 96-120hour Dex-treated MDM had 
slightly higher basal levels of phagocytosis of apoptotic neutrophils, but exhibited a 
protein S-dependent increase in phagocytosis (fig. 5.13). Thus, addition of Dex to the 
culture medium at later time points during monocyte differentiation also revealed a 
requirement for a protein S-dependent clearance mechanism, suggesting that Dex 
treatment induces acquisition of a protein S-mediated phagocytic pathway 
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Figure 5.13: Effect of short-term treatment of human MDM with Dex on 
phagocytic capacity for apoptotic neutrophils. 
MDM were cultured in the absence or presence of 1M Dex for 5 days (0-120h) or 
for the final day of culture (96-120h), and MDM phagocytosis of serum-free 
cultured heterologous apoptotic neutrophils was determined in the absence (white 
bars) or presence (black bars) of 2.5g/ml purified protein S. Short term-treatment of 
human MDM with Dex resulted in acquisition of a protein S-dependent pathway for 
enhanced ingestion of apoptotic neutrophils. Mean phagocytosis  SEM, n=3 where 
n = the number of different macrophage donors. (*** p<0.001 when compared to 
uptake by MDM in the absence of protein S, one-way ANOVA with a Bonferroni 





5.4.1 Isolation of a high molecular weight protein fraction that contains the pro-
phagocytic activity of human serum  
In this chapter, I designed a multi-step purification scheme in order to isolate the pro-
phagocyic component from fresh human serum. Protein capture during anion 
exchange chromatography was optimised by applying human serum to mono Q 
Sepharose using buffering conditions that allowed the protein of interest to bind 
while minimising binding of protein contaminants. By performing step-wise elution 
of bound proteins, achieved by increasing the buffering ionic strength from 0.2M to 
0.5M NaCl by 0.1M increments, we found that many of the proteins could be eluted 
from the column with 0.2M NaCl. The pro-phagocytic serum component was found 
to bind to mono Q Sepharose at pH7 (50mM HEPES and 0.14M NaCl) and could be 
eluted with 0.2M NaCl (pH7, 50mM HEPES), indicating that the serum factor has a 
pI<7 and associates with mono Q sepharose weakly at pH7. Importantly, no 
enhancing activity was observed in the flow through, demonstrating that the pro-
phagocytic component could be efficiently isolated from large volumes of serum that 
contain a highly complex mixture of proteins. Although great care was taken with the 
gel filtration column, only partial purification of proteins from 0.2M anion exchange 
fractions could be achieved. It is unlikely that high-resolution separation so that a 
protein could be confined to one single fraction would be achievable, as 0.2M anion 
exchange samples still contained a significant number of proteins. However, 
chromatographic patterns obtained were quite reproducible, consistently producing 
two partially overlapping peaks of protein that corresponded to high- and low-
molecular weight proteins, and HMW fractions with an estimated molecular weight 
of >300-kDa were found to contain the pro-phagocytic activity of serum. Among the 
several candidate proteins identified by mass spectrometry, we were interested in 
assessing the phagocytic effect of alpha-2 macroglobulin, IgM and C4BP. 
Interestingly, several reports have demonstrated alpha-2 macroglobulin, a ~720-kDa 
human plasma protein that inhibits the function of proteases like trypsin and 
thrombin (Hall and Roberts, 1978), to be a Dex-inducible protein (Lerner et al., 
2003). Furthermore, ligation of the alpha-2 macroglobulin receptor, CD91, on 
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macrophages by calreticulin on the surface of apoptotic neutrophils triggers Rac 
activation and membrane ruffling in macrophages, and internalisation of apoptotic 
neutrophils (Gardai et al., 2005). However, we were unable to demonstrate a role for 
alpha-2 macroglobulin in enhancement of Dex-MDM phagocytic capacity. IgM, a 
pentameric molecule of five subunits joined by disulphide bridges with a very high 
molecular weight (900-kDa), has been suggested to indirectly promote phagocytosis 
of apoptotic cells by untreated murine MDM by increasing the deposition of 
complement opsonins on the apoptotic cell surface (Ogden et al., 2005). However, 
previous studies in our lab have shown IgM to be devoid of pro-phagocytic activity 
(data not shown). Interestingly, IgM was identified as a contaminant following C4BP 
purification from human plasma using the method of barium citrate adsorption 
followed by ion exchange and affinity chromatography, suggesting that co-
purification of IgM with C4BP may be a common occurrence during application of 
chromatography techniques for protein purification from plasma/serum, possibly due 
to the high affinity of C4BP for IgM (Villiers et al., 1981, Dahlback et al., 1983).  
 
C4BP, a macromolecular weight glycoprotein (~570-kDa) composed of seven 
identical 70-kDa -chains, each of which contain a binding site for activated 
complement C4b, and a single 45-kDa -chain, is synthesised in the liver and 
circulates in human plasma at a concentration of ~200g/ml (Dahlback, 1983). C4BP 
functions as an important regulator of complement activation by enhancing the 
proteolytic inactivation of C4b by factor I, thereby preventing assembly of the 
classical pathway C3 convertase (C4bC2a) and limiting amplification of the 
complement cascade (Gigli et al., 1979). Interestingly, Moffat et al reported that 
treatment of the mouse liver cell line, NmuLi with 1M Dex rapidly and 
dramatically increased C4BP mRNA and protein levels, suggesting that regulation of 
complement activation may represent an additional anti-inflammatory effect of 
glucocorticoids (Moffat et al., 1992). From our mass spectrometry results, multiple 
hits for C4BP were obtained from the several protein bands that were analysed, 
which we propose may be due to the presence of residual dimers/trimers as a result 
of incomplete reduction of -chain linked disulphide bonds prior to gel 
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electrophoresis (fig. 5.6b). To assess whether C4BP was the high molecular weight 
protein that conferred augmentation of Dex-MDM phagocytic capacity for 
apoptotic neutrophils, we attempted to immunodeplete C4BP from 0.2M anion 
exchange fractions. However, depletion experiments using a very high concentration 
of anti-C4BP antibody failed to have an effect on the pro-phagocytic activity of 
serum. Furthermore, when the anti-C4BP mAb was tested out for immunoblotting, 
high concentrations and significantly long exposure times were required before 
C4BP bands were detected, and immunoblotting for C4BP in 0.2M anion exchange 
fractions demonstrated that that this antibody did not significantly deplete C4BP. 
C4BP free from protein S was not commercially available when these experiments 
were performed, and immunodepletion experiments using a different anti-C4BP 




5.4.2 Dex-MDM utilise a protein S-dependent pathway for enhanced removal of 
apoptotic neutrophils  
In human plasma, the most common form of C4BP exists in a high molecular weight 
complex with protein S (Dahlback, 1983). Protein S is a vitamin K-dependent 
glycoprotein (DiScipio and Davie, 1979) composed of an N-terminal Gla domain, a 
thrombin-sensitive region, four epidermal growth factor (EGF)-like domains, and a 
C-terminal sex hormone-binding globulin (SHBG)-like domain (Hoskins et al., 1987, 
Gershagen et al., 1987), which is involved in high affinity binding to the -chain of 
C4BP (Evenas et al., 1999). In humans, protein S is mainly synthesised by liver 
hepatocytes, but also by megakaryocytes, leydig cells of the testis and endothelial 
cells (Fair and Marlar, 1986, Malm et al., 1994), and is constitutively present in 
plasma at a relatively high concentration of 25g/ml where is can exist either as a 
free form or in complex with C4BP (Dahlback, 1983). Free protein S (~40%; 
10g/ml) acts as a cofactor for the anti-coagulant activity of activated protein C in 
the inactivation of factor VIIIa (Dahlback, 1983, Walker et al., 1987). The remaining 
60% of protein S (15g/ml) circulates in plasma bound to C4BP, and displays no 
anticoagulant function (Dahlback, 1983, Dahlback, 1986).  
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By performing direct immunofluorescent labelling of apoptotic BL-41 cells with 
biotinylated human protein S followed by co-staining with FITC-avidin and PE–
labelled annexin V, Anderson et al demonstrated that protein S bound exclusively to 
annexin V-positive apoptotic cells (Anderson et al., 2003). Furthermore, Trouw and 
co-workers found that protein S bound to both “early” and “late” apoptotic Jurkat T 
cells, with the kinetics of protein S binding similar to that of annexin V-binding, 
suggesting that PS exposure was sufficient for binding of protein S (Trouw et al., 
2005). Webb and co-workers have shown protein S to bind apoptotic neutrophils in a 
PS-dependent manner, an effect that is inhibitable with a monoclonal antibody 
directed against the Gla domain of protein S (Webb et al., 2003). We performed 
indirect protein S labelling of 20-24 hour serum-free cultured apoptotic neutrophils, 
requiring detection of bound unlabelled protein S with a FITC-labelled secondary 
antibody. There are potential drawbacks to indirect labelling of protein binding, and 
our experiment was complicated by the requirement for three binding steps (human 
protein S, rabbit anti-human protein S Ab, anti-rabbit FITC-conjugated Ab). 
However, this experimental approach was found to be sufficient for detecting protein 
S binding to apoptotic neutrophils. We have demonstrated human protein S to 
opsonise apoptotic neutrophils in a calcium-dependent manner, consistent with 
findings by Anderson et al using apoptotic BL-41 cells (Anderson et al., 2003). 
While we found that the pattern of protein S binding to serum-free cultured apoptotic 
neutrophils strongly resembled binding of annexin V-APC, double staining of 
apoptotic neutrophils resulted in a large population of double-positive cells. The lack 
of inhibition of protein S binding by annexin V-APC is in contrast to findings of 
Anderson et al, where binding of protein S to apoptotic BL-41 cells could be 
inhibited by a 20-fold molar excess of annexin V (Anderson et al., 2003). However, 
the potential of a high molar excess of annexin V to deplete calcium from the binding 
buffer may inadvertently affect protein S binding, and supplementary calcium may 
be required to prevent this. Whether higher concentrations of annexin V-APC are 
required to inhibit protein S binding, or protein S binds to a site on the surface of 
apoptotic neutrophils distinct from PS, remains to be determined. 
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Free human protein S has been reported to stimulate uptake of “early”, membrane-
intact (annexin V+/propidium iodide-) apoptotic targets (BL-41 human Burkitt’s 
lymphoma cells and Jurkat T cells) by untreated human MDM to a similar extent as 
human serum and FBS (Anderson et al., 2003, Kask et al., 2004). Based upon our 
findings in Chapter 3, where serum was found to augment Dex-MDM phagocytosis 
of “early” apoptotic neutrophils (Chapter 3, fig. 3.9), we were interested in assessing 
whether protein S was required. Using a highly purified commercial preparation (free 
form of protein S, >95% purity as judged by SDS PAGE), we found that human 
protein S augmented Dex-MDM phagocytosis of apoptotic neutrophils in a dose-
dependent manner, with maximal levels of phagocytosis equivalent to that conferred 
by human serum achieved in the presence of 250ng/ml protein S, a much lower 
concentration than was required for phagocytosis by untreated macrophages, where 
the maximal pro-phagocytic effect required 13g/ml of protein S (52-fold higher 
concentration) (Anderson et al., 2003). Furthermore, the concentration we used for 
the remaining experiments (2.5g/ml) only produced half-maximal phagocytic 
activity for untreated macrophages (Anderson et al., 2003), whereas the half-
maximal effect on Dex-MDM phagocytosis was observed at only 75ng/ml protein 
S. Intriguingly, our data suggest that the efficiency of protein S-dependent clearance 
of apoptotic neutrophils by untreated MDM could be significantly increased 
following short-term exposure to Dex, suggesting that glucocorticoids have the 
capability to induce phagocytic potential in already differentiated MDM by 
promoting the acquisition of a protein S-dependent clearance mechanism, an 
observation that is consistent with the ability of macrophages to functionally adapt to 
changing environmental signals (Stout and Suttles, 2004). The efficiency of this 
pathway for uptake of apoptotic neutrophils by 5-day Dex-MDM was confirmed by 
the total loss of pro-phagocytic activity of 0.2M anion exchange fractions following 
immunodepletion of protein S with a polyclonal antibody. Importantly, phagocytic 
activity could be restored upon “add back” of purified protein S, indicating that 





5.4.3 Protein S augments Dex-MDM phagocytosis of apoptotic neutrophils: role 
of free form versus complex 
Based upon the pI values for protein S (5–5.5) and C4BP (6.7) (as shown in table 1), 
it would be reasonable to hypothesise that both proteins would be negatively charged 
at pH7 and hence bind to the positively charged mono Q Sepharose, resulting in 
isolation of both free and C4BP-complexed forms of protein S. Interestingly, we 
found that only HMW fractions contained the pro-phagocytic activity of serum, and 
the presence of protein S in these fractions, presumably present in complex with 
C4BP, was confirmed by immunoblotting experiments. The C4BP-protein S complex 
has a 1:1 stoichiometry, and the interaction is non-covalent and of very high affinity 
(Kd ~ 10-10M) (Dahlback, 1983, Schwalbe et al., 1990). Although protein S was not 
identified as a candidate protein by mass spectrometry, it is noteworthy to mention 
that our sample was run under reducing conditions, and C4BP appeared as a wide 
~75-kDa band due to reduction of disulphide-linked polypeptide chains. It is 
therefore possible that protein S, a monomeric protein which has a molecular weight 
of ~80-kDa, would conjugate with C4BP under reducing conditions. Indeed, it has 
been reported that the C4BP-protein S complex appears as a single band on reduced 
gels because of the predominance of the C4BP -chains in the complex (Dahlback et 
al., 1983, Kask et al., 2004), which therefore could have masked the signal from the 
lower abundance protein S during mass spectrometry analysis.  
 
Although we have shown that the pro-phagocytic activity of 0.2M anion exchange 
fractions was lost entirely upon immunodepletion of protein S, it was impossible to 
determine whether the phagocytic activity was conferred by free protein S or C4BP-
protein S complexes, or indeed both. Restoration of Dex-MDM phagocytic capacity 
by a HMW serum fraction raised the possibility that the C4BP-protein S complex can 
augment uptake of apoptotic neutrophils by Dex-MDM in some circumstances, and 
supports of preliminary data achieved using fresh ultrafiltered serum that indicated 
the serum component was larger than 100-kDa in molecular mass (Chapter 4, fig. 
4.1). This would be in contrast to findings by Kask and co-workers, who reported 
that C4BP-protein S complexes strongly inhibited untreated MDM phagocytosis of 
apoptotic lymphocyte cell lines (Kask et al., 2004). Furthermore, an anti-phagocytic 
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role for C4BP has been reported for alternative phagocytic targets, including 
pathogenic bateria (Berggard et al., 2001). C4BP is a large protein complex with 
seven -chains of 33nm in length which form an octopus-like structure when 
surface-bound (Dahlback, 1983), causing speculation that the size of the C4BP-
protein S complex, which projects out of the membrane by 56nm (Schwalbe et al., 
1990), could steroically block interaction between apoptotic cell ligands or surface-
bound serum modulators and their phagocytic counterparts on untreated MDM. 
Alternatively, binding of C4BP to protein S may specifically inhibit phagocytosis by 
untreated MDM by masking the SHBG domain required for interaction with 
macrophage receptors such as the tyrosine kinase receptor, Tyro-3 (Evenas et al., 
2000). Furthermore, C4BP may indirectly inhibit MDM phagocytosis via inhibition 
of complement activation and deposition of C3b opsonin on the surface of apoptotic 
cells that may be important for apoptotic cell clearance by untreated macrophages 
(Mevorach et al., 1998a), but not Dex-MDM (Chapter 4, fig. 4.5a). 
 
To address the anomaly of the pro-phagocytic effect of free protein S and C4BP-
protein S complexes when using commercially purified protein S and our 
chromatography samples, respectively, HMW fractions were treated with DTT to 
dissociate C4BP disulfide-linked alpha chains followed by irreversible alkylation to 
prevent re-association, and we hypothesised that C4BP-complexed protein S would 
become “free” protein S. In these experiments, we found that reduction of HMW 
fractions resulted in complete irreversible loss of phagocytic activity, with several 
possible interpretations for this. Firstly, the C4BP-protein S complex may be 
required for augmentation of Dex-MDM phagocytosis. Although pro-phagocytic 
activity was not recoverable upon dialysis to remove excess DTT, the reducing agent 
may have irreversibly altered protein structure to prevent reassociation of protein S 
and C4BP into the HMW complex. However, the absence of C4BP-protein S 
complexes from bovine serum/plasma, despite the ability of bovine protein S to form 
a complex with human C4BP (Dahlback, 1986), together with the observation that 
FBS confers augmentation of Dex-MDM phagocytosis of apoptotic neutrophils 
(Chapter 3, fig. 3.5d) suggests that in fact the complex is not required. Furthermore, 
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the inability to indentify a -chain homologue in murine C4BP, which consists solely 
of seven -chains (Moffat et al., 1992), indicates that murine serum enhances Dex-
MDM phagocytosis (Chapter 3, fig. 3.5c) in the absence of C4BP-protein S 
complexes. Additionally, fresh autologous serum augments Dex-MDM phagocytic 
capacity for “early” apoptotic neutrophils (see Chapter 3, fig. 3.9), despite the 
absence of C4BP-protein S complex binding at this stage of apoptosis (Trouw et al., 
2005). Since protein S has a pI value of 5–5.5, it would be expected to bind to mono 
Q Sepharose at pH6. However, we found that pH6 bound elutions were devoid of 
phagocytic activity, suggesting that the serum component had a pI value of >6. Based 
upon these findings, we would hypothesise that efficient isolation of protein S by 
anion exchange chromatography at pH7 occurred by means of its high affinity 
interaction with C4BP, which in turn bound specifically to the column, and this may 
explain the absence of pro-phagocytic activity in LMW fractions (see fig 5.4, 
fractions D – G). One way of testing this hypothesis would be to perform anion 
exchange and gel filtration chromatography under the same conditions using purified 
protein S.  
 
Our data obtained using purified protein S suggested that the free form of protein S 
was sufficient to confer augmentation of Dex-MDM phagocytosis. Interestingly, the 
LMW fraction used for reduction and alkylation experiments had an estimated 
molecular weight of 80-kDa and protein S in the free form was detected in this 
fraction by immunoblotting, albeit at a much lower level than observed in HMW 
fractions (fig. 5.9a). Furthermore, the free protein S-containing fraction increased 
Dex-MDM phagocytosis of apoptotic neutrophils from 11.7% to 27.8%, consistent 
with a pro-phagocytic role for free protein S (fig. 5.9b). When proteins in HMW 
fractions were resolved by SDS PAGE and immunoblotted with anti-protein S, we 
were surprised to find that protein S in reduced and alkylated samples appeared as a 
lower molecular weight band than in untreated samples, and this was not recoverable 
by removal of the reducing agent by dialysis. Hence, the loss of phagocytic activity 
for both HMW and LMW fractions raises the possibility that DTT-induced reduction 
may have irreversibly altered protein S structure and/or phagocytic function. Calcium 
plays an essential role in protein S conformation and function, and binding to C4BP 
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and membranous surfaces (Nelsestuen et al., 1978, Dahlback et al., 1990, Schwalbe 
et al., 1990, Stenflo, 1999), hence modification of the calcium-binding sites in the 
EGF-like domains of protein S (Handford et al., 1991) may affect the phagocytic 
potential of protein S. One approach to testing this would be to examine the effect of 
DTT-treatment of purified protein S, followed by dialysis to remove excess reducing 
agent, on the pro-phagocytic activity of this molecule.  
 
Since protein S binding can be demonstrated following incubation of serum-free 
cultured apoptotic neutrophils with either the HMW fraction or purified protein S, 
one possibility is that under certain conditions, protein S can dissociate from C4BP 
on the apoptotic neutrophil surface to promote clearance by Dex-MDM. 
Interestingly, the rate of dissociation of protein S from C4BP in solution can be 
influenced by altering the temperature and calcium content of buffering conditions 
(Dahlback, 1983, Schwalbe et al., 1990, Pauls et al., 2000). When added to 
phagocytosis assays at 37C, the rate of dissociation would be significantly enhanced 
compared to when HMW fractions were stored at 4C, so that a significant 
proportion of protein S would be free during the 30min phagocytosis assay 
(Dahlback, 1983). Although Dahlback et al estimated the dissociation rate in human 
plasma to be 40-fold higher at 37C, they examined C4BP-protein S interaction in 
calcium-free buffer (Dahlback, 1983), whereas calcium-containing medium (IMDM; 
~1.5mM) was consistently used in our study based on the requirement of calcium for 
protein S opsonisation of apoptotic neutrophils. In this regard, Schwalbe et al 
demonstrated that C4BP-protein S complexes assemble rapidly on phospholipid 
vesicles in the presence of calcium, and  ~50% of C4BP dissociated from membrane-
bound protein S at 37C in buffer containing 0.4mM calcium after only ~8min. 
Plasma membranes can accommodate a high molar density of free protein S than the 
C4BP-protein S complex due to the bulky structure of the complex preventing tight 
packing (Schwalbe et al., 1990). Release of C4BP from protein S may be triggered 
by a conformational change induced upon binding of the protein S portion of the 
complex to the apoptotic neutrophil surface, which may occur when a certain 
threshold of binding is reached and can no longer accommodate the sheer size of the 
complex (Schwalbe et al., 1990). Alternatively, the binding of C4BP-protein S to the 
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apoptotic cell surface may represent an equilibrium reaction requiring the release of 
only a few molecules of C4BP to allow access of the protein S receptor on Dex-
MDM. Furthermore, the “free” protein S in our reduced and alkylated samples 
likely remains bound to the -chain of C4BP by way of non-covalent bonds that, as 
mentioned above, may inhibit the pro-phagocytic effect of protein S on macrophages 
by masking the SHBG domain recognised by macrophage receptors (Evenas et al., 
2000). The dissociation of protein S from C4BP to allow association of free protein S 
on “early” apoptotic neutrophils is consistent with the observation by Trouw et al 
that “early” apoptotic cells were capable of binding free protein S, with little 
evidence of C4BP-protein S complex binding (Trouw et al., 2005). Furthermore, a 
recent report by Uehara et al suggested that human protein S can form multiple 
layers on the apoptotic cell surface, an effect that was required for protein S 
enhancement of phagocytosis by untreated macrophages (Uehara and Shacter, 2008). 
Interestingly, protein S oligomerisation on the apoptotic cell surface required 
formation of disulfide bonds between protein S monomers, an effect that we would 
predict to be absent on apoptotic neutrophils cultured with DTT-treated HMW 
fractions. Furthermore, human protein S may be prone to self-aggregation and 
formation of multimers in vitro (Pauls et al., 2000, Sere et al., 2006), resulting in 
binding of protein S multimers to apoptotic neutrophils that may show decreased 
ability to bind C4BP (Sere et al., 2006). Indeed, the concentration of purified protein 
S consistently used in phagocytosis assays (2.5g/ml) appeared to form aggregates 
when resolved on 9% acrylamide gels (fig. 5.7a). Another possibility is that naturally 
occurring multimers of protein S present in plasma (Heeb et al., 2006) can also bind 
to apoptotic neutrophils. 
 
Although our data point towards a pro-phagocytic role for protein S over the C4BP-
protein S complex, there may be additional benefits of complex binding independent 
of phagocytic function. Apoptotic neutrophils can activated and become opsonised 
with complement proteins due to the loss of membrane complement regulatory 
molecules DAF (CD55), MCP (CD46), and CR1 (CD35) (Jones and Morgan, 1995). 
Loss of protection against excessive complement attack would leave apoptotic 
neutrophils vulnerable to complement-mediated lysis if they did not acquire other 
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means of protection. Despite the suggested inhibitory effect on apoptotic cell 
clearance by untreated MDM, protein S localisation of C4BP, a fluid-phase 
regulator of complement activation, to the surface of apoptotic neutrophils 
(Furmaniak-Kazmierczak et al., 1993) during later stages of apoptosis may provide 
local regulation of the complement system to suppress complement-mediated lysis 
and inflammation in the vicinity of apoptotic cells (Webb et al., 2003, Kask et al., 
2004, Trouw et al., 2005, Trouw et al., 2007), a process that is essential for 
maintanence of normal physiologic function of host tissues and organs. 
 
 
5.4.4 Protein S deficiency in vivo: consequences for coagulation and apoptotic cell 
clearance pathways 
The functional importance of protein S as an anti-coagulant is demonstrated by the 
high risk of venous thrombosis in patients with hereditary protein S deficiency 
(Comp and Esmon, 1984, Schwarz et al., 1984, Broekmans et al., 1985). Although 
the prevalence in the general population is unknown, an investigation using 3788 
Scottish blood donors found protein S deficiency to have a relatively low prevalance 
of between 0.03% and 0.13% (Dykes et al., 2001). Inherited protein S deficiency 
may result either from reduced plasma levels of protein S (quantitative; 95% of 
cases) or a defect in protein S function with normal protein level (qualitative; 5% of 
cases) (Rezende et al., 2004). Several reports have indicated an acquired aspect to 
protein S deficiency, and protein S levels may be amenable to biological influences 
such as age and hormonal levels (Comp et al., 1986, Boerger et al., 1987). 
Interestingly, several studies have shown men to have higher levels of free and total 
protein S than females (Boerger et al., 1987, Henkens et al., 1995), a factor that must 
be taken into consideration with regards to phagocytic variability in my system, as 
serum donors used were not sex-specific. Given the importance of free and 
complexed protein S in regulation of inflammation, apoptosis and phagocytosis 
pathways, the in vivo implications of reduced protein S levels could be immense in 
terms of inflammatory and/or autoimmune consequences. Indeed, protein S 
deficiency has been suggested to provoke exaggerated inflammatory responses 
(Kasuno et al., 1997). Moreover, anti-protein S autoantibodies and acquired protein S 
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deficiency are often observed in patients with SLE, an autoimmune disease 
characterised by inefficent clearance of apoptotic cells (Song et al., 2000). The in 
vivo consequence of protein S-deficiency on the apoptotic cell clearance capacity of 
macrophages remains to be determined, and could be investigated in vitro using 
serum obtained from protein S-deficient human donors. From our protein S 
immunodepletion data, we would predict that Dex-MDM phagocytic capacity may 
be reduced in the presence of protein S-deficient human serum and could be 
recovered upon restoration of protein S levels. Protein S may therefore represent a 
novel therapeutic agent for the treatment of autoimmune diseases such as SLE due to 
the combined anti-coagulant and pro-resolving effects. However, administration 
would need to be tightly regulated to prevent hyper-anticoagulation. Interestingly, 
protein S infusion in a murine model of ischaemic stroke resulted in decreased motor 
neurologic deficit, infarction and oedema volumes, possibly as a consequence of the 
pro-resolving apoptotic cell clearance effects of protein S (Liu et al., 2003). 
 
 
In this chapter, I performed chromatography techniques to isolate a protein fraction 
that contains the pro-phagocytic activity of serum. Our data in Chapter 3 indicated 
that a common pro-phagocytic component present in sera from different mammalian 
species can enhance Dex-MDM phagocytosis of apoptotic neutrophils (Chapter 3, 
fig. 3.5). We propose that protein S, present in human, bovine, murine, porcine, 
monkey, rabbit and rat sera with much identity between protein S species (Lundwall 
et al., 1986, Dahlback, 1986, Dahlback, 2007), represents the common serum factor 
required. To our knowledge, protein S has not been identified in goat serum and may 
account for the lack of enhancing activity when added to phagocytosis assays. The 
pattern of protein S interaction with C4BP or membranous structures, and the 
phagocytic potential of this molecule appears to be extremely complex and subject to 
modulation by several environmental factors. The degree by which protein S 
enhances Dex-MDM phagocytosis is mainly determined by the C4BP-protein S 
complex from which we propose protein S must dissociate from to confer this 
augmentation. 
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CHAPTER 6: PROTEIN S AUGMENTS DEX-MDM 
PHAGOCYTOSIS OF APOPTOTIC NEUTROPHILS THROUGH 
STIMULATION OF MERTK  
 
6.1 Introduction 
The ability of glucocorticoids to augment human MDM phagocytic capacity for 
apoptotic neutrophils was found to be highly dependent upon the stage of maturation 
that monocytes were exposed to glucocorticoids, with a greater potentiation observed 
in first 24 hours of culture (Liu et al., 1999, Giles et al., 2001). The glucocorticoid 
effect could be reversed following treatment with RU38486 glucocorticoid 
antagonist (Liu et al., 1999), indicating that GR-mediated alterations in the monocyte 
gene expression profile during maturation “programme” a highly phagocytic MDM 
phenotype. The acquisition of phagocytic ability during MDM differentiation may 
be due to altered expression of cell surface molecules or intracellular signalling 
components that facilitate the uptake of apoptotic neutrophils. Indeed, Dex-enhanced 
MDM phagocytic potential is associated with increased levels of active Rac (Giles 
et al., 2001). Previous work in our lab provided some insight into the effect of 
changes in gene expression at the level of the GR on Dex-MDM phagocytic 
phenotype. By using synthetic glucocorticoid analogues that predominately mediated 
transactivation  (ZK57740, ZK77945) or transrepression (RU24782, RU24858) by 
the GR (Heck et al., 1997, Vayssiere et al., 1997), Giles et al found that Dex-
enhanced MDM phagocytosis required both mechanisms of transcriptional 
regulation (Katherine Giles, unpublished data). It is possible that the two 
mechanisms of action are not mutually exclusive, and optimal induction of MDM 
phagocytic capacity probably requires combinatorial transactivation and 
transrepression actions to induce alterations in the transcriptional profile during 
monocyte maturation. Interestingly, Dex-enhanced MDM phagocytosis of apoptotic 
neutrophils could be reversed by treatment with the protein synthesis inhibitor 
cycloheximide, supporting the requirement for a GR-induced transactivation process 
during monocyte differentiation, possibly the induction of a pro-phagocytic receptor 
(Liu et al., 1999).  Previous investigations into the effects of glucocorticoids on 
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monocyte/macrophage surface receptor expression, either through specific mAb 
binding and flow cytometry or by oligonucleotide arrays, revealed glucocorticoid-
induced alterations in the levels of cell surface expression of CD163 scavenger 
receptor, mannose receptor, CD36 and v3 and 1 integrins (Giles et al., 2001), 
FPR1 and Mertk (Ehrchen et al., 2007). However, the relevance of these alterations 
in glucocorticoid-enhancement of phagocytic capacity has remained elusive. 
 
The function performed by macrophages depends on their activation state, and can be 
highly influenced by the cytokine microenvironment. The presence of bacterial LPS 
and IFN during monocyte maturation, mediators associated with “classical” 
macrophage activation (M-1 cells) and induction of pro-inflammatory responses 
(Goerdt et al., 1999, Mills et al., 2000), may regulate phagocytic potential through 
effects on macrophage morphology and phenotype, possibly by altering the 
predominance for utilisation of a specific apoptotic cell clearance pathway. 
Treatment of monocytes with IFN in vitro induces the formation of MNGCs (Most 
et al., 1990, Fais et al., 1994) that phagocytose apoptotic neutrophils poorly 
(Heasman et al., 2004). Interestingly, treatment of human monocytes with Dex 
overrides the effect of IFN on morphology, inducing a homogeneous population of 
MDM devoid of MNGCs, with similar alterations in intracellular signalling 
molecules and adhesion status observed for Dex-only MDM cultures (Heasman et 
al., 2004). Co-treatment of human monocytes with Dex and IFN (Heasman et al., 
2004), LPS or TNF (Michlewska et al., 2009) abolished the potentiating effect of 
Dex on MDM phagocytosis, suggesting that the cytokine microenvironment can 
significantly modulate glucocorticoid effects on macrophage function.  
 
In chapter 5 of this study, I demonstrated the requirement of protein S for enhanced 
removal of apoptotic neutrophils by Dex-MDM. Protein S has been reported to 
enhance phagocytosis of apoptotic lymphoma cells by untreated human MDM 
through stimulation of Mertk (Uehara and Shacter, 2008). In this chapter, I wanted to 
investigate whether the Mertk receptor pathway was utilised by Dex-MDM for 
protein S-dependent clearance of apoptotic neutrophils, and to determine whether 
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6.2 Materials and methods 
 
6.2.1 Immunoprecipitation and western blotting for Mertk on human MDM 
12 x 106 MNCs were added per well of 6-well tissue culture plates and allowed to 
adhere for 1 hour at 37°C in 5% CO2. Non-adherent lymphocytes were removed by 
washing 3 times with IMDM and adherent monocytes (roughly 1.2 x 106) were 
cultured for 5 days in IMDM containing 10% fresh autologous serum  1M Dex. 
Cells were washed with 1 x TBS containing 0.1mM NaVO3 before addition of 300l 
RIPA lysis buffer (1mM Na3VO4, 50mM NaCl, 50mM Tris pH7.4, 0.5% 
Deoxycholate, 0.1% SDS, 1% NP-40, 1mM EGTA pH8, 1mM NaF. 10mM NaV and 
10l of protease inhibitor cocktail (Sigma) were added to 1ml of lysis buffer 
immediately prior to lysis) for 30min, 4C with continual shaking and cells detached 
using a cell scraper. The contents of the wells were transferred to appropriately 
labelled eppendorfs and centrifuged at 13,000 x g, 4C for 15min. l of lysate was 
removed to estimate protein concentration by the Pierce BCA kit procedure and the 
protein concentration in different cell lysates were made equivalent using RIPA lysis 
buffer. 100l lysate (approximately 150g protein) was incubated with 1:100 mouse 
IgG1 control or 5g/ml anti-Mer at room temperature on ice for 30min, and 
immunoprecipitation of Mertk was achieved by incubation for 1 hour with agarose-
coupled goat anti-mouse IgG at 4°C on a rotator. Immunoprecipitates were then 
washed twice (13,000 x g, 4C for 1min) in 1 x TBS, pH7.5, 0.1% Triton X-100 to 
remove non-specifically bound proteins, then washed once (13,000 x g, 4C for 1 
minute) in 25mM Tris, pH8, 0.05% SDS to remove salt. Agarose beads were boiled 
for 5min in 2x non-reducing sample buffer and 10l was loaded per well of a 9% 
acrylamide gel to resolve proteins by SDS PAGE (see Chapter 2, 2.13 SDS 
polyacrylamide gel electrophoresis). Immunoblotting for Mertk was performed as 
described in Chapter 2, 2.14 Western blotting, using 1:1000 dilutions of anti-Mer 
mAb and 1:2500 of goat anti-mouse HRP. 
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6.2.2 LPS and IFN treatment of human MDM 
Human monocytes were cultured in 48-well plates for 5 days in IMDM containing 
10% fresh autologous serum in the absence or presence of 1M Dex plus 10ng/ml 
IFN. To examine the effect of short-term LPS treatment, 5-day Dex-MDM were 
either untreated (No LPS) or treated for 1, 2 or 3 hours with 10ng/ml LPS prepared in 
IMDM containing 10% autologous serum. 
 
6.2.3 Induction of neutrophil apoptosis 
CMFDA-labelled neutrophils were cultured at 4 x 106/ml in serum-free medium 
(IMDM) at 37C for 20-24 hours to render neutrophils apoptotic. Neutrophil 
populations were then centrifuged at 200 x g for 5min and resuspended in fresh 






6.3.1 Mertk expression is upregulated on the surface of Dex-MDM 
Protein S bound to the surface of apoptotic lymphoma cells has been suggested to 
promote their clearance through Mertk on untreated human MDM (Uehara and 
Shacter, 2008). We hypothesised that engagement of this receptor pathway may be 
responsible for high capacity clearance of apoptotic neutrophils by Dex-MDM. 
Initially, we performed indirect immunofluorescence as described in Chapter 2, 2.15 
Flow cytometry, using a anti-Mer mAb to confirm surface expression of Mertk on 
MDM. Mertk expression on Dex-MDM was increased 2.2-fold compared to 
untreated MDM (fig. 6.1a) (McColl et al., 2009). Downregulation of CD44 
expression on human MDM (1.8-fold) following Dex treatment confirms previous 
findings (Giles et al., 2001). The percentage of MDM expressing Mertk was also 
increased, possibly as a result of induction of greater homogeneity in macrophage 
Mertk expression, whereas the percentage of cells expressing CD44 was unaltered 
i.e. the surface expression of CD44 decreased, but all cells remained positive for 
CD44 (fig. 6.1b). Interestingly, the percentage of Mertk-positive Dex-MDM 
(~80%) corresponded well with the percentage of Dex-MDM capable of protein S-
dependent phagocytosis of apoptotic neutrophils (~70-80%). We have confirmed 
Mertk expression (~210-kDa) on untreated and Dex-MDM by western blotting, 
performed as described in 6.2.1 Immunoprecipitation and western blotting for Mertk 











Figure 6.1: Effect of Dex treatment on human MDM expression of Mertk and 
CD44. 
A and B, Analysis of surface receptor expression by untreated (thin lines) and Dex-
MDM (dark lines) by flow cytometry. Data are presented as Mean  SEM, n=7 
where n = number of different macrophage donors used (* p<0.05; paired t test). A, 
Treatment with Dex resulted in increased expression of Mertk (2.2-fold), but 
decreased expression of CD44 (1.8-fold). B, Treatment with Dex increased the 
percentage of MDM positive for Mertk expression, whereas the percentage of 
MDM positive for CD44 was unaltered. C, MDM lysates were resolved by SDS 
PAGE on 9% gels under non-reducing conditions and immunoblotted for Mertk with 
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6.3.2 Blocking Mertk on Dex-MDM significantly inhibits serum- and protein S-
dependent phagocytosis of apoptotic neutrophils  
We next wanted to evaluate whether this receptor pathway was important for protein 
S-dependent clearance of apoptotic neutrophils by Dex-MDM. For this, we pre-
treated Dex-MDM with 10g/ml anti-human Mer mAb for 10min prior to 
phagocytosis to “block” Mertk function. Although anti-Mer had no effect on 
phagocytosis by Dex-MDM in the absence of protein S, anti-Mer significantly 
reduced Dex-MDM phagocytosis of serum-free cultured apoptotic neutrophils in 
the presence of 2.5g/ml of protein S (fig. 6.2a; *** p<0.001, n=3) (McColl et al., 
2009). Blockade of Mertk also significantly inhibited Dex-MDM phagocytosis in 
the presence of 10% fresh autologous serum (fig. 6.2b; 67% reduction, ** p<0.01, 
n=3) (McColl et al., 2009). However, full inhibition of serum-dependent 
phagocytosis by Dex-MDM was never achieved with anti-Mer, suggesting that 
another receptor pathway may be responsible for the residual phagocytosis observed. 
Importantly, we found that anti-Mer had no effect on number of Dex-MDM 
recovered and therefore represents a specific inhibitory effect on phagocytosis, 
implying that the Mertk pathway is critical for glucocorticoid augmentation of 




























































Figure 6.2: Effect of anti-Mer on serum- and protein S-enhanced Dex-MDM 
phagocytosis of apoptotic neutrophils. 
Pre-incubation of Dex-MDM (black bars) with 10g/ml anti-Mer mAb for 10min 
inhibited the enhancing effect of 2.5g/ml protein S (A) and 10% fresh autologous 
serum (B) on Dex-MDM phagocytosis of serum-free cultured heterologous 
apoptotic neutrophils. Mean phagocytosis  SEM, n=3 where n = the number of 
different macrophage donors. (** p<0.01 and *** p<0.001 when compared to uptake 
by Dex-MDM in the presence of autologous serum and 2.5g/ml protein S, 
respectively, one-way ANOVA with a Bonferroni post test). Phagocytosis by 





6.3.3 Mertk expression on the surface of Dex-MDM is downregulated following 
short-term treatment with LPS: effect on Dex-MDM phagocytic capacity 
Surface expression of Mertk is dynamically regulated during cell culture, with 
metalloproteinase-mediated cleavage of the extracellular domain of Mertk resulting 
in the production a soluble form of the receptor that is constitutively released from 
cultured cells (Sather et al., 2007). Mertk cleavage is amenable to environmental 
signals, and can be enhanced by treatment with bacterial LPS (Sather et al., 2007). 
Since untreated and Dex-MDM display differential capacities for serum-dependent 
phagocytosis of apoptotic neutrophils (Chapter 3, fig. 3.2), we hypothesised that 
upregulation of macrophage Mertk surface expression following treatment with Dex 
may be responsible for efficient phagocytosis by Dex-MDM and that LPS would 
inhibit Dex-induced expression of Mertk.  
 
LPS was found to rapidly downregulate surface expression of Mertk on Dex-MDM, 
with a significant decrease in the geometric mean fluorescence intensity observed 
after 1 hour, with further reductions in the level of Mertk expression after 3 hours 
(figs. 6.3a and b). Furthermore, LPS treatment significantly reduced the percentage 
of Dex-MDM positive for Mertk expression (fig. 6.3c). We hypothesised that LPS-
mediated downregulation of Mertk on Dex-MDM would result in a mirrored 
downregulation of phagocytic capacity to untreated control levels. However, we 
were surprised to find that downregulation of Mertk expression resulted in only a 
partial inhibition of protein S-dependent phagocytosis of apoptotic neutrophils by 
Dex-MDM, with LPS treatment for 1, 2 and 3 hours resulting in only 35%, 29.8% 
and 37.1% reduction, respectively (fig. 6.4; p<0.05, n=3). Interestingly, LPS-induced 
downregulation of Mertk had a more profound impact on serum-enhanced Dex-
MDM phagocytosis, with LPS treatment for 1, 2 and 3 hours resulting in 48.7%, 


















Figure 6.3: Effect of short-term LPS treatment on Dex-MDM expression of Mertk. 
A, Analysis of Dex-MDM surface expression of Mertk (thick line) by flow 
cytometry. Binding of mouse IgG1 (thin line) is shown as a control. A and B, LPS 
treatment of 5-day Dex-MDM for 1, 2, or 3 hours resulted in downregulation of 
Mertk expression by 1.4-, 1.5-, and 1.6-fold, respectively. C, LPS treatment also 
decreased the percentage of human MDM positive for Mertk expression. Data are 
presented as Mean  SEM, n=3 where n = the number of different macrophage 
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Figure 6.4: Effect of short-term LPS treatment on serum- and protein S-enhanced 
phagocytosis of apoptotic neutrophils by Dex-MDM. 
MDM were cultured in the presence of 1M Dex for 5 days, and Dex-MDM 
phagocytosis of serum-free cultured heterologous apoptotic neutrophils was assessed 
in the absence or presence of 10% fresh autologous serum or 2.5g/ml human 
protein S. Short-term treatment of Dex-MDM with LPS (1, 2, or 3 hours) 
significantly reduced the pro-phagocytic effect of serum, but not protein S. Mean 
phagocytosis  SEM, n=3 where n = the number of different macrophage donors. (* 
p<0.05, ** p<0.01 and *** p<0.001 when compared to uptake by Dex-MDM in the 
absence of serum, * p<0.05 and ** p<0.01 when compared to uptake by Dex-MDM 








6.3.4 Mertk expression on the surface of Dex-MDM is downregulated upon co-
culture with IFN: effect on Dex-MDM phagocytic capacity 
Previous studies in our lab showed that the potentiating effect of Dex on human 
MDM phagocytosis could be reversed with the pro-inflammatory cytokine, IFN 
(Heasman et al., 2004). As found for short-term LPS treatment (fig. 6.3), increased 
Mertk expression induced by Dex treatment could be reversed by co-culture with 
IFN (figs. 6.5a and b). Furthermore, whilst the percentage of human MDM 
positive for Mertk expression increased almost two-fold upon Dex treatment, this 
was returned to untreated control levels upon co-culture with IFN (fig. 6.5c). 
Phagocytosis of serum-free cultured apoptotic neutrophils by 5-day untreated-
MDM, Dex-MDM and Dex/IFN-MDM was assessed in the absence or presence 
of 10% fresh autologous serum or 2.5g/ml human protein S. In confirmation of our 
previous data, we found that uptake of apoptotic neutrophils by Dex-MDM was 
enhanced in the presence of human serum or 2.5g/ml protein S (fig. 6.6). However, 
IFN had no significant effect on serum-dependent or protein S-dependent (fig. 6.6; 
36% reduction; p>0.05, n=3) Dex-MDM phagocytosis of apoptotic neutrophils. 
 
Together, these results show that pro-inflammatory mediators such as LPS and IFN 
negatively regulate Mertk expression on Dex-MDM, but fail to block acquisition of 
a pro-phagocytic phenotype by Dex, suggesting that additional molecular 



















Figure 6.5: Effect of IFN on Dex-MDM expression of Mertk. 
A, Analysis of human MDM surface expression of Mertk (thick line) by flow 
cytometry. Binding of mouse IgG1 (thin line) is shown as a control. A and B, Co-
treatment of human MDM with 1M Dex and 10ng/ml IFN for 5 days inhibited 
Dex-induced upregulation of Mertk expression, with geometric mean fluorescence 
intensity of binding (B) and the percentage of human MDM positive for Mertk 
expression (C) equivalent to untreated MDM. Data are presented as Mean  SEM, 
n=3 where n = the number of different macrophage donors. (* p<0.05, ** p<0.01, 
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Figure 6.6: Effect of IFN on serum- and protein S-enhanced phagocytosis of 
apoptotic neutrophils by Dex-MDM. 
MDM were cultured in the absence or presence of 1M Dex  10ng/ml IFN for 5 
days, and MDM phagocytosis of serum-free cultured heterologous apoptotic 
neutrophils was assessed in the absence or presence of 10% fresh autologous serum 
or 2.5g/ml human protein S. Co-treatment of human MDM with Dex and IFN for 
5 days did not alter the potentiating effect of Dex on MDM phagocytosis (p>0.05). 
Mean phagocytosis  SEM, n=3 where n = the number of different macrophage 
donors. (* p<0.05 and *** p<0.001 when compared to uptake by Dex/IFN-MDM 
(striped bars) in the absence of serum or 2.5g/ml protein S, *** p<0.001 when 
compared to uptake by Dex-MDM (black bars) in the absence of serum or 2.5g/ml 
protein S, one-way ANOVA with a Bonferroni post test). Phagocytosis by untreated 







6.3.5 Mertk expression is upregulated on the surface of untreated MDM following 
treatment with a TACE-inhibitor peptide: effect on untreated MDM 
phagocytic capacity 
Since the Mertk pathway was found to be critically required for protein S-dependent 
phagocytosis of apoptotic neutrophils by Dex-MDM, we next investigated whether 
increased surface expression of Mertk on untreated-MDM could enhance the 
phagocytic potential of these cells. For this experiment, 5-day untreated MDM were 
either untreated or treated with 50g/ml TNF-converting enzyme (TACE) inhibitor 
peptide (KD–1X–73.5) for 1 hour to inhibit Mertk shedding. We observed a 1.7-fold 
increase in Mertk surface expression following TACE inhibitor treatment when 
compared to untreated controls (fig. 6.7a). Interestingly, CD44 expression also 
increased 2-fold (fig. 6.7a), suggesting that expression of Mertk and CD44 on the 
surface of human MDM can be dynamically regulated by TACE metalloproteinase. 
Although the increase in Mertk expression by untreated-MDM following treatment 
with TACE-inhibitor peptide (1.7-fold) was similar to that induced by long-term Dex 
treatment of monocytes (2.2-fold), this was not paralleled by an increase in protein S- 
or serum-dependent phagocytosis of apoptotic neutrophils (fig. 6.7b; p>0.05, n=3), 
suggesting that additional mechanisms independent of Mertk expression are required 






























Figure 6.7: Effect of inhibition of TACE/ADAM17 metalloproteinase on Mertk 
expression and phagocytic ability of untreated MDM. 
A, Analysis of human untreated MDM surface expression of Mertk by flow 
cytometry. Treatment of 5-day untreated MDM with 50g/ml TACE inhibitor 
peptide for 1 hour increased expression of Mertk and CD44. Data are presented as 
Mean  SEM, n=3 where n = the number of different macrophage donors. (* p<0.05; 
paired t test). B. Enhanced Mertk expression was not accompanied by increased 
MDM phagocytic potential (black bars) for heterologous apoptotic neutrophils in 
the presence of 10% fresh autologous serum or 2.5g/ml human protein S. Data are 
presented as Mean  SEM, n=3 where n = the number of different macrophage 
donors. (p>0.05, when compared to phagocytosis by untreated MDM not exposed 
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6.3.6 Human MDM express v5 integrin on their surface and this is 
downregulated on Dex-MDM  
We next wanted to determine whether the differential capacities of untreated and 
Dex-MDM for protein S-dependent phagocytosis of apoptotic neutrophils was due 
to altered association of Mertk with other receptors on the cell membrane following 
Dex treatment. In light of results presented by Wu and co-workers, where efficient 
phagocytosis of human lymphocytes appeared to require molecular cooperation of 
Mertk with v5 integrin (Wu et al., 2005), we were interested in examining 
whether this mechanism was required for protein S-enhanced phagocytosis by Dex-
MDM. Interestingly, flow cytometric analysis revealved that surface expression of 
v5 on human MDM was downregulated (1.4-fold) following long-term treatment 
of human monocytes with Dex (fig. 6.8a). Furthermore, Dex treatment was 
associated with a decrease (2-fold) in the percentage of v5-positive MDM from 
~47.8% to ~24.2%.  
 
 
6.3.7 Blocking v5 on Dex-MDM has no significant effect on serum- and protein 
S-dependent phagocytosis, but may affect the adhesive ability of these cells 
To evaluate the potential contribution of the v5 integrin receptor pathway to 
protein S-dependent clearance of apoptotic neutrophils by Dex-MDM, 5-day Dex-
MDM were pre-treated with 10g/ml anti-human v5 antibody for 10min prior to 
phagocytosis to “block” v5 function. Anti-v5 had no effect on the basal levels 
of phagocytosis by Dex-MDM (fig. 6.9). Although blockade of v5 had no effect 
on the protein S-dependent phagocytosis of apoptotic neutrophils by Dex-MDM, 
there was a significant inhibitory effect on serum-dependent phagocytosis by Dex-
MDM (fig. 6.9; 39% inhibition, ** p<0.01. n=3). Interestingly, we found that anti-
v5 had a notable effect on the number of Dex-MDM recovered under basal 
conditions (10% autologous serum in the absence of neutrophils; 29% less), and also 
when neutrophils were added in the presence of 10% autologous serum (24.2% less) 
but not 2.5g/ml human protein S (3.4% less), suggesting that v5 may be an 





















Figure 6.8: Effect of Dex treatment on human MDM expression of v5. 
A, Analysis of human MDM surface expression of v5 (thick line) by flow 
cytometry. Binding of mouse IgG1 (thin line) is shown as a control. A and B, Human 
MDM expression of v5 integrin was reduced (1.4-fold) by 5-day treatment of 
monocytes with Dex. C, Dex treatment also decreased the percentage of human 
MDM positive for v5 expression. Data are presented as Mean  SEM, n=3 where 











































































Figure 6.9: Effect of anti-v5 on serum- and protein S-enhanced Dex-MDM 
phagocytosis of apoptotic neutrophils. 
5-day Dex-MDM were untreated (black bars) or treated with 10g/ml anti-v5 
mAb for 10min prior to phagocytosis assays. Dex-MDM phagocytosis of serum-
free cultured heterologous apoptotic neutrophils was assessed in the absence or 
presence of 10% fresh autologous serum or 2.5g/ml human protein S. Blocking 
v5 receptor significantly reduced the pro-phagocytic effect of serum but not 
protein S on Dex-MDM, an effect that may be associated with reduced number of 
Dex-MDM recovered in serum-containing cultures (24.2% less) compared to 
protein S-containing cultures (3.4% less). Mean phagocytosis  SEM, n=3 where n = 
the number of different macrophage donors. (* p<0.05, *** p<0.001 when compared 
to uptake by Dex-MDM in the absence of serum, ** p<0.01 when compared to 
uptake by Dex-MDM in the presence of serum, one-way ANOVA with a 




6.4.1 Mertk is critically required for protein S-dependent clearance of apoptotic 
neutrophils by Dex-MDM 
Mertk, a member of the Tyro-3/Axl/Mer (TAM) family of receptor tyrosine kinases, 
is composed of an extracellular region comprising two immunoglobulin-like and two 
fibronectin type III motifs, a transmembrane region, and an intracellular tyrosine 
kinase domain (Graham et al., 1994, Graham et al., 1995). Mertk expression has been 
detected in peripheral blood monocytes, monocyte-derived macrophages and 
dendritic cells, but not by granulocytes or lymphocytes, and is highly expressed in 
testis, ovary, prostate, lung, kidney, and eye (Graham et al., 1994, Graham et al., 
1995, Behrens et al., 2003, Seitz et al., 2007). Moreover, Lu et al performed in situ 
hybridisation to show that Mertk is expressed in macrophage zones of the spleen, 
lymph node and thymus (Lu and Lemke, 2001). Thus, Mertk is expressed 
predominately by macrophages that are required for efficient clearance of apoptotic 
cells in vivo and in organs where high cell turnover is evident. Mertk expression at 
the protein level changes with both developmental and activation status (Seitz et al., 
2007), being essentially absent from peripheral blood monocytes and increases as 
these cells differentiate into tissue macrophages (Behrens et al., 2003). Long-term 
treatment of human monocytes with Dex resulted in increased surface expression of 
Mertk, consistent with previous observations that Mertk is a glucocorticoid-
regulatable protein (Ehrchen et al., 2007). Pre-treatment of Dex-MDM with an anti-
Mer mAb significantly reduced the pro-phagocytic effect of human serum and 
protein S on apoptotic neutrophil clearance. However, the Mertk-independent 
phagocytosis observed for Dex-MDM suggests that additional serum-dependent 
pathways are involved. Interestingly, a calcium-independent serum opsonisation 
event was responsible for a partial augmentation of Dex-MDM phagocytosis, 
representing 38% of the serum-enhancing effect (Chapter 3, fig. 3.8), a percentage 
that is similar to the Mertk-independent pro-phagocytic effect of serum (33% 
augmentation). However, it must be noted that anti-Mer had a slight stimulatory 
effect on the basal levels of Dex-MDM phagocytosis which may account for these 
effects. 
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6.4.2 Mertk is required for phagocytosis of apoptotic neutrophils by Dex-MDM, 
but not untreated-MDM: a glucocorticoid-induced “switch” in apoptotic 
cell recognition mechanisms 
The results presented in this thesis support the requirement of the Mertk pathway for 
protein S-dependent phagocytosis of “early”, membrane-intact apoptotic neutrophils 
by Dex-MDM. However, we were unable to show a requirement for Mertk-
dependent phagocytosis by untreated MDM. Since both untreated and Dex-MDM 
populations examined in this study expressed Mertk, the reason why Dex-MDM are 
enabled to utilise a protein S-dependent clearance pathway is not clear. The 
predominance for utilisation of a specific molecular pathway for apoptotic cell 
clearance is not constant between different populations of phagocytes and can be 
influenced by environmental stimuli. Untreated MDM represent a highly 
heterogeneous population of cells in terms of morphology and receptor expression 
(Giles et al., 2001), and may have been “imprinted” with different mechanisms for 
apoptotic cell clearance during differentiation. This is in contrast to the 
morphological and functional homogeneity exhibited by Dex-MDM, and 
homogeneity in Mertk expression may explain why more MDM are capable of 
using this recognition pathway. Another possibility is that the observed upregulation 
of Mertk expression on the surface of Dex-MDM was sufficient to confer 
phagocytic potential. We found that exposure of Dex-MDM to bacterial LPS (short-
term) and IFN (long-term) resulted in downregulation of Mertk expression to levels 
expressed by untreated MDM. However, this alteration was not accompanied by 
loss of protein S-dependent phagocytosis by Dex-MDM. This is an important 
observation, as cytokine inhibition of a Dex-MDM pro-phagocytic phenotype 
would have implications for the efficacy of glucocorticoid treatment in vivo when 
stimuli such as LPS or IFN might also be present. Interestingly, inhibition of serum-
dependent phagocytosis following pre-treatment of Dex-MDM with LPS for 3 
hours (62.2% reduction) was remarkably similar to effects of blockade of Mertk with 
an anti-Mer mAb (67% reduction; ** p<0.01, n=3) (fig. 6.2b). The lack of IFN-
mediated inhibition of serum-dependent phagocytosis by Dex-MDM is in contrast 
to previous reports where co-treatment with Dex and IFN for 5 days abolished the 
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effect of Dex on MDM phagocytic capacity (Untreated: ~13%; Dex: ~66%; 
Dex/IFN: ~23%) (Heasman et al., 2004). Similar human MDM culture conditions 
and IFN concentration, albeit a different source of IFN, were used in this study. 
Based upon the inhibitory effect of LPS on Dex-MDM phagocytic potential 
reported in this study and by Michlewska et al (Michlewska et al., 2009), inhibition 
of Dex-MDM phagocytosis as reported by Heasman et al may not have been a 
specific effect mediated by IFN but instead a consequence of LPS-contamination of 
the IFN. Addition of polymyxin B, a substance that binds and neutralises LPS 
(Ferrari et al., 2004), during culture would have permitted analysis of IFN on the 
pro-phagocytic effect of Dex in the absence of LPS contamination, although this 
experiment would need to be tightly controlled to exclude false negative 
(cytotoxicity) or false positive results (stimulation by polymyxin).  
 
Proteolytic cleavage of cell surface proteins, or ectodomain “shedding”, plays an 
essential role in regulating the pattern of surface protein expression and/or function. 
TACE/ADAM17 metalloproteinase has been implicated in the shedding of a number 
of distinct cell surface proteins, including cytokines (TNF), cytokine receptors 
(TNF receptors I and II), and adhesion molecules (L-selectin) (Black et al., 1997, 
Moss et al., 1997, Peschon et al., 1998, Reddy et al., 2000, Li et al., 2006). By using 
a TNFα protease inhibitor (TAPI-0), Sather et al recently demonstrated that Mertk 
expression on the surface of the mouse macrophage cell line, J774, can be regulated 
by TACE metalloproteinase (Sather et al., 2007). Inhibition of TACE-mediated 
cleavage of Mertk on the surface of untreated human MDM revealed that enhanced 
expression of Mertk is not sufficient to confer a pro-phagocytic MDM phenotype. 
Surface expression is not always an indicator of receptor function, as demonstrated 
by loss of 2 integrin function during neutrophil apoptosis independently of 
expression (Dransfield et al., 1995). Alternatively, efficient phagocytosis may require 
a conformational change in the Mertk receptor on Dex-MDM to increase affinity 
for protein S, in a manner analogous to that described for the integrin-dependent 
interaction of activated leukocytes with endothelial cells (Hogg et al., 2002). 
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Mertk may also interact with other receptors on the cell membrane following Dex 
treatment. Induction of co-operative action of receptors may allow regulation of 
phagocytosis of apoptotic cells in response to different environmental cues 
encountered during the inflammatory response. Co-precipitation studies with fusion 
proteins of Tyro-3/Axl/Mertk, composed of the extracellular ligand-binding domain 
of the receptors fused to the Fc region of human IgG1, suggested that TAM receptors 
are expressed as disulphide-linked homodimers capable of binding Gas6, but not 
protein S (Nagata et al., 1996). Human Gas6, a protein S homologue (44% amino 
acid sequence identity) (Manfioletti et al., 1993), has been suggested to preferentially 
bind and stimulate Axl, yet can bind to Tyro-3 and Mertk albeit with a lower affinity 
(Ohashi et al., 1995, Godowski et al., 1995, Nagata et al., 1996, Chen et al., 1997, 
Sather et al., 2007, Seitz et al., 2007). Gas6 may opsonise apoptotic cells for 
phagocytosis mediated by Axl or Mertk (Ishimoto et al., 2000, Scott et al., 2001, Wu 
et al., 2005), and Gas6 expression in the retina may be important for Mertk-mediated 
phagocytosis of rod outer segments by RPE cells (D'Cruz et al., 2000). Interestingly, 
murine macrophages express both Gas6 and protein S and this may endow 
macrophages with all three receptors pathways (Seitz et al., 2007). However, the 
human plasma concentration of Gas6 is 1000-fold lower than protein S (Balogh et 
al., 2005), making it unlikely that Gas6 in human serum could also confer Mertk-
dependent phagocytosis by Dex-MDM in our system. Ligand-activated Mertk 
forms dimers in the membrane, resulting in Mertk autophosphorylation and 
activation (Schlessinger, 2000), and heterodimerisation with other TAM family 
receptors following glucocorticoid treatment may be required for interaction with 
protein S or to provide synergistic signalling for efficient Mertk-dependent 
phagocytosis (Seitz et al., 2007). Interestingly, platelets also express all three 
receptors and appear to require heterodimerisation for receptor tyrosine 
phosphorylation (Angelillo-Scherrer et al., 2005). Since murine macrophages express 
all three TAM receptors on their surface (Seitz et al., 2007), it would be interesting to 
determine the effect of Dex on Axl and Tyro-3 surface expression and membrane 
localisation on human Dex-MDM with respect to Mertk, and whether anti-Axl or 
anti-Tyro-3 antibodies can similarly inhibit protein S-dependent phagocytosis of 
apoptotic neutrophils by Dex-MDM.  
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Alternatively, protein S-dependent phagocytosis by Dex-MDM may require 
collaboration of Mertk with other membrane receptors involved in the phagocytic 
process. Cooperation of receptor pathways for opsonin-dependent recognition of 
apoptotic neutrophils has been demonstrated for untreated MDM, where a v3–
CD36 molecular complex is required for recognition of TSP-1-opsonised apoptotic 
neutrophils (Savill et al., 1992). Molecular crosstalk between Mertk and scavenger 
receptor A (SR-A) or v5 receptor pathways may provide synergistic signalling 
required for efficient phagocytosis of apoptotic cells (Wu et al., 2005, Todt et al., 
2008). Expression of v5 integrin has been suggested to be important for binding 
outer segments by RPE cells (Anderson et al., 1995, Finnemann et al., 1997), and 
subsequent triggering of Mertk-dependent internalisation (Finnemann, 2003). 
Although our results indicate that Mertk-dependent phagocytosis of apoptotic 
neutrophils by Dex-MDM does not involve an v5-dependent clearance 
mechanism, we found that Dex-MDM were prone to detachment when 
phagocytosis assays were performed in the presence of anti-v5. Ligation of v5 
integrin, an important modulator of cell adhesion, induces the formation of the 
DOCK180/Crk/p130cas signalling complex (Albert et al., 2000). Interestingly, co-
immunoprecipitation studies indicate that Mertk under conditions of limited receptor 
expression, such as that found on untreated MDM, induces p130cas in an v5-
dependent manner (Wu et al., 2005). We propose that downregulation of v5 
integrin on the surface of Dex-MDM may contribute to the loss of p130cas 
expression and reduced formation of adhesive contacts in these cells (Giles et al., 
2001) and may be required for acquisition of a Mertk-dependent phagocytic 
phenotype, whereas functional cooperation between v5 and Mertk on untreated 
MDM may contribute to the more adhesive nature of these cells. One possible 
approach to testing this hypothesis would be to “knock-down” v5 expression in 
human untreated MDM using siRNA and examine the effects on morphology and 
adhesion status. Interestingly, phagocytosis of apoptotic neutrophils by Dex-MDM 
was markedly inhibited in the presence of 500g/ml fucoidin, indicating scavenger 
receptor involvement (Giles et al., 2001). Furthermore, SR-A mediates divalent 
cation-independent adhesion to serum-coated cell culture plastic (Fraser et al., 1993), 
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and it would be interesting to investigate whether this receptor pathway mediates the 
calcium-independent effect of serum on Dex-MDM, possibly acting as a Mertk-
independent tethering receptor. 
 
Receptor tyrosine kinases play an essential role in transducing signals from the 
extracellular environment to influence a variety of cellular processes including 
migration, survival, proliferation, and differentiation (Ullrich and Schlessinger, 1990, 
Fantl et al., 1993, Schlessinger, 2000). Glucocorticoids may influence engagement of 
downstream signalling pathways critical for Mertk-dependent phagocytosis 
independently of Mertk expression, including regulation of cytoskeletal organisation 
(Guttridge et al., 2002). Dex-MDM exhibit reduced phosphorylation and 
localisation of paxillin and pyk2 to podosome-like adhesion structures, together with 
increased Rac activity (Giles et al., 2001). Interestingly, the Rac guanine nucleotide 
exchange factor Vav1 is activated downstream of Mertk (Mahajan and Earp, 2003). 
The phagocytic defect in Mertkkd mice may be due to the loss of residues in the 
activation-loop domain of the Mer kinase region, including the autophosphorylation 
sites Tyr749, Tyr753, and Tyr754 (Ling et al., 1996). One possibility is that 
phosphorylation of Mertk at Tyr867 (Tibrewal et al., 2008), a residue required for 
binding of Grb2 and subsequent recruitment of PI3-kinase (PI3K) to Mertk 
(Georgescu et al., 1999), in the absence of assembly of adhesion structures promotes 
MDM phagocytic activity. Pre-treatment of Dex-MDM for 1 hour with 100M of 
a PI3K inhibitor, LY294002, significantly inhibited Dex-MDM phagocytosis of 
apoptotic neutrophils (from ~41% to ~8% phagocytosis) (Katherine Giles, 
unpublished data). PI3K is required for membrane recycling during extension of 
cellular processes (Cox et al., 1999), suggesting that the high membrane activity 
displayed by Dex-MDM may contribute to their phagocytic potential. Furthermore, 
ligation of Mertk receptor induces rapid activation of ERK1 and ERK2, Akt and p38 
MAPK (Guttridge et al., 2002). Thus, altered association of Mertk with the actin 




6.4.3 Consequences of Mertk deficiency for apoptotic cell clearance in vitro and in 
vivo 
The physiological role of Mertk in apoptotic cell clearance has been addressed in 
vivo through targeted disruption of Mertk using homologous recombination to delete 
53 residues in the activation-loop domain of the Mertk cytoplasmic kinase domain, 
generating Merk kinase-dead mice (Mertkkd) (Lu et al., 1999). Mertkkd mice contain 
abnormally high numbers of apoptotic cells in many of their tissues due to an in vivo 
defect in the apoptotic cell clearance capacity of macrophages (Lu et al., 1999, Scott 
et al., 2001). Mertkkd macrophages demonstrate a marked impairment in their ability 
to phagocytose apoptotic thymocytes in vitro (83-94% less efficient than wild-type 
m), yet FcR-mediated phagocytosis and uptake of other particles including bacteria 
and latex beads was unaffected, suggesting an essential role for Mertk in facilitating 
macrophage phagocytosis of apoptotic cells (Scott et al., 2001). In contrast to 
dramatically reduced clearance of apoptotic thymocytes observed in Mertkkd mice 
(Seitz et al., 2007), with a seven-fold increase in remnant apoptotic thymocytes in the 
thymi of Mertkkd mice compared to wild-type control mice following injection of 
Dex to induce thymocyte apoptosis (Scott et al., 2001), apoptotic thymocyte removal 
was found to be normal in Axl/Tyro3-deficient mice (Seitz et al., 2007), indicating 
that the Mertk receptor pathway is critically required for efficient macrophage 
clearance of a high load of apoptotic cells in the thymus. Interestingly, the opposite is 
true for dendritic cell phagocytosis, which does not require Mertk and instead has 
been suggested to be mediated by Tyro-3 and Axl (Behrens et al., 2003, Seitz et al., 
2007), indicating that Tyro-3 and Axl may be involved in the normal homeostatic 
response to apoptotic cells. Mertk-deficient mice develop an SLE-like autoimmune 
disease characterised by high levels of autoantibodies to nuclear chromatin and 
DNA, probably resulting from impaired removal of apoptotic cells before lysis (Lu et 
al., 1999, Scott et al., 2001, Lu and Lemke, 2001, Cohen et al., 2002). Interestingly, 
the functional mutation in Mertk was found to render Mertkkd mice blind (Scott et al., 
2001). The Royal College of Surgeons (RCS) rat model of retinal degeneration has a 
naturally occurring splice variation that renders Mertk non-functional, resulting in 
retinal dystrophy and eventually blindness due to impaired clearance of rod outer 
segments (ROS) by associated retinal pigmented epithelial (RPE) cells (D'Cruz et al., 
 176
2000). A Mertk-specific defect in apoptotic cell clearance has also been reported for 
RPE cells of the human eye (Gal et al., 2000).  
 
Scott et al performed binding assays to determine whether the phagocytic defect of 
Mertkkd macrophages was due to an inability to bind apoptotic thymocytes in the 
absence of this receptor (Scott et al., 2001). Analysis by scanning electron 
microscopy showed that wild type and Mertkkd macrophages were equally capable of 
binding apoptotic thymocytes. However, while wild-type macrophages proceeded to 
ingest bound thymocytes within the 1 hour assay, apoptotic thymocytes remained 
bound to the surface of Mertkkd macrophages with negligable ingestion. Hence, 
Mertk-deficient macrophages display normal recognition and binding, but a 
deficiency in internalisation of apoptotic thymocytes. Analysis of Dex-MDM 
phagocytosis of apoptotic neutrophils by confocal microscopy (Chapter 3, fig. 3.7) 
indicated that Dex-MDM were capable of binding apoptotic neutrophils in the 
absence of serum, but internalisation required the presence of human serum during 
phagocytic interaction, probably as a source of protein S for stimulation of Mertk. 
Thus, binding and internalisation of apoptotic neutrophils by Dex-MDM may be 
separate events requiring distinct receptor mechanisms. We have shown anti-Mer to 
inhibit serum- and protein S-dependent uptake of apoptotic neutrophils by Dex-
MDM, however it would be interesting to determine whether Dex-MDM binding 
of apoptotic neutrophils is Mertk-dependent. The contribution of Mertk to apoptotic 
neutrophil binding could be assessed by pre-treating Dex-MDM with anti-Mer 
before performing binding experiments at 4C in the absence or presence of human 
serum or protein S. Additional experiments are required to determine whether a 
tethering receptor is employed by Dex-MDM for serum-independent binding of 
apoptotic neutrophils, and if this interaction is critical for efficient uptake of 
apoptotic neutrophils. Several receptor mechanisms have been implicated in 
clearance of apoptotic cells in vitro, yet relatively few of these clearance mechanisms 
impair apoptotic cell clearance in vivo when tested in genetically deficient mice. 
Intriguingly, expression of Mertk, MFG-E8 and C1q, proteins critically required for 
apoptotic cell clearance in vivo (Botto, 1998, Scott et al., 2001, Taylor et al., 2000, 
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Hanayama et al., 2004), were upregulated in human monocytes upon exposure to 
glucocorticoids (Ehrchen et al., 2007). We have demonstrated that Dex-MDM 
phagocytosis of apoptotic neutrophils is Mertk-dependent, but C1q-independent and 
MFG-E8 independent (via inhibition of v5). 
 
 
6.4.4 Mertk signalling is linked to anti-inflammatory effects in macrophages 
Glucocorticoids dramatically alter the expression profile of monocytes during 
maturation to induce a more anti-inflammatory macrophage phenotype (Ehrchen et 
al., 2007) that displays enhanced capacity for nonphlogistic phagocytosis of 
apoptotic neutrophils (Liu et al., 1999, Heasman et al., 2004). For example, uptake of 
apoptotic neutrophils by methylprednisolone-treated MDM failed to trigger the 
release of IL-8 and MCP-1, chemokines that can promote influx of more leukocytes 
and therefore prolong inflammation (Liu et al., 1999). Therefore, glucocorticoids 
promote “safe” clearance of cells dying by apoptosis and may directly contribute to 
the resolution of inflammation. Importantly, Dex-MDM are not completely 
dissociated from pro-inflammatory signalling, retaining the ability to respond to LPS 
and IFN via modification of surface receptor expression. Members of the TAM 
family of receptor tyrosine kinases perform an essential immunoregulatory role by 
regulating macrophage responses to environmental stimuli, for example by limiting 
toll-like receptor (TLR)-mediated immune responses (Camenisch et al., 1999, Lu and 
Lemke, 2001, Lemke and Lu, 2003). The repression of the pro-inflammatory 
macrophage responses is directly coupled to the recognition of apoptotic cells 
(Cvetanovic and Ucker, 2004). Interestingly, Gas6-mediated ligation of Mertk in the 
presence of apoptotic cells enhanced apoptotic cell clearance by microglial cells, 
associated with Vav phosphorylation and activation of Rac, while actively inducing 
anti-inflammatory signalling that was sufficient to suppress LPS-induced expression 
of iNOS and IL-1 (Grommes et al., 2008). Furthermore, apoptotic cells protect mice 
against LPS-induced shock (Ren et al., 2008). Mertk expression on the surface of 
human MDM was subject to positive and negative regulation by anti- (Dex) and 
pro-inflammatory (LPS or IFN) molecules, respectively. Altered expression of 
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Mertk would be critically required for the ability of macrophages differentiated in the 
presence of Dex respond to bacterial infection in vivo by releasing pro-inflammatory 
mediators upon stimulation of TLRs.  
 
Mertk may therefore play a dual role in the pro-resolving effect of glucocorticoids. 
Induced expression of Mertk and protein S by glucocorticoids may promote 
acquisition of a negative-feedback pathway to both switch off pro-inflammatory 
cytokine production (Rothlin et al., 2007) while enhancing phagocytic capacity for 
apoptotic cells. The efficacy of glucocorticoids in treatment of autoimmune diseases 
like SLE that are characterised by impairment of apoptotic cell clearance may be 
due, in part, to engagement of these pro-resolution mechanisms. Manipulation of the 
Mertk pathway may represent a novel approach to engage aspects of glucocorticoid 




CHAPTER 7: SUMMARY AND FUTURE DIRECTIONS 
 
The aim of this study was to determine the molecular mechanisms required for 
efficient clearance of apoptotic neutrophils by human MDM, a process that may be 
conducive for the resolution of inflammation. Glucocorticoids are potent anti-
inflammatory agents that exhibit pro-resolving actions through modulation of 
inflammatory neutrophil survival and function, and augmentation of macrophage 
phagocytic capacity for apoptotic neutrophils in vitro (Liles et al., 1995, Cox, 1995, 
Meagher et al., 1996, Liu et al., 1999, Giles et al., 2001). These findings have serious 
implications in the clinical setting where unresolving chronic inflammatory diseases 
characterised by inefficient or dysregulated resolution processes cause considerable 
morbidity and untimely death. Indeed, it has recently been demonstrated that 
manipulation of apoptosis in vivo may result in enhanced resolution of inflammation 
(Rossi et al., 2006, Sawatzky et al., 2006), thereby highlighting the potential to 
manipulate processes involved in the resolution of inflammation for therapeutic gain 
(Serhan et al., 2007, Rossi et al., 2007). When the work in this thesis was started, 
little was known of the phagocytic receptor mechanisms(s) required for enhanced 
uptake of apoptotic neutrophils by human MDM following treatment with the 
dexamethasone. We hypothesised that glucocorticoids specifically induce a distinct 
mechanism for apoptotic cell clearance. Apoptotic cell clearance is a complex 
process thought to involve numerous interactions between the apoptotic prey and 
macrophages, and soluble bridging molecules can bind to the apoptotic surface to 
modulate the phagocytic interaction. The diversity of receptor pathways involved in 
the phagocytic interaction may represent redundancy in receptor mechanisms, or may 
equip different phagocyte populations with specific receptor profiles required for 
specialisation of phagocytic function, targeted recognition of different apoptotic 
prey, or to allow adaptability in macrophage phagocytic capacity based upon the 
tissue load of apoptotic cells. We focused on understanding the interaction between 
Dex-MDM and apoptotic neutrophils at the receptor level, and we have found that 
exposure of human monocytes to Dex immediately following isolation for the 
duration of their maturation into macrophages induced a highly phagocytic 
phenotype associated with a “switch” from a serum-independent clearance 
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mechanism employed by untreated MDM to a highly efficient serum-dependent 
mechanism. In summary, long-term treatment with Dex: 
 
Increased phagocytosis of 20 hour serum-cultured neutrophils 2-fold, consistent 
with results from previous studies (Liu et al., 1999, Giles et al., 2001) 
Failed to enhance uptake of 20 hour serum-free cultured neutrophils 
Increased phagocytic capacity critically required the presence of serum during 
the phagocytic interaction 
Serum promotes internalisation of “early” apoptotic neutrophils by Dex-
MDM, but not untreated MDM 
Human albumin, IgG, complement C1q and C3b, fibronectin, pentraxin-3, 
annexin-1, a platelet-derived factor and alpha-2 macroglobulin were found to 
be devoid of pro-phagocytic activity 
High molecular weight fractions, containing protein S and C4BP, conferred 
the pro-phagocytic activity of human serum 
Protein S binds to the surface of apoptotic neutrophils in a calcium-dependent 
but PS-independent manner to enhance clearance by Dex-MDM  
Immunodepletion of protein S abolished the pro-phagocytic activity of 0.2M 
anion exchange fractions and phagocytosis was restored upon addition of 
purified protein S to depleted fractions 
Reduction and alkylation abolished the pro-phagocytic activity of high 
molecular weight gel filtration fractions 
 
Although our data indicated that a high molecular weight complex of C4BP-protein 
S was required for augmented phagocytosis of apoptotic neutrophils by Dex-MDM, 
we found that purified protein S was sufficient to confer augmentation. The failure of 
low molecular weight fractions to enhance Dex-MDM phagocytosis may be due to 
inefficient isolation of the free form of protein S during anion exchange. Incubation 
of C4BP-protein S complexes with guanidium chloride to dissociate C4BP with the  
chain from protein S followed by gel filtration and dialysis, as performed by Kask et 
al (Kask et al., 2004), may be a valuable future experiment for testing the phagocytic 
contribution of C4BP and protein S in their free and complexed forms. 
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By performing inhibitor studies of Dex-MDM phagocytosis using mAbs, we found 
that the Mertk receptor pathway was critically required for protein S-dependent 
clearance of apoptotic neutrophils by Dex-MDM, but not untreated MDM. The 
environmental stimuli monocytes are exposed to during differentiation are therefore 
likely to enable the promotion of specific phagocytic mechanisms. We propose that 
long-term exposure of monocytes to Dex induces a “switch” to a Mertk-dependent 
pathway for efficient apoptotic cell clearance. We hypothesised that Dex-mediated 
transactivation of Mertk expression was sufficient for increasing the phagocytic 
potential of human MDM. However, LPS- and IFN-mediated downregulation of 
Mertk on Dex-MDM did not abolish the phagocytic potential of these cells. 
Furthermore, we demonstrated that serum-enhanced Dex-MDM phagocytosis of 
apoptotic neutrophils: 
 
Involved a partial calcium-independent opsonisation event 
Was only partially inhibited by blocking Mertk 
By promoting internalisation of bound apoptotic neutrophils, with binding 
possibly mediated by a serum-independent mechanism 
 
These data suggest that while Mertk mediates efficient internalisation of protein S-
opsonised apoptotic neutrophils, other pathways may contribute to the phagocytic 
potential of Dex-MDM. Indeed, it may be naïve to expect such a complex process 
to be influenced by a single molecule. The enhancing effect of serum on Dex-MDM 
phagocytosis of apoptotic neutrophils is likely complex and multifaceted, and 
alterations in intracellular cytoskeletal organisation in macrophages may also be 
important (Giles et al., 2001).  
 
The studies in this thesis have been performed entirely in vitro using cells isolated 
from human peripheral blood. Although this approach allows the intricate dissection 
of molecular pathways, it cannot replicate the in vivo tissue microenvironment that 
has the potential to further influence the mechanisms involved in clearance of 
apoptotic neutrophils. The cytokine and matrix composition will determine the 
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differentiation status of MDM populations during progression of an inflammatory 
response. Although untreated human MDM differentiated in the presence of M-CSF 
may utilise a protein S-dependent apoptotic cell clearance mechanism (Uehara and 
Shacter, 2008), our data indicates that untreated human MDM cultured in the 
presence of autologous serum do not utilise a protein S-dependent recognition 
pathway. The production and release of potential opsonins (complement components, 
pentraxins, annexins, protein S, etc.) is also regulated during inflammation, and 
production of both protein S and C4BP in the liver appears to be controlled by 
inflammatory mediators including IL-6 and TNF (Hooper et al., 1995, de Wolf et 
al., 2006). Levels of protein S are reduced in patients with ischaemic stroke (Akyol et 
al., 2006), possibly via the effects of TNF on endothelial cells (Hooper et al., 1994). 
In contrast, glucocorticoids have been reported to elevate levels of protein S (Oner et 
al., 2005). Based upon data presented in this thesis, we propose that a major effect of 
glucocorticoids on MDM differentiation is the induction of the capacity to 
recognise a distinct set of molecular cues that are presented on the apoptotic 
neutrophil surface. The surface molecular signature of an apoptotic cell may 
therefore be interpreted differently by different MDM populations, allowing 
functional diversity in MDM responses, for example whether apoptotic cells are 
encountered during normal homeostasis, in the presence of inflammatory signals, or 
during the resolution of inflammation. What receptor mechanism(s) are engaged 
likely depends upon the phagocytic and apoptotic target cell types (Fadok et al., 
1992a), with the cytokine milieu and presence of activatory signals (e.g. bacterial 
LPS) also having an influence over the activation state of the phagocyte, surface 
receptor expression and the availability of opsonins. 
 
An alternative approach to investigating the role of Mertk in protein S-dependent 
phagocytosis by Dex-MDM would be to use specific genetic mouse “knock-outs” 
of Mertk, or to “knock-down” Mertk expression in human MDM using siRNA, to 
explore how the absence of Mertk affects monocyte to macrophage differentiation 
and aqcuisition of phagocytic capability when exposed to Dex. Murine Mertk shows 
remarkable homology to the human form (88% amino acid sequency identity) 
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(Graham et al., 1995), and murine Mertk may be similarly involved in serum-
enhanced clearance of apoptotic neutrophils following Dex treatment of murine 
MDM (Liu et al., 1999, Cortes-Hernandez et al., 2002). It would be interesting to 
compare the phagocytic efficiency of Mertk-deficient macrophages in vivo under 
homeostatic conditions or in the presence of inflammatory signals. It is possible that 
a Mertk-independent receptor mechanism may mediate apoptotic neutrophil 
clearance during normal homeostasis. However, higher rates of neutrophil apoptosis 
evident during persistent or chronic inflammation may require a more efficient 
apoptotic cell clearance mechanism by MDM, such as the Mertk pathway facilitated 
by glucocorticoid treatment. Indeed, upregulation of Mertk mRNA in alveolar 
macrophages in response to an increased apoptotic cell load may reflect adaptation of 
macrophages to increase their apoptotic cell clearance capacity (Kazeros et al., 
2008). Thus, we would predict that the pro-resolving effects of glucocorticoid 
treatment would be impaired in Mertk-deficient mice compared to wild type control 
mice, which could be tested experimentally by assessing the effect of Dex treatment 
on the secretory responses and apoptotic neutrophil clearance by Mertk-deficient 
macrophages when compared to wild type macrophages. However, the inability of 
anti-Mer to entirely abolish phagocytosis by human Dex-MDM in the presence of 
10% autologous serum suggests that Mertk-deficient macrophages may utilise 
additional Mertk-independent receptor pathways. Furthermore, this approach may be 
complicated by the redundancy in apoptotic cell clearance mechanisms, and it is 
impossible to predict whether Tyro-3 and Axl, additional members of the TAM 
receptor family, may compensate for the loss of Mertk in vivo, particularly during 
development (Lu et al., 1999). The development of a macrophage-specific Mertk 
knock-out using Cre-Lox recombination may represent a more targeted approach to 
determining the contribution of Mertk to macrophage clearance capacity in vivo. 
However, it would be beneficial to assess the contribution of Axl and Tyro-3 to Dex-
MDM phagocytic capacity in vitro prior to in vivo experiments. 
 
An alternative to specific genetic deletion of Mertk to define the role of this receptor 
in glucocorticoid-enhanced phagocytosis would be to specifically over-express 
Mertk in cell lines previously deficient as phagocytes i.e. ‘knock in’ or transfection. 
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This approach has been reported by Ren et al to confer a phagocytic phenotype 
following transfection of CD36 into human Bowes melanoma cells and monkey 
COS-7 cell lines (Ren et al., 1995). However, there are potential limitations to this 
approach as additional uncharacterised receptor mechanisms may be required for 
“binding” of apoptotic neutrophils by Dex-MDM independent of Mertk (Scott et 
al., 2001). Furthermore, the effect of Dex on MDM phagocytic capacity may also 
require modification of MDM morphology and adhesive ability through altered 
expression/phosphorylation of cytoskeletal proteins (Giles et al., 2001) that would be 
absent from transfected macrophages. Indeed, we found that increased Mertk 
expression on the surface of untreated MDM was not sufficient to confer a pro-
phagocytic MDM phenotype. Thus, the glucocorticoid effect is probably too 
complex for such an approach to be successful. Addition of soluble Mertk during in 
vitro phagocytosis assays was found to inhibit Mertk-dependent clearance of 
apoptotic Jurkat T cells by the mouse macrophage cell line, J774 (Sather et al., 
2007), and we predict that similar inhibitory effects on protein S-dependent 
phagocytosis by Dex-MDM would be achieved using soluble Mertk. We 
hypothesise that uptake of apoptotic neutrophils could also be inhibited by adhering 
Dex-MDM to protein S-coated surfaces, but not to surfaces coated with control 
proteins, before addition of apoptotic neutrophils in the presence of soluble protein S, 
due to redistribution of Mertk from the apical surface where it is accessible to protein 
S-coated neutrophils, to the lateral surface where it mediates adherence. This 
experiment may also be a useful indicator of whether other receptors can compensate 
for the loss of Mertk. 
 
We have characterised the molecular mechanism of glucocorticoid action on 
macrophage phagocytic capacity using human neutrophils as apoptotic targets 
throughout our study. Dex has been shown to augment macrophage phagocytosis of 
alternative phagocytic targets, including human eosinophils and lymphocytes (Liu et 
al., 1999). Moreover, Van der Goes et al suggested that glucocorticoids enhance the 
general phagocytic capacity of human MDM for several particles including latex 
beads and bacteria (van der Goes et al., 2000). Whether the protein S-Mertk receptor 
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mechanism is a pattern recognition mechanism induced by glucocorticoids to 
enhance MDM phagocytic capacity in general remains to be examined, although 
our data suggests that the mechanism utilised by MDM for apoptotic cell 
recognition depends upon the subpopulation of MDM and is independent of the 
type of apoptotic cell. Ligation of CD44 with a monoclonal antibody promotes 
uptake of apoptotic neutrophils by human MDM, however the precise mechanism 
remains to be fully characterised. Previous suggestions include redistribution of 
ligated CD44 to faciliate the apoptotic neutrophil-MDM phagocytic interaction, or 
CD44-mediated signal transduction to modify MDM phagocytic potential (Vivers 
et al., 2004). An interesting future experiment would be to investigate whether the 
protein S-Mertk pathway is required for enhanced phagocytosis mediated by CD44 
and other pro-phagocytic stimuli such as IL-10.  
 
The resolution of inflammation is a dynamically regulated process that may be 
subverted in many pathological conditions. Pharmacological manipulation of the 
processes involved in physiological clearance of neutrophils from inflamed sites may 
therefore represent a therapeutic approach to treatment of inflammatory diseases. 
Glucocorticoids are potent modulators of macrophage phagocytic capacity, however 
glucocorticoid action is pleiotropic and relatively non-specific, and there are side 
effects associated with long-term treatment of chronic disease (Rosen and Miner, 
2005). If their desired anti-inflammatory actions could somehow be uncoupled from 
their side effects, the clinical benefits would be immense. It has become widely 
accepted that such uncoupling might be achieved through separation of activatory 
and inhibitory effects of glucocorticoids on gene expression. The development of 
dissociated steroids may appear to be a good strategy in theory, yet it does not 
account for the likelihood that the in vivo situation might be more complex. 
Glucocorticoids modulate inflammatory processes during various stages of 
inflammation, via distinct cell- and tissue-specific effects that require different 
mechanisms of action, be it induction of anti-inflammatory mediators or suppression 
of NFB-mediated gene transcription. It is likely that the optimal effect of 
glucocorticoids on macrophage phagocytic ability requires dynamic integration of 
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both immunoenhancing and immunosuppressive actions during monocyte 
maturation. Production of relatively non-specific steroid analogues devoid of 
transactivational ability may lack an important component of glucocorticoid-
mediated anti-inflammatory action, so it is debatable whether such compounds would 
yield the predicted clinical benefits.  
 
A way of treating inflammatory diseases is to tackle the major underlying 
mechanisms involved in disease pathogenesis; cytokine dysregulation and 
accumulation of potentially injurious apoptotic neutrophils may play a contributory 
role. Grommes et al have shown ligation of Mertk in the presence of apoptotic cells 
attenuates pro-inflammatory signalling in macrophages (Grommes et al., 2008). Our 
results suggesting that a protein S-dependent pathway for apoptotic cell clearance 
could be inducible in already differentiated human MDM, and that Dex-MDM 
could modify receptor expression independent of phagocytic function in response to 
pro-inflammatory stimuli is consistent with the ability of macrophages to 
functionally adapt to changing environmental signals (Stout and Suttles, 2004). It 
would be interesting to assess whether short-term Dex treatment could induce 
acquisition of a protein S-mediated phagocytic pathway in monocytes that have been 
differentiated in the presence of pro-inflammatory mediators such as LPS, TNF or 
IFN that may be present during non-resolving inflammation and produce MDM 
that are normally poorly phagocytic for apoptotic cells (Heasman et al., 2004, 
Michlewska et al., 2009). A more comprehensive understanding of whether 
macrophages show plasticity in phagocytic function, and indeed in other important 
pro-resolving qualities, may allow therapeutic targeting of these cells in disease. We 
therefore propose that dissection of the signalling pathways triggered following 
protein S stimulation of Mertk on Dex-MDM may provide a valuable insight into 
the intracellular molecular mechanisms that charaterise a pro-phagocytic macrophage 
phenotype. The high level of active Rac suggests that guanine nucleotide exchange 
factor (GEF) activity may be elevated in Dex-MDM (Giles et al., 2001). GEFs such 
as Grb2 or Vav1 may couple Mertk to activation of Rac1 (Bustelo, 2001, Turner and 
Billadeau, 2002, Mahajan and Earp, 2003, Grommes et al., 2008). Future 
experiments are required to determine whether tyrosine phosphorylation and 
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therefore GEF activity in MDM is altered following exposure to Dex. It would be 
interesting to evaluate whether there is chronic suppression of MDM Mertk 
expression due to the presence of abundant pro-inflammatory mediators during 
chronic inflammation that may impede the pro-resolving function of macrophages. 
Since Mertk expression is relatively restricted to cells of the monocyte/macrophage 
lineage (Graham et al., 1994, Graham et al., 1995), manipulation of the Mertk 
pathway may allow the development of novel strategies that are more selective in 
their action for promoting inflammatory resolution in vivo of chronic inflammatory 
diseases characterised by neutrophilic inflammation, such as rheumatoid arthritis, 
inflammatory bowel disease, COPD and SLE.  
 
In conclusion, this study has provided a novel insight into the molecular mechanisms 
required for a pro-phagocytic macrophage phenotype. The data presented in this 
thesis suggests that long-term glucocorticoid treatment promotes a “switch” to a 
Mertk-dependent apoptotic cell recognition mechanism that is pivotal to immune 
regulation and for processes involved in the resolution of inflammation. 
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Abstract
Phagocytic clearance of apoptotic cells is an important physiologic homeostatic mechanism that is associated with non-
inflammatory or anti-inflammatory sequalae. Disruption of the process of apoptotic cell clearance may contribute to
development of a number of inflammatory and autoimmune diseases. In this review, we summarize the molecular pathways
that have been suggested to account for phagocytic clearance of apoptotic cells. We discuss potential mechanisms for
regulation of phagocytosis and the implications for development of autoimmunity.
Keywords: Phagocytosis, apoptosis, macrophage, inflammation, autoimmunity
Introduction
Apoptosis, in contrast to necrosis (cell disintegration),
does not provoke pro-inflammatory responses and
plays a fundamental role in almost all physiological
processes [1,2]. Apoptotic cells are characterised by
rapid shrinkage of the cytoplasm, nuclear coalescence,
membrane budding and formation of one or more
apoptotic bodies. Importantly, membrane integrity
during apoptosis is maintained preventing liberation
of intracellular histotoxic contents thereby limiting the
potential for propagation and exaggeration of inflam-
matory processes. To avoid cell disintegration (sec-
ondary necrosis), apoptotic cells must be efficiently
and rapidly removed by macrophages [3], dendritic
cells (DC) [4] or in certain circumstances other cell
types such as endothelial cells [5], vascular smooth
muscle cells [6], and fibroblasts [7]. Moreover,
clearance of apoptotic cells results in diminished
pro-inflammatory mediator release and an augmented
secretion of anti-inflammatory cytokines TGF-b, IL-
10, [8], whereas uptake of necrotic cells including
secondarily necrotic cells derived from nonengulfed
apoptotic cells, stimulates release of pro-inflammatory
mediators (TNFa, IL-1b and NO) [9]. It is now
widely accepted that failed clearance of apoptotic cells
and consequent secondary necrosis may lead to the
development of diseases that have an autoimmune
component such as systemic lupus erythematosus
(SLE) [10], type II diabetes [11], cystic fibrosis
[12] and chronic obstructive pulmonary disease
(COPD) [13].
Recognition of apoptotic cells by phagocytes
Removal of apoptotic cells usually involves three
central elements: (1) attraction of phagocytes via
soluble “find me” signals, (2) recognition and
phagocytosis via displayed “eat me” and absence of
“don’t eat me” signals, and (3) altered production of
pro- and anti-inflammatory cytokines. In higher
organisms secretion of specialised chemotactic signals
by apoptotic prey appears to be an important factor in
recruiting phagocytic populations and preventing
secondary necrosis. Although “find me” signals are
so far poorly characterised, recent studies demon-
strated that apoptotic bodies secrete the phospholipid
lysophosphatidylcholine (LPC) attracting phagocytic
cells to apoptotic cells in a caspase-3-dependent
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fashion [14]. Other examples of recruitment signals
include S19 (ribosomal protein dimer) [15], split
human tyrosyl-tRNA synthetase [16] and thrombo-
spondin-1 (TSP-1) [17]. Recognition and engulfment
of apoptotic particles involves multiple ligand–
receptor interactions including “eat me” signals
(molecules enabling recognition of apoptotic cells by
phagocytes), bridging molecules and phagocytic
receptors. One of the most extensively studied “eat
me” signal is loss of phospholipid asymmetry and
translocation of phosphatidylserine (PS) to the outer
leaflet of the plasma membrane during apoptosis [18].
Inhibition of the flippase that normally confines PS to
the inner leaflet together with activation of a
bidirectional non-specific phospholipid scramblase
may lead to loss of lipid asymmetry [19]. In addition
the ATP binding cassette transporter ABC1 has also
been reported to have a role in phospholipid
redistribution [20]. Masking of external PS on the
apoptotic cell surface with annexin V usually blocks
phagocytosis [21]. However, some viable cells, such as
CD45RB low T lymphocytes [22], neutrophils in
Barth syndrome [23] or activated B cells [24] also
expose PS on the outer leaflet of the cell membrane
and these cells fail to be ingested by either amateur or
professional phagocytes.
Attempts to identify a phagocyte receptor that
recognises PS using phage display and monoclonal
antibody 217 (mAb 217) that inhibited binding of PS
liposomes and engulfment of apoptotic cells by
macrophages lead to cloning of this putative phospha-
tidylserine receptor (PSR) [25]. Although interaction of
PS and this putative PSR promoted engulfment of
apoptotic targets by phagocytes [26] Bose et al. showed
that the ablation of putative PSR function resulted in
developmental abnormalities during embryogenesis but
failed to affect macrophage capacity to remove apoptotic
cells both in vitro and in vivo. Furthermore, no
differences in expression of the antigen recognised by
mAb217 was found between wild-type and knockout
mice whilst blotting with commercially generated
antibody against PSR showed that this protein did
disappear from knockout mice [27]. In addition, Cui
et al. demonstrated nuclear localisation of GFT-tagged
putative PSR which was consistent with the presence of
five nuclear localisation signals [28]. One conclusion is
that a phage displayapproachhas the potential to identify
weak cross-reacting epitopes present on the nuclear
protein belonging to iron-oxidase family [29] and that
the real PS receptor remains to be identified [30].
. Recently it has been shown that PS interacts with a
number of bridging molecules including annexin I
(Anx I or lipocortin) [31], milk-fat-globule-EGF-
factor 8 (MFG-E8), growth-arrest-specific 6 (Gas 6)
and b2-glycoprotein-I (b2-GPI) [32]. These inter-
actions may facilitate PS interaction with other
phagocyte receptors, e.g. avb3-integrin, the recep-
tor-tyrosine kinase Mer, and the b2-GPI receptor
by acting as a bridge between the apoptotic cell and
the phagocyte [33]. Interestingly, a recent manuscript
has demonstrated that the macrophage class B
scavenger receptor CD36 interacts with membrane
associated oxidised PS (oxPS) on the surface of
apoptotic cells [34].
Apart from translocation of PS (or oxPS), apoptotic
cells are characterised by surface exposure of oxidised
low-density lipoproteins (oxLDL) [35] recognised by
diverse scavenger receptors: SR-A (class A macro-
phage scavenger receptor) [36], lectin-like oxLDL-
receptor-1 (LOX-1) [37], CD-68 [38] and CD36
[39]. Another class of rather poorly characterised “eat
me” signals are sites binding TSP-1 [40], complement
proteins C1q or C3b/bi [41] or collectins like mannose
binding lectin (MBL) or lung surfactant proteins-A
and -D (SP-A and SP-D) [42]. CD36 and integrin
avb3 bind apoptotic cells to the phagocyte via TSP-1
[43,44], integrins amb2 and axb2 (complement
receptors: CR3, CR4) recognise complement protein
C3b/bi [45], whereas scavenger complex calreticulin
(CRT)–CD91 interacts with lung surfactant pro-
teins-A and -D (SP-A and SP-D), MBL and
collectin-like complement protein C1q [46]. Exposure
of CRT on the cell surface increases during
apoptosis and this is consistent with a potential role
in phagocytic clearance. Removal of apoptotic
CRT-deficient cells by macrophages is impaired and
this effect is reversed by addition of soluble CRT.
Moreover CRT interacts with CD91 also known as
low-density lipoprotein receptor-related protein
(LRP1) or a2 macroglobulin receptor which is a
highly effective internalisation receptor on phagocytes
[47]. Since CRT may be exposed on the apoptotic cell
or the phagocyte surface, CRT activation of LRP may
occur either in trans or cis action [48]. The differential
anti-inflammatory or pro-inflammatory outcomes of
clearance of apoptotic and late apoptotic/secondarily
necrotic cells may be a consequence of engagement
of specific receptors and adaptor molecules.
For example, CD36 triggers strong anti-inflammatory
responses from both monocytes and macrophages
including inhibition of TNFa, IL-1b, IL-12 pro-
duction and up-regulation of IL-10 or TGF-b
[49,50]. In contrast, complement components C1q,
C3 and C4 seem to bind only to primary or secondary
necrotic cells, opsonising those cells not cleared by
other mechanisms [51]. C1q cooperates with serum
DNase 1 in the degradation of chromatin from
necrotic cells, enabling uptake of chromatin fragments
by monocyte-derived phagocytes [52] and C-reactive
protein (CRP) fails to bind to early apoptotic
neutrophils but binds to late apoptotic cells, membra-
ne-permeable cells [53]. Some receptors including
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TSP–CD36–avb3 complex, CD14 and putative PSR
may also be involved in uptake of both apoptotic and
necrotic cells [54,55].
The presence of “eat me” signals on viable cells raises
the possibility that inhibitory signals, termed “don’t eat
me” signals, prevent phagocytosis of those cells [56].
One paradigm for this might be the expression of
inhibitory receptors by NK cells, e.g. killer cell Ig-like
receptor (KIR) which binds self major histocompat-
ibility complex (MHC) class 1 molecules and
subsequently suppress elimination of target cells by
NK cells. This effect may be due to recruitment of src-
homology 2—containing protein tyrosine phospha-
tase-1 (SHP-1) and SHP-2 to two immunoreceptor
tyrosine-based inhibitory motifs (ITIMs) [57].
A similar mechanism may also be operative in
macrophage activation and viable cells may express
surface molecules that bind to macrophage inhibitory
receptors such as signal regulatory protein a (SIRPa)
display markers of “self” in form of ubiquitously
expressed surface molecules that bind to macrophage
inhibitory receptors such as signal regulatory protein a
(SIRPa) [58].
-Brown et al. demonstrated that homophilic inter-
action of CD31 promotes detachment of viable cells
from phagocytes, whereas apoptotic cells are unable to
detach and become internalised by macrophages. In
addition CD31 expressed by apoptotic cells failed to
associate with the cytoplasmic signalling molecules
SHP-1 and SHP-2 indicating disruption in CD31-
mediated signalling in apoptotic cells [59]. CD47 may
also suppress removal of “self” viable cells when
binding to extracellular domain of SIRPa on macro-
phages [60]. CD47 acts as a “don’t eat me” signal on
normal red blood cells (RBC) [61] and is also highly
express on the surface of some cancer cells (i.e. ovarian
cancer cells) and virally-infected cells leading to
impaired immune defence [62].
Engulfment pathways
Studies in the nematode Caenorhabditis elegans, fruit
fly Drosophila melanogaster and mammalian cells
revealed conservation of the engulfment machinery
[63,64] involving two signalling pathways influencing
the balance of membrane Rho family GTPases activity
[65]. RhoA and Rac-1 regulate phagocytosis of
apoptotic cells in opposite manner—RhoA inhibits
this process while Rac-1 is obligatorily required for
engulfment [66]. Assembly of a trimolecular complex
trimolecular complex of ELMO, CrkII and
DOCK180 in mammals (known respectively as
CED-12, CED-2 and CED-5 in the worm) [67]
activates the guanine nucleotide guanine nucleotide
exchange activity of DOCK180 for Rac (CED-10),
which in turn promotes cytoskeletal rearrangements
crucial for the uptake of target particles [68]. The
upstream components required for Rac activation are
different. One pathway identified in both mammalian
cells and worms involves RhoG/MIG-2 and the
guanine nucleotide exchange factor TRIO/UNC-73
[69], although the surface receptor remains unknown.
The second pathway involves the cell surface receptor
proteins ABC1/CED-7 and CD-91/CED1 and the
adaptor protein GULP/CED-6. ABC1/CED-7 down-
stream ligands have not been identified yet [70].
Pharmacological modulation of phagocytosis
Our group and others have shown that macrophage
phagocytic capacity is modulated by pharmacological
or immunological intervention. For example, anti-
inflammatory glucocorticoids augment the ability of
macrophages to phagocytose apoptotic cells in a
concentration—and time-dependent manner via
the glucocorticoid receptor [71]. Glucocorticoid
treatment was suggested to reprogram macrophage
differentiation towards a highly phagocytic phenotype
with high levels of active Rac, increased formation of
lamellipodia and cellular extensions as assessed by time
lapse video microscopy and decreased cellular
adhesion [72,73]. Furthermore, one important
mediator of glucocorticoid action, the anti-inflamma-
tory protein Anx-1, has been suggested to be essential
for phagocytosis. Macrophages from Anx-1 null mice
have reduced phagocytic capacities in vitro and in vivo
associated with decreased expression of CD11b
receptor protein [74].
Extracellular matrix (ECM) proteins such as
fibronectin and collagen may also influence macro-
phage phagocytic abilities. Their interaction with
macrophages through b1 integrin receptor was shown
to upregulate phagocytosis [75]. However, exposure
to cigarette smoke causes post-translational carbonyl
modification of ECM proteins as well as lipid
peroxidation resulting in increased macrophage
adherence but decreased macrophage uptake of
apoptotic neutrophils [76].
CD44 has been demonstrated to act as an adhesion
receptor for ECM molecules and mediates a number of
cellular functions such as adhesion and proliferation of
lymphocytes, cytocidal activity of NK cells and tumor
metastasis [77]. Cross linking of human monocyte-
derived macrophage CD44 with bivalent antibodies
rapidly and specifically augmented uptake of apoptotic
neutrophils in vitro [78] suggesting the possibility that
ligation of CD44 in vivo may selectively promote
clearance of apoptotic neutrophils and subsequently
resolution of inflammation. Studies on CD44 deficient
mice administrated with bleomycin to induce inflam-
mation in alveolar interstitium, confirmed this sugges-
tion. A 13-fold increase in the number of apoptotic cells
was detected in lung tissue of CD44 deficient animals
in comparison to control, indicating impaired clear-
ance of apoptotic cells resulting in development of lung
injury in these mice [79].
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The close relationship between cell adhesion and
phagocytosis is further revealed in studies with agents
that elevate intracellular cAMP levels such as
prostaglandins (PG). Pretreatment of macrophages
with PGE2 or PGD2 or cAMP stable analogues such as
dibutyryl-cAMP and 8-bromo-cAMP significantly
reduced the proportion of macrophages that phagocy-
tosed apoptotic cells and caused alterations in
macrophage adhesion, loss in membrane activity and
cell locomotion [80]. It has been reported that variety
of inflammatory mediators, including PG, that
stimulate activity of adenylate cyclase and PKA are
likely to inhibit clearance of apoptotic cells [81].
Furthermore, PKA is able to phosphorylate Rho, a key
negative regulator of cytoskeletal organisation, indi-
cating that cAMP may play a pivotal role in regulation
of the phagocytic process [82]. All Rho family GTPases
require prenylation (covalent attachment of lipid
adducts) and subsequent membrane insertion for
activity. Since the cholesterol lowering drugs (statins)
inhibit activity of HMG-CoA reductase they also
reduce production of prenylation substrates and it has
been recently reported that lovastatin may enhance
phagocytosis of apoptotic cells via suppression of
prenylation and membrane localization of RhoA,
altering the RhoA–Rac-1 membrane balance towards
Rac-1—a positive regulator of phagocytosis [83].
The lipoxins represent further arachidonic acid
metabolites that play an important role in resolution of
inflammation. Their strong inhibitory effects on
neutrophil chemotaxis and adhesion is well documen-
ted, but more recent data show that LXA4 and its
stable synthetic analogues augmented clearance of
apoptotic neutrophils in a concentration-dependent
manner [84]. It has been also demonstrated that
Anx-1 and LXA4 converge onto the same specific
membrane lipoxin A4 receptor [85]. In addition the
stable cAMP analogue 8-bromo-cAMP attenuated
and the PKA inhibitor, Rp-cAMP, mimicked LXA4
effects indicating that lipoxin may inhibit PKA activity.
The lack of additive effects of Rp-cAMP and LXA4
suggested they act through the same pathway.
Interestingly, LXA4 was shown to inhibit PKA activity
induced by PGE2, consistent with an important role
for PKA in regulation of phagocytosis. One potential
substrate for PKA is scavenger receptor CD36 [86]
and loss of CD36 phosphorylation in platelets
results in increased cytoadhesion [87]. Monoclonal
antibodies against CD36 blocked macrophage
phagocytosis of apoptotic neutrophils induced by
LXA4 raising the possibility that LXA4-mediated
dephosphorylation of CD36 may promote phagocyte-
apoptotic cell recognition [88].
Clearance deficiency and autoimmunity
Impairment of apoptotic cell clearance may result in
exacerbation of inflammation and tissue injury,
together with loss of production of cytokines (i.e. IL-
10) that maintain an anti-inflammatory environment
[89]. On the contrary, enhancement of phagocyte
clearance capacity by IL-10 [90] may further promote
an environment of tissue repair and resolution of
inflammation. There is now a wealth of evidence that
support the hypothesis that defects in clearance of
apoptotic cells have a role in pathogenesis of human
autoimmune diseases. For an instance in SLE patients
phagocytic activity is impaired [91], including
clearance of autologous apoptotic material [92,93].
Apoptotic cells undergoing secondary necrosis within
tissue represent a source of pro-inflammatory stimuli
and potentially immunogenic autoantigens. As shown
at Figure 1 presentation of autoantigens by DC and
macrophages may drive production of autoantibodies
[94]. Nucleosomal proteins released from DNA as a
result of internucleosomal cleavage during apoptosis
represent one of the most abundant class of autoanti-
gens found in patients with autoimmune disorders [95].
Antibodies against nucleosomes are a serological
hallmark of SLE but also other autoimmune diseases.
Additionally, delayed uptake of apoptotic cells may
generate caspase-derived neoantigenic peptides that are
capable of triggering autoimmune responses, inducing
loss of tolerance by B cells and formation of immune
complexes (IC) [96]. Autoantibodies opsonising apop-
totic corpses may further alter phagocytic clearance
pathways. It has been demonstrated that anti-phospho-
lipid antibodies may bind to externalised PS on
apoptotic cell surfaces and promote Fc receptor-
dependent phagocytosis which may have pro-inflam-
matory sequelae [97]. It could be postulated that whilst
low number of apoptotic cells are disposed of in a non-
inflammatory manner, problems may arise when tissue
phagocytes are faced with an overwhelming load of
apoptotic cells following infection or serious tissue
injury. We have recently demonstrated that IC bind to
“enabled” FcgRIIA on apoptotic human neutrophils
[98]. Surprisingly, opsonisation of apoptotic neutro-
phils with IgG-containing IC allowed their rapid
clearance by macrophages without production of pro-
inflammatory cytokines, thus providing a mechanism
for preventing release of intracellular antigens (particu-
larly nuclear constituents) even in the face of a heavy
apoptotic cell load. Paradoxically, therefore, IC may
have beneficial effects, acting to limit development of
autoimmunity in some circumstances.
Impairment of apoptotic cell removal by macro-
phages in peripheral or lymphoid tissues may result in
late apoptotic cells become accessible to tissue or
follicular DC. The capacity of DC to induce tolerance
or immune activation is strongly related to the levels of
“maturation” and expression of co-stimulatory mol-
ecules. Thus, cross-presentation of self or foreign
antigens to CD8þ cytotoxic T lymphocytes (CTL) and
stimulation of production of antibodies by B cells may
depend on local micro-environmental conditions that
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regulate levels of DC maturation [99]. Pro-inflamma-
tory signals such as LPS, TNFa, IL-1b or IFN-a as
well as viral or bacterial proteins, high antigen load or
uptake of necrotic cells appear to be very powerful
inductors of DC maturation and activators of immune
response [100]. On the other hand, anti-inflammatory
cytokines such as TGF-b or IL-10 or more importantly
uptake of apoptotic cells strongly suppress maturation
of DC and promotes peripheral tolerance [100]. It has
been shown that engulfment of apoptotic material by
DC may inhibit even such strong pro-maturation signal
as LPS, indirectly reducing DC capacity to stimulate
T cells [101]. Furthermore, uptake of apoptotic cells
by DC fails to stimulate effective antigen presentation
to lymphocytes. In contrast, uptake of necrotic cells
induces maturation of DC and a break in peripheral
tolerance [102,103]. Therefore, the current model for
the development of autoimmunity involves two
important factors: (i) production of autoantigens, and
(ii) a strongly pro-inflammatory environment, both of
which are closely linked to deficiency in clearance of
apoptotic cells.
However, although this association is supported by
some studies using mice lacking apoptotic cell
recognition molecules, e.g. C1q, in some cases
defective clearance of apoptotic cells may have no
consequences in terms of development of autoanti-
bodies and autoimmunity, for example, CD-14
deficient animals show a defect in the clearance of
apoptotic cells in the absence of an overt autoimmune
phenotype [104]. There is convincing evidence linking
complement protein C1q deficiency with development
of SLE. It has been reported that lack of complement
pathway proteins results in accumulation of apoptotic
material and elevated levels of self-antigens and IC, and
consequently in direct induction of tissue inflam-
mation, maturation of DC and production of auto-
antibodies. Complement fragments also deliver
regulatory signals to Tand B lymphocytes maintaining
peripheral tolerance to self-antigens and absence of
stimulation results in decrease thresholds of activation
for Tand B cells [100,105].
Another example of condition with an autoimmune
component and clearance deficiency is cystic fibrosis
characterised by massive recruitment of inflamma-
tory cells and release of intracellular sources into the
lung. Patients are also characterised by increased
number of apoptotic cells in airways and it is highly
probable that impaired clearance may result from
elastase-mediated inhibition of phagocytosis causing
chronic inflammation and progressive lung tissue
damage [106].
Figure 1. Diagram illustrating cascade of events resulting from efficient (A) or impaired (B) clearance of apoptotic cells. Efficient clearance
of apoptotic cells prevents cell necrosis and stimulates production of anti-inflammatory mediators by phagocytes. In anti-inflammatory
environment maturation of antigen presenting cells (i.e. DC) and immune response is inhibited. On the contrary, when clearance of apoptotic
cells is affected, accumulated apoptotic cells undergo secondary necrosis resulting in production of autoantigens and pro-inflammatory
mediators. In the presence of pro-inflammatory mediators maturation of DC is induced. Mature DC, after gaining access to autoantigens,
present them to T helper cells followed by subsequent B cell production of autoantibodies and development of autoimmunity.
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Type-1 diabetes is another disease condition in
which autoimmunity and clearance of dying cells play a
crucial role. This autoimmune disease usually emerges
in genetically predisposed children, most likely in
response to an environmental insult. Humoral and cell-
mediated immunities trigger chronic apoptotic cell
death amongst the insulin-secreting b-cells of the
pancreatic islets of Langerhans [107]. It has since been
postulated that the apoptotic b-cells themselves
constitute a trigger for autoimmunity and that impaired
clearance of apoptotic cells is central to development of
the disease, perhaps on account of harmful autoanti-
gens released during the apoptotic process and
resultant infiltration of T-cells [108]. Results from
animal studies suggest that the underlying cause of
impaired clearance is likely to be due to a deficiency in
the macrophages themselves [109] but the mechanism
has yet to be fully elucidated.
Closing remarks
Apoptosis and subsequent clearance by professional
or non-professional phagocytes is a complex and
dynamic process crucial for normal tissue homeostasis
and modulation of immune responses and develop-
ment of autoimmunity. Uptake of late apoptotic or
necrotic cells engages different receptors and signal-
ling pathways than early apoptotic cells with profound
implications for regulation of immunity. As our
knowledge of the phagocytic clearance mechanisms
and the potential for modulation of macrophage
phagocytosis increases, we may uncover new ways to
treat patients with autoimmune conditions arising
from defective removal of apoptotic cells.
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The glucocorticoid (GC) drugs are one of the most commonly prescribed and effective 
anti-inflammatory agents used for the treatment of many inflammatory disorders through 
their ability to attenuate phlogistic responses. The glucocorticoid receptor (GCR) 
primarily mediates GC actions via activation or repression of gene expression. GCs 
directly induce the expression of proteins displaying anti-inflammatory activities. 
However, the likely predominant effect of GCs is the repression of multiple inflammatory 
genes that invariably are overexpressed during nonresolving chronic inflammation. 
Although most GC actions are mediated through regulation of transcription, rapid 
nongenomic actions have also been reported. In addition, GCs modulate inflammatory 
cell survival, inducing apoptosis in immature thymocytes and eosinophils, while delaying 
constitutive neutrophil apoptosis. Importantly, GCs promote noninflammatory 
phagocytosis of apoptotic cell targets, a process important for the successful resolution 
of inflammation. Here, the effects and mechanisms of action of GC on inflammatory cell 
apoptosis and phagocytosis will be discussed. 
KEYWORDS: glucocorticoids, apoptosis, inflammation, macrophage phagocytosis 
 
INTRODUCTION 
Inflammation is an important physiological host defence mechanism against infection and injury. 
Granulocytes, such as neutrophils and eosinophils, are crucial in innate immune defence against bacterial 
and parasitic infections, respectively[1]. However, the persistent recruitment and/or enhanced survival of 
granulocytes at inflamed sites may result from dysregulated expression of proinflammatory genes, such as 
cytokines (IL-1, TNFα, GM-CSF, etc.), chemokines (IL-8, IL-5, MIP-1α), and adhesion molecules 
(ICAM-1 and E-selectin)[2]. Uncontrolled leukocyte responsiveness will lead to release of inflammatory 
mediators, such as eicosanoids (prostaglandins, leukotrienes, and thromboxanes), cytokines (IL-8, etc.), 
reactive oxygen/nitrogen species (O2
–, NO), and granular enzymes (e.g., elastase)[3], resulting in damage 
to the surrounding tissue and propagation of the inflammatory response. This likely contributes to 
persistent dysregulated inflammation, resulting in the pathogenesis of disorders such as chronic 
obstructive pulmonary disease (COPD) and bronchial asthma[4].  
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Apoptosis is a programmed form of cell death[5] that regulates the number and fate of leukocytes at 
inflamed sites and, in contrast to necrosis, is associated with maintenance of cell membrane integrity and 
damage limitation[6]. Granulocytes are terminally differentiated cells and undergo constitutive apoptosis 
during in vitro culture[6,7], which is amenable to lineage-specific modulation by intrinsic and extrinsic 
factors including cAMP[8], IL-5[7], GM-CSF[9], prostaglandins[10], and TNFα[11]. Synthetic 
glucocorticoids (GCs), such as dexamethasone, initially demonstrated to induce apoptosis of immature 
thymocytes[12], also accelerate apoptosis in eosinophils while, surprisingly, prolong neutrophil 
survival[13,14]. This observation has led to speculation that GCs may be exerting part of their beneficial 
effect in eosinophil-dominant diseases (e.g., asthma) by inducing apoptosis of lymphocytes and 
eosinophils while maintaining beneficial neutrophil-dependent antimicrobial responses. Consequently, it 
is possible that direct pharmacological triggering of cell-specific apoptosis may be a novel therapeutic 
strategy in the treatment of inflammatory disorders[15,16]. However, for this to be considered as a 
successful tactic, efficient removal of the apoptotic leukocytes is also required. Failure to do so may lead 
to apoptotic cells undergoing secondary necrosis with deleterious consequences in terms of tissue damage 
and the outcome of the inflammatory response. An additional anti-inflammatory effect of GCs is the 
profound potentiation of phagocytic clearance of intact apoptotic leukocytes described in vitro[17,18] and 
possibly in vivo[19]. These recently described effects of GCs, together with limiting inflammatory cell 
recruitment and activation, may prevent further injury through the release of noxious intracellular 
contents and may be important for promoting the resolution of inflammation. However, there are potential 
limitations to the application of GCs in disease, particularly as a consequence of the undesirable side 
effects associated with long-term treatment. Delineating the precise mechanisms of GC action would 
provide a significant insight into the anti-inflammatory role of GCs and allow the development of novel 
strategies that are more selective in their action. 
THE GLUCOCORTICOID RECEPTOR 
GCs mediate most of their effects by binding to glucocorticoid receptors (GCRs). The GCR is a member 
of the nuclear receptor superfamily, which includes receptors for mineralocorticoids and sex 
hormones[20]. Alternative splicing of the gcr gene generates two or more GCR isoforms with distinct 
functions. Although GCRα is the predominant isoform and is responsible for GC binding, GCRβ is a c-
terminally truncated variant that cannot bind GC or regulate transcription, but can form heterodimers with 
GCRα to modulate GCRα function[21,22]. Inactive GCR resides in the cytoplasm as part of a 
multiprotein complex, being bound to chaperone molecules including heat shock proteins (HSP90) and 
immunophilin[23]. HSP90 forms interactions with GCR in the c-terminal domain essential for 
maintaining the correct configuration of GCR and also masks a nuclear localisation signal to prevent 
translocation of the unoccupied GCR to the nucleus[24]. Upon binding of GC to GCR, these chaperone 
proteins dissociate from the GCR, unmasking the nuclear localisation signal required for the activated 
GC-GCR complex to translocate to the nucleus[24]. Here, GCR can directly or indirectly modulate the 
transcription of multiple target genes.  
MECHANISMS OF GC ANTI-INFLAMMATORY ACTION 
Transactivation: Induction of Anti-Inflammatory Gene Expression 
One mechanism whereby GCs can mediate their action is via direct binding of GCRs to DNA to increase 
the transcription of anti-inflammatory genes, a process known as transactivation (Table 1). Ligand-
activated GCRs translocate to the nucleus and bind specifically to palindromic glucocorticoid-responsive 
elements (GREs) found in the promoter region of GC-responsive genes[25,26]. The central domain of the 
GCR contains two zinc fingers essential for GCR dimerisation and binding to GRE sequences[26,27], 
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with a point mutation in the D-loop of the central domain abolishing transactivation[28]. Thus, 
transcription of GC-responsive genes requires GCRs to be in the homodimeric form. GCR “switching on” 
of gene transcription also requires the recruitment of specific transcriptional coactivator proteins, which 
are important for localised chromatin remodelling and stabilisation of the basal transcriptional 
machinery[29].  
This mechanism directly modulates the expression of secretory leukocyte proteinase inhibitor 
(SLPI)[30], IL-1 receptor antagonist[29], and C1q [31]. Annexin I (or Lipocortin 1) is an additional GC-
inducible protein thought to mediate many of the anti-inflammatory actions of GCs. This is confirmed by 
studies in deficient mice, which have altered expression of annexins, COX-2, and cPLA2; exaggerated 
responses to carrageenin- or zymosan-induced inflammation; and partial resistance to the anti-
inflammatory effects of GCs[32]. Administration of exogenous annexin I confers anti-inflammatory 
activity in some models of inflammatory disease[33]. Conversely, infusion of annexin I antibodies 
neutralises the effect of annexin I and abrogates the anti-inflammatory activities of GCs[33]. It has been 
suggested that autoantibodies to annexin I may contribute to GC resistance and the pathogenesis found in 
inflammatory diseases where GCs may be used as a treatment, such as rheumatoid arthritis and systemic 
lupus erythematosus (SLE)[34]. Additionally, annexin I–derived peptides have been shown to mimic 
some of the anti-inflammatory effects of endogenous annexin I, including a role in phagocytic clearance 
of apoptotic cells[35]. GCs also enhance the expression of other anti-inflammatory proteins that may be 
important in switching off signalling pathways engaged during persistant inflammation. Mitogen-
activated protein kinase (MAPK) phosphatase 1 (MKP-1) dephosphorylates and inactivates MAPKs, such 
as p38 MAPK and c-Jun terminal kinase (JNK), which contribute to enhanced expression of 
proinflammatory mediators[36]. The suppressive effect of GCs on MAPK signalling is impaired in MKP-
1 knockout mice, which show enhanced expression of proinflammatory genes, including COX2, TNFα 
and IL-1[36]. Thus, the anti-inflammatory action of GCs via transactivation may be important in aiding 
the resolution of inflammation and in boosting innate immune defence through the induction of protective 
proteins. Nevertheless, it is doubtful that all the effects mediated by pleiotropic GCs could be explained 
by enhanced production of a small number of proteins with anti-inflammatory properties. 
Transrepression: Inhibition of Proinflammatory Gene Expression 
Although a small number of genes can be regulated directly, many more genes are regulated indirectly by 
the GCR via suppression of gene expression, a process known as transrepression (Table 1). Originally, 
this repression was thought to result from homodimeric GCRs binding to putative negative GRE sites in 
the promoter regions of proinflammatory genes to switch off their transcription[37]. However, the 
majority of genes repressed by GCs do not contain negative GRE sequences; therefore, alternative 
mechanisms to DNA binding must be engaged.  
Ligand-activated GCRs can “switch off” inflammatory gene expression by a DNA-independent 
mechanism through direct protein-protein interactions with activated NFκB and AP-1 transcription 
factors[38,39]. Since NFκB and AP-1 induce the transcription of multiple inflammatory and immune 
genes characteristic of various inflammatory disorders[40,41], this mechanism of GC action is extremely 
important and probably accounts for most of the inhibitory effects of GCs on inflammation. Although 
cytoplasmic interaction of ligand-activated GCR with transcriptional regulators has been reported, more 
recent data indicate that GCR may interfere with NFκB and AP-1 at a later stage after they have bound to 
DNA to influence transcription[39,42]. Reichardt and colleagues introduced a point mutation A458T into 
the GCR gene by a gene-targeting technique involving Cre/loxP recombination[28,42,43]. Specifically, 
the mutation was “knocked in” to the D-loop of the central domain of the GCR, preventing DNA binding, 
GCR dimerisation (GCRdim), and transactivation. However, transrepression of NFκB- and AP-1–mediated 
gene expression remained intact, indicating that this process is mediated by monomeric GCR. Application 
of the GCRdim mouse model would allow investigation into the process of transrepression in the absence 
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of transactivation and allow elucidation of GC mechanism of action in various processes during 
inflammation in vivo. Interestingly, higher concentrations of GCs are required for induction of anti-
inflammatory gene expression, while gene repression by the GCR can occur at much lower, more 
clinically relevant concentrations of GC[24]. Indeed, it has been questioned whether DNA binding is 
required at all for physiological GCR function[44]. Thus, although GCs can induce anti-inflammatory 
gene expression, the repression of activated proinflammatory transcription factors appears to be the 
dominant mechanism of GC action. Moreover, these modes of GC effect may even occur concurrently, 
where the induction of IκBα and glucocorticoid-inducible leucine zipper (GILZ) may contribute to later 
onset inhibition of NFκB and AP-1, respectively[20]. 
Table 1.  
Mechanisms of Glucocorticoid Anti-Inflammatory Action 
 
Chromatin Remodelling, HATs, and HDACs 
It is now apparent that an additional DNA binding-independent mechanism of GC action may involve 
reversible alterations in chromatin structure and histone acetylation. Gene expression and repression are 
associated with alterations in chromatin structure through modification of core histones[45] (Fig. 1). In a 
resting cell, the DNA is tightly coiled around core histone proteins and is inaccessible to transcriptional 
regulators, a configuration referred to as “closed” and is associated with gene silencing[46]. Initiation of 
transcription by NFκB and AP-1 requires slackening of chromatin and unwinding of DNA for 
transcriptional cofactors and RNA polymerase II to gain access to genes. Upon binding to DNA, NFκB 
and AP-1 recruit and activate coactivator proteins, such as cAMP response element binding (CREB) 
binding protein (CBP) and p300/CBP-associated factor, which have intrinsic histone acetyltransferase 
(HAT) activity[46]. Acetylation of key lysine residues in histones by coactivator proteins initiates 
chromatin remodelling required for gene transcription[45]. Reversal of histone acetylation results in 
tightening of chromatin around DNA and hinders binding of NFκB and AP-1. Deacetylation is controlled 
by corepressor proteins, such as histone deacetylases (HDACs) and nuclear receptor corepressor (NcoR), 
and is associated with gene repression[29]. This process may be important for “switching off” genes once 
the stimulus is removed and inflammation is no longer required, and failure to do so could contribute to 
the development of persistent or chronic inflammation. 
GCR Interacts with HATs and HDACs to Regulate Their Function 
GCR can directly interact with NFκB and AP-1 to suppress the expression of proinflammatory genes, a 
process that may involve reversal of histone acetylation[39] (Fig. 1). The exact mechanism involved here 
is uncertain, although a competitive role between GCR, NFκB, and AP-1 for binding to coactivators 
remains controversial[47]. GCRs may carry out their repressive function by directly suppressing the HAT 
Mechanism of GC Action Genes Affected 
Transactivation: Induction of anti-inflammatory 
gene expression 
SLPI, IL-1 receptor antagonist, C1q, annexin I, MKP-1, 
GILZ, IκBα 
Transrepression: Suppression of proinflammatory 
gene expression 
Cytokines (IL-1, TNFα, GM-CSF), chemokines (IL-8, 
MIP-1α), adhesion molecules (ICAM-1, E-selectin) 
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activity of coactivators[2]. Alternatively, activated GCRs may recruit corepressors, such as HDAC2, to 




FIGURE 1. Effect of GCR on chromatin remodelling, HATs, and HDACs. Gene expression and repression are regulated by modification of core 
histones. In the resting state, DNA is tightly coiled around histones and is inaccessible to transcriptional cofactors and RNA polymerase II. Upon 
binding to DNA, NFκB and AP-1 recruit and activate coactivator proteins, such as CBP and p300/CBP-associated factor, which have intrinsic 
HAT activity. Histone acetylation results in slackening of chromatin and unwinding of DNA, allowing the transcriptional machinery to gain 
access to genes and initiate transcription. Deacetylation is controlled by corepressor proteins, such as HDACs and NcoR, and is associated with 
gene repression. Activated GCRs may interact with HATs and HDACs to regulate their function. Suggested mechanisms of GR transrepression 
include (1) GCR competes with NFκB and AP-1 for binding to coactivators, (2) direct suppression of HAT activity of coactivators by GCR, (3) 
recruitment of corepressors by GCR to reverse histone acetylation. 
Nongenomic Effects 
The genomic effects of GCs have a lag period of around 30 min to a few hours/days[20], result from GC 
binding to cytoplasmic GCR, and are blocked by inhibitors of transcription and translation, such as 
cycloheximide[49]. Some data indicate that GCs may exert more rapid actions (seconds to minutes) that 
are most likely transcriptional independent[50]. Furthermore, it has been suggested that some immediate 
GC effects may be GCR independent, for instance, inhibition of superoxide production by 
macrophages[51] or alteration of plasma membrane properties[50]. Other investigations have implicated 
GCR-dependent nongenomic effects of GCs via post-transcriptional regulation, both at the level of 
mRNA and protein[52]. This may provide an immediate inhibitory effect of GCs on the expression, 
synthesis, and release of proinflammatory mediators. For this, a putative membrane-associated form of 
the GCR (mGCR) may bind GC and transduce signals via MAPKs, PI-3K, and PKC, which mediate the 
rapid effects[49,53]. Investigations by Croxtall and colleagues have implicated GCR-dependent effects of 
dexamethasone via altered phosphorylation status of annexin I, leading to inhibition of cPLA2 activation 
and arachidonic acid release[54]. Whether any of these nongenomic effects described occur at 
physiological concentrations of GC and have a contributory role to the anti-inflammatory effect of these 
steroids remains controversial. 
 




GCs are pleiotropic steroids with the ability to attenuate many phlogistic responses, making them the 
most effective clinical treatment for various inflammatory disorders, e.g., asthma. However, a small 
proportion of asthmatic patients do not respond well to GC treatment and may require high doses of 
GC[55]. Several mechanisms have been postulated to contribute to GC resistance. Increased expression of 
GCRβ has been suggested to interfere with GCRα function[21,22]. Interestingly, the level of GCRβ is 
increased by proinflammatory cytokines[56] and in peripheral blood mononuclear cells from patients with 
GC-resistant rheumatoid arthritis[57]. The level of intracellular GC is much lower than the extracellular 
concentration due to expulsion of GC from the cell by members of the ABC family of transporter 
molecules[52]. Overexpression of these proteins may contribute to the development of GC resistance. 
COPD is an inflammatory disorder where GCs are not usually a beneficial treatment and patients are 
relatively resistant to these steroids even when given high doses[24]. This ineffectiveness has been linked 
to factors such as smoking and oxidative stress[58].  
GC SIDE EFFECTS 
Despite being the mainstay therapy for treatment of inflammatory disease, long-term GC use is associated 
with many undesirable side effects, the molecular mechanisms of which are extremely complex and are 
not entirely understood. Endocrine and metabolic side effects leading to diabetes and osteoporosis have 
been linked to transactivation of genes by the ligand-activated GCR[59]. For example, GCs may increase 
glucose synthesis through transactivation of enzymes involved in gluconeogenesis[59]. GCRdim mutants, 
which are transactivation deficient, retain many of their beneficial anti-inflammatory effects through 
transrepression of NFκB- and AP-1–mediated gene expression[28,42,43]. Hence, identification of 
“dissociated steroids” that can mediate transrepression of proinflammatory genes without induction of 
transactivation would represent an attractive therapeutic strategy. Such compounds may provide a safer 
approach to treatment of inflammatory diseases through this ability to convey the beneficial actions of 
GCs with reduced adverse effects[60]. However, some side effects, such as skin atrophy and suppression 
of the hypothalamic-pituitary-adrenal axis, may be mediated by the transrepressive function of the 
GCR[59] or may even involve a combination of both GCR mechanisms that would complicate the use of 
dissociated steroids in therapy. It is imperative, therefore, that the specific molecular mechanisms 
involved in GC-induced side effects are delineated to allow the development of more selective therapies. 
GCS AS A THERAPY FOR INFLAMMATORY DISEASE 
Inflammation is Normally Self-Resolving 
Under normal circumstances, inflammation is beneficial to the host and is self-resolving, requiring 
controlled clearance of granulocytes from inflamed sites[6]. Apoptosis of granulocytes, in contrast to 
necrosis, is associated with maintenance of membrane integrity[6] and down-regulation of potentially 
injurious secretory responses[61]. For granulocytes, functional attenuation is also achieved by surface 
changes during the apoptotic process, including down-regulation of FcγRIII (CD16)[62] and L-selectin 
expression[63], and uncoupling β2 integrins[63]. Cells undergoing apoptosis display specific surface 
alterations important for signalling rapid recognition and internalisation by phagocytes[64,65,66]. Many 
receptor mechanisms have been acknowledged in the direct recognition and engulfment of apoptotic cells 
by phagocytes[67,68,69], including the vitronectin receptor[70], scavenger receptors[71], CD31[72], 
putative phosphatidylserine receptor (PSR)[73], C1q receptor calreticulin[74], and the tyrosine kinase 
receptor, MER[75]. Blocking individual receptors on phagocytes only partially inhibits phagocytosis of 
apoptotic cells, suggesting redundancy in the engulfment pathways and underlining the importance of 
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phagocytic clearance of apoptotic cells. During resolving inflammation, macrophages (or other cells with 
phagocytic capacity) are required to remove the potentially histotoxic apoptotic cells rapidly and 
efficiently[76]. Phagocytic removal of apoptotic cells normally occurs early on in the death process when 
the dying cell is still intact[6] and, in contrast to phagocytosis of necrotic cells, fails to induce the release 
of proinflammatory mediators, such as eicosanoids, GM-CSF, or IL-8, and MCP-1 chemoattractants from 
the phagocytic cell[77,78,79]. Engulfment of apoptotic cells also actively induces anti-inflammatory and 
immunosuppressive effects in the phagocyte by, for example, inducing the production of IL-10, TGFβ, 
PGE2, and platelet-activating factor[80,81]. Thus, rapid recognition, ingestion, and degradation of dying 
cells by phagocytes are nonphlogistic and equally as vital as the process of apoptosis itself. Both 
apoptosis and subsequent phagocytic clearance are prerequisites for efficient clearance of granulocytes 
and other inflammatory cells from tissues and, ultimately, for the resolution of inflammation. 
Disease: Failure of Natural Resolution Process? 
Neutrophils and eosinophils have been implicated in the pathogenesis of many inflammatory and allergic 
disorders, such as COPD and bronchial asthma. Accumulation of leukocytes reflects a mismatch between 
their infiltration into the inflamed site in response to cytokines, chemokines, and adhesion molecules, 
which are overexpressed during chronic inflammation and the mechanisms required for their clearance. 
Defective apoptosis or failure to remove intact apoptotic cells efficiently before lysis may play a 
contributory role in the disease pathogenesis through release of histotoxic granulocyte contents that have 
the capacity to damage the surrounding tissue and by stimulating proinflammatory macrophage secretory 
responses. Indeed, impaired phagocytosis of apoptotic cell material may contribute to the severity of 
disease in human SLE[82,83]. Mouse models of C1q deficiency develop spontaneous/persistant 
inflammation that resembles an SLE-like disease and may be due to defective clearance of apoptotic 
cells[84,85]. In both cases, a systemic autoimmunity is developed against autoantigens that may be 
displayed on or released by the noningested apoptotic cells. This underlines the importance for “safe” and 
efficient removal of these potentially harmful cells and the therapeutic value of agents that promote this. 
Our laboratory and others have identified GCs as important regulators of both apoptosis and phagocytic 
removal of apoptotic cells in diseases where these processes may be inefficient or dysregulated. Indeed, it 
has recently been demonstrated that manipulation of apoptosis in vivo may result in enhanced resolution 
of inflammation[86,87], thereby highlighting the potential to manipulate processes involved in the 
resolution of inflammation for therapeutic gain[15,16]. Consequently, the effects of glucorticoids on the 
resolution process, in our opinion, are highly clinically relevant.  
GLUCOCORTICOID REGULATION OF APOPTOSIS IN INFLAMMATORY CELLS 
Internal Controls of Apoptosis 
Apoptosis plays a crucial role in regulation of the inflammatory response. Neutrophils have a short life 
span with a circulating half-life of 6–10 h, which is delayed by redundant mediators present at inflamed 
sites (24–48 h)[88]. Eosinophil apoptosis occurs at a much slower rate than in neutrophils[7]. Despite 
their derivation from a common precursor cell, apoptosis in these granulocytes is controlled quite 
differently. Many of the inflammatory mediators present at an inflamed site can exert either anti- or 
proapoptotic influences. For example, G-CSF, GM-CSF, C5a, and LPS profoundly inhibit neutrophil 
apoptosis[14,89,90], as does increased cAMP[8] or a hypoxic environment[91]. Eosinophil survival is 
promoted in response to GM-CSF, IL-3, and IL-5[92], and PGD2[10]. 
T cells are an essential component of the adaptive immune system, and apoptosis is important for 
their development and maintenance. Apoptosis is fundamental in regulating T-cell development in the 
thymus during selection of developing thymocytes bearing a functional TCR[93]. Regulation of apoptosis 
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in T cells differs from that in granulocytes. Thymocytes undergo apoptosis upon elevation of intracellular 
calcium concentrations in response to calcium ionophores[94], whereas increased levels of intracellular 
calcium delays eosinophil apoptosis[10]. Additionally, cycloheximide accelerates the constitutive rate of 
apoptosis in both neutrophils[95] and eosinophils[13], but not T cells[4]. Apoptosis is also essential for 
maintenance of mature T cells in the periphery. Upon encounter with cognate antigen, mature T cells 
undergo significant clonal expansion and removal of these expanded cells once the stimulus has been 
cleared is by activation-induced cell death[93], which involves activation of the extrinsic pathway of 
apoptosis by ligation of death receptors such as FasL[96]. Hence, apoptosis is an indispensable process to 
avoid autoimmunity.  
From the knowledge gained on the internal controls of apoptosis, it may be possible to induce 
apoptotic death of specific inflammatory cells involved in the pathogenesis of diverse inflammatory 
diseases. In support of this suggestion, in vitro studies suggest that apoptosis in the closely related 
neutrophil and eosinophil granulocytes appears to be controlled by different mechanisms.  
GC Modulation of Apoptosis 
Physiological concentrations of GCs can regulate the intrinsic rate of apoptosis in many leukocytes and 
their efficacy depends upon a number of modulatory factors, including the GC type and concentration. 
GC regulation of granulocyte survival is dose dependent and occurs through the GCR (blocked by 
mifepristone)[13,14]. The GCs dexamethasone, methylprednisolone, and hydrocortisone all prolonged 
neutrophil viability from 12 to 48 h, however non-GC progesterone failed to inhibit development of 
apoptosis[14,97], indicating this is not due to nonspecific effects of high dose GCs. Endogenous cortisone 
also mediates these effects on granulocyte survival, albeit to a lesser extent[13]. Differential effects of 
GCs on granulocyte apoptosis have also been shown in a rat peritoneal model[98], where various GCs 
induce eosinophil apoptosis, but delay neutrophil apoptosis with most significant effects observed at GC 
concentrations of 10–6 and 10–8 M, respectively. Thus, GCs used at optimal concentrations for eosinophil 
apoptosis prolong neutrophil survival, indicating that the beneficial effects of GC treatment for asthma 
may involve suppressing eosinophilic airway inflammation while maintaining antimicrobial responses. 
This is a more specific therapeutic approach to treatment of inflammatory diseases compared to general 
nonspecific immunosuppressive agents, such as cyclosporine. However, the anti-inflammatory action of 
GCs is not reproducible for COPD, a neutrophil-dependent disease. Here, GC-mediated neutrophil 
survival may contribute to tissue damage with increased potential for release of intracellular contents. 
NFκB plays a vital role in the regulation of granulocyte apoptosis by inducing the expression of 
prosurvival genes[99] and targeted inhibition may be an approach to induce neutrophil apoptosis in 
COPD. Indeed, the NFκB inhibitor gliotoxin induces apoptosis in granulocytes alone or synergistically 
with TNFα[99]. 
GCs can also induce apoptosis in thymocytes[12] and, hence, are used in the treatment of lymphoid 
diseases. Interestingly, thymocyte sensitivity to GCs seems to be dependent upon their developmental 
stage where GCs induce apoptosis in CD4+CD8+ double positive thymocytes, but not upon maturation to 
single positive thymocytes[93]. In contrast, mature T cells are relatively resistant to GC-induced 
apoptosis, and some investigations have even reported GCs to prevent activation-induced cell death in 
these cells[100]. The effect of GCs on monocyte viability is more controversial. Although GCs have been 
suggested to induce apoptosis in monocytes[101], a recent study by Ehrchen et al. showed that monocytes 
were protected from staurosporine-induced apoptosis, mediated by reactive oxygen species (ROS), by 
increasing the expression of antioxidant molecules upon GC treatment[102].  
GC influence on cell survival is initiated by GC binding to the cytoplasmic GCR and involves 
alterations in gene expression. However, there has been much controversy over the mechanism used by 
the GCR, whether by transactivation of death genes, transrepression of survival genes or both.   
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MECHANISMS OF GC EFFECTS ON APOPTOSIS 
Evidence for Transrepression 
Helmberg and colleagues[103] have suggested that interference with proinflammatory signalling through 
the transrepressional activity of GCR is an important mechanism of GC-induced apoptosis. This was 
derived from studies using T-cell leukaemia cell lines expressing mutant GCRs that were DNA-binding 
and transactivation defective, but retained the ability to repress NFκB and AP-1 transcriptional capability. 
These mutants were sufficient to induce apoptosis in these cells in response to GCs, implicating a role for 
GCs in apoptosis via the transrepression of prosurvival genes. Transrepression by GCR is suggested to be 
the main mechanism of suppressing the expression of cytokines and other inflammatory mediators that 
modulate granulocyte survival, and this may contribute to GC-induced apoptosis. In a recent study, Novac 
and colleagues provide data that support the role of GCR repression of gene expression in GC-induced 
apoptosis[104]. Here, GCs transiently suppress the level of the death receptor FasL and subsequently 
inhibit activation-induced T-cell apoptosis. Regulation of FasL expression was suggested to be a result of 
GCR binding directly to DNA, specifically to negative GREs that overlap an NFκB site. Hence, 
repression of FasL by GCR binding in cis may be due to competition for a common binding site and their 
rationalisation of this mechanism is that it would slow down T-cell apoptosis so that macrophages are not 
overwhelmed with a massive apoptotic cell load. 
Evidence for Transactivation 
Ramdas and Harmon[105] used a transactivation-defective mutant GCR that retained transrepressional 
activity, but did not mediate GC-induced apoptosis in human leukaemic T cells, suggesting that DNA 
binding by the GCR is important. Similarly, Reichardt and coworkers used a GCRdim mutant to show the 
requirement for transactivation in GC-induced thymocyte apoptosis[28]. New protein synthesis has been 
implicated in the regulation of apoptosis and, indeed, GC-induced thymocyte apoptosis and neutrophil 
survival can be abolished with cycloheximide[106]. This indicates that neutrophil survival requires 
ongoing gene expression and continuous synthesis of a prosurvival factor(s), a process that requires 
continued presence of GC[106], whereas GC-induced thymocyte apoptosis may be due to transactivation 
of death genes. Alternatively, GC induction of IκB expression may block proinflammatory signalling and 
contribute to induction of apoptosis in responsive cells[105]. 
Effects of GCs on the Mitochondrial Pathway–Regulated Apoptosis 
Regulation of apoptosis may occur at the level of the mitochondria, an intracellular organelle with a 
central role in the apoptotic process. During the early stages of apoptosis, loss of mitochondrial 
membrane potential and increase in outer mitochondrial membrane permeability allow the release of 
factors such as Cytochrome C[8], which initiates downstream effects culminating in caspase activation 
and ultimately apoptosis[107]. Human eosinophils stimulated with dexamethasone show morphological 
changes characteristic of apoptosis, including DNA fragmentation, caspase-3 activation, and loss of 
mitochondrial membrane permeability[107]. Inhibition of mitochondrial permeabilisation, but not 
caspase-3 activity, prevented both mitochondrial disruption and apoptosis in response to dexamethasone. 
This suggests that GC-induced eosinophil apoptosis occurs through activation of the mitochondrial 
pathway, possibly resulting from the release of caspase-independent apoptosis-inducing factor 
(AIF)[107]. Loss of mitochondrial membrane potential and induction of eosinophil apoptosis may result 
from oxidant-induced mitochondrial injury, a process enhanced by GCs through production of ROS and 
sustained activation of proapoptotic JNK[3]. Ruiz and coworkers used the glucose-glucose oxidase 
system to achieve a constant production of hydrogen peroxide as a source of ROS to stimulate oxidative 
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stress in neutrophils and, hence, apoptosis[108]. Dexamethasone delayed ROS-induced apoptosis in a 
concentration-dependent manner, with most significant inhibition at 10–6 M dexamethasone at 12 and 24 h 
time points[108].  
Although some studies described above do not implicate a role for caspases, GC-induced apoptosis in 
thymocytes and lymphoma cells can be blocked by pharmacological inhibition of caspases (z-VAD-
fmk)[109], showing an additional level of apoptosis regulation, at least in these cell types, by GCs.  
Involvement of Bcl-2 Family Members in GC-Induced Apoptosis 
Bcl-2 proteins play a crucial role in apoptosis by regulating mitochondrial membrane stability[88]. 
Neutrophils express proapoptotic (Bak and Bax) and antiapoptotic (A1 and Mcl-1) members of the bcl-2 
family[88]. GCs may delay neutrophil apoptosis resulting from mitochondrial dysfunction by increasing 
the abundance of antiapoptotic A1 mRNA, while decreasing the level of proapoptotic Bak mRNA in a 
GCR-dependent manner[88]. GC-induced thymocyte apoptosis may also result from mitochondrial 
dysfunction[110] as a consequence of alterations in the levels of pro- and antiapoptotic bcl-2 factors. 
Indeed, thymocyte apoptosis in response to dexamethasone is accelerated by bcl-2 deficiency[111], 
whereas bcl-2 overexpression inhibits GC-induced lymphoma cell apoptosis[112]. Furthermore, 
alterations in the phosphorylation status of bcl-2 family members in response to GCs may lead to 
mitochondrial injury and subsequent eosinophil apoptosis[3]. Thus, the intrinsic mitochondrial pathway 
may contribute significantly to determining the fate of cells by integrating signals from pro- and 
antiapoptotic members of the bcl-2 family of proteins and this may be regulated by GCs. This apoptotic 
pathway is also inhibited in human neutrophils by a cell permeable analogue of cAMP, dibutyryl cAMP 
(db-cAMP), resulting in neutrophil survival[8], whereas proinflammatory mediators G-CSF and GM-CSF 
increase the expression of proapoptotic bcl-2 proteins and, hence, may promote apoptosis[88].  
MODULATION OF PHAGOCYTIC REMOVAL OF APOPTOTIC CELLS BY 
MACROPHAGES 
In situations where cells are stimulated to undergo apoptosis at a high rate (for example, when there are 
overwhelming proapoptotic signals), the tissue load of apoptotic cells may be in danger of exceeding the 
removal capacity by phagocytes and noningested apoptotic cells may then undergo secondary necrosis 
with detrimental consequences[113]. Thus, the phagocytic clearance of cells dying by apoptosis plays a 
pivotal role in determining the inflammatory outcome and may be a prerequisite for effective resolution 
of inflammation. Hence, in order for deliberate induction of apoptotic cell death to be considered as a 
therapeutic strategy, parallel strategies for their efficient removal will also be required. 
Pharmacological Modulation 
Our laboratory is interested in the way inflammation resolves and we have made attempts to modulate 
macrophage phagocytic potential via pharmacological means. Increased levels of cAMP in human 
monocyte-derived macrophages (MDMφ), using db-cAMP, specifically inhibits phagocytosis of apoptotic 
neutrophils[114], whereas ligation of macrophage surface CD44 rapidly and specifically augments 
phagocytic uptake of apoptotic neutrophils, but not apoptotic lymphocytes[115]. Adhesion to the matrix 
protein fibronectin also rapidly increases macrophage capacity for internalisation of apoptotic 
neutrophils[116]. Particular focus is being made now on interpreting the influence of GCs on the 
mechanisms by which acute inflammation normally resolves. We have demonstrated that GCs augment 
phagocytic potential for nonphlogistic clearance of apoptotic leukocytes, a process that is essential for the 
resolution of inflammation. Pretreatment of 5-day human MDMφ for the first 24 h of culture with GCs 
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methylprednisolone, dexamethasone, and hydrocortisone induced a prophagocytic phenotype displaying 
augmented phagocytosis of neutrophils undergoing apoptosis[17]. GCs also enhance macrophage 
capacity for uptake of other apoptotic targets, including Jurkat T cells and eosinophils, and also promote 
uptake of apoptotic neutrophils by alternative phagocytes, including human glomerular mesangial cells. 
GC action on phagocytosis is specific, as non-GCs aldosterone, estradiol, and progesterone did not exert 
this effect and GCs did not promote ingestion of Ig-opsonised erythrocytes. These observed effects are 
GCR dependent, being inhibited by the GCR antagonist mifepristone, and are reversed by cycloheximide, 
indicating the requirement for new protein synthesis.  
Reprogramming of Monocyte Differentiation by GCs 
Freshly isolated monocytes lack the capacity to ingest apoptotic targets, an ability that is gradually 
acquired during in vitro culture as adherent monocytes differentiate into macrophages[117]. GCs 
potentiate the phagocytic capacity of MDMφ cultured for 5 days in vitro, with a greater potentiation 
observed the earlier monocytes were exposed to GCs during maturation[17]. Furthermore, we have 
demonstrated that long-term exposure (5 days) of monocytes to GCs induced differentiation of monocytes 
into MDMφ displaying enhanced phagocytosis of apoptotic cells (up to threefold) and, hence, represents a 
proresolution phenotype[18]. Macrophages that had been treated with GC for this period were a more 
homogenous population of smaller, more rounded, and less well-spread cells with a phenotype 
characterised by reduced phosphorylation and, hence, recruitment of paxillin and pyk2 to sites of 
adhesion, with consequential loss of actin- and paxillin-containing podosomes, and loss of p130cas 
expression, an important adaptor molecule in integrin adhesion signalling through the 
DOCK180/Crk/p130cas pathway. Despite their altered adhesion, time-lapse video microscopy revealed 
that GC-treated MDMφ remained membrane active with extension and retraction of cellular process, 
probably as a result of increased levels of active Rac. GC-treated MDMφ also displayed homogeneity in 
surface receptor expression, as shown by their laser scatter properties from flow cytometry, which 
identified a more uniform expression of HLA-DR, CD14, and CD44, consistent with reprogramming 
during monocyte differentiation. Although GC-treated MDMφ exhibit elevated surface expression of the 
haemoglobin scavenger receptor, CD163, no single surface receptor was identified that would define a 
prophagocytic macrophage phenotype. Combinatorial treatment with GC and the “classical activator” 
IFNγ abolished GC potentiation of macrophage phagocytic capacity for apoptotic cells[118]. The first 24 
h of culture with GC was critical for acquisition of a prophagocytic phenotype as this was overridden by 
subsequent treatment with IFNγ, with less pronounced inhibition the later IFNγ was added. Interestingly, 
IFNγ did not have an observed effect on GC-mediated morphology or surface receptor expression 
indicating that GC-treated MDMφ adhesion status can be dissociated from phagocytic capacity. This has 
implications for the application of GC therapy in Th1-mediated diseases characterised by high levels of 
IFNγ.  
Induction of an Anti-Inflammatory Macrophage Phenotype by GCs 
GCs are associated with induction of an anti-inflammatory macrophage phenotype. Importantly, GC 
potentiated phagocytosis of apoptotic cells did not stimulate the release of proinflammatory mediators, 
including MCP-1 and IL-8 chemokines[17]. Therefore, GCs promote “safe” clearance of cells dying by 
apoptosis and may directly contribute to the resolution of inflammation. The GC-inducible protein 
annexin I undergoes caspase-dependent recruitment from the cytosol to the outer plasma membrane 
during apoptosis to colocalise with phosphatidylserine and may be required for efficient clearance of 
dying cells[33]. Alternatively, GC-induced expression of annexin I in macrophages and subsequent 
release may enhance apoptotic cell uptake[35]. Indeed, macrophages from annexin I knockout mice show 
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defective phagocytosis of apoptotic cells acting through the FPRL1[35]. This has been furthered by a 
recent study by Scannell et al., who report that annexin I is a prophagocytic factor released by apoptotic 
cells and actively promotes the FPRL1-dependent clearance of apoptotic cells by macrophages[119]. 
Thus, transactivation of annexin I expression by the GCR may contribute to enhanced recognition and 
internalisation of apoptotic cells in response to GC treatment. 
C1q is an important subcomponent of complement C1, which activates the classical pathway upon 
binding to immune complexes or CRP and its expression in monocytes/macrophages can be induced by 
GCs or inhibited by IFNγ and LPS[31,120]. C1q binds to apoptotic cells[121] and may aid in their 
removal by phagocytes. Interestingly, Botto and colleagues demonstrated C1q deficiency in mice to cause 
an SLE-like disease with high titres of autoantibodies and accumulation of apoptotic cells in 
glomeruli[85] and defective clearance of apoptotic cells is also observed in human SLE patients[82,83]. 
Thus, C1q may protect against development of SLE by targeting apoptotic cells for clearance. This has 
been supported by in vitro studies where C1q-deficient human macrophages show impaired phagocytosis 
of apoptotic cells, and this is restored with purified human C1q[84]. Hence, induction of innate proteins 
by GCs may contribute to their anti-inflammatory effect by enhancing removal of dying cells.  
A recent study by Ehrchen and coworkers used a microarray system to analyse the expression profile 
in human monocytes treated with GCs[102]. Their data signify the multitude of GC effects, where the 
expression of over 100 genes were GC regulated with a more pronounced induction of genes that are 
important in monocyte/macrophage functions such as phagocytosis, apoptosis, and adhesion. Important to 
the process of phagocytosis, there was induced expression of CD163, FPR1, and MER tyrosine kinase 
receptors, and MFG-E8 and C1q serum proteins, however, the relevance of this in GC-potentiated 
phagocytic capacity is unclear. These results indicate that GC effects on monocytes are not simply 
immunosuppressive, but also immunomodulatory. GCs promote induction of an anti-inflammatory 
phenotype important for the resolution of inflammation, challenging the concept that transrepression is 
the dominant mechanism of GC action on monocytes.  
CONCLUSION 
Apoptosis is a fundamental process in cell and tissue homeostasis that, in contrast to necrosis, is 
associated with maintenance of cell membrane integrity and noninflammatory clearance by phagocytes. 
Failure or inefficient apoptosis and/or phagocytosis may result in necrosis with detrimental 
proinflammatory consequences. GCs modulate inflammatory cell survival and promote nonphlogistic 
phagocytosis of apoptotic cell targets in vitro, a situation that could be deemed proresolution with 
consequent implications in the clinical setting where unresolving chronic inflammatory diseases cause 
considerable morbidity and untimely death. Thus, considerable effort to elucidate the precise molecular 
and cellular mechanisms of action of GCs, as well as improve existing GCs, is being made.  
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Glucocorticoids Induce Protein S-Dependent Phagocytosis of
Apoptotic Neutrophils by Human Macrophages1
Aisleen McColl,* Stylianos Bournazos,* Sandra Franz,* Mauro Perretti,† B. Paul Morgan,‡
Christopher Haslett,* and Ian Dransfield2*
During resolution of an inflammatory response, recruited neutrophil granulocytes undergo apoptosis and are removed by tissue
phagocytes before induction of secondary necrosis without provoking proinflammatory cytokine production and release. Promo-
tion of physiological neutrophil clearance mechanisms may represent a viable therapeutic strategy for the treatment of inflam-
matory or autoimmune diseases in which removal of apoptotic cells is impaired. The mechanism underlying enhancement of
macrophage capacity for phagocytosis of apoptotic cells by the powerful anti-inflammatory drugs of the glucocorticoid family has
remained elusive. In this study, we report that human monocyte-derived macrophages cultured in the presence of dexamethasone
exhibit augmented capacity for phagocytosis of membrane-intact, early apoptotic cells only in the presence of a serum factor. Our
results eliminate a role for a number of potential opsonins, including complement, pentraxin-3, and fibronectin. Using ion-
exchange and gel filtration chromatography, we identified a high molecular mass serum fraction containing C4-binding protein
and protein S responsible for the augmentation of phagocytosis of apoptotic neutrophils. Because the apoptotic neutrophils used
in this study specifically bind protein S, we suggest that glucocorticoid treatment of macrophages induces a switch to a protein
S-dependent apoptotic cell recognition mechanism. Consistent with this suggestion, pretreatment of macrophages with Abs to Mer
tyrosine kinase, a member of the Tyro3/Axl/Mer family of receptor tyrosine kinases, prevented glucocorticoid augmentation of
phagocytosis. Induction of a protein S/Mer tyrosine kinase-dependent apoptotic cell clearance pathway may contribute to the
potent anti-inflammatory effects of glucocorticoids, representing a potential target for promoting resolution of inflammatory
responses. The Journal of Immunology, 2009, 183: 2167–2175.
S uccessful restoration of a tissue to its original state after aninflammatory insult requires that large numbers of extrav-asated neutrophil granulocytes are cleared from the in-
flamed site. During this resolution phase of inflammation, recruited
neutrophils undergo apoptosis and are subsequently removed by
phagocytosis (1), a rapid and efficient process that does not stim-
ulate proinflammatory macrophage responses (2). Conversely, in-
efficient or defective clearance of membrane-intact apoptotic neu-
trophils may result in release of their histotoxic intracellular
contents as a consequence of secondary necrosis, potentially caus-
ing local tissue damage and contributing to pathogenesis of in-
flammatory disease (3). An attractive approach for therapeutic
intervention in inflammatory diseases would therefore be to ma-
nipulate the processes involved in physiological clearance of neu-
trophils from inflamed sites. Although promotion of neutrophil
apoptosis may be achievable pharmacologically (4), under some
circumstances in vivo it will be important to ensure that the ca-
pacity for apoptotic cell clearance within tissues is matched to
avoid potential deleterious consequences of the presence of non-
phagocytosed apoptotic cells (5).
We have previously reported that the powerful anti-inflammatory
drugs of the glucocorticoid family (methylprednisolone, hydrocorti-
sone, or dexamethasone (Dex))3 specifically enhance noninflamma-
tory phagocytosis of apoptotic cells by human and murine macro-
phages (6, 7). Glucocorticoids have been shown to modulate the
expression of over 100 genes, including those known to be associated
with apoptotic cell phagocytosis, such as CD163, FPR1, and Mer
tyrosine kinase (Mertk) receptors and MFG-E8 and C1q serum pro-
teins (8). Furthermore, we have shown that human monocytes differ-
entiated for 5 days in the presence of glucocorticoids exhibit a more
homogeneous phenotype with reduced phosphorylation of molecules
involved in integrin signaling and cytoskeletal rearrangement (7).
However, the precise mechanism(s) by which glucocorticoids aug-
ment phagocytosis of apoptotic cells has remained elusive.
In this study, we have examined the mechanism underlying aug-
mentation of human monocyte-derived macrophage (MDM) ca-
pacity for phagocytosis of early membrane-intact apoptotic human
neutrophils following exposure to glucocorticoids. Apoptotic neu-
trophils display a distinct surface molecular phenotype important
for attenuation of functional responses (9) with additional surface
changes that target dying cells for removal by phagocytes (10). A
number of soluble factors present in serum, including complement
C1q and C3b, properdin, collectins, long pentraxin-3, MFG-E8,
galectin-3, and 2-macroglobulin, have been reported to bind to
apoptotic human cells (11–18) and consequently modulate their
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recognition and uptake by macrophages via a number of different
surface receptors, including scavenger receptors, complement re-
ceptors, receptors for phosphatidylserine, and Mertk (19–22).
However, it is important to note that some of these opsonization
events occur relatively late during the apoptotic process and ac-
company loss of membrane integrity (23).
In this study, we demonstrate that glucocorticoid augmentation
of MDM phagocytosis is associated with a switch from a serum-
independent to a serum-dependent apoptotic cell recognition
mechanism, which can be recapitulated with purified protein S, a
75-kDa vitamin K-dependent anticoagulation factor that is present
in plasma at a relatively high concentration of 25 g/ml (24),
and involves macrophage Mertk, a member of the Tyro3/Axl/Mer
family of immunoregulatory receptor tyrosine kinases (25). Our
data strongly suggest that glucocorticoids critically regulate a
switch in apoptotic cell clearance mechanisms used by macro-
phages, potentially contributing to their potent anti-inflammatory
effects and thus representing a target for promoting inflammatory
resolution.
Materials and Methods
Sera, serum proteins, and other reagents
All chemicals were purchased from Sigma-Aldrich, unless otherwise
stated. Culture medium (IMDM), buffers (HBSS and PBS without divalent
cations), and trypsin-EDTA were from PAA Laboratories. Percoll was
from GE Healthcare. Dextran T500 was from Pharmacosmos. Dex was
obtained from Organon. Roscovitine was from Merck. Serum, from coag-
ulated whole blood, was obtained by cardiac puncture from wild-type,
annexin I-deficient (26), and C1q-deficient (27) mice on a C57BL/6 back-
ground. C1q-depleted human serum was obtained from Merck. A soluble
recombinant form of human complement receptor 1 was used for inhibition
of C3 activation in serum (28). A dose of 250 g/ml completely blocks
complement activity, as assessed by hemolytic assays. Proteins purified
from human serum/plasma were obtained from the following sources: pro-
tein S (Enzyme Research Laboratories), C1q (Merck), and 2-macroglob-
ulin (Sigma-Aldrich).
Antibodies
Primary Abs were from the following sources: polyclonal rabbit anti-
protein S Ab (1:5000; DakoCytomation), anti-human Mer mAb (clone
125508, murine IgG2b, 1:50; R&D Systems), and CD44 mAb (clone 5A4,
IgG1, 1:50; provided by G. Dougherty, University of California, San Fran-
cisco, CA). Control mouse Igs (IgG1, IgG2b; 1:50) were from Serotec.
HRP-conjugated goat anti-rabbit Igs (1:2500) and FITC-conjugated F(ab)2
goat anti-mouse Igs (1:50) were from DakoCytomation. PE-conjugated
anti-CD16 mAb (clone 3G8, IgG1) was obtained from BD Biosciences.
Agarose-coupled goat anti-rabbit Ig was obtained from Sigma-Aldrich.
Cell isolation
Mononuclear and polymorphonuclear leukocytes were isolated from
freshly drawn, citrated human blood by dextran sedimentation and centrif-
ugation over a discontinuous Percoll gradient (final concentrations of 55,
70, and 81% Percoll), as previously described (29). Mononuclear cells
were aspirated from the 55/70% interface, and neutrophils from the 70/81%
interface. Autologous serum was prepared by recalcification of platelet-rich
plasma (final CaCl2 concentration: 22 mM), as previously described (24).
In vitro culture of human MDM
Mononuclear cells were resuspended at 4  106/ml in IMDM and adhered
to 48-well tissue culture plates for 1 h at 37°C in 5% CO2. Nonadherent
lymphocytes were removed by washing with IMDM, and adherent mono-
cytes were cultured for 5 days in IMDM containing 10% autologous se-
rum  1 M Dex. These cells are 90% CD14 at 5 days with functional
and phenotypic characteristics of macrophages (Dex-MDM) (7).
In vitro culture of neutrophils to induce apoptosis
Neutrophils were cultured at 4  106/ml in IMDM either in the absence
of serum or in the presence of 10% autologous serum at 37°C in 5%
CO2 atmosphere for 20 –24 h, during which time a proportion of the
cells underwent apoptosis (1). Apoptosis and secondary necrosis were
determined by annexin V-FITC binding (Roche Applied Sciences) and
propidium iodide staining (Sigma-Aldrich), respectively. Alternatively,
neutrophils were resuspended in IMDM at 2  107/ml and labeled with
the fluorescent cell tracker dye 5-chloromethylfluorescein diacetate
(CMFDA; Invitrogen), 2 g/ml for 15 min at 37°C in 5% CO2. Neu-
trophils were then washed and cultured for 20 –24 h, as described
above.
Apoptotic cell phagocytosis assay
Phagocytosis of apoptotic cells was assessed essentially as described (30),
using a method that has been carefully characterized and shown to dis-
criminate between bound and internalized apoptotic cells, comparing fa-
vorably with microscopy analysis. CMFDA-labeled apoptotic neutrophils
were centrifuged at 200  g and resuspended at 2.5  106/ml in IMDM,
and 0.5 ml was overlaid onto MDM that had been cultured in 48-well
plates (200,000 MDM/well, a ratio of 10 neutrophils per macro-
phage) and then coincubated for 30 min at 37°C in 5% CO2. Medium was
then gently aspirated from the wells, and all cells were detached with 500
l of trypsin-EDTA before determination of phagocytosis (percentage of
FL-1-positive MDM, identified by their distinct forward and side scatter
properties) by flow cytometry using a FACScan (BD Biosciences). For
assays conducted in the presence of serum or purified proteins, neutrophils
were resuspended in IMDM containing either 1% autologous serum, 10
g/ml either purified protein, or 1 mg/ml protein fractions from ion-ex-
change or gel filtration chromatography, unless otherwise stated in the
figure legends. For experiments requiring preincubation with either Abs or
other protein fractions from ion-exchange or gel filtration chromatography,
MDM or neutrophils were incubated with saturating concentrations of
Abs (final concentration of 10 g/ml as determined by flow cytometric
analysis) or 10 g/ml either purified protein or 1 mg/ml protein fractions
from ion-exchange or gel filtration chromatography, unless otherwise
stated in the figure legends. Cells were washed and resuspended in IMDM
before use in phagocytosis assays.
Serum fractionation
Human serum was dialyzed against 50 mM HEPES buffer (pH 7.0) containing
0.14 M NaCl overnight before anion-exchange chromatography using Q
Sepharose (Sigma-Aldrich). Proteins were eluted using 50 mM HEPES con-
taining 0.2 M NaCl, and fractions containing the highest amount of protein
were combined before dialysis against 50 mM Tris (pH 7.4) containing 0.14 M
NaCl (TBS) and concentrated before gel filtration chromatography using
Sephacryl S-300 (GE Healthcare). The protein concentration in eluted frac-
tions was estimated by measurement of absorbance at 280 nm (A280) using
a spectrophotometer or using a bicinchoninic acid protein assay kit, as
specified by the manufacturer (Pierce). Gel filtration fractions containing
phagocytic activity were analyzed by SDS-PAGE, immunoblotting, and
mass spectrometry to determine the proteins present (two separate analy-
ses; J. Creanor, University of Edinburgh, Edinburgh, U.K.).
Immunodepletion and Western blotting
The 0.2 M NaCl eluate from anion-exchange chromatography was in-
cubated with protein S Ab (5 g/ml eluate) for 1 h on ice. Immu-
nodepletion was achieved by incubation for 1 h with agarose-coupled
goat anti-rabbit IgG at 4°C on a rotary mixer, followed by centrifuga-
tion at 13,000  g for 1 min to pellet the agarose. To ensure efficient
protein depletion, the supernatant was subjected to three rounds of de-
pletion. Samples were resolved by SDS-PAGE using 9% gels under
nonreducing conditions, unless otherwise stated, and transferred elec-
trophoretically (80 V for 50 min) onto either polyvinylidene difluoride
or nitrocellulose membranes (Millipore). Membranes were blocked
overnight in TBS containing 0.1% Tween 20 before probing with Abs.
Binding of anti-protein S Ab was detected with HRP-conjugated goat
anti-rabbit Igs together with ECL (GE Healthcare).
Flow cytometry
All incubations were performed on ice to prevent internalization of Ab.
Adherent MDM were detached by incubation in HBSS without divalent
cations containing 0.1% BSA and 3 mM EDTA. After washing with ice-
cold HBSS containing 2% FBS, cells (105/assay) were incubated with sat-
urating concentrations of mAb for 30 min. Cells were then washed twice
in HBSS containing 2% FBS before incubation with FITC-conjugated
F(ab)2 goat anti-mouse Igs for 30 min before analysis using a FACScan
flow cytometer (29).
2168 GLUCOCORTICOID-INDUCED SWITCH IN APOPTOTIC CELL PHAGOCYTOSIS
Analysis of results
Results are presented as mean  SEM, and n  number of independent
experiments using macrophages from different donors. Results were ana-
lyzed by repeated measures one-way ANOVA with a Bonferroni posttest.
Results
Glucocorticoid-augmented clearance of apoptotic neutrophils by
macrophages is serum dependent
Previous studies relating to glucocorticoid-enhanced phagocytosis
of apoptotic cells used monocyte-derived macrophages and apo-
ptotic cell targets that had been cultured in the presence of serum
(6, 7). To evaluate the potential role of serum opsonization in
promoting apoptotic neutrophil clearance, human blood mono-
cytes were cultured for 5 days in the absence or presence of Dex,
and neutrophils were rendered apoptotic by overnight culture in
serum-free conditions (Fig. 1A). Neutrophil populations cultured
in serum-free conditions for 20 h exhibit a slightly higher percent-
age (63–70%, n  35, 95% confidence limit) of annexin V/pro-
pidium iodide (apoptotic) cells when compared with neutrophils
cultured in the presence of serum (50–60%, n  10), consistent
with the presence of a survival factor(s) in human serum. In ad-
dition, there were significantly higher percentages of annexin V/
propidium iodide (secondarily necrotic) neutrophils in serum-
free cultures (18–26%, n  35) when compared with neutrophils
cultured in the presence of serum (8–17%, n  10).
When we determined the proportion of untreated MDM and
Dex-MDM that were capable of phagocytosis of neutrophils, we
were surprised to find that there was no significant augmentation of
phagocytosis of serum-free apoptotic neutrophils observed for
Dex-MDM (Fig. 1, C and E). In contrast, in the presence of 10%
autologous serum, we observed increased phagocytic capacity for
Dex-MDM (Fig. 1, D and E). The presence or absence of serum
also had a small, but statistically significant stimulatory effect upon
phagocytosis of apoptotic neutrophils by untreated MDM (Fig.
1E). The effect of serum on phagocytosis by Dex-MDM was
concentration dependent and reached significance at 1% (data not
shown). The possibility that the presence of serum acts to promote
phagocytic activity of MDM directly was excluded in a series of
experiments in which preincubation of apoptotic neutrophils with se-
rum was found to confer augmentation of Dex-MDM phagocytic
capacity (data not shown), raising the possibility that a serum factor
binds to the apoptotic neutrophil surface to promote phagocytosis by
Dex-MDM.
Augmentation of phagocytosis by serum is independent of the
presence of necrotic neutrophils
Neutrophils undergo apoptosis in a relatively heterogeneous man-
ner during in vitro culture (Fig. 1A), making it difficult to deter-
mine whether enhanced phagocytosis following opsonization de-
pends upon the presence of apoptotic or secondarily necrotic cells.
We therefore treated neutrophils with roscovitine, a cyclin-depen-
dent kinase inhibitor that induces neutrophil apoptosis rapidly and
uniformly without induction of secondary necrosis (4). Neutrophil
populations cultured with 20 M roscovitine in serum-free condi-
tions for 4 h exhibit a high percentage (80–90%) of annexin V/
propidium iodide (apoptotic) cells with less than 3% annexin
V/propidium iodide (secondarily necrotic) cells (Fig. 1B). Se-
rum-dependent enhancement of phagocytosis of roscovitine-
treated apoptotic neutrophils by Dex-MDM confirmed that op-
sonization of early apoptotic cells was required (33.7  9.3% and
51.8  6.3% for Dex-MDM in the absence and presence of se-
rum, respectively). Data are mean percentage phagocytosis 
SEM, n  3 (, p 	 0.01).
Serum-dependent enhancement of phagocytosis of apoptotic
neutrophils does not require complement activation
Down-regulation of complement regulatory molecules CD55 (de-
cay-accelerating factor), CD46 (membrane cofactor protein), and
CD35 (CR1) on the surface of human apoptotic neutrophils (31)
may allow complement proteins present in serum to bind, and
hence promote their removal by phagocytes (11). We found that
addition of commercially available C1q-depleted human serum
FIGURE 1. Augmentation of phagocytosis of apoptotic neutrophils by
glucocorticoid-treated macrophages is serum dependent. Staining with an-
nexin V (AnxV)-FITC (FL-1) and propidium iodide (FL-2) was used to
determine the proportion of apoptotic (AnxV/propidium iodide) and
secondarily necrotic (AnxV/propidium iodide) cells present in neutro-
phil populations used for phagocytosis assays. Representative two-param-
eter histograms of flow cytometric data are shown for A, neutrophils cul-
tured for 20 h in serum-free conditions (n  35), and B, neutrophils
cultured for 4 h in serum-free conditions in the presence of 20 M rosco-
vitine (n  3). Mean data for the proportion of viable, apoptotic, and
secondarily necrotic cells present for each treatment are shown in the ap-
propriate quadrant together with 95% confidence intervals. Phagocytosis of
fluorescently labeled neutrophils was determined by flow cytometry using
forward scatter and fluorescence to define FL-1high phagocytic and FL-1low
nonphagocytic MDM populations. Representative dot plots for Dex-
MDM incubated with CMFDA-labeled neutrophils in the absence (C) or
presence (D) of 10% autologous serum are shown. FSC, forward light
scatter. E, Percentage of phagocytosis (SEM) recorded for untreated
MDM () and Dex-MDM (f) following incubation with neutrophils
for 30 min is shown. Phagocytosis of apoptotic neutrophils by Dex-MDM
was significantly augmented by 10% autologous serum (AS). The presence
of serum also had a small, but statistically significant stimulatory effect
upon phagocytosis by untreated MDM. Data are mean percentage phago-
cytosis  SEM, n  75. , p 	 0.001.
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failed to confer augmentation of phagocytosis (Fig. 2A), suggest-
ing that C1q was the serum opsonin binding to apoptotic neutro-
phils. However, addition of 70 g/ml human C1q alone (Fig. 2A)
or to C1q-depleted serum (data not shown) did not restore phago-
cytosis by Dex-MDM to levels observed in the presence of au-
tologous serum. In a series of experiments examining the effects of
sera from different species, we noted that augmentation of phago-
cytosis by Dex-MDM was also observed when apoptotic neutro-
phils were incubated in serum obtained from mice, allowing us to
use specific knockouts to define serum components (data not
shown). We found that serum derived from either male or female
C1q-deficient mice was able to significantly augment phagocytosis
of apoptotic neutrophils by Dex-MDM, demonstrating that C1q
was not the serum opsonin required (Fig. 2B). We next inhibited
complement activation and subsequent deposition of C3b on the
surface of apoptotic neutrophils by pretreating autologous serum
with 250 g/ml C3 inhibitor for 10 min before the assay. The
effects of C3 inhibitor-treated serum were indistinguishable from
control PBS-treated serum in enhancement of Dex-MDM phago-
cytosis (Fig. 2C). Further confirmation of a lack of requirement for
complement activation and opsonization of targets was made
through use of heat-inactivated serum (Fig. 2D).
Identification of a serum component required for augmentation
of apoptotic neutrophil phagocytosis by Dex-MDM
A number of serum factors have been reported to modulate apo-
ptotic cell phagocytosis by macrophages, ranging from small mol-
ecules to very large protein complexes. A series of experiments
using size fractionation of serum indicated the serum component to
be greater than 100 kDa (data not shown). We initially sought to
use an “add back” approach to evaluate the role of well-charac-
terized serum proteins in the observed opsonization phenomenon.
This strategy eliminated a role for IgG, pentraxin-3, fibronectin,
platelet-derived factors, and immune complexes (Table I). An-
nexin I and lipoxin A4 are anti-inflammatory mediators that are
regulated by glucocorticoids and can act to stimulate phagocytosis
of apoptotic cells through the formyl-peptide receptor-like 1 (32).
However, pretreatment of Dex-MDM with 10 M WRW4 (a
formyl-peptide receptor-like 1 antagonist) for 1 h before assess-
ment of phagocytosis of apoptotic neutrophils in the presence of
10% autologous serum showed no inhibitory effects (50.5  9.1%
and 42.5  6.5% for Dex-MDM with or without pretreatment;
mean percentage phagocytosis  SD, n  3). Similarly, compar-
ison of phagocytosis of apoptotic cells in the presence of either
control or annexin I-deficient mouse serum demonstrated that this
pathway is not used by Dex-MDM for recognition of apoptotic
neutrophils (80.4  6.3% and 79.3  3.23% for Dex-MDM in
the presence of wild-type and annexin I knockout serum, respec-
tively; mean percentage phagocytosis  SD, n  3).
Identification of a serum fraction with phagocytic activity
Preliminary experiments showed that the serum factor could be bound
to Q Sepharose in a 50 mM HEPES buffer at pH 7.0 or above and
eluted with 0.2 M NaCl (data not shown). Because fewer proteins
would bind at pH 7.0, we ran subsequent separations at this pH to
facilitate identification of the factor. Further fractionation of the 0.2 M
NaCl eluate using Sephacryl S-300 column yielded two partially over-
lapping peaks of protein with descending size (Fig. 3, A and B), as
might be expected for a crude protein fraction with the first peak,
representing high molecular mass proteins (300 kDa), able to confer
augmentation of phagocytosis (Fig. 3C).
Identification of the serum component using mass spectrometry
Mass spectrometry analysis of the major proteins present in the
high molecular mass fraction revealed that the principal proteins
present were IgM, 2-macroglobulin, and C4-binding protein
(C4BP), most likely in complex with protein S (33). The presence
of protein S in the high molecular mass fractions isolated from gel
filtration chromatography was confirmed by immunoblotting anal-
ysis (Fig. 3D). Previous work had eliminated a role for IgM in the
augmentation of phagocytosis of apoptotic cells by Dex-MDM
(data not shown). Phagocytosis of apoptotic neutrophils by Dex-
MDM in the presence of 20 g/ml 2-macroglobulin was not
augmented, suggesting that 2-macroglobulin was not involved
either (Fig. 4A), whereas addition of purified protein S during the
FIGURE 2. Glucocorticoid-enhanced phagocytosis of apoptotic cells
does not require complement activation. Phagocytosis of apoptotic neutro-
phils by untreated MDM () and Dex-MDM (f) was assessed in a
30-min assay by flow cytometry. A, Phagocytosis of apoptotic neutrophils
by Dex-MDM in the presence of serum was not augmented by C1q-
depleted serum (C1qd), whereas addition of 70 g/ml C1q failed to restore
augmentation of phagocytosis (n  3; , p 	 0.001 compared with
Dex-MDM in the presence of serum). B, Serum derived from either
male (M) or female (F) C1q-deficient mice restored serum-dependent
augmentation of phagocytosis of apoptotic neutrophils by Dex-MDM
(n  3; , p 	 0.01 compared with Dex-MDM in the absence of
serum). C, Autologous serum (AS) pretreated with 250 g/ml soluble hu-
man rCR1 to inhibit C3 activation or with PBS as a control for 10 min did
not affect phagocytosis of apoptotic neutrophils by Dex-MDM in the
presence of serum (n  4; NS), and D, heat inactivation of autologous
serum (HI AS; 56°C for 30 min) failed to affect phagocytosis of apoptotic
neutrophils by Dex-MDM (n  4; NS). Data are mean percentage phago-
cytosis  SEM.
Table I. Effect of sera and serum proteins on Dex-MDM
phagocytosisa
Add Back (during phagocytosis)
Phagocytosis by Dex-MDM
(as percentage of phagocytosis
by Dex-MDM in the absence
of serum)
Autologous serum 301.4







a Data are shown as percentage of phagocytosis relative to that recorded for Dex-
MDM in the absence of serum (equivalent to 100%) for at least three independent
experiments.
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assay restored phagocytosis of apoptotic neutrophils by Dex-
MDM to levels similar to those observed in the presence of 10%
serum (Fig. 4B). We therefore tested whether immunodepletion of
protein S from the 0.2 M NaCl eluate affected Dex-MDM phago-
cytosis of apoptotic neutrophils. As shown in Fig. 5A, immu-
nodepletion did not result in the nonspecific removal of proteins
from the 0.2 M NaCl eluate as assessed by total protein staining.
Confirmation of the depletion of protein S from the 0.2M NaCl
eluate containing the prophagocytic activity was made by immu-
noblotting (Fig. 5B). In contrast to a mock Ab depletion of the 0.2
M NaCl eluate, protein S-depleted 0.2 M NaCl eluate failed to
confer augmentation of phagocytosis by Dex-MDM (Fig. 5C).
Together with data presented in Fig. 3C, these data suggested that
protein S, possibly complexed with C4BP, was required to confer
full phagocytic capacity of Dex-MDM. Interestingly, addition
of 250 ng/ml purified human protein S (equivalent to the con-
centration of protein S present in 1% serum) to protein S-de-
pleted 0.2 M NaCl eluate from ion-exchange chromatography
fully restored Dex-MDM phagocytosis (Fig. 5C). These data
raised the possibility that protein S acts as an opsonin, binding
to the surface of apoptotic neutrophils to specifically promote
clearance by Dex-MDM.
Protein S binds to apoptotic neutrophils in a calcium-dependent
manner to mediate their removal by Dex-MDM
To confirm that protein S was able to opsonize apoptotic neutro-
phils, we preincubated serum-free apoptotic neutrophils with either
the high molecular mass fraction from gel filtration chromatogra-
phy or 2.5 g/ml human protein S before washing in IMDM with
or without the addition of 5 mM EDTA. Binding of protein S to
neutrophils in a Ca2-dependent manner could be detected by flow
cytometry using anti-protein S Ab together with CD16 staining to
define apoptotic and nonapoptotic cells (29). The possibility that
anti-protein S Abs were binding nonspecifically through FcR-me-
diated interactions was excluded by use of a rabbit Ig control (Fig.
6A) and by mAb blockade of FcRIIa (data not shown). In the
presence of Ca2, protein S binds to apoptotic (CD16 low-express-
ing) and also nonapoptotic (CD16 high-expressing) cells, but the
FIGURE 3. Identification of a high molecular mass factor required for
augmentation of phagocytosis using anion-exchange chromatography and
gel filtration. Serum proteins were fractionated using a combination of
anion-exchange chromatography (Q Sepharose) together with gel filtration
(Sephacryl S-300) of a 0.2 M NaCl eluate from the Q-Sepharose column.
A, Protein elution profile of a typical gel filtration separation (of five that
were performed) determined by measurement of absorbance at 280 nm
(A280) reveals two partially overlapping peaks of protein. B, Gel filtration
samples (labeled A–G) were separated by SDS-PAGE on a 9% gel under
reducing conditions and stained with 0.5% Coomassie blue (M, molecular
mass marker; 0.2, 0.2 M NaCl eluate). C, The effect of different protein
fractions on phagocytosis of apoptotic neutrophils by Dex-MDM (f) was
determined using a 30-min phagocytosis assay. Samples were standardized
for protein content, and phagocytosis of apoptotic neutrophils by untreated
MDM () is shown for comparison. Significant augmentation of Dex-
MDM phagocytosis of apoptotic neutrophils was observed for two frac-
tions. Data are mean  SEM; n  3. , p 	 0.001, and , p 	 0.01
compared with Dex-MDM in the absence of serum. D, The presence of
protein S in the high molecular mass gel filtration fraction (fraction A) was
confirmed by immunoblotting, as described in Materials and Methods.
FIGURE 4. Protein S, but not 2-macroglobulin, stimulates phagocyto-
sis of apoptotic neutrophils by Dex-MDM. The effect of addition of either
20 g/ml 2-macroglobulin (A) or different concentrations of protein S (B)
on phagocytosis of apoptotic neutrophils by Dex-MDM (f) was assessed
in a 30-min assay. Phagocytosis of apoptotic neutrophils by untreated
MDM () is shown for comparison. Addition of 2-macroglobulin failed
to restore augmented phagocytosis by Dex-MDM, whereas protein S sig-
nificantly augmented macrophage phagocytosis at concentrations of 250
ng/ml or higher. Data are mean  SEM; n  3. , p 	 0.001, and , p 	
0.05 and NS, compared with Dex-MDM in the absence of serum.
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level of binding to apoptotic cells was 2.3-fold higher relative to
that observed for nonapoptotic cells (Fig. 6B). In contrast, protein
S binds poorly to cells in the absence of divalent cations (Fig. 6C).
Interestingly, high levels of protein S binding to secondarily ne-
crotic cells was observed (CD16 intermediate cells; Fig 6A), as
demonstrated for many other opsonins, including C-reactive pro-
tein and C1q (23, 34). Apoptotic neutrophils bind protein S when
washed in divalent cation-containing medium, but not when
FIGURE 5. Protein S depletion from a 0.2 M NaCl elution fraction from
Q-Sepharose abolished augmentation of phagocytosis by Dex-MDM. Im-
munodepletion of protein S was achieved by three rounds of depletion
using a polyclonal rabbit anti-protein S Ab and agarose-coupled goat anti-
rabbit IgG, as detailed in Materials and Methods. A mock depletion was
performed using agarose-coupled goat anti-rabbit IgG alone. Samples were
separated by SDS-PAGE on a 9% gel under nonreducing conditions and
then transferred to nitrocellulose. A, The presence of protein S (85 kDa)
in the 0.2 M NaCl eluate from anion-exchange chromatography and in
depleted fractions was confirmed by colloidal gold labeling of transferred
protein (lane 1, 0.2 M NaCl eluate; lane 2, protein S-depleted 0.2 M NaCl
eluate; lane 3, mock depletion of 0.2 M eluate; lane 4, anti-protein S-
immunodepleted material, to confirm the presence of protein S). B, Specific
depletion of protein S in the samples shown in A was confirmed by im-
munoblotting, as described in Materials and Methods. In view of the pres-
ence of Ab in the immunodepleted sample (lane 2), only the outlined sec-
tion of the membrane in A is shown. C, The effects of protein S depletion
upon phagocytosis of apoptotic neutrophils by Dex-MDM (f) were as-
sessed in a 30-min assay. Phagocytosis of apoptotic neutrophils by un-
treated MDM () is shown for comparison. In contrast to a mock de-
pletion of protein S (PSmd), protein S depletion from a 0.2 M NaCl fraction
(PSd) abolished augmentation of phagocytosis by Dex-MDM, an effect
that was restored by addition of 250 ng/ml human protein S (equivalent to
level in 1% autologous serum). Data are mean  SEM; n  3. , p 	 0.05
compared with Dex-MDM in the presence of 0.2 M NaCl eluate.
FIGURE 6. Protein S binds to neutrophils in a calcium-dependent man-
ner and confers augmentation of phagocytosis by Dex-MDM. Neutro-
phils cultured for 20 h in serum-free conditions were preincubated with 1%
autologous serum for 30 min in the presence of 1.5 mM CaCl2. During
subsequent steps, incubations were performed in TBS in either the presence
or absence of 1.5 mM CaCl2 throughout. Neutrophils were washed before
labeling with either A, rabbit Igs (as control), or B and C, rabbit anti-human
protein S for 30 min. Neutrophils were then washed twice, labeled with
PE-conjugated CD16 mAb for 20 min, and washed before flow cytometric
analysis. Levels of CD16 expression can be used to define apoptotic (low),
secondarily necrotic (intermediate), and nonapoptotic (high) neutrophils.
Representative histograms for binding in either the presence (A and B) or
absence (C) of 1.5 mM CaCl2 are shown. D, Calcium-dependent effects of
protein S upon phagocytosis of neutrophils cultured for 20 h in serum-free
conditions. Preincubation of neutrophils with either 10% autologous serum
or 250 ng/ml purified protein S for 1 h, followed by washing in either the
presence (IMDM) or absence (5 mM EDTA) of divalent cations before
assessment of phagocytosis of apoptotic neutrophils in a 30-min assay by
untreated MDM () and Dex-MDM (f). Augmentation of phagocy-
tosis of apoptotic neutrophils by Dex-MDM following protein S prein-
cubation was lost when neutrophils were washed in EDTA-containing
IMDM before assessment of phagocytosis. Data are mean  SEM; n  3.
, p 	 0.001 compared with Dex-MDM in the presence of protein S.
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washed in EDTA-containing medium, consistent with a calcium-
dependent opsonization event (Fig. 6D). However, we also ob-
served low levels of protein S binding to nonapoptotic neutrophils
in the presence of divalent cations, suggesting that the prophago-
cytic effect of protein S on uptake of apoptotic neutrophils by
Dex-MDM may require additional cell surface signals.
We also tested the effects of preincubation of neutrophils with or
without protein S and then anti-protein S Ab before assessment of
phagocytosis. In two experiments that were performed, the results
for glucocorticoid-treated macrophages were as follows: no serum
(18%), 1% serum (56%), and 1% serum plus anti-protein S (68%).
One possibility is that binding of anti-protein S Ab to neutrophils
(as shown in Fig. 6, A–C) may lead to their opsonization with IgG
leading to phagocytosis by FcR-mediated pathways. In the ab-
sence of commercially available Fab preparations of anti-protein
S Ab to test this possibility directly, we used function-blocking
mAb, IV.3, to block the interaction of IgG bound to the neutrophil
surface with macrophage FcRII (CD32). Treatment with IV.3 did
not influence phagocytosis (65% phagocytosis for Dex MDM
with 1% serum plus anti-protein S; 62% phagocytosis for
DexMDM with 1% serum plus anti-protein S in the presence of
IV.3; n  2). These data may indicate either that the polyclonal Ab
to protein S used in this study does not neutralize the prophago-
cytic activity or that multiple FcRs (FcRIII and/or FcRI) ex-
pressed by MDM mediate the uptake of anti-protein S-opsonized
neutrophils.
Protein S-enhanced phagocytosis by Dex-MDM is dependent
on Mertk
Surface expression of Mertk, a potential receptor for protein S
(35), was increased (1.6-fold) on Dex-MDM compared with un-
treated MDM (Fig. 7A), consistent with previous reports using
oligonucleotide arrays (8). The observed up-regulation of Mertk
expression was not due to a nonspecific increase in receptor ex-
pression because CD44 was decreased on the surface of Dex-
MDM relative to untreated MDM (Fig. 7A). To assess the
contribution of Mertk to protein S-dependent phagocytosis, Dex-
MDM were pretreated with an anti-human Mer Ab for 10 min
before phagocytosis. Although anti-Mer had no effect on phago-
cytosis in the absence of protein S, anti-Mer significantly inhibited
phagocytosis by Dex-MDM in the presence of 2.5 g/ml protein
S (Fig. 7B). Similar experiments were undertaken to determine
whether Abs to protein S would exert similar inhibitory effects on
phagocytosis. However, pretreatment of neutrophils with anti-
protein S resulted in an augmentation of macrophage phagocytosis,
possibly through an opsonization event (see Fig. 6) leading to
FcR-mediated phagocytosis. In contrast, blockade of Mer also
significantly inhibited phagocytosis in the presence of 10% autol-
ogous serum, implying that the Mertk pathway is critical for glu-
cocorticoid augmentation of phagocytosis of apoptotic neutrophils
(Fig. 7C). We also examined the effects of short-term treatment of
MDM with Dex upon the protein S dependency of phagocytosis
of apoptotic neutrophils. MDM that had been cultured in the
absence of Dex for 96 h were then treated for 24 h with Dex.
Compared with untreated MDM (18  5% phagocytosis in the
absence of protein S), 96- to 120-h Dex-treated MDM had
slightly higher basal levels of phagocytosis of apoptotic cells in the
absence of protein S (25  6%), but exhibited increased phago-
cytosis in the presence of protein S (60  8%).
Discussion
In this study, we have examined the mechanisms that underlie the
requirement for serum in augmentation of human macrophage
phagocytosis of apoptotic neutrophils following treatment with
glucocorticoids. We demonstrated that protein S opsonizes early
apoptotic neutrophils (induced by treatment with roscovitine) to
promote their internalization by Dex-MDM, and that the pres-
ence of cells that had undergone secondary necrosis was not nec-
essary. This is an important observation because a number of se-
rum opsonins have been reported to bind to late apoptotic or
secondary necrotic neutrophils, including C1q, and the pentraxins,
C-reactive protein and pentraxin-3 (18, 23, 34). Restoration of
phagocytic capacity of Dex-MDM by a high molecular mass se-
rum fraction raised the possibility of a requirement for a C4BP-
protein S complex, which has been reported to inhibit phagocytosis
of apoptotic lymphocyte cell lines (36). Our data showing the pres-
ence of protein S in the high molecular mass fraction would imply
that the C4BP-protein S complex can augment phagocytosis
under some circumstances. Because protein S binding can be
demonstrated following incubation of neutrophils cultured in
the absence of serum with either the high molecular mass frac-
tion from gel filtration or purified protein S, one possibility is
that under certain conditions, protein S can dissociate from
C4BP and subsequently oligomerize at the apoptotic neutrophil
surface (35). Our data clearly demonstrate that protein S alone
is able to confer the augmentation of phagocytosis of apoptotic
neutrophils that we observe.
The importance of complement proteins in apoptotic cell opso-
nization has been highlighted in studies of complement deficiency.
In C1q deficiency, impaired clearance of apoptotic cells is thought
to contribute to the development of an systemic lupus erythema-
tosus-like autoimmune disease (27). For Dex-MDM, C1q did not
restore levels of phagocytosis to those observed in the presence of
serum even when C1q-binding proteins such as pentraxin-3 or fi-
bronectin (37, 38) were present. Moreover, C1q-deficient mouse
serum was able to confer phagocytic activity, demonstrating that
FIGURE 7. Protein S-enhanced phagocytosis by Dex-MDM is depen-
dent on Mertk. A, Surface expression of Mer on MDM was assessed by
indirect immunofluorescence together with flow cytometry. Representative
overlay histograms show expression of Mertk and CD44 for untreated MDM
(dotted lines) and Dex-MDM (solid lines) compared with binding of control
IgG1 mAb. Expression of Mertk (as determined by mean fluorescence inten-
sity) was increased 1.6-fold in five separate comparisons that were made. In
contrast, CD44 expression was down-regulated on the surface of Dex-MDM,
as previously reported (7). Preincubation of Dex-MDM (f) with 10 g/ml
anti-Mer Ab for 10 min inhibited subsequent phagocytosis of apoptotic
neutrophils in the presence of either 2.5 g/ml protein S (B) or 10% au-
tologous serum (C). Pretreatment with anti-Mer alone had no effect on
phagocytosis by Dex-MDM in the absence of protein S or serum. Data
are mean  SEM; n  3. , p 	 0.001, and , p 	 0.05.
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C1q was not required for efficient phagocytosis of apoptotic neu-
trophils by Dex-MDM. We were also unable to demonstrate a
role for opsonization of apoptotic neutrophils with C3bi for re-
moval through CR3 and CR4, as reported by Elkon and colleagues
(11). Furthermore, the data presented in this study argue against a
role for IgG, pentraxin-3, fibronectin, annexin I, platelet-derived
factors, and immune complexes in phagocytosis of apoptotic neu-
trophils by Dex-MDM.
We believe that this is the first report demonstrating a switch in
the molecular mechanism used by human MDM for apoptotic
cell clearance. Our observations are clearly different from the in-
duction of phosphatidylserine-dependent recognition of apoptotic
murine thymocytes by bone marrow-derived murine macrophages
treated with 1,3 glucan reported by Fadok et al. (39). Treatment
with 1,3 glucan did not increase phagocytic potential when com-
pared with untreated bone marrow-derived macrophages, but did
alter the molecular mechanism used. In contrast, our findings dem-
onstrate that phagocytosis of apoptotic cells by Dex-MDM is
profoundly augmented by glucocorticoids, promoting a critical
switch from a protein S-independent to a protein S-dependent rec-
ognition pathway.
The tissue microenvironment has the potential to influence the
mechanisms involved in apoptotic cell removal and thus apoptotic
cell clearance capacity. The cytokine and matrix composition will
determine the differentiation status of phagocyte populations dur-
ing progression of an inflammatory response. Interestingly, protein
S-dependent recognition of an apoptotic B cell line was previously
characterized in MDM generated by differentiation in M-CSF
(35), which promotes the development of M2 macrophages that
have anti-inflammatory phenotype properties and respond to TLR
stimulation by producing IL-10 (40). We find that when MDM
were cultured in the presence of autologous serum, apoptotic cell
recognition pathways that are used are predominantly protein S
dependent-independent (as shown in Fig. 1). In contrast with dex-
treated MDM, these MDM have a more proinflammatory phe-
notype and release IL-12 in response to TLR stimulation, suggest-
ing that protein S-dependent recognition pathways may be
restricted to macrophage phenotypes associated with resolution of
inflammation.
The production and release of potential opsonins (complement
components, pentraxins, annexins, protein S, etc.) are also regu-
lated during inflammation. A number of reports indicate that in-
flammation and the coagulation cascade are closely regulated, par-
ticularly during the acute-phase response. Protein S is produced in
the liver and by endothelial cells (41). Production of both protein
S and C4BP in the liver appears to be controlled by inflammatory
mediators, including IL-6 (42, 43). Levels of protein S are reduced
in patients with ischemic stroke (44) and in patients with sepsis
(45), possibly via the effects of TNF on endothelial cells (46). In
contrast, glucocorticoids have been reported to elevate levels of
protein S (47). Based upon data presented in this work, we propose
that a major effect of glucocorticoids on macrophage differentia-
tion is the induction of the capacity to recognize a distinct set of
molecular cues that are presented on the apoptotic cell surface.
Apoptotic cells display a complex surface molecular signature as a
consequence of cell death with altered expression of receptors to-
gether with binding (or opsonization) of a number of different pro-
teins. One implication of our observation is that the surface mo-
lecular signature of an apoptotic cell may be interpreted differently
by different phagocyte populations.
We have also examined the effects of treatment of differentiated
MDM with Dex for 24 h (6) upon acquisition of the capacity for
protein S-dependent phagocytosis of apoptotic cells. Our data sug-
gest that augmentation of phagocytosis observed following short-
er-term treatment is also associated with use of a protein S-depen-
dent pathway for recognition of apoptotic cells. Because both
untreated MDM and Dex-MDM populations examined in this
study express Mertk, the reason that Dex-MDM are enabled to
use a protein S-dependent clearance pathway is not clear. One
possibility is that the observed up-regulation of Mertk expression
on the surface of Dex-MDM may be sufficient to confer phago-
cytic potential. Alternatively, Mertk may interact with other re-
ceptors on the cell membrane following glucocorticoid treatment.
Ligand-activated Mertk forms dimers in the membrane, resulting
in Mertk autophosphorylation and activation (48), and may het-
erodimerize with other Tyro3/Axl/Mer family receptors or co-
operate with other receptors involved in the phagocytic process,
such as scavenger receptor A (49) or v5 (50). Induction of
cooperative action of receptors may allow regulation of phago-
cytosis of apoptotic cells in response to different environmental
cues encountered during the inflammatory response.
Alternatively, glucocorticoids may influence engagement of
downstream signaling pathways critical for Mertk-dependent
phagocytosis. We have previously demonstrated that glucocorti-
coid-treated MDM exhibited reduced phosphorylation and local-
ization of paxillin and pyk2 to podosome-like adhesion structures,
together with increased Rac activity (7). Interestingly, Rac guanine
nucleotide exchange factor Vav1 is activated downstream of Mertk
(51). Mertk has also been reported to induce FAK phosphorylation
and recruitment to v5 and formation of p130Cas/CrkII/Dock180
complex (50, 52). One possibility is that phosphorylation of Mertk
at Tyr867 in the absence of assembly of adhesion structures pro-
motes MDM phagocytic activity (52).
Induced expression of Mertk and protein S by glucocorticoids
may promote acquisition of a negative-feedback pathway to both
switch off proinflammatory cytokine production (53) and enhance
phagocytic capacity for apoptotic cells. The efficacy of glucocor-
ticoids in treatment of autoimmune diseases such as systemic lupus
erythematosus that are characterized by impairment of apoptotic
cell clearance may be due, in part, to engagement of these pro-
resolution mechanisms. Manipulation of the Mertk pathway may
represent a novel approach to engage aspects of glucocorticoid
action that favor resolution of inflammation without promoting
deleterious side effects.
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